microRNAs in Cancer: biological effects of microRNAs in colorectal cancer by Almeida, Maria Inês
U
M
in
h
o
|
2
0
1
2
Maria Inês da Cunha Doutel de Almeida
Julho de 2012
microRNAs in Cancer:
Biological Effects of microRNAs in
Colorectal Cancer
microRNAs em Cancro:
Efeitos Biológicos de microRNAs no
Cancro Colorectal
Universidade do Minho
Escola de Ciências da Saúde
M
a
ri
a
 I
n
ê
s
 d
a
 C
u
n
h
a
 D
o
u
te
l 
d
e
 A
lm
e
id
a
m
ic
r
o
R
N
A
s
 i
n
 C
a
n
c
e
r
: 
B
io
lo
g
ic
a
l 
E
ff
e
c
ts
 o
f 
m
ic
r
o
R
N
A
s
 i
n
 C
o
lo
r
e
c
ta
l 
C
a
n
c
e
r
m
ic
r
o
R
N
A
s
 e
m
 C
a
n
c
r
o
: 
E
fe
it
o
s
 B
io
ló
g
ic
o
s
 d
e
 m
ic
r
o
R
N
A
s
 n
o
 C
a
n
c
r
o
 C
o
lo
r
e
c
ta
l

Tese de Doutoramento em Ciências da Saúde
Supervisores:
Orientador Científico
Doutor Rui Manuel Vieira Reis
Professor Auxiliar na Escola de Ciências da Saúde
Universidade do Minho, Braga, Portugal
Co-orientador Científico
Doutor George Adrian Calin
Associate Professor, The University of Texas MD
Anderson Cancer Center, Houston, USA
Maria Inês da Cunha Doutel de Almeida
Julho de 2012
microRNAs in Cancer:
Biological Effects of microRNAs in
Colorectal Cancer
microRNAs em Cancro:
Efeitos Biológicos de microRNAs no
Cancro Colorectal
Universidade do Minho
Escola de Ciências da Saúde

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A tese de doutoramento aqui apresentada foi 
desenvolvida no âmbito de uma bolsa individual 
de doutoramento financiada pela FCT, com a 
referência SFRH/BD/47031/2008. 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Os estudos aqui apresentados foram realizados com o co-financiamento do Programa 
Operacional Ciência e Inovação (POCI), POCI/BIA – BCM/59252/2004 e do Fundo Social 
Europeu (FSE).  
 
 
 
v 
 
 
Agradecimentos / Acknowledgements 
 
Ao longo deste percurso, muitos foram os que directa ou indirectamente 
contribuíram para que este trabalho se tornasse possível. Detenho-me a pensar nos 
inúmeros sentimentos e experiências que me transmitiram: a curiosidade, o 
entusiasmo, a responsabilidade, a esperança, a empatia, a solidariedade, a 
cooperação, a coragem, o ânimo, a força, a amizade e o empenho. É uma teia infinita 
de relações humanas que foram sendo construídas para que este trabalho ganhasse 
forma e assim, a curiosidade levasse a um maior entendimento sobre o modo como o 
nosso organismo funciona a nível molecular, com vista ao melhoramento dos cuidados 
de saúde, bem essencial de todos. Peço perdão a todas as pessoas e amigos que não 
enumerei mas que me ajudaram e acompanharam neste percurso: estão impressos no 
meu coração e na minha memória. 
Along the way, many were those who directly or indirectly contributed to this 
thesis. I hold myself thinking about the countless feelings and experiences that they 
have given me: curiosity, enthusiasm, responsibility, hope, empathy, cohesion, 
cooperation, courage, liveliness, strength, friendship, and commitment. It is an endless 
web of human relationships that have been built. They shaped this work. All of these to 
find new therapies in order to improve health care, a primary right of all. I apologize to 
those who are not listed but who helped me along the way:  you are imprinted in my 
heart and memory. 
Ao Prof. Doutor Rui Reis, meu orientador, pela oportunidade e pela confiança 
depositada em mim. Por me ter dado a possibilidade de voar sobre um oceano mas ao 
mesmo tempo segurando-me para que os meus pés não saíssem da terra. Obrigada 
por ter sido e continuar a ser um porto firme. Obrigada pelos conselhos e pelo 
contributo fundamental e inequívoco que teve na minha formação científica.  
Ao Instituto de Investigação em Ciências da Vida e da Saúde (ICVS), como parte 
integrante da Escola de Ciências da Saúde da Universidade do Minho, instituição que 
vi 
 
me acolheu logo após a minha licenciatura. Obrigada por me terem aceitado como 
membro desta família. 
À Prof. Cecília Leão, presidente da Escola de Ciências da Saúde e directora do 
Instituto de Investigação em Ciências da Vida e da Saúde, muito tenho a agradecer. 
Tanto, que se torna difícil expressá-lo em palavras. Agradeço a oportunidade de fazer 
parte deste instituto de excelência. A sua paixão pela ciência e a responsabilidade com 
que conduz este instituto sempre foram exemplo e testemunho para mim e 
influenciaram determinantemente a minha carreira científica. Mas agradeço 
sobretudo a bondade, a ajuda, a disponibilidade, a compreensão e os sorrisos. 
Obrigada por tudo. Não posso deixar de agradecer também ao Dr. Leão pois com a sua 
ajuda me tornei bióloga.   
To Dr. George Calin, my supervisor, that made everything that looked 
impossible to become possible. First of all, I thank you for welcoming me and for letting 
a young researcher entering your lab (without breaking or destroying anything). It was 
such an honor for me to be able to work with you! Gratitude is perhaps the only word 
that best expresses what I feel. Thanks for all the discussions about the projects, the 
results, the experiments. Thanks for constantly caring about us, for keeping our mind 
happy so that we could perform a good job. Thanks for all the opportunities you gave 
me (that are innumerable). Thanks for your support in the difficult times. Thanks for 
always showing me life and science in a different perspective. THANKS, THANKS, 
THANKS! You are my “scientific father”.  
“Be happy, have fun and enjoy life.” 
To The University of Texas MDAnderson Cancer Center, my host institution in 
the US, for giving me the chance to work in the number 1 hospital for cancer treatment 
in the US. Being given the possibility to live and work in the largest medical center in 
the world, I was able to broaden horizons and understand that together, clinicians, care 
givers and researchers are able to “make cancer history”.  I embraced MDAnderson 
core values of caring, integrity and discovery.  
I must thank to all Calin´s lab members in Houston (all bright scientists):  to my 
dear friends Milena Nicoloso and Riccardo Spizzo, for sharing all their knowledge with 
 
 
vii 
 
 
me, for helping me with the experiments and for giving me their opinions and ideas, for 
always protecting me, for all their kindness, and for a friendship that crosses space and 
time; to Jana, my Slovenian “sister”, for all the support inside and outside the lab; to 
Masa, Sang Kil, Eung Jung, Hui and Tetsuro for making me fall in love by the Asian 
culture; to Roxana and Maitri for all the confidences and all the shared moments, I will 
never forget those times and what you have done for me; to Simona, for welcoming me 
so well in the first times;  to Angélica, Jaqueline, Aline and Vanessa, for all the Brazilian 
attitude that makes me smile; to Katrien, for bringing an European refreshment to the 
lab; to Franziska for being my bench neighbor and for all our coffees together; to all 
other members in the lab Su Youn, Rachel, Ivan, Pablo, Chen, Julia, Alexander, Aida, 
Ellen, Annie, Khanh…I´m so glad I could meet you. I will never forget all we lived 
together. 
I would also like to thank to the researchers from other laboratories in 
MDAnderson with whom I collaborated with, in particular to Dr Patrick and Dr Lopez ´s 
labs, and to Lawrence (Xiao-Feng Le).  
I also have to acknowledge to those that helped me having a great life in 
Houston, outside the lab. To Burju, Rakhan and Burak for our great friendship; to 
Sharonda and Azita for helping me adapt to the first months in Houston; to Roxana and 
all our Brazilian friends for all the support in the most difficult times; to Ana Brett, it 
was great to meet a Portuguese in Houston; and finally, but not least, to Chiara for the 
uncountable moments, for sharing, for our lives, for being there for me (without you 
this PhD would not had been possible). 
Gostaria ainda de agradecer a todos os meus amigos que sempre me apoiaram 
(ao longo deste percurso e sempre). Uma palavra especial para as minhas amigas do 
rebanho Marta, Banas e Débora; e para os meus amigos de Guimarães, Rodolfo, Xico e 
Zé.  
Esta tese foi construída também com a ajuda de todos os meus colegas do 
domínio das Ciências Cirúrgicas, desde o ID4 ao actual I1.02, Ana Xavier, Bruno, Céline, 
Dina, Filipe, Inês Guimarães, Márcia, Marta Pereira, Marta Pojo, Marta Tibúrcio, 
viii 
 
Mónica, Joana, Sandra, Sara, Olga, Tatiana, Vera. Em especial, agradeço à Sandra Costa 
pela ajuda e paciência que sempre teve comigo; e ao Bruno Costa e à Marta Pereira 
pela partilha contínua, pela coragem, pelas ideias e pelo apoio constante nas decisões.  
Agradeço também à Prof. Fátima, ao Adhemar e à Raquel Andrade por serem 
sempre prestáveis e contribuírem criticamente nos trabalhos desenvolvidos ao longo 
destes anos. 
À minha Família, avós, padrinhos, tios e primos que estão sempre unidos a 
mim, onde quer que eu esteja, pelos valores postos em prática que me transmitiram. É 
por eles que me rejo. Obrigada família. 
À minha mãe, ao meu pai e ao meu irmão. O amor que nos une é o meu pilar e 
a minha solidez. Esta tese é dedicada a vós! 
Agradeço a Deus por me ter guiado ao longo deste percurso e por ter tornado 
tudo isto possível.  
 
 
ix 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary / Resumo 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
 
  
 
 
xi 
 
 
Summary 
 
Non-coding RNAs are a class of RNA transcripts that do not codify for protein. 
Included in this class are the microRNAs, small RNAs with approximately 20 
nucleotides in length. microRNAs act post-transcriptionally by binding to 5´-
ultraconserved regions, coding regions or 3´-ultraconserved regions of messenger 
RNAs and inhibit its translation or cause messenger RNA cleavage. Additionally, 
microRNAs can also bind to pseudogenes and are involved in RNA decoy functions. A 
single microRNA can bind to several RNAs and a single RNA can be targeted by 
different microRNAs. Therefore, microRNAs constitute master regulators of gene 
expression and major key players in the control of cellular functions. 
microRNAs are deregulated in all tumor types and can act as tumor suppressors 
or as oncogenes in a tissue- and cell-specific manner. microRNAs control biological 
mechanisms essential for cancer cells, such as proliferation, cell death, cell cycle, 
metabolism, hypoxia, angiogenesis, inflammation, migration, invasion, metastasis and 
cancer stem cells self-renewal. Besides microRNAs´ importance as diagnostic and 
prognostic tools in cancer, and due to their involvement in cancer biology, microRNAs 
have been regarded as new therapeutic targets. This thesis focuses on the role of 
microRNAs on colorectal cancer. Despite the great improvement in therapeutics, 
colorectal cancer is still one of the most commonly diagnosed tumor types and a 
frequent cause of cancer-related death. We intend to understand the biological effects 
of miR-28 in this tumor type. To achieve this goal both in vitro and in vivo approaches 
were used. 
In the microRNA biogenesis pathway, usually a primary-microRNA is processed 
into a precursor-microRNA, which originates a single mature microRNA. However, in 
some cases, two mature miRNAs are processed. This occurs with the precursor-miR-28 
that is processed into two mature microRNAs that were named miR-28-5p and miR-28-
3p. We identified for the first time that both mature forms of miR-28 were deregulated 
in colorectal cancer. Contrary to some tumor and cell types in which miR-28 was found 
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to be upregulated, in colorectal cancer miR-28 is downregulated in tumor compared 
with normal colorectal tissue. However, the two mature forms have distinct functions. 
Our in vitro results revealed that miR-28-5p overexpression decreased proliferation, 
increased apoptosis, caused a G1-arrest in the cell cycle, and decreased migration and 
invasion, while miR-28-3p overexpression had no effect on proliferation but increased 
migration and invasion. This was the first description of miR-28 dual role in colorectal 
cancer cells. As miR-28 mature forms are transcribed together, we analyzed the overall 
result in vivo. Xenografts of colorectal cancer cells overexpressing miR-28 caused a 
slower tumor growth in mice, while increased metastasis, when compared with the 
control group. In this thesis we also discuss the strategies to inhibit or restore 
microRNAs function. The dual role of miR-28 has great impact on the design of 
therapies using microRNAs, in particular for upregulation of microRNA levels using 
expression vectors. 
Variation in expression levels of microRNAs has a tremendous impact on the 
intracellular signaling networks. We determined that miR-28-5p targets Cyclin D1, an 
important regulator of cell cycle progression, in particular of the G1-S phase transition. 
Additionally, miR-28-5p directly targets HOXB3, a transcription factor described to be 
upregulated in colon cancer. On the other hand, miR-28-3p directly regulates the 
expression of NM23-H1, an anti-metastatic gene.  
miR-28 is part of an extensive number of microRNAs deregulated in colorectal 
cancer. It is essential to understand the effect of the microRNAs in cancer to be able to 
interfere with the tumor biology and consequently generate therapeutic strategies 
based on microRNAs as an approach to fight cancer. 
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Resumo 
 
RNAs não codificantes são uma classe de transcritos de RNA que não codificam 
proteína. Dentro desta classe encontram-se os microRNAs, pequenos RNAs com 20 
nucleótidos de comprimento. Os microRNAs actuam após a transcrição e ligam-se por 
complementariedade de bases a RNAs mensageiros, nas suas regiões 5´- ou 3´-ultra-
conversadas e nas regiões codificantes. Os microRNAs inibem a tradução ou causam a 
degradação do RNA mensageiro. Além disso, os microRNAs podem também ligar-se a 
pseudo-genes e estar envolvidos em funções de RNA “decoy”. Um único microRNA 
pode ligar-se a vários RNAs, e um único RNA pode ser o alvo de vários microRNAs. 
Assim sendo, os microRNAs constituem excelentes reguladores da expressão genética 
e são elementos chave no controlo das funções celulares. 
Os microRNAs estão desregulados em todos os tipos de tumor e podem actuar 
como supressores tumorais ou como oncogenes, dependendo do tipo de tecido e de 
célula. Os microRNAs controlam mecanismos biológicos essenciais para as células 
neoplásicas, incluindo a proliferação, a morte e o ciclo celular, o metabolismo, a 
hipoxia, a angiogénese, a inflamação, a migração, a invasão, a metastização e a auto-
renovação das células estaminais tumorais. Para além da importância dos microRNAs 
como ferramentas de diagnóstico e prognóstico oncológico, e devido ao seu 
envolvimento na biologia tumoral, os microRNAs têm sido apresentados como novos 
alvos terapêuticos. Esta tese analisa o papel dos microRNAs no cancro colorectal. 
Apesar dos significativos avanços terapêuticos, o cancro colorectal continua a ser um 
dos tipos tumorais mais diagnosticados e uma frequente causa de morte por cancro. 
No trabalho aqui apresentado, pretende-se analisar o efeito biológico do miR-28 neste 
tipo tumoral. Para atingir este objectivo utilizámos ferramentas in vitro e in vivo. 
Geralmente, na via da biogénese dos microRNAs, um microRNA-primário é 
processado constituindo o microRNA-precursor que, por sua vez, origina um único 
microRNA maduro. No entanto, em alguns casos, são originados dois microRNAs 
xiv 
 
maduros. Esta situação ocorre com o precursor do miR-28 que é processado em dois 
microRNAs maduros designados de miR-28-5p e miR-28-3p. Identificámos, pela 
primeira vez, ambas as formas do miR-28 maduro como estando desreguladas em 
cancro colorectal. Contrariamente a outros tipos de tumores/células nas quais o miR-
28 está sobreexpresso, no cancro colorectal o miR-28 está subexpresso no tumor 
quando comparado com os seus níveis de expressão no tecido colorectal normal. No 
entanto, as duas formas maduras têm funções distintas. Os estudos in vitro revelaram 
que a sobreexpressão do miR-28-5p diminui a proliferação, aumenta a apoptose, 
impede a progressão do ciclo celular na fase G1, e diminui a migração e a invasão; 
enquanto que a sobreexpressão do miR-28-3p não tem efeito na proliferação mas 
aumenta a migração e a invasão. Esta é a primeira descrição do duplo papel do miR-28 
em neoplasia colorectal. Visto que as formas maduras do miR-28 são transcritas 
conjuntamente, analisámos o resultado global da expressão do miR-28 in vivo. A 
injecção, em murganhos, de células neoplásicas colorectais que sobreexpressam miR-
28 causou um crescimento mais lento dos tumores, mas provocou um aumento no 
número de metastases, quando comparámos com o grupo control. Nesta tese, 
discutimos as estratégias para inibir ou restaurar a função dos microRNAs. O duplo 
papel do miR-28 tem um vasto impacto no desenho de terapias que recorram a 
microRNAs, em particular na sobreexpressão dos níveis de microRNAs usando vectores 
de expressão. 
A variação dos níveis de microRNAs tem um impacto tremendo na rede de 
sinalização intracellular. Observámos que o miR-28-5p tem como alvo a Cyclin D1, um 
importante regulador da progressão no ciclo celular, em particular na transição G1-S. 
Além disso, o miR-28-5p tem como alvo directo o HOXB3, um factor de transcrição 
descrito como estando sobreexpresso no cancro do colon. Por outro lado, o miR-28-3p 
regula directamente a expressão de NM23-H1, um gene anti-metastático.    
O miR-28 faz parte de um extenso número de microRNAs que está desregulado 
em neoplasias. Compreender o efeito dos microRNAs no cancro é essencial para 
interferir com a sua biologia e, consequentemente, gerar estratégias terapêuticas 
utilizando microRNAs na luta contra esta doença devastadora. 
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Objectives and Thesis Layout 
 
microRNAs are key players in regulation of biological processes, by controlling the 
expression of protein-coding messenger RNAs and non-protein-coding transcripts. In cancer, 
microRNAs control proliferation, apoptosis, cell-cycle, cancer stem cells self-renewal, 
metastasis and angiogenesis. In addition, microRNAs can be vehicles of resistance to cancer 
treatment and are considered potential therapeutic targets. 
 The general aim of the work reported in this thesis is to understand how deregulated 
microRNAs can contribute to tumorigenesis, with a very special emphasis in colorectal cancer, 
by investigating the role of strand-specific microRNAs (-5p, -3p), originated from the same 
precursor-microRNA, in this tumor type. In the quest to accomplish this objective, this thesis is 
organized in individual chapters, for a better elucidation of the work performed, as presented 
below. 
 
Chapter 1 presents a general introduction on the state of the art of microRNAs and 
colorectal cancer. It is divided in two sections. The first section focuses on microRNAs (sub-
chapter 1.1). It aims to summarize the main reports on the topic and it includes a historical 
perspective on how microRNAs were discovered, a description of the microRNA´s biogenesis 
pathway and of the microRNA´s functions, a highlight on the most significant reports 
associating microRNAs to cancer, an explanation of the utility of microRNAs as molecular 
biomarkers for diagnosis, prognosis and prediction of therapeutic response in cancer, and 
finally, a report on the most successful strategies for the use of microRNAs to treat diseases. 
The second section focuses on colorectal cancer and intends to prepare the reader for a 
general overview on this disease (sub-chapter 1.2). Regarding colorectal cancer, it stresses the 
incidence and risk factors, screening methods and diagnostic tools, tumor origin and classical 
classification, molecular classification and disrupted genetic pathways, and finally some of the 
currently treatment strategies used. Also in this section, connections between colorectal 
cancer and microRNAs are established. 
Chapter 2 presents the study that explored the biological roles of miR-28 in colorectal 
cancer. It results from the investigation on the strand-specific miR-28-5p and miR-28-3p effects 
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in vitro and the overall effect of the miR-28 in vivo. This work comprises three specific aims: 1) 
to analyze the miR-28 expression levels in colorectal cancer and normal colorectal tissue 2) to 
understand how miR-28 contributes to tumorigenesis in colorectal cancer; 3) to identify miR-
28 targets in colorectal cancer cells.  
Chapter 3 attempts to discuss and bring together the findings accomplished on 
chapter 2 with the milieu of other relevant published data. A general concluding remarks 
section is also included and it emphasises the major findings of the work presented throughout 
the thesis. 
Finally, an Appendix section was included and it encloses the additional related studies 
performed during the PhD time course. 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
1. General Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
  
3 
 
 
 
 
 
 
 
 
 
 
Part of the introduction presented throughout this chapter was: 
(i) Published as review articles or commentaries in international peer reviewed 
journals: 
Appendix section: PAPER III - Almeida MI, Reis RM, Calin GA. BRCA1, microRNAs 
and cancer predisposition: challenging the dogma. Cell Cycle. 2011;10(3): 377. 
 
Appendix section: PAPER V - Almeida MI, Reis RM, Calin GA. MicroRNA history: 
discovery, recent applications, and next frontiers. Mutation Research. 
2011;717(1-2): 1-8. 
 
Appendix section: PAPER VII - Spizzo R, Almeida MI, Colombatti A, Calin GA. 
Long non-coding RNAs and cancer: a new frontier of translational research? 
Oncogene. 2012. (in press) 
 
Appendix section: PAPER VIII - Almeida MI, Reis RM, Calin GA. Decoy activity 
through microRNAs: the therapeutic implications. Expert Opinion on Biological 
Therapy. 2012. (in press) 
  
4 
 
  
5 
 
1. GENERAL INTRODUCTION 
 
1.1. microRNAs: SMALL NON-CODING RNAS 
For decades, the majority of the molecular geneticists focused their work on a 
protein-centric view that was based on the central dogma that deoxyribonucleic acid 
(DNA) is transcribed into ribonucleic acid (RNA) which is then traduced into protein. 
According to this view, the RNA was regarded as a mere intermediate between DNA 
and proteins [1]. However, the human genome projects came to clarify that the 
majority of the human DNA does not codify for protein. In fact, humans have 
approximately the same number of protein coding genes (~20,000) than 
Caenorhabditis elegans, even though humans contain about 1014 cells while 
Caenorhabditis elegans contains merely ~1000 cells [2]. Surprisingly, along evolution it 
is not the extent of protein coding genes that increases, but the extent of non-protein 
coding DNA, which reaches 98,8% in humans. This suggests that higher developmental 
complexity may rely on the non-protein coding sequences [2]. Additionally, while only 
2% of the mammalians genome codifies for protein, the majority of the genome is 
transcribed, composing the class of non-coding RNAs (ncRNAs) [2]. The use of 
massively parallel sequencing platforms of the “next-generation sequencing”, with the 
RNA sequencing (RNA-seq) application, revealed thousands of transcripts and opened 
the door to a comprehensive study of the non-protein-coding transcriptome [3, 4]. 
Although the majority of these transcripts have not been experimentally tested yet, 
what was previously assumed to be “junk” DNA because it was poorly understood and 
because of established dogmas, is now regarded as extremely important regulatory 
elements that may hold the key for the evolutionary complexity and for the control of 
the biological mechanisms [2, 5, 6]. Therefore, it is not surprising that, when disrupted, 
ncRNAs interfere with normal cellular function and contribute to disease pathogenesis 
[5, 7]. 
Presently, several classes of ncRNAs have been established and their functions 
are being revealed. ncRNAs can be classified in main classes: long-ncRNAs (e.g.,  long 
intergenic ncRNAs, antisense ncRNAs, transcribed-ultraconserved regions, promoter 
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upstream transcripts); structural RNAs (e.g., transfer RNAs, small nuclear RNAs, 
spliceosomal RNAs); and small-RNAs (e.g., microRNAs [miRNAs], piwi-interacting RNAs, 
small nucleolar RNAs, promoter-associated small RNAs, transcription initiation RNAs). 
For a complete revision on long-ncRNAs, including it definition, classification, function 
and involvement in cancer please refer to Appendix section (PAPER VII). This thesis will 
focus on the subclass of small-ncRNAs called miRNAs that are among all ncRNAs 
probably one of the most explored in disease so far. 
miRNAs are approximately 20 nucleotides (nt) in length and regulate gene 
expression posttranscriptionally by binding to 3´untranslated regions (UTR), coding 
sequences (CDS) or 5´UTR of target messenger RNAs (mRNAs), and lead to inhibition of 
translation or mRNA degradation [8-10]. miRNAs control the expression of genes 
involved in several biologic processes, including proliferation, apoptosis, 
differentiation, and metastasis [8-10]. Two decades ago, both the existence and the 
importance of miRNAs were completely unknown. Until then, the scientific community 
focused on genes that codify for protein. The classical dogma that DNA is transcribed 
into RNA, which then is translated into protein, pushed aside the study of all the non-
protein-coding sequences. Only in 1993 did the importance of miRNAs begin to be 
revealed [11, 12].  
Currently, thousands of miRNAs have been identified in humans and other 
species. miRNA online sequences repositories, such as the miRBase database 
(http://www.mirbase.org/), are available [13–15]. The miRBase release18 contains 
18226 entries representing hairpin precursor miRNAs (pre-miRNAs), expressing 21643 
mature miRNA products, in 168 species. Furthermore, current tools and softwares 
developed for miRNA target prediction facilitate studies about the miRNAs functional 
network [16, 17]. Currently, in PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), the 
number of publications has been exponentially growing [18], accounting for more than 
15,000 publications (PubMed entries that reference the term ‘microRNA’). The most 
significant publications on the miRNA field since 1993 are represented in Figure 1 [19].  
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1.1.1 Historical Perspective on microRNAs 
1.1.1.1 Discovery of the First microRNA: lin-4 
Lin-4 was the first miRNA to be discovered, in 1993, by the joint efforts of 
Ambros’s and Ruvkun’s laboratories [11, 12]. In the nematode Caenorhabditis elegans, 
heterochronic genes control the temporal development pattern of all larval stages. 
One of these genes is lin-4, discovered by the isolation of a null mutation that causes a 
failure in temporal development [20, 21]. Animals with lin-4 loss-of-function mutations 
are missing some adult structures, are incapable of laying eggs, and reiterate early 
development programs at inappropriate late larval stages. Lin-4 activity is required for 
the transition from the L1 to L2 stage of larval development [21, 22]. In 1987, Ferguson 
et al., at Horvitz’s laboratory, found that a suppressor mutation in the gene lin-14 was 
able to revert the null-lin-4 mutation phenotype [23]. In fact, null mutations in lin-14 
gene caused an exactly opposite phenotype of the null-lin-4 mutations [22, 23]. This 
interesting opposite phenotype between defects in lin-4 and lin-14 genes indicated 
that lin-4 could negatively regulate lin-14 [22]. In 1989, Ambros worked with Ruvkun, 
at Horvitz’s laboratory, to clone the lin-14 gene [22, 24]. At this time, the two 
colleagues followed two independent research careers, with Ambros focusing on the 
lin-4 gene and Ruvkun on the lin-14 gene. Ambros, together with Lee and Feinbaum, 
found that a 700-base pair fragment could contain lin-4 gene but could not find the 
conventional start and stop codons. Even so, they introduced mutations in the putative 
open reading frame but lin-4 function remained unchanged. Therefore, Ambros 
concluded that lin-4 did not encode a protein [11, 22]. In addition, they found two very 
small lin-4 transcripts of only 61 nt and 22 nt in length [11]. On the other hand, Ruvkun 
and his colleagues Wightman and Ha found that lin-14 was downregulated at a 
posttranscriptional level and that the lin-14 3´UTR region was sufficient for the 
temporal regulation [12]. The two groups shared their unpublished data, and in June 
1992 Ambros and Ruvkun independently came to the same conclusion: lin-4 
transcripts were complementary to a repeated sequence in the 3´UTR of the lin-14 
gene [11, 12, 22]. In December 1993, Ambros and Ruvkun independently reported in 
the same issue of Cell that the small and non-protein-coding transcript lin-4 regulates 
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lin-14 through its 3´UTR region [11, 12, 22]. A new unexpected cellular regulatory 
mechanism involving a non-protein-coding transcript had been found! 
 
1.1.1.2 Discovery of a Second microRNA: let-7 
Likewise lin-4, let-7 is a heterochronic gene of Caenorhabditis elegans and was 
the second miRNA to be discovered, in 2000, seven years after the finding of the first 
miRNA. Reinhart et al. at Ruvkun’s laboratory reported that let-7 was a 21-nt RNA 
controlling the L4-to-adult transition of larval development [25]. Loss of let-7 activity 
causes reappearance of larval cell fates during the adult stage of development, while 
increased let-7 activity causes precocious expression of adult fates [25]. Remarkably, 
the authors found that the retarded let-7 phenotype could partially suppress lin-41 (a 
let-7 target) loss-of- function mutations [25]. In fact, let-7 is complementary to two 
closely spaced sites in lin-41 3´UTR. Deletion of the lin-41 3´UTR and let-7 mutations 
abolish lin-41 downregulation, showing that both partners are necessary for this 
mechanism [26, 27]. Let-7 controls late temporal transitions during development 
across animal phylogeny. Unlike lin-4, the let-7 sequence is conserved across species 
from flies to humans [28], a fact that had a major effect on the study of miRNAs in 
other organisms [29, 30]. Let-7 RNA was detected in vertebrate, ascidian, 
hemichordate, mollusk, annelid, and arthropod but not in RNAs from plant and 
unicellular organisms [28, 30]. In humans, it was detected at different expression levels 
in the majority of the tissues, including brain, heart, kidney, liver, lung, trachea, colon, 
small intestine, spleen, stomach, and thymus [28]. The let-7 miRNA family refers to 
miRNAs that share complete sequence identity with let-7 at the 5´ends, termed seed 
regions, and therefore can regulate the same targets [29]. The let-7 family within 
humans comprises 12 miRNAs. Some members of the let-7 family identified and 
functionally analyzed in Caenorhabditis elegans include miR-48, miR-84, and miR-241 
[31–33]. These miRNAs act redundantly to control the L2-to-L3 transition, by 
repressing hbl-1 [33]. Functional cooperation among miRNA family members continues 
to be studied [34]. The discovery that let-7 is conserved across species triggered a 
revolution in the research of the new class of small ncRNAs, called miRNAs.  
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1.1.2 Biogenesis Pathway 
miRNAs are encoded in the genome as long primary transcripts (named pri-
miRNAs) that contain a cap structure at the 5´end and are poly-adenylated at the 
3´end. Pri-miRNAs are processed by the cellular RNaseII enconucleaseIII Drosha, 
together with DGCR8/Pasha protein, into a structure of 60–110 nt, called precursor-
miRNA (pre-miRNA), which is then exported from the nucleus to the cytoplasm by an 
Exportin-5-dependent mechanism. In the cytoplasm, the pre-miRNA is cleft by the 
RNaseIII enzyme Dicer, together with TRBP/PACT proteins, producing a short imperfect 
double-stranded miRNA duplex. This duplex is then unwound by an helicase into a 
mature miRNA, approximately 20 nt in length. Mature miRNA is then incorporated into 
a multicomponent complex known as RNA-induced silencing complex (RISC), which 
core components are Argonaute family protein members [35, 36] (Figure 2). 
In a historical perspective, the knowledge acquired from RNAi was determinant 
for understanding miRNAs processing and activity. In 2000, Zamore et al. studied the 
RNAi process and found that double-stranded RNA fragments of 21–23 nt were 
targeting the mRNA cleavage [37]. The functional unit of RNA interference (RNAi) was 
therefore the same size as miRNAs. In 2001, two reports were crucial for elucidation of 
the miRNA biogenesis mechanism, as both reports suggested an involvement of RNAi 
pathway components in miRNAs maturation [38, 39]. Grishok and colleagues showed 
that a homologue of Drosophila Dicer (dcr-1) and two homologues of rde-1 (alg-1 and 
alg-2) were essential for lin-4 and let-7 activity in Caenorhabditis elegans. Inactivation 
of these genes caused phenotypes similar to lin-4 and let-7 mutations [38]. 
Simultaneously, Hutvágner et al. found that let-7 pre-miRNA is cleaved by Dicer. In 
fact, when cells were transfected with siRNA duplex corresponding to human Dicer 
enzyme, pre-let-7 accumulated in the cells [39]. Taken together, these two studies 
corroborated the intersection between RNAi and miRNA pathway and opened the 
door for understanding the formation of mature miRNAs.  
In the miRNA biogenesis pathway, Drosha and Dicer are spatially separated, 
being localized in the nucleus and the cytoplasm, respectively (Figure 2). In 2004, Lund 
11 
 
et al. reported that Exportin-5 was the key player mediating the efficient nuclear 
export of the short miRNA precursors [40]. However, some miRNAs such as miR-29b 
are predominantly located in the nucleus [41]. In 2007, Hwang et al. found that some 
miRNAs contain additional sequence elements that control their subcellular 
localization. In fact, miR-29b possesses a hexanucleotide terminal motif that directs its 
import into the nucleus. These authors showed that, despite the small size of miRNAs, 
they can contain additional cis-acting regulatory motifs that might influence their 
posttranscriptional behavior, and they concluded that miRNAs with common 5´ends, 
predicted to regulate the same targets, might have distinct functions [41].  
 
Figure 2. miRNA biogenesis pathway. A primary-miRNA (pri-miRNAs) is transcribed 
from the genome by a RNA polymerase (Pol) II. Pri-miRNAs harbor a 5´methylated cap 
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and a 3´poly(A) tail, and forms a hairpin-loop structure. It is then processed by 
DROSHA/DiGeorge syndrome critical region gene 8 (DGCR8) into a precursor-miRNA 
(pre-miRNA), which is exported from the nucleus to the cytoplasm via GTP-dependent 
Exportin 5. The hairpin pre-miRNA is processed by Dicer together with PACT and Dicer-
TAR RNA binding protein (TRBP) into a mature miRNA duplex. This duplex is unwound 
by a helicase. The mature miRNA is incorporated into the RNA-induced silencing 
complex (RISC). Depending upon the degree of complementarity between the mRNA 
and the miRNA sequence, miRNAs can inhibit mRNA translation or cause mRNA 
degradation. 
 
1.1.3 Function 
miRNAs’ main function is to inhibit protein synthesis of protein-coding genes, 
either by inhibition of translation or mRNA degradation (Figure 2). However, the 
relative contribution of each mechanism to repression was unknown until recently. In 
an elegant study, Guo et al. used ribosome profiling to measure the overall effects on 
protein production and simultaneously measured effects on mRNA levels. They 
concluded that inhibition of translation (no changes in mRNA levels of miRNA targets) 
had a modest influence on repressing protein levels, whereas mRNA destabilization 
was the predominant miRNAs mechanism of action to decrease their targets levels 
[42]. In addition to mRNAs repression, miRNAs have been also reported to activate 
translation of targeted mRNAs [43, 44]. Vasudevan et al. were the first to clearly 
demonstrate that, in some instances, miRNAs can work as translational activators. 
TNFα AU-rich elements recruited miR-369-3 to mediate translation upregulation, 
exclusively under serum starvation conditions. In addition, upon cell cycle arrest, let-7 
and the synthetic miRNA-cxcr4 induced translation, whereas they repressed 
translation in proliferating cells. Therefore, miRNAs can switch between translation 
repression and activation in coordination with the cell cycle [44]. In 2008, Place et al. 
provided new evidence that miRNAs can induce gene expression and were the first to 
show that miRNAs can target gene promoters. These authors showed that miR-373 
targets the promoter of E-cadherin and CSDC2 and induced their expression [45]. For a 
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long time, studies on miRNA-target interaction were confined to 3´UTR of mRNAs, 
probably because the first studies on miRNAs focused on this region. In 2007, Lytle et 
al. were the first to suggest that miRNAs could associate to any position of target 
mRNAs and demonstrated that mRNA targets were efficiently repressed by miRNA-
binding sites in 5´UTR [46]. In 2008, Tay et al. reported that binding sites in coding 
sequences are abundant and experimentally showed that mouse Nanog, Oct4, and 
Sox2 have miRNA-binding sites in their coding sequences. miRNAs targeting these 
mRNAs modulate embryonic stem cell differentiation [47].  
Recently, another function for miRNAs was found: the decoy activity. In 2010, 
Eiring et al. reported a remarkable finding for our understanding of how miRNAs 
function. These authors found that, in addition to miRNAs gene silencing activity 
through base pairing with mRNA targets, miRNAs also have decoy activity that 
interferes with the function of regulatory proteins [48]. hnRNP E2 is a member of the 
family of RNA-binding proteins whose members are involved in mRNA processing, 
nucleocytoplasmic export, and translation of mRNAs [49]. In cells in which the BCR/ABL 
oncogene is expressed, causing an arrest of differentiation in myeloid blast crisis 
chronic myelogenous leukemia, there is an increase of hnRNP E2 protein [50]. hnRNP 
E2 interacts with the transcription factor CEBPA, inhibiting the translation of mRNA. 
Using RNA electrophoretic mobility shift assays, UV crosslinking, and RNA 
immunoprecipitation assays, the authors found that miR-328 that is downregulated in 
a BCR/ABL-dependent manner competes with CEBPA mRNA for the hnRNP E2 binding 
site [48]. They also proved that restoration of miR-328 expression interferes with 
hnRNP E2 function of translation inhibition by preventing CEBPA::hnRNPE2 binding and 
consequently restores, in vivo and in vitro, CEBPA mRNA translation [48]. Besides the 
decoy activity, miR-328 also functions in the canonical way by suppressing translation 
of mRNA encoding the PIM1 protein kinase through base pairing interaction [48]. 
Later the same year, Poliseno et al. reported in Nature the intriguing discovery 
that pseudogenes could function as a decoy for miRNAs’ effects on corresponding 
protein-coding genes [51]. The authors used as a model the well-known tumor 
suppressor PTEN and its pseudogene PTENP1, which has a high sequence homology 
with part of the PTEN 3´UTR [51]. The authors proved that PTENP1 is targeted by some 
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of the miRNAs that target also PTEN, including miR-19b and miR-20a. Through a 
miRNA-dependent mechanism, overexpression of PTENP1 3´UTR resulted in the 
derepression of PTEN (and consequently proved that PTENP1 has a role as a tumor 
suppressor), and expression of PTEN 3´UTR resulted in the derepression of PTENP1 
[51]. In addition, the authors showed that the same decoy mechanism is present when 
analyzing other genes and their related pseudogenes, such as the KRAS gene and its 
pseudogene KRAS1P [51]. This new concept was further developed one year later, 
when the same group showed that not only non-coding genes can compete for 
miRNAs binding sites, but also protein-coding transcripts can compete with one 
another [52]. Transcripts that have the same miRNA binding sites (or miRNA response 
elements [MREs]) are called “competing endogenous RNAs” (ceRNAs) [53] and may act 
as natural miRNA sponges. The authors used bioinformatics (MRE enrichment—
MuTaME—analysis) and biological approaches to validate ceRNA for PTEN [52]. Some 
of these mRNAs are SERINC1, VAPA, and CNOT6L, whose expression in human prostate 
cancer and glioblastoma samples was significantly different between PTEN-high and 
PTEN-low groups [52]. In addition, silencing of these ceRNAs resulted in a decrease in 
luciferase activity when cells were co-transfected with a luciferase vector containing 
the PTEN 3´UTR. The authors further proved that this correlation was dependent on 
the miRNAs, since regulation of PTEN expression by SERINC1, VAPA, and CNOT6L 
ceRNAs vanished in the cells with a defect in the miRNA processing machinery [52]. 
In the same issue of Cell, three articles reported “out-of-the-box” discoveries 
about coding transcripts and competing endogenous RNAs. Sumazin et al. used a 
multivariate analysis method, named Hermes, to combine gene expression data with 
miRNA profiles in glioblastoma and found 7,000 genes whose transcripts were involved 
in sponge regulatory interactions (modulator and sponges share miRNAs binding sites) 
and 148 genes that were involved in nonsponge regulatory interactions (modulator 
and sponges that do not necessarily share miRNA binding sites) [54]. Moreover, the 
authors focused on the PTEN transcript to perform validation studies for PTEN miRNA-
mediated decoy in glioblastoma cell lines [54]. 
In another study, Karreth et al. identified PTEN ceRNAs in a mouse model of 
melanoma with use of the sleeping beauty transposon system [55]. The authors 
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further validated ZEB2 as a ceRNA decoy for PTEN by demonstrating that ZEB2 
depletion downregulates PTEN and that this reduction was dependent on the 3´UTR 
(ZEB depletion suppressed luciferase activity of PTEN 3´UTR reporter) and on miRNAs 
(ZEB2 depletion does not reduce PTEN expression in cells with a defect in the miRNA 
processing machinery) [55]. Finally, Cesana et al. reported that a long noncoding RNA, 
linc-MD1, acts as a ceRNA for MAML1 and MEF2C mRNAs, two transcription factors 
that regulate muscle-specific genes, by interacting with miR-133 and miR-135, thereby 
regulating muscle differentiation [56]. All of the above-mentioned studies were crucial 
to a new understanding of the importance of miRNAs in mediating mRNA decoys, and 
their significance has been highlighted in several articles. For example, McCarthy [57] 
stated that a subtle reduction in few mRNA could cause widespread effects. Rigoutsos 
and Furnari [58] indicated that the relative amount of mRNAs and corresponding 
ceRNAs should be considered and they introduced the intriguing hypothesis that the 
decoy mechanism may also occur in cases in which PTEN levels are reduced without 
mutation, such as in Cowden disease and Bannayan-Zonana syndrome. In addition, 
Swami [59] questioned how this decoy applied in noncancer-related genes.  
In conclusion, the canonical sense of miRNAs function is the gene silencing 
activity through base pairing with mRNA targets. Additionally, miRNA play a role in 
decoy activities, which introduces another level of complexity on the miRNAs gene 
regulatory effects.  
 
1.2.4 microRNAs in Disease 
1.1.4.1 microRNAs Involvement in Cancer 
The first report suggesting a role of miRNAs in cancer was published in 2002 
[60]. miR-15 and miR-16 were found to be located at chromosome 13q14, a region 
frequently deleted in chronic lymphocytic leukemia (CLL). Calin et al. discovered that 
both genes were deleted or downregulated in greater than 60% of B-cell human CLL, 
indicating that these genes behave as tumor suppressors in CLL [60]. Consequently, the 
same group found that a significant percentage of miRNAs is located at fragile sites 
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and in regions altered in cancers, including regions of amplification or loss of 
heterozygosity or breakpoints, suggesting that miRNAs have a relevant role in human 
cancer pathogenesis [61]. Oligonucleotide miRNA microarrays and, more recently, 
deep sequencing (next generation sequencing) have permitted the analysis of the 
entire known miRNAome. In addition, other methods such as bead-flow cytometry, 
quantitative real-time polymerase chain reaction, and high-throughput array-based 
Klenow enzyme assay have been used to assess miRNA expression in tumors and other 
diseases. To date, altered miRNA expression had been reported in almost all types of 
cancer [62]. In 2005, the first reports addressing the biological function of miRNAs in 
cancer were published. miRNAs can act as oncogenes (oncomirs) or tumor suppressors 
and are involved in a variety of pathways deregulated in cancer [63]. In March 2005, 
Johnson et al. reported the first miR-target interaction with relevance to cancer. The 
authors demonstrated that in Caenorhabditis elegans let-7 targets let-60, encoding the 
Caenorhabditis elegans ortholog of human oncogene RAS. In addition, they showed 
that human RAS expression is regulated by let-7 in cell culture. Accordingly, let-7 
expression is decreased in lung cancer compared with normal tissue, and it correlates 
with the increased RAS protein levels detected in lung tumor samples [64]. Cimmino et 
al. reported that miR-15 and miR-16, the first two miRNAs associated with cancer, play 
a role in apoptosis regulation by targeting the anti-apoptotic BCL2 mRNA [65]. Also in 
2005, He et al. studied for the first time the contribution of miRNAs to tumor 
development in vivo. By overexpressing the miR-17-22 cluster, which is upregulated in 
human lymphoma, they were able to accelerate lymphomagenesis in a mouse B-cell 
lymphoma model carrying c-myc oncogene [66]. Furthermore, O’Donnell et al. 
reported for the first time that a transcription factor, specifically MYC, modulated the 
expression of the same cluster of miRNAs and consequently the E2F1 expression [67]. 
From 2005 until the present, thousands of scientific communications have reported on 
the role of miRNAs in tumors, as well as the regulation of miRNAs by other 
transcription factors such as TP53 (for a detailed review see [68]). In 2010, Medina et 
al. reported results in mice that conditionally overexpressed miR-21 (without other 
predisposing genetic backgrounds), clearly demonstrating that overexpression of a 
single miRNA, specifically miR-21, was sufficient to cause tumor development. In 
addition, these authors proved that tumor volume and survival were dependent on 
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miR-21 overexpression and that the tumors regressed when miR-21 was inactivated, 
proving for the first time an oncogenic miRNA addiction for tumor cells [69].  
miRNAs deregulation can be caused by several mechanisms including deletion, 
amplification, mutation, or dysregulation of transcription factors that target specific 
miRNAs. In addition, miRNAs can be controlled by epigenetic mechanisms. In 2006, 
Saito et al. were the first to demonstrate that miRNAs expression could be controlled 
by the two major epigenetic mechanisms: DNA methylation and histone modifications 
[70, 71]. When Saito et al. simultaneously treated a human bladder carcinoma cell line 
with 5-aza-2- deoxycytidine (a DNA methylation inhibitor) and 4-phenylbutyric acid (a 
histone deacetylase inhibitor), 17 of 313 human miRNAs were found to be 
upregulated. In particular, miR-127 was upregulated after treatment with these drugs 
and expression of one of its targets, BCL6, was suppressed [70]. Accordingly, miR-127 
expression was downregulated in primary human bladder and prostate tumors 
compared with normal tissue [70]. Therefore, these authors concluded that in cancer 
tissue miR-127 is subject to epigenetic silencing [70]. This finding opened the field of 
epigenetics to miRNAs regulation [71]. Interestingly, a bidirectional connection 
between epigenetics and miRNAs has been established. On the one hand, epigenetic 
mechanisms control miRNAs; on the other hand, miRNAs can target essential 
epigenetic key players. One of the first reports suggesting methylation could be 
controlled by miRNAs was published in 2004; Bao et al. suggested that miR-165/166 
are important for methylation of PHB gene in Arabidopsis [71, 72].  
In cancer patients, metastasis is the principal cause of death. The metastatic 
process involves multiple steps: cell motility, invasion of adjacent stroma, 
intravasation, systemic dissemination (though either the blood or lymph), 
extravasation into the parenchyma of distant tissues, and finally proliferation at a new 
site, giving rise to a secondary tumor. In this process, miRNAs have a dual role as they 
can promote or inhibit metastasis [73]. The first finding about miRNAs functioning as 
metastasis activators was reported by Ma et al. [74]. MiR-10b positively regulates cell 
migration and invasion in vitro and is capable of initiating tumor invasion and 
metastasis in vivo. MiR-10b acts by directly targeting HOXD10, which is a 
transcriptional repressor of RHOC, a key player in metastasis. Concordantly, miR-10b 
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expression is elevated in about 50% of metastatic breast tumors compared with 
metastasis-free tumors or normal breast tissues [74]. Three years later, the same 
group found that miR-9 directly targeted E-cadherin (encoded by CDH1), a 
transmembrane protein whose primary function is to mediate cell adhesion [75]. Loss 
of E-cadherin expression is one of the hallmarks of epithelial-mesenchymal transition 
(EMT) process [76]. miR-9 upregulation in breast cancer cells suppresses E-cadherin 
that consequently loses its capacity to sequester β-catenin and potentiates the Wnt 
signaling [75]. Study by Ma et al. is exciting because the authors demonstrate the 
contribution of miR-9 not only for EMT but also for induction of angiogenesis that is 
essential for metastasis to develop [75]. VEGFA is a key pro-angiogenic protein and a 
target of β-catenin [77]. Ma et al. show that miR-9 overexpression upregulates VEGFA 
and that it correlates with E-cadherin expression (for a complete description, refer to 
Appendix section) [75]. Along the same line, Huang et al. found that human miR-373 
and miR-520c stimulated cancer cell migration and invasion in vitro and in vivo [78]. In 
contrast, miRNAs can prevent tumor metastasis. Tavazoie et al. published the initial 
study of miRNAs as metastasis suppressors [79]. In breast cancer, patients with low 
expression levels of miR-335, miR-126, and miR-206 had a shorter median time to 
metastatic relapse. Restoration of their expression in breast cancer cell lines decreased 
the number of metastases in inoculated mice. These miRNAs have distinct mechanisms 
for metastasis suppression: restoration of miR-126 expression significantly suppressed 
overall tumor growth, whereas restoration of miR-335 or miR-206 levels altered cell 
morphology, possibly causing a decrease in cell motility [79]. It was therefore not 
surprising that Lujambio et al. reported in 2008 that DNA methylation-associated 
silencing of tumor suppressor miRNAs contributed to the development of human 
cancer metastasis and that the reintroduction of miR-148a and miR-34b/c in cancer 
cells with epigenetic inactivation inhibited their motility, reduced tumor growth, and 
inhibited metastasis formation in xenograft models, with an associated 
downregulation of the miRNA oncogenic target genes, such as C-MYC, E2F3, CDK6, and 
TGIF2 [80]. 
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1.1.5 microRNAs as Molecular Biomarkers 
In a clinical context, miRNAs can be extremely useful in disease diagnosis and 
prognosis and in prediction of therapeutic response. In 2004, Takamizawa and 
coworkers were the first to pinpoint the prognostic value of miRNAs by showing that 
let-7 expression was reduced in lung cancers and that lung cancer patients with low 
let-7 expression levels have a significantly shorter survival after potentially curative 
resection [81]. In 2005, Calin et al. reported the first study showing the 
diagnostic/prognostic importance of miRNAs at the genome-wide level [82]. These 
authors found that miRNA expression profiles could be used to distinguish normal B 
cells from malignant B cells in patients with CLL. In fact, a unique miRNA expression 
signature is associated with prognostic factors such as ZAP-70 expression (predictor of 
early disease progression) and mutational status of IgVh. In addition, these authors 
found nine miRNAs that were differently expressed between patients with a short 
interval from diagnosis to initial therapy and patients with a significantly longer 
interval. Furthermore, this study also highlighted the fact that one mechanism of 
miRNA deregulation is mutation: a germline mutation in the precursor of miR-16-1-
miR15a caused low levels of miRNA expression both in vitro and in vivo [82]. Currently, 
the clinical utility of miRNAs as diagnostic/prognostic biomarkers has been 
demonstrated in several types of cancer by numerous studies using tumor samples 
removed during surgery or biopsies [63]. For non-malignant diseases, however, larger 
and more studies should be conducted. 
 
1.1.5.1 microRNAs as Biomarkers in Plasma or Serum 
Current techniques for cancer diagnosis commonly involve a biopsy of the 
cancer tissue. Because this technique is invasive and unpleasant for patients, some 
studies have been focused on the search for biomarkers in human fluids such as 
plasma/serum, urine, or saliva. Blood samples from patients are usually readily 
available and many biological molecules, as circulating nucleic acids, can be found in 
blood serum/plasma, including miRNAs [83, 84]. These small non-coding RNAs in the 
blood are incorporated into microparticles and exosomes (50- to 90-nm membrane 
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vesicles) that prevent their degradation, conferring an advantage to the use of miRNAs 
as markers in serum [83]. In addition, detection of miRNAs in serum is easy owing to 
highly sensitive PCR detection methods, the lack of post-processing modifications of 
miRNAs, and simple methods of miRNAs extraction from serum [83]. The first report 
addressing the utility of miRNAs as diagnostic tools in biological fluids was published in 
2008 by Chim et al. in a study that detected placental miRNAs in the maternal plasma 
[85]. In the same year, Lawrie et al. [86], by comparing serum from patients with 
diffuse large B-cell lymphoma and healthy controls, found that miR-155, miR-210, and 
miR-21 levels were significantly upregulated in patients. Interestingly, these miRNAs 
have been shown to be deregulated in tumors. Moreover, high expression of miR-21 in 
patients serum was correlated with improved relapse-free survival times [86]. To date, 
miRNAs deregulation in serum of cancer patients have been described for several 
cancers, including leukemia, lymphoma, and gastric, colorectal, lung, oral and 
squamous cell, breast, ovarian, prostate, pancreatic, and hepatocellular cancers [84]. 
Furthermore, miRNAs plasma levels are also potential diagnostic markers for non-
oncologic diseases, eg. rheumatoid arthritis or osteoarthritis, as differences in miRNA 
plasma levels between patients with these disease and healthy control groups were 
reported [87, 88]. To translate the evaluation of miRNAs expression in serum into a 
clinical routine for diagnosis and prognosis, it is still necessary to standardize the 
methodologies used for these studies, i.e., serum/plasma extraction procedures and 
storage conditions, housekeeping miRNAs for normalization in serum samples, or the 
use of the same statistical methods for data analysis [83]. In addition, large studies 
reporting miRNA levels in plasma and serum with detailed clinical data information, 
together with normal controls from both sexes and different ages, are still needed 
[84]. Besides blood, miRNAs can also be found in other body fluids such as saliva and 
urine [89]. 
 
1.1.6 Therapeutic Implications 
miRNAs are aberrantly expressed in several diseases; therefore, it is not 
surprising that these small ncRNAs represent potential therapeutic targets for the 
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diseases they are functionally associated with. miRNAs that are upregulated in 
diseases should be targeted using anti-miRNAs, which are antisense oligonucleotides 
with specific modifications [90]. For instance, antagomirs, a class of anti-miRNAs that is 
cholesterol-conjugated to facilitate cellular intake and serum protein binding, could be 
used to block oncomirs in cancer [90, 91]. In 2004, Hutvágner et al. successfully copied 
the phenotype of let-7 loss-of-function mutation by injecting a 2´-O-methyl 
oligonucleotide complementary to let-7 miRNA into Caenorhabditis elegans larvae 
[92]. In 2005, Krützfeldt et al. reported for the first time the use of antagomirs in vivo 
in mammals [93]. Using a mouse model, Krützfeldt and colleagues systemically 
delivered via intravenous injection antagomirs against miR-16, miR-122, miR-192, and 
miR-194 that specifically downregulated the corresponding miRNAs. Silencing of 
miRNAs using antagomirs was long lasting, and miR-16-antagomir effects were 
detected in multiple tissues, except in the brain, possibly due to the blood-brain 
barrier [90, 91, 93, 94]. Other approaches to efficiently inhibiting miRNAs in vivo 
include the use of locked nucleic acid (LNA) oligonucleotides or 2´-O-methoxyethyl 
phosphorothioate modification [91]. Elmén et al. evaluated for the first time the effect 
of an LNA-anti-miRNA in non-human primates, with surprising results. These authors 
intravenously injected an LNA-anti-miRNA-122 into African green moneys and were 
able to efficiently silence the mature miR-122. The effect was long-lasting and safe, as 
neither toxicity associated with LNA nor histopathological changes were detected [95]. 
Two years later, Lanford et al. described the utility of anti-microRNAs for the clinical 
practice. miR-122 is a liver-expressed miRNA essential for hepatitis C virus (HCV) 
replication. Using an LNA-anti-miR-122, the authors were able to suppress HCV viremia 
in chronically HCV-infected chimpanzees. Moreover, this therapy generated a high 
barrier to resistance, and no side effects were detected [96]. In addition to these 
direct-inhibitory methodologies, an indirect technology can be used through 
downregulation of miRNA biogenesis pathway components. Tetracycline-inducible 
short hairpin RNAs (shRNAs) could be used to downregulate Dicer or Drosha, key 
components of the miRNA-biogenesis pathway; however, this mechanism should be 
tightly controlled, as downregulation of this pathway will have an effect on all miRNAs 
[90, 91]. On the other hand, when miRNAs downregulation promotes disease, as it is 
the case of some miRNAs downregulated in tumors and that function as tumor 
22 
 
suppressors, a therapeutic approach would be to restore the mature miRNA levels in 
the proper tissue/cells. In this situation, it should be used synthetic RNA duplexes, 
resembling siRNA molecules, that will mimics miRNAs duplex and will be recognized by 
RISC complex [91]. This complex will process it as the endogenous miRNA, by loading 
the stand with the sequence identical to the mature miRNA. This approach still needs 
to be evaluated in vivo because some challenges, such as stability and delivery 
strategies, need to be improved [90, 91, 97]. The use of short-hairpins driven by Pol III 
promoters could be a strategy for re-expression of miRNAs in the cells [97], although 
the dosage used in this mechanism has to be narrowly controlled, since sustained 
shRNA high-level expression in livers of adult mice has been shown to be fatal [98]. In 
2009, Kota et al. demonstrated how useful systemic administration of miRNAs can be 
for anti-cancer therapy. miR-26a is expressed at low levels in hepatocellular carcinoma 
but normally expressed in other tissues. These authors used an adeno-associated virus 
to mediate miR-26a delivery in a mouse model of liver cancer and were able to reduce 
cancer cell proliferation and induce tumor cell apoptosis, which consequently caused 
tumor regression. Since only cancer cells present miR-26a downregulation, the delivery 
was highly specific and did not affect normal tissue, which was tolerant to miR-26a 
restoration [99]. 
 
1.2 COLORECTAL CANCER 
1.2.1 Incidence 
Cancer is a worldwide leading cause of death, with 12,7 million new cancer 
cases and 7,6 million cancer deaths in 2008 [100, 101]. According to the last worldwide 
statistics for cancer occurrence and outcome performed by the International Agency 
for Research on Cancer (IARC) in 2008 collected data, colorectal cancer is the third 
most commonly diagnosed tumor type, after lung and breast cancer, accounting for 
1,23 million cases (9,7% of total number of cancers) [100, 102, 103]. It is the fourth 
most common cause of cancer-related death, account for approximately 698,000 
deaths. Generally, incidence is higher in men (663,000 cases) than in women (570,000 
cases) and the same tendency is observed when mortality is analyzed. Both colorectal 
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cancer new cases and mortality are higher in developed countries than in developing 
countries [101] (Figure 3). Developed regions including Australia/New Zealand, Europe 
and North America have a high number of cases and the highest mortality rates are 
observed in Central and Eastern Europe [100, 101] (Figure 3).  
Among all tumor types, 2008 statistics indicate that in Europe, colorectal cancer 
is the most common (436,000 cases, 13,6% of the total) and the second most common 
cause of death from cancer (212,000 deaths, 12,3%) [104]. If we consider the 
distribution by gender, it is the third and the second major cancer diagnosed in men 
and women, respectively; and the second leading cause of cancer related death for 
both men and women [104]. In the United States, data from the National Center for 
Health Statistics, projected 1,5 million new cases and 569,490 deaths from cancer in 
2010, from which 142,570 were estimated new cases of colorectal cancer (third most 
commonly diagnosed cancer type in both men and women), and 51,370 were 
estimated deaths from colorectal cancer (third most commonly cancer related death in 
both in men and women) [105].  
In Portugal, the Globocan project reported, for 2008, an incidence of colorectal 
cancer of 3951 and 3001 cases in men and women, respectively, and 2112 and 1579 
deaths in men and women, respectively [106]. The Report on the Implementation of 
the Council Recommendation on Cancer Screening by the European Commission and 
IARC, that analyzed the estimates for 2006 in the 27 Member States of the European 
Union, rank Portugal in the top 10 members with the highest age-standardized rates of 
mortality of colorectal cancer [107].  
Colorectal cancer mortality rates both in Europe and in the US have been 
declining since last years [104, 105], which reflects more effective screening and 
prevention by detecting precancerous polyps and tumor at  early stages, a reduction in 
the risk factors and an improvement in cancer treatment [108]. 
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Figure 3. Worldwide incidence and mortality rates by colorectal cancer in men 
and woman in 2008 (adapted from Globocan 2008 [102, 103]; Ferlay J [106]) 
 
1.2.3 Colorectal Cancer Classification and the Tumor-Node-Metastasis Staging 
System 
For over 50 years, the classification system “T (tumor) N (lymph Node) M 
(metastasis) created by the Union for International Cancer Control and the American 
Joint Committee on Cancer has been used to classify tumor stages [109, 110]. The 
system is used to guide treatment strategies, since it allows clinicians to stratify the 
patients according to primary tumor invasion (Figure 4), lymph nodes metastasis or 
distant metastasis. It is currently the main tool to provide prognostic information and 
to determine treatment protocols [111].  
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Other tumor classifications, based on clinical and pathological features that 
consider, for example, proximal versus distal, mucinous versus nonmucinous, well-
moderate versus poorly differentiated, among others, are extensively used [112]. 
According to the World Health Organization epithelial colorectal tumors can be 
classified as adenoma, intraepithelial neoplasia (dysplasia) associated with chronic 
inflammatory diseases, carcinoma, carcinoid (well differentiated endocrine neoplasm) 
and mixed carcinoid-adenocarcinoma [113]. The colorectal carcinomas can be 
subclassified as adenocarcinoma, mucinous carcinomas, signet-ring cell carcinoma, 
serrated adenocarcinoma, medullary carcinoma, cribriform comedo type 
adenocarcinoma, micropapillary carcinoma, adenosquamous carcinoma, squamous 
cell (epidermoid) carcinoma and undifferentiated carcinoma [114, 113]. Due to the 
tumors heterogeneity, besides clinical and histopathological examination, molecular 
features are currently used to classify the disease. It additionally allows a better 
understanding of the pathogenesis, increases knowledge about the therapeutic targets 
and leds to a personalized therapeutic approach.  
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Figure 4. Human colon and rectum. Structure, lymph nodes, and the tissue layers that 
constitute colorectal wall [Adapted from Cancer Staging Manual 7th edition – American 
Joint Committee on Cancer (http://www.cancerstaging.org/staging/index.html#)]. A 
histologic representation of colorectal cancer is shown. 
 
1.2.3 Risk Factors in Colorectal Cancer 
1.2.3.1 Lifestyle, Environmental and Dietary Colorectal Cancer Risk Factors 
Due to the high incidence of colorectal cancer worldwide and in order to be 
able to prevent and control this disease, epidemiologic studies are essential. Both 
lifestyle, environmental, dietary, and genetics factors are associated to an increased 
risk of colorectal cancer. A recent study grouped the carcinogenic agents according to 
the different tumor types. According to the authors, alcoholic beverages, tobacco 
smoking, X-radiation and gamma-radiation are carcinogenic agents with sufficient 
evidences to be associated with colorectal cancer. Limited evidences were found for 
the association of asbestos and Schistosoma japonicum with colorectal cancer [115].  
Regarding dietary and nutritional factors, the consumption of red meat has 
been associated with colorectal cancer by the majority of the studies [116]. The fact 
that rural Africans have a diet high in fiber and a low incidence of colorectal cancer led 
to the hypothesis raised in 1971 by Burkitt et al. suggesting that a diet rich in fiber 
could reduce colorectal cancer risk [117, 118]. However, studies are controversial. 
Aune et al. analysed 25 prospective studies and concluded that, although the majority 
of the studies did not provide enough details, including the subtypes of fiber analyzed 
and also lacked information about other dietary and lifestyle factors, there was an 
association between dietary fiber intake (cereal fiber and whole grains) and a linear 
reduction in the risk of colorectal cancer [117]. The same authors, in a meta-analysis of 
prospective studies, reported there was a weak inverse association between fruit and 
vegetable intake and colorectal cancer [119]. Also, an inverse association was observed 
in studies that assessed vitamin D intake and blood 25-hydroxyvitamin D levels 
(precursor of vitamin D active form) in relation to the risk of colorectal cancer [120]. In 
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an attempt to diminish cancer incidence, nutrition guidelines have been published, e.g. 
by the American Cancer Society and the American Institute for Cancer Research [121, 
122]. It is estimated that good allowance to dietary guidelines is associated to a 21% 
reduced risk of colorectal cancer [123]. 
 
1.2.3.2 Diseases and Syndromes Associated to Colorectal Cancer 
The inflammatory bowel disease presents in two major forms, Crohn’s disease 
and ulcerative colitis, and has been associated to colon cancer.  In fact, this connection 
is one of the paradigms that link inflammation to cancer. Although colorectal cancer 
does not always develop after a history of inflammatory bowel disease, the association 
between both dates far backs the late 40´s and early 50´s [124-126]. Due to biases and 
methodological errors, colorectal cancer risk is difficult to quantify. Depending on the 
studies, it is estimated that the probability of developing colorectal cancer in patients 
with ulcerative colitis is 0,4-2% after 10 years, 1,1-8% after 20 years and 3,1-18% after 
30 years  of the diagnosis. Similar probability of developing colon cancer is found when 
patients with longstanding Crohn’s colitis are considered [127-130]. Moreover, the risk 
of inflammatory bowel disease patients to develop colorectal cancer is higher in male 
than in female [131]. Several factors affect  colorectal cancer risk in inflammatory 
bowel disease and these include, the duration and extension of the colitis, family 
history of colorectal cancer, presence/absence of primary sclerosing cholangitis, 
severity of histologic cholangitis, age of the inflammatory bowel disease onset, history 
of dysplasia, surveillance colonoscopy or chemoprevention [132].  
Furthermore, there are major cancer susceptibility syndromes that confer an 
increased risk for colorectal cancer and/or colorectal polyposis, and among these are 
included, the Lynch syndrome (also known as hereditary nonpolyposis colorectal 
cancer syndrome - HNPCC), Muir–Torre syndrome, Turcot syndrome, familial 
adenomatous polyposis (FAP), attenuated familial adenomatous polyposis, MUTYH-
Associated Polyposis syndrome, hyperplastic polyposis syndrome, Peutz–Jeghers 
syndrome, juvenile polyposis, and the PTEN hamartoma tumor syndrome [133, 134].  
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Among the non-polyposis syndromes, Lynch syndrome is the most common, 
accounting for 1-6% of all colon cancers and approximately 10% of the cases before 
the age of 50 years [133, 134]. This syndrome can also predispose to other tumor 
types, like endometrium, stomach or ovary, and it is characterized by an autosomal 
dominant inheritance, an early age of onset and a proximal localization, comparing to 
sporadic tumors [133, 135].  
Among polyposis syndromes, FAP is the most common, accounting for <1% of 
all colon cancer cases [133]. It is characterized by hundreds of thousands of 
precancerous colonic polyps [134, 136] and it is transmitted by an autosomal dominant 
inheritance. It development generally begins, on average, by the age of 16 years, and 
by the age of 35, 95% of the individuals with this syndrome have polyps [136]. 
 
1.2.3.3 Polymorphisms and Colorectal Cancer Risk 
Genome-wide association studies of cancer susceptibility have revealed several 
polymorphisms that confer an increased risk of colorectal cancer [137]. From all known 
human genetic variants, single-nucleotide polymorphisms (SNPs) are the most 
frequent and have been extensively explored for disease susceptibility and clinical 
outcome studies [138]. As between distinct populations, SNP frequencies vary 
extensively, studies may not be in consensus.  Some of the SNPs that have been 
associated to colorectal cancer risk are rs961253 located in 20p12 (in Asian and 
European population) [139], rs603965 located in CCND1, G870A polymorphism 
(especially in Caucasians) [140], rs1800734 located in MLH1 promoter [141], 
rs12953717 located in SMAD7 gene (in a study where 91% of the population under 
study was non-Hispanic white and that considered colon cancer only) [142]. Strong 
candidates for low penetrance susceptibility alleles are HRAS1-variable number 
tandem repeat, and MTHFR variants [143]. Among all the colorectal cancer associated 
variations, it is important to highlight the I1307K mutation in the APC gene that is 
present in 6% of the Ashkenazi Jews [133]. Within this population, but not in 
Caucasians, this missense mutation causes a substitution of lysine for isoleucine and 
confers an absolute lifetime risk of around 20% [133, 144]. 
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Genetic variations in miRNAs or in miRNA targets might interfere with miRNA-
mRNA interaction by reinforcing, weakening or disrupting it, which consequently may 
affect expression levels of several proteins involved in cancer genesis and 
development, such as oncogenes and tumour suppressor genes [145, 137] [Figure 5). 
SNPs in miRNAs themselves or in miRNA-binding sites may affect individual's risk of 
cancer [146] (for an example, refer to Appendix section). Regarding SNPs in miRNAs, in 
the Korean population, Min et al. found a significantly increased colorectal cancer risk 
in individuals with the miR-196a-2-CC (rs11614913) genotype compared with the -
TT/CT genotype [147]. In the Chinese population, it was also found that miR-196a-2-CC 
genotype increased colorectal cancer risk [148, 149], but studies are not unanimous 
[150]. It is necessary to consider that SNPs´ frequencies may vary between 
populations. A meta-analysis concluded that miR-196a-2-CC genotype is only 
associated with Asian but not in Caucasian population [151]. In addition, larger studies 
are needed. Regarding miRNA-target SNPs in colorectal cancer, the first studies were 
reported by Landi et al. group.  The authors performed in silico predictions and case–
control association studies and determined that variants predicted to be within 
miRNA-binding sites in CD86 and INSR genes were associated with colorectal cancer 
risk [152]. Later, the same group reported association of colorectal cancer 
susceptibility also with alleles of rs709805-KIAA0182 and rs354476-NUP210 genes that 
are within miRNA target sites [153, 154]. Besides in silico predictions, same studies also 
explore the function significance of the miRNA-target variants. Nicoloso et al. clearly 
show through luciferase activity assays and measurement of target protein levels in 
miRNA post-transfected cells that alleles of the breast cancer associated SNPs 
rs1982073-TGFB1 and rs1799782-XRCC1 differently interact with miR-187 and miR-
138, respectively [155]. However, extensive functional studies are generally missing for 
colorectal cancer. 
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Figure 5. miRNAs and cancer predisposition (Appendix section, PAPER III, [137]). 
 
1.2.4 Screening Methods and Diagnostic Tools 
Individuals at risk should be subject to screening that might include 
colonoscopy, flexible sigmoidoscopy, computed tomography colonography and 
double-contrast barium enema for detection of polyps and cancer, and high-sensitive 
fecal occult blood test (FOBT), fecal DNA test and fecal immunochemical test for 
detection of cancer [156]. Colonoscopy is nowadays one of the gold standard methods 
for colorectal cancer screening [157]. However, it is an invasive technique which 
causes inconveniences for the patients and it is discouraged, under a public-health 
perspective, for the entire population [157]. Non-invasive methods are available and 
are commonly used, such as the FOBT, which is performed in patient stool.   
miRNAs are detected and are relatively stable in stool and therefore may serve 
as potential diagnostic tools for the future. In 2009, Ahmed et al. detected seven 
miRNAs upregulated (miR-21, miR-106a, miR-96, miR-203, miR-20a, miR-326, and miR-
92) and seven miRNAs downregulated (miR-320, miR-126, miR-484-5p, miR-143, miR-
145, miR-16 and miR-125b) in stool and tissue of colorectal cancer patients compared 
with controls [158]. miR-21 was validated in two other studies [159, 160]. Link et al. 
study showed that miR-21, as well as miR-106a, have a higher expression in stool 
specimens from colorectal cancer (or adenoma) than in control group [159]. Wu et al. 
found that miR-21 and miR-92a were significantly increased in feces of colorectal 
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cancer patients, although only miR-92a, but not miR-21, was higher in stool from 
patients with polyps than controls [160]. Koga et al. isolated exfoliated colonocytes 
from feces and found increased expression of miR-17-92 cluster and miR-135 in 
colorectal cancer patient samples than in healthy controls [161]. In 2011, two 
interesting studies were published by Bernardini group [162, 163]. The first 
demonstrated that epigenetic silencing of miR-34b/c through hypermethylation was 
present in 97.5% of primary colorectal tumors [162]. Afterwards, the authors analyzed 
if this result could also be found in the stool of the patients and detected 
hypermethylation of miR-34b/c was found in 75% of fecal samples [162]. In the second 
study, the authors suggested miR-144* as a potential colorectal cancer marker based 
on investigations in stool from patients [163]. 
Besides fecal samples, and as previously stated, miRNAs can also be found in 
circulating plasma/serum and its screening can contribute to colorectal cancer 
diagnosis. Deregulated miRNA in plasma may indicate the presence of colorectal 
cancer. Chen et al. was the first to look into miRNAs in plasma from colorectal patients 
and found that 69 miRNAs were detected in colorectal cancer but not in the normal 
control group [164]. Ng et al. used Real-Time Polymerase Chain reaction (RT-PCR) to 
examine the expression levels of miRNAs in plasma samples collected from colorectal 
cancer patients and normal controls and found that miR-17-3p and miR-92 were 
elevated in the plasma of colorectal cancer patients [165]. Notably, plasma levels of 
these miRNAs were reduced 7 days after tumor surgical removal, when compared with 
the pre-operatory levels, proving circulating miR-17-3p and miR-92 are of tumor origin 
[165]. Using an independent set of samples, the authors further determined that 
plasma miR-92 expression levels in colorectal cancer patients were different from 
gastric cancer and inflammatory bowel disease and from normal subjects [165]. The 
impact of miRNA expression levels in plasma as a diagnostic tool could be increased if 
differences were detected at early stages of the disease as these have a higher 
probability of survival than late disease stages [166]. In Ng et al. study, the authors 
detected as increased miR-92 expression level already in TNM stage I, compared with 
normal controls; however, the number of cases used in this study was low [165, 166]. 
Huang et al. focused his work on evaluating miRNAs in plasma that could serve as early 
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detection tools for colorectal cancer [167]. Firstly, the authors found miR-29a and miR-
92a significantly upregulated in plasma from colorectal patients comparing with 
controls [167]. The authors did not consider miR-17-3p, detected in Ng et al. study as a 
potential biomarkers, because it levels were very low to be detected by RT-PCR. 
Secondly, the same miRNAs were found to be upregulated in advanced adenomas 
compared with normal controls, proving the diagnostic value in early lesions of 
colorectal cancer development [167]. Pu et al. study focused solely on 3 miRNAs. The 
authors found miR-221 plasma levels to be upregulated in colorectal cancer patients 
(compared with normal controls). Noteworthy, miR-211 is not only a potential 
biomarker for colorectal cancer diagnosis but its´ plasma levels are also a predictor of 
the overall survival in colorectal cancer [168]. Furthermore, Chen et al. experiments 
demonstrated that high plasma levels of miR-141 are associated with stage IV colon 
cancer and that miR-141 plasma levels correlate with poor survival [169]. The authors 
suggested circulating miR-141 might be a potential novel biomarker for metastatic 
colon cancer [169]. Moreover, Wang et al. study aimed to find miRNA plasma markers 
for colorectal cancer metastasis. miR-29a levels in serum were significantly higher in 
liver metastases of colorectal cancer patients than in non-metastatic colorectal 
patients, providing evidences of a potential biomarker for early detection of colorectal 
liver metastasis [170].  In conclusion, analysis of expression levels of a panel of miRNAs 
present in colorectal cancer patients’ feces or bloodstream may be a tool for diagnosis 
and prognosis of this disease. 
 
1.2.5 Adenoma-Carcinoma Sequence and the Serrated Polyp Pathway 
Traditionally, colorectal cancers are believed to arise from epithelial polyps, 
named neoplastic polyps or adenomas, following an adenoma – carcinoma sequence 
[171, 172]. Adenomas have potential malignancy and are regarded as precursors of 
most colorectal cancers [171]. Classically, in a model proposed by Fearon et al. in 1990 
[173], evolution of colorectal cancer was understood as linear sequence of steps, with 
the earliest genetic alteration being APC inactivation [174]. APC is a tumor suppressor 
gene that, together with glycogen synthase kinase 3 β (GSK-3ß) and Axin proteins, 
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regulate free β-catenin [175]. Binding of β-catenin to this complex leads to β-catenin 
phosphorylation and consequently it is rapidly degraded [175].  Upon APC loss of 
function, unphosphorylated β-catenin accumulates in the cell and after translocation 
to the nucleus, it binds to transcription factors of the T-cell factor (TCF)/lymphoid-
enhancer factor (LEF) family leading to an increased expression of several specific 
target genes including c-Myc, cyclin D1, MMP-7, and ITF-2  (canonical Wnt pathway) 
[175]. Mutations in APC, Axin or β-catenin all lead to deregulation of Wnt signaling 
[175]. Wild-type APC is also able to downregulate non-phosphorylated oncogenic 
forms of β-catenin. However, in colorectal cancer, APC loss of function is much more 
common than β-catenin mutations [175]. About 60% to 80% of sporadic adenomas and 
adenocarcinomas harbor somatic APC mutations (the majority of which generates 
premature stop codons and consequently truncated proteins; though missense 
mutations can also been found in a very reduced percentage) [176]. Loss of 
heterozygosity (LOH) in chromosome 5q, where APC gene is located, have been found 
[173, 174]. Approximately 20% percent of colorectal adenocarcinoma lost one of the 
alleles in chromosome 5q that was present in normal tissue [174, 177]. Of note, the 
main hallmark of FAP is a germ-line mutation of APC gene. Moreover, miRNAs can 
regulate APC levels. miR-135a and miR-135b, which are highly expressed in colorectal 
adenomas and carcinomas,  regulate APC by binding to its 3´UTR and induce B-catenin 
signaling [178]. On the other hand, miRNAs can also be downstream targets of APC. 
Using a colon cell line and comparing miRNA levels before and after restoration of APC 
function, Wang et al. could find 6 upregulated miRNAs and 8 downregulated miRNAs, 
among which is miR-122a [179]. 
As previously stated, APC mutation is the earliest genetic alteration in the 
genesis of colorectal cancer being found in the earliest stages of the adenoma–
carcinoma sequence (in the aberrant crypt foci stage) [174]. Then, mutations in KRAS 
gene, possibly together with events affecting other genes, contribute to adenoma 
growth [173, 174]. KRAS mutations are found in approximately 50% of sporadic 
colorectal adenomas and carcinomas [174] and confer constitutive activation of the 
Ras/MAPK pathway [180]. KRAS can be targeted by several miRNAs. This is the case of 
miR-143 that, in colorectal cancer, was experimentally proven to directly target KRAS 
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[181]. miR-143 mimics inhibit KRAS expression and consequently inhibits constitutive 
phosphorylation of ERK1/2 [181]. In contrast, miRNAs expression profiles can be 
differentiated according to the KRAS status. Particularly, increased expression of miR-
127-3p and miR-92a is observed in KRAS mutant tumors compared with KRAS wild-
type tumors [182].  Later in the progression stages, LOH in chromosome 18q, where 
two members of TGF-β pathway, SMAD2 and SMAD4, are located, and in chromosome 
17p, where TP53 tumor suppressor gene located, and are found in late progression 
stages [174]. About 75% of 17q loss is found in carcinoma while less than 5% is found 
in early adenoma [173]. Interestingly, miR-34a, a miRNA downregulated in colon 
cancer, is regulated by P53; miR-34 in turn targets SIRT, which interacts with p53 and 
mediates deacethylation of its Lys382 residue, causing a decrease in p53-mediated 
transcriptional activation and reduced the downstream protein such as p21 and PUMA 
levels, generating therefore a miR-34-SIRT-P53 feedback loop [183].  Importantly, miR-
34 links p53 to WNT pathway, since the p53-regulated miRNA-34 targets Wnt genes 
resulting in suppression of TCF/LEF transcriptional activity [184]. In conclusion, 
regarding colorectal carcinomas arising from conventional adenomas through the 
adenoma-carcinoma sequence, APC mutation is considered an early event and it is 
followed by several key players as KRAS mutation, or SMAD2/4 and P53 loss, among 
others. miRNAs are implicated as both regulators and downstream targets of these 
players [185]. Some of the miRNAs involved in colorectal cancer tumorigenesis and 
progression are represented in Figure 6. 
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Figure 6. Example of some miRNAs as regulators of major players in colorectal cancer 
progression (adapted from Fearon et al., [185]) 
 
Alternatively to the adenoma-carcinoma sequence, increasing evidences 
pinpoint cancers that arise via the serrated polyp pathway (approximately 15-20% of 
all colorectal tumors) that implicate the previously thought non-premalignant 
hyperplastic polyps as potential precursors of colorectal cancer [171, 172]. In fact, 
colorectal tumors are heterogeneous and serrated carcinomas are clinically, 
morphologically, and molecularly distinct from colorectal cancers originating via 
adenoma-carcinoma. Serrated polyps comprise typical hyperplastic polyps (most 
common serrated polyps, comprising 80–90%), sessile serrated adenomas (atypical 
hyperplastic polyps variants), and dysplastic serrated polyps [171, 186]. Adenoma, are 
distinguishable at the microscopic level from hyperplastic polyps and the cancers 
caused by the latest are more likely to be found in females, located in the proximal 
colon and occur later than the cancers of adenoma origin  [171, 187]. Some of the 
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carcinomas arising via the serrated pathway have mutations in BRAF, a gene that plays 
a role in regulating the MAP kinase/ERKs signaling pathway [188]. KRAS works in the 
same pathway and BRAF and KRAS mutations are usually mutually exclusive [188]. 
While BRAF mutations were found to be much more frequent in sessile serrated 
adenomas and mixed polyps when compared with traditional hyperplastic polyps, and 
are rarely found in conventional adenomas, KRAS mutations are more commonly 
associated with the adenoma-carcinoma sequence [188]. Lesions bearing BRAF 
mutations are prone to methylation of the CpG island promoter regions resulting in 
the epigenetic silencing of a number of genes [188, 189]. 
 
1.2.6 Molecular Classification and Genetic Pathways 
The pathogenesis of colorectal cancer involves distinct genetic pathways: the 
microsatellite instability (MSI) and the chromosome instability (CIN) pathways, which 
are described in sub-chapter 1.2.6.1 and 1.2.6.2, respectively [190]. Additionally, a 
more recent unique subset of colorectal cancer was established according to the 
tumors´ degree of methylation, named CpG island methylator phenotype (CIMP), 
described in sub-chapter 1.2.6.3 [191]. All these pathways contribute to the acquisition 
of genomic instability. 
 
1.2.6.1 Microsatellite Stable and Microsatellite Unstable Tumors and DNA Mismatch 
Repair System 
DNA mismatch repair (MMR) system is responsible for correction of errors that 
occur during DNA cell replication [192]. This system involves mainly 4 processes 
including, surveillance of base-base mismatches or insertion-deletion loops, removal of 
these lesions, correction of the sequence, and religation to DNA [193]. Components of 
the MMR system are conserved from prokaryotic or single-cell eukaryotic organisms to 
humans. MMR system functions as hetereodimer complexes. The complex hMutS 
recognizes mismatches and is characterized by 2 major forms: hMutSα, constituted by 
the dimer MSH2-MSH6 that has a higher affinity to recognize base-base mismatches 
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and short insertion-deletion loops; and hMutSβ, constituted by MSH2-MSH3 that 
mainly detects large mismatches. When hMutS binds DNA lesions, it recruits the 
complex hMutL. This last complex may be presented in 3 different forms according to 
the protein that dimerizes with MLH1: hMutLα (heterodimer MLH1-PMS2), hMutLβ 
(heterodimer MHL1-PMS1), hMutLγ (MLH1-MLH3) [193, 194, 195].   Failure of the 
MMR function can be caused by either mutations or deletions or epigenetic silencing 
[196]. As MSH2 and MLH1 are the common components of hMutS and hMutL, 
respectively, loss of either proteins abolishes MMR activity [196]. Mutation rates in 
cancer cells with a deficient MMR system are 100–1,000 fold greater than in normal 
cells [193].  
Microsatellites are tandem repeats of short DNA sequences (1-6 nt) distributed 
throughout the genome. Microsatellite instability (MSI) is caused by loss of DNA repair 
activity [194]. Therefore, when DNA MMR system is not properly functioning, 
insertions and deletions in the microsatellite regions (that are especially susceptible to 
accumulation of mutations since DNA polymerases cannot bind DNA efficiently) are 
not repair, causing an expansion or contraction of the microsatellites [192, 195]. This is 
known as MSI (or MIN) [195]. This phenomenon has been observed not only in 
colorectal tumors but also in other tumor types, including gastric, endometrial, 
ovarian, sebaceous carcinomas, glioblastoma, lypmphomas and medulloblastoma 
[192, 197]. As MSI is the indicator of defects in the DNA MMR system, a panel of 
microsatellite markers is indicated for tumor MSI diagnosis, according to the Revised 
Bethesda Guidelines [198, 199]. According to this, tumors can be classified as MSI-high 
(MSI-H), MSI-low (MSI-L) and microsatellite stable (MSS) [200]. Tumors with MSI-H are 
distinctly characterized from MSI-L and MSS, in particular, MSI-H tumors tend to be 
poorly differentiated, mucinous, histologically heterogeneous formed in the proximal 
colon, have an expansile growth pattern, and an increase tumor infiltrating 
lymphocytes with a prominent inflammatory reaction [200]. Two algorithms based on 
clinical and histologic parameters have been developed to predict MSI-H colorectal 
cancer tumors, namely ‘‘MsPath’ and ‘‘MSI probability score” models [195, 201, 202]. 
Importantly, MSI tumors have a slightly better prognosis than other types of colorectal 
cancer and respond differently to chemotherapeutics [194, 200].  MSI-H frequency on 
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colorectal sporadic tumors is 10-15% [200]. In sporadic cases, instability is usually 
caused by hypermethylation of MLH1 promoter. The loss of MLH1 expression increases 
with age [194]. Moreover, 3% of all colorectal cancers are MSI tumors associated with 
Lynch syndrome [194]. This is caused by germline mutations in MLH1, MSH2, MSH6 
and PMS2 [192]. In addition, although it was thought to be exclusive from MSI-
sporadic tumors, a small subset of tumors derived from Lynch syndrome also have 
MLH1 epigenetic inactivation by hypermethylation of its promoter [196]. Considering 
the Knudson two-hit hypothesis of tumorigenesis, in Lynch syndrome the “first hit” is, 
as mentioned above, a germline mutation and the “second hit” may occur through 
deletion, gene conversion, methylation or point mutation [203]. It is also important to 
take into consideration that miRNAs can control mismatch repair levels. Valerie et al. 
suggested that this can be one of the mechanisms to explain the 5% MSI cases not 
justified by MMR mutations/epigenetic inactivation [204]. The authors showed that 
miR-155, which is overexpressed in colorectal cancer specimens compared with 
adjacent normal tissue, targets hMLH1, hMSH2, and hMSH6 and that it overexpression 
induces a mutator phenotype and MSI [204]. Further support of this hypothesis is the 
fact that miR-155 expression is inversely related to MLH1 and MSH2 proteins 
expression in human colorectal cancer tissues [204]. 
Nowadays, it is common to apply MSI tests and perform MMR protein 
evaluation by immunohistochemistry in order to screen for MSI-tumors and Lynch 
syndrome [195]. BRAF is an oncogene involved in the Ras/Raf/Map kinase pathway. A 
hotspot mutation in BRAF (V600E), which aminoacid change results in constitutive 
activation of the BRAF kinase and promotes cell transformation [174], is present in a 
portion of sporadic MSI-H colorectal tumors (40-50%) but it is extremely rare in 
colorectal cancer originated from Lynch syndrome [196]. Also, it is highly associated 
with MLH1 promoter methylation [203]. When MLH1 protein is lost, both BRAF 
(V600E) mutation test and MLH1 promoter methylation testing (though a small 
percentage of Lynch syndrome may present MLH1 methylation) are useful tools to 
discriminate between Lynch syndrome and MSI-H sporadic colorectal cancer cases 
[203]. Other features may help distinguishing Lynch syndrome from MSI-H sporadic 
colorectal cancer, as patients´ age - tumor diagnosis at less than 50 years is more 
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common in patients with Lynch syndrome and diagnosis at more than 70 years is more 
common in MSI-H sporadic colorectal cancer; patients´ gender – MSI-H sporadic 
colorectal cancer is more common in females than males; tumor budding – it is more 
frequent in Lynch syndrome tumors; serrated precursors – the frequent mucious 
histology and serration is probably due to their origin from serrated precursors and is 
an attribute of MSI-H sporadic CRC but not Lynch syndrome tumors [195].  
In MSI tumors, genes that contain repetitive elements can be mutated. As a 
consequence, in MSI-H sporadic tumors, several tumor suppressor genes that are 
implicated in tumor progression, including TGFβ-RII, BAX, IGF2R, CASP5, MSH3 and 
MSH6, can be mutated [195, 200, 205]. 
Due to the different molecular characteristics between MSI and MSS tumors, it 
is therefore not surprising that unique miRNA signatures exist between colorectal 
tumors based the microsatellite instability status. The first study that addressed this 
issue was reported in 2007 [206]. Using microarrays, Lanza et al. identified 14 miRNAs 
distinctly expressed between MSS and MSI tumor´ groups. To point out that among 
these are members of the miR-17-92 family, including miR-17-5p, miR-20, miR-25, miR-
92-1, miR-92-2, miR-93-1 and miR-106a, up-regulated in MSS versus MSI-H colon 
cancer [206]. Additionally, the study also found 451 differently expressed mRNAs and 
supports that expression profiles that combine miRNA/mRNA expression are a good 
approach to discrimination between MSI-H and MSS human colon cancer [206]. Earle 
et al. used a panel of selected miRNAs and performed RT-PCR to analyze the 
differences between MSI and MSS groups [207]. miR-155, -31, -223 and -26b  
increased relative expression was significantly associated to MSI-H (miR-31 and miR-
223 in patients with Lynch syndrome) and miR-92, let-7a and miR-145 increased 
relative expression was associated with MSI-L, while miR-196a increased relative 
expression was associated with MSS status [207]. Finally, in a genome-wide miRNA 
expression profile analysis, Balaguer et al. found a subset of miRNAs whose expression 
was discriminated between sporadic MSI and MSS tumors, including miR-938, miR-
615-5p, miR-1184, miR-551a, miR-622 (upregulated in MSI versus MSS) and miR-17-5p, 
miR-192*, and miR-337-3p (downregulated in MSI versus MSS) [208]. Most 
importantly, this study distinguished miRNA profiles in sporadic MSI and Lynch 
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syndrome, specifically miR-30a*, miR-16-2*, 362-5p and miR-1238 (upregulated in 
Lynch syndrome tumors vs sporadic MSI) and miR-622 (downregulated in Lynch 
syndrome tumors vs sporadic MSI) [208]. In conclusion, considering these studies, the 
discrepancies on the results are obvious. These inconsistences can be explained by 
biological differences other than MSI [208]. However, they can also originate from the 
different biological samples used (e.g., tumors collection time and sources, formalin-
fixed paraffin-embedded and frozen samples) or the different technical approached 
used in the different studies (e.g., types of arrays, analysis methods) [208]. Hence, if 
future studies are able to overcome these pitfalls, the MSI/MSS miRNA-associated 
expression patterns could be translated into a useful tool for the clinics and aid in 
patient´s personalized treatment based on their molecular classification.  
 
1.2.6.2 Chromosomal Instability 
Another genetic signature can be found in colorectal cancer that contributes to 
the activation of oncogenes and inactivation of tumor suppressor genes: CIN [190]. It is 
the most common form of genomic instability in colorectal cancer, accounting for 80%-
85% of all colorectal cancers. CIN and MSI mechanisms are generally mutually 
exclusive [209]. Thus, the CIN-positive tumors are MSS tumors [209]. FAP is associated 
to the CIN mechanism [209]. It is characterized by genetic deletions, duplications and 
chromosomal rearrangements and it is translated into aneuploidy. Therefore, CIN can 
be recognized by determining tumor DNA ploidy, through cytometry or cytogenetic 
techniques [190, 210]. Lee et al. showed that CIN-positive colorectal cell lines are more 
likely to exhibit multi-drug resistance than CIN-negative (diploid) colorectal cell lines 
[210]. The same authors showed that CIN-positive tumors confer a worse prognosis 
(lower overall survival and progression-free survival) than diploid tumors after 
patients´ treatment with cytotoxic therapy. Hence, CIN seems to confer survival and 
adaptation qualities to tumor cells [211]. CIN appears to arise due to defective 
surveillance of mitosis but the molecular basis of CIN remains largely unclear [210]. 
Particularly, Cahill et al. showed that the basis for CIN can be loss of function of mitotic 
checkpoints (eg, gene BUB1) [212]. Amplification of the cell cycle-regulated kinase 
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Aurora kinase A (29% in human colorectal tissues) may also cause CIN, by disruption of 
CDC4-cyclin E pathway [213]. Furthermore, APC gene mutations are likely to elicit CIN, 
through spindle stress [174, 211]. Other candidate for CIN origin includes APC and P53 
mutations [174]. 
 
1.2.6.3 CpG Island Methylator Phenotype 
Issa´s group introduced the term CIMP [214] to designate a genetic signature 
present in colorectal cancers, which is characterized by the exhibition of frequent and 
concurrent hypermethylation at specific promoter genes [215]. It is the most common 
source of epigenetic inactivation of the MMR gene MLH1, the main cause of the MSI-
sporadic tumors [190, 216]. However, CIMP was also associated with non-MSI/non-
LOH tumors, suggesting an independent pathway for tumor development [190]. 
Clinically, CIMP is associated with elderly female patients, proximal tumor localization, 
and frequent mucinous and poor differentiation [193, 216]. It is usually linked to 
serrated polyps rather than classical adenomas, being methylation, instead of 
mutation of tumor suppressor genes, the driving force [215]. Therefore, in CIMP-
positive/MSI-H tumors, mutations of APC, KRAS, P53 and CTNNB are infrequent [166]. 
Molecularly, a consensus on the methylation markers to define CIMP-positive has not 
been established [215]. CIMP-positive colorectal cancers have frequent MSI. CIMP is 
highly associated with activating mutations in BRAF gene (V600E) [190, 215].  Although 
BRAF and KRAS mutations are mutually exclusive, several reports found an association 
between CIMP phenotype and activating KRAS mutations [190, 215]. Boland et al. 
suggests that aberrant DNA methylation is a common event of sporadic and Lynch 
syndrome colorectal cancers [190]. Although at the moment there are no reported 
studies describing miRNA expression profiles between CIMP-positive and CIMP-
negative colorectal tumors, Slattery et al. analyzed miRNA profiles in CIMP-positive 
colorectal tumors and normal tissue, and found that 230 miRNA probes (comprising 
129 miRNAs) had greater than 50% differential expression in CIMP-positive colon 
cancer versus normal tissue, while 205 miRNA probes (comprising 129 miRNAs) had 
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greater than 50% differential expression in CIMP-positive rectal cancer versus normal 
tissue [217]. 
 
1.2.7 Therapeutic Strategies (5-fluorouracil, irinotecan, oxaliplatin, cetuximab, 
panitumumab) 
  5-fluorouracil (5-FU), irinotecan and oxaliplatin are commonly used drugs for 
colorectal cancer. 5-FU, one of the most extensively used, is almost always 
administrated with folinic acid (leukovorin) to be more effective [218].  It is common 
that 5-FU is combined with other chemotherapy drugs. Capecitabine is an oral 5-FU 
prodrug [219]. Irinotecan is a topoisomerase I inhibitor that interrupts DNA replication 
during transcription [219]. Oxaliplatin is a second-generation platin-based drug whose 
mechanism of action is diverse and includes induction of DNA lesions and arrest and 
inhibition of nucleic acid synthesis [220]. miRNAs are involved in resistance to 
therapies that use these clinical agents.  There are several reports showing miRNA 
expression differences between sensitive and resistant colorectal cancer cells to the 
therapeutics agents. For instances, Ross et al. described 5-FU drug upregulated 
expression levels of 19 miRNAs while downregulated the expression of 3 miRNAs 
[221]. Studying the effect of 5-FU and oxaliplatin on miRNA expression, there were 56 
up- and 50 downregulated miRNAs significantly associated to the treatment [222]. 
Zhao et al. suggested a pathway in which 5-FU induces a decrease in c-Myc expression, 
which regulates miR-17-92 cluster that, by its turn, targets thrombospondin mRNA that 
translates into an adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix 
interactions and plays a role in angiogenesis and tumorigenesis [223]. Core MMR 
components are critical players in therapy resistance. Consequently, miRNAs that 
regulate protein levels of these genes may contribute to resistance. This is the case of 
miR-21 that induces resistance to 5-FU by targeting hMSH2 [224]. Additionally, miRNAs 
involved in cell cycle may be implicated in drug resistance. In response to 5-FU, miR-
19b was overexpressed in 5-FU-resistant colorectal cells (DLD-1 derived cell line) and 
its targets are predicted to be involved in cell cycle [178]. Akao et al. used the same 
cell line to show downregulation of miR-34a in 5-FU-resistant DLD-1 cells versus the 
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parental cells [225]. miR-20a can modulate the resistance to 5-FU, oxaliplatin and 
teniposide by targeting BNIP2 [226], and miR-19b can be a potential indicator of 
chemosensitivity to the common 5-FU-based chemotherapy regimen by targeting BIM, 
a key mediator of chemotherapy-induced cell death [227].  miR-192/miR-215 targets 
cell cycle progression in colorectal cancer by decreasing S-phase cells  and these 
miRNAs are suggested to be  important in 5-FU resistance [228]. Experiments 
performed in HCT116 colorectal cell line revealed that miR-143, besides reducing cell 
viability and increasing apoptosis, also increases sensitivity of these cells to 5-FU, 
through the regulation of proteins involved in ERK5/NF-kB pathways [229]. The same 
cell line was used to prove that anti-miR-31 by itself has no effect on cell proliferation 
but when combined with 5-FU it is able to inhibit proliferation [230]. One source of 
treatment-resistant cells are cancer stem cells (CSC) and Bitarte et al. explored 
whether miRNAs´ modulation could influent CSC drug-resistance [231]. In fact, 
colonospheres with properties of CSCs derived from colon carcinoma cells had miR-451 
downregulated levels that, when restored, caused chemoresistance to irinotecan 
[231]. 
Epithelial growth factor receptor (EGFR) is a transmembrane glycoprotein 
receptor tyrosine kinase of about 170,000 kDa, also known as HER1 [2312 233]. Upon 
ligand binding, EGFR stimulates a downstream cell signaling cascade that regulates 
proliferation, apoptosis and metastasis [231]. Activation of EGFR triggers two main 
signaling pathways, RAS/RAF/MEK/ERK and PI3K/AKT, and also Src tyrosine kinases, 
PLCγ, PKC and STAT. EGFR is overexpressed in several epithelial tumors and is critical 
for tumor development [233]. Accordingly, expression levels of two miRNAs controlled 
by EGFR, namely miR-143 and miR-145, are downregulated in colorectal tumors [234]. 
Zho et al. showed that blockage of EGFR caused upregulation of miR-143 and miR-145 
in a colorectal cancer cell line [234]. Additionally, transfection of miR-143/miR-145 
inhibits epithelial growth factor (EGF, a EGFR ligand)-induced proliferation and DNA 
synthesis [234]. Cetuximab and panitumumab are two anti-EGFR monoclonal 
antibodies, which target the extracellular domain of the receptor and inhibit ligand-
dependent EGFR signal transduction [233, 235].  Both antibodies are approved by the 
US Food and Drug Administration (FDA) and are effective in metastatic colorectal 
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cancer, but response rates are limited [232, 236]. In addition, tyrosine kinases 
inhibitors, such as gefitinib (FDA approved only for a small cohort of non-small-cell 
lung carcinoma [NSCLC] patients) and erlotinib (FDA approved as monotherapy for the 
treatment of NSCLC patients who did not respond to at least one prior chemotherapy, 
or in combination with gemcitabine for advanced pancreatic cancer patients who have 
not received previous chemotherapy), are able to specifically inhibit EGFR, by blocking 
the ligand-induced receptor autophosphorylation, but are presently not FDA approved 
for colorectal cancer treatment [233]. As EGFR mutations are rare in colorectal cancer, 
the main mechanism of resistance to cetuximab and panitumumab is mutations in 
KRAS, an oncogene that plays a critical role as downstream effector of EGFR signaling. 
KRAS mutations occur in approximately 30% to 40% of colorectal cancer patients [236]. 
Currently, KRAS mutation status (most commonly in codon 12 and 13) defines which 
patients will benefit from the anti-EGFR antibodies therapy, since the treatment 
benefits those patients those tumors lack KRAS activating mutations [232, 236].  
Furthermore, the mutation V600E in the BRAF gene, which is one of the main 
effectors of KRAS, has been shown to impair responsiveness to cetuximab and 
panitumumab in patients with metastatic colorectal cancer [174, 237]. Nicolantonio et 
al. studied metastatic colorectal cancer patients treated with cetuximab or 
panitumumab and showed that none of the BRAF-mutated patients responded to 
treatment and had a significantly shorter progression-free survival than the other 
patients, while none of the responders carried BRAF mutations [238].  Additionally, in 
the PI3K pathway, mutations in PIK3CA (present in 20% of colorectal cancers) can 
constitutively activate its kinase activity and KRAS signaling pathways and 
consequently interfere with the response to cetuximab and panitumumab [174, 236]. 
In the same pathway, the main negative regulator, the tumor suppressor PTEN, is lost 
in 19% to 24% of colorectal cancers [236]. Loss of PTEN also correlates with patients´ 
reduced response to cetuximab-based therapy. In the largest cohort analyzed to date 
of patients with chemotherapy-refractory metastatic colorectal cancer treated with 
cetuximab plus chemotherapy, De Roock et al. found that together with KRAS, BRAF 
and PIK3CA mutations, also NRAS mutations were significantly associated with a low 
response rate to cetuximab [239]. Furthermore, an antibody can be used as a strategy 
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to oppose angiogenesis [240]. This antibody is named bevacizumab and is directed 
against VEGF [240]. Unlike cetuximab, in which the KRAS gene status can be used to 
determine who will benefit from the treatment, bevacizumab lacks a known predictive 
marker of efficacy [240]. 
Ragusa et al. tested whether miRNAs could be involved in resistance to 
cetuximab by analyzing miRNA differences in two colon cell lines, one sensitive and 
other resistant to the drug. Within the differently expressed miRNAs, the authors 
found 12 miRNAs predicted to target mRNAs reported to be involved in either the 
cetuximab pathway or the colorectal cancer [241]. Some of these miRNAs could be 
considered as candidate molecular markers for cetuximab resistance [241]. The 
authors also found miR-146b-3p and miR-486-5p to be more abundant in KRAS–
mutated samples with respect to wild-type ones [241].  
 It is well known that miRNAs are involved in drug resistance [242]. We can 
hypothesize that therapeutic modulation of miRNA levels could be a way to overcome 
drug resistance. For instance, if in cancer a miRNA that regulates a protein involved in 
blocking drug activity is suppressed, it is expectable that restoring miRNA levels would 
decrease the expression of that specific drug-resistance protein. Also, the opposite 
mechanism can be postulated – if in cancer a miRNA that target genes involved in the 
induction of cell death by the drug is upregulated, it is necessary to suppress it so that 
we can increase the malignant cell sensitivity to the drug and consequently decrease 
cell survival and resistance to a particular chemotherapeutic regimen. Importantly, not 
only the levels of miRNAs but also the levels of ceRNAs should be considered. In 
conclusion, the concept of miRNA pharmacogenomics is a novel and promising field of 
research that holds new possibilities for medical therapy, including for colorectal 
cancer [242]. 
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tBACKGROUND & AIMS: MicroRNAs (miRNAs) can
romote or inhibit tumor growth and are therefore being
eveloped as targets for cancer therapies. They are diverse
ot only in the messenger RNAs (mRNA) they target, but
n their production; the same hairpin RNA structure can
enerate mature products from each strand, termed 5p
and 3p, that can bind different mRNAs. We analyzed the
expression, functions, and mechanisms of miR-28-5p and
miR-28-3p in colorectal cancer (CRC) cells. METHODS:
We measured levels of miR-28-5p and miR-28-3p expres-
sion in 108 CRC and 49 normal colorectal samples (47
paired) by reverse transcription, quantitative real-time
polymerase chain reaction. The roles of miR-28 in CRC
development were studied using cultured HCT116, RKO,
and SW480 cells and tumor xenograft analyses in immu-
nodeficient mice; their mRNA targets were also investi-
gated. RESULTS: miR-28-5p and miR-28-3p were down-
regulated in CRC samples compared with normal colon
samples. Overexpression of miRNAs in CRC cells had
different effects and the miRNAs interacted with different
mRNAs: miR-28-5p altered expression of CCND1 and
HOXB3, whereas miR-28-3p bound NM23-H1. Overexpres-
sion of miR-28-5p reduced CRC cell proliferation, migra-
tion, and invasion in vitro, whereas miR-28-3p increased
CRC cell migration and invasion in vitro. CRC cells over-
expressing miR-28 developed tumors more slowly in mice
compared with control cells, but miR-28 promoted tumor
metastasis in mice. CONCLUSION: miR-28-5p and
miR-28-3p are transcribed from the same RNA hairpin
and are down-regulated in CRC cells. Overexpression
of each has different effects on CRC cell proliferation
and migration. Such information has a direct applica-
tion for the design of miRNA gene therapy trials.
Keywords: Transcript Regulation; Gene; RNA Processing.
Colorectal (CRC) cancer is the third most commonlydiagnosed cancer in men and the second in women.1
In the United States, it is the third leading cause of death
by cancer, with 51,371 estimated deaths and 142,570
estimated newly diagnosed cases in 2010.2 Therefore, newtherapeutic approaches and prognostic markers are
needed. In 2002, new players in cancer biology were iden-
tified: microRNAs (miRNAs).3 These are a large family of
mall noncoding RNAs with approximately 20-nt length
hat regulate gene expression post-transcriptionally by
nhibition of translation or messenger RNA (mRNA) deg-
adation.4 miRNA targeting occurs by binding to 3=-un-
ranslated regions, coding sequences, or 5=-untranslated re-
ions of target mRNA that can be involved in diverse
iological processes, such as proliferation, apoptosis, inflam-
ation, differentiation, and metastasis.4 miRNAs can func-
ion as either oncogenes or tumor suppressor genes, depend-
ng on the type of tumor or the cellular context.5 In CRC,
iRNAs have been involved in tumor susceptibility (as poly-
orphisms in miRNA-binding sites have been associated
ith CRC risk) and in diagnosis (as miRNAs can be detected
n feces or blood and used as biomarkers).6 In addition,
iRNA expression is dysregulated in CRC, as well as in other
ancer types, and miRNAs have emerged as potential new
herapeutic targets.6,7 Therefore, understanding the role of
miRNAs in CRC is crucial for the development of new
therapies.
In the miRNA biogenesis pathway, long primary tran-
scripts transcribed from the genome are processed by the
cellular RNase enzyme III Drosha into a structure of 60 to
110 nt called precursor miRNA (pre-miRNA), which is
then exported to the cytoplasm by an Exportin 5-depen-
dent mechanism.4 The pre-miRNA is cleaved by the RNase
III enzyme Dicer-1 producing a short, imperfect, double-
stranded miRNA duplex, which is unwound by a helicase,
creating a mature miRNA.4 In some cases, 2 mature miRNAs
can be excised from the same stem-loop pre-miRNA.8 These
5p and 3p miRNAs, although generated from a single pri-
mary transcript, have different sequences and therefore tar-
Abbreviations used in this paper: CRC, colorectal cancer; miRNA,
microRNA; MSS, microsatellite stable; mRNA, messenger RNA; MSI,
microsatellite unstable; PCR, polymerase chain reaction; SCR, scram-
bled negative control; PARP1, poly(adenosine diphosphate-ribose) poly-
merase 1; pre-miRNA, precursor miRNA.
© 2012 by the AGA Institute
0016-5085/$36.00doi:10.1053/j.gastro.2011.12.047
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April 2012 ROLE OF miR-28-5p AND miR-28-3p IN COLON CANCER 887get different mRNAs. In humans, 2 different mature miRNA
sequences are excised from opposite arms of the stem-loop
pre-miR-28 and generate 2 different miRNAs—hsa-miR-
28-5p and hsa-miR-28-3p. Despite nearly a decade of studies
on miRNA roles in cancer,3 the comparative roles of strand-
pecific mature miRNAs that originated from the same
tem-loop precursor (5p and 3p) have not yet been fully
tudied.
To our knowledge, the roles miR-28-5p and miR-28-3p
lay in CRC have never been described. Therefore, the
urpose of our study was to analyze miR-28-5p and miR-
8-3p expression and to use in vitro and in vivo ap-
roaches to understand, for the first time, the functions
nd mechanisms of these 2 miRNAs in CRC.
Materials and Methods
Colorectal Samples
Eighty-five CRC samples and 26 normal colorectal tissue
samples (of which 24 were paired) were collected between 2003
and 2008 at the University Hospital of Ferrara in Ferrara, Italy
(first sample set). Forty-two tumors were classified as microsat-
ellite stable (MSS), and 43 tumors were classified as microsatel-
lite unstable (MSI) (Supplementary Methods). For a confirma-
tion set of samples, we obtained 23 paired samples of tumor and
adjacent colorectal tissue that were collected between 2002 and
2005 at the Istituto per lo Studio e la Cura dei Tumori della
Romagna in Meldola, Italy (second sample set). Tumors were
classified according to the World Health Organization patho-
logic classification system. All patients provided informed con-
sent, and collection of the samples was approved by the institu-
tional review board at each institution. Patients did not receive
any therapy before surgery. Upon resection, fresh surgical spec-
imens were immediately snap-frozen in liquid nitrogen and
stored at 80°C. Total RNA from tissue samples was isolated
using Trizol reagent (Invitrogen, Carlsbad, CA), according to
manufacturer’s instructions (Supplementary Methods).
Reverse Transcription Quantitative Real-Time
Polymerase Chain Reaction
RNA purity was assessed by measuring absorbance at
260, 280, and 230 nm. Mean 260/280 ratio was 1.97 0.05, with
a range between 1.86 and 2.05, and mean 260/230 ratio was 2.17
0.11, with a range between 2.00 and 2.31. In addition, as recom-
mended by the Minimum Information for Publication of Quan-
titative Real-Time PCR Experiments guidelines,9,10 we analyzed
NA integrity by gel electrophoresis and clearly defined 28S and
8S ribosomal RNA bands were visualized. Samples with low
uality that did not meet these criteria were excluded. We quan-
ified miR-28-5p and miR-28-3p expression with real-time quan-
itative polymerase chain reaction TaqMan miRNA assays (Ap-
lied Biosystems, Foster City, CA), namely assay 000411 for
iR-28-5p, assay 002446 for miR-28-3p, and assay 001973 for
6 snRNA (Supplementary Methods). The efficiency of the Taq-
an assays used in this study was determined (Supplementary
igure 1 and Supplementary Table 1). Relative expression levels
ere calculated using the Ct11 and the Pfaffl method.12
In Vitro Cell Proliferation Assays
HCT116 and RKO cells transfected with scrambled neg-ative control (SCR), miR-28-5p, or miR-28-3p were seeded ontoa 12-well plate at 1  105 cells/well in triplicate. Cells were
harvested and counted at 0, 24, 48, 72, and 96 hours after
transfection using the Vi-CELL cell viability analyzer (Beckman
Coulter, Brea, CA). In order to further confirm our results, a
3-(4,5-dmethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide as-
say was performed (Supplementary Methods). The experiment
was repeated twice independently.
In Vitro Cell Migration and Invasion Assays
To determine the effect of miR-28-5p and miR-28-3p on
cell migration, we used 6.5-mm diameter Transwell chambers
with 8-m pore size polycarbonate membranes (Corning Incor-
orated, Lowell, MA). To determine the effect of these miRNAs
n cell invasion, we used BioCoat growth-factor reduced Matri-
el invasion chambers (BD Biosciences, Bedford, MA). Cells
ransfected with SCR, miR-28-5p, or miR-28-3p were resus-
ended in serum-free medium and plated on the top of the
ranswell chambers. Fetal bovine serum was used as a chemoat-
ractant on both assays. Each assay was performed in triplicate
nd in 2 independent experiments. Additional details are de-
cribed in Supplementary Methods.
In Vivo Studies of Tumorigenesis and
Metastatic Potential
For the in vivo tumorigenesis assay, 1.5  106 HCT116-
pBABE-miR-28 or HCT116-pBABE-empty cells were subcutane-
ously injected into the flanks of NOD-SCID-IL2Rdeficient
mice (n  9; stock #005557; The Jackson Laboratory, Bar Har-
bor, ME). Tumor size was measured every 2 days. Animals were
sacrificed 21 days after injection, and final tumor volume was
determined. Tumor size was determined by digital caliper mea-
surements (length and width in mm), and tumor volume (mm3)
as estimated using the following formula: tumor volume  ½
length  width2).
For the in vivo tumor-metastasis assay, 4  106 HCT116-
BABE-miR-28 and HCT116-pBABE-empty cells were injected
nto the tail vein of NOD-SCID-IL2R–deficient mice (n  11/
roup). Thirty-five days after injection the mice were sacrificed.
ll of the organs were examined at necropsy. Tumors were
ectioned, stained with H&E and antigreen fluorescent protein
ntibody (Ab13970; Abcam, Cambridge, MA), and examined
istologically.
All animal care and handling was approved by The University
f Texas MD Anderson Institutional Animal Care and Use Com-
ittee.
Statistical Analysis
Shapiro–Wilk test was used to verify the clinical samples’
distribution. Differences were analyzed using the nonparametric
test Mann–Whitney–Wilcoxon. To compare the paired groups,
paired t test was used. For in vitro and in vivo studies, the
differences between groups were analyzed using Student t test
(2-tailed), assuming unequal variance. Discrete variables were
compared with the Fisher exact test. Graphics represent the
mean  standard deviation, unless otherwise stated. Statistical
analysis was performed in R (version 2.11.0). Statistical signifi-
cance was considered if P  .05.
Additional methods, including cell culture, STR DNA finger-
printing, and miRNA mimics transfection, apoptosis quantifi-
cation, caspase activity, cell cycle analysis by flow cytometry,
establishment of miR-28–expressing cell line, miRNA target
prediction, Western blot, and luciferase reporter assays, are avail-
able in Supplementary Methods.
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miR-28-5p and miR-28-3p Are
Down-regulated in CRC
Expression levels of miR-28-5p and miR-28-3p
were analyzed by quantitative real-time polymerase chain
reaction (PCR) in 85 human CRC specimens and 26
normal human colorectal specimens. In order to ensure
that the reference gene snRNA U6 does not change be-
tween normal and tumor samples, we calculated the mean
Ct values as 2Ct. Levels of U6 did not differ between
ormal and tumor tissue, 2CtTumor/2CtNormal  0.94 (P 
41) (Supplementary Figure 2). Both miRNA-28-5p and
iR-28-3p were significantly down-regulated in CRC sam- dles (miR-28-5p, P  .005; miR-28-3p, P  .005) (Figure
1A). Both MSS (n 42) and MSI (n 43) tumors showed
own-regulation of miR-28 expression compared with the
ormal colon tissue (miR-28-5p normal vs MSS, P  .005
nd normal vs MSI, P  .005; miR-28-3p normal vs MSS,
 .005 and normal vs MSI, P  .005); however, no
ignificant differences between MSS and MSI tumors were
ound (miR-28-5p MSS vs MSI, P  .418; miR-28-3p MSS
s MSI, P  .996) (Figure 1B). We also analyzed the
xpression of these miRNAs in the subset of 24 pairs of
ormal and tumor tissue samples from the same patients,
nd in agreement with these data, we found significant
Figure 1. Expression of miR-
28-5p and miR-28-3p in colon tis-
sue samples. (A) Quantitative real-
time PCR analysis shows that
miR-28-5p and miR-28-3p are
down-regulated in colon cancer
samples compared with normal
colorectal tissue samples. (B)
Both MSS and MSI tumors ex-
press significantly less miR-28-5p
and miR-28-3p levels when com-
pared with normal colon tissue.
No differences were found when
comparing miR-28-5p and miR-
28-3p levels of MSS and MSI tu-
mors. (C) miRNAs down-regula-
tion in CRC tumors paired with
normal tissue from the second set
of patients. All values of miRNA
expression levels were normalized
to small nuclear RNA U6. Mean
standard error of the mean are
represented in the images (***P
.005, Mann–Whitney–Wilcoxon
test, and paired t test for paired
normal vs tumor groups).own-regulation of miR-28-5p and miR-28-3p in CRC
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April 2012 ROLE OF miR-28-5p AND miR-28-3p IN COLON CANCER 889samples (miR-28-5p, P  .005; miR-28-3p, P  .005)
Supplementary Figure 3). In order to confirm these re-
ults, we used a second independent set of CRC samples.
n 23 paired samples of tumors and adjacent normal
issue, we also found that both miRNAs were down-
egulated (miR-28-5p, P  .001; miR-28-3p, P  .001)
(Figure 1C). Values of expression are presented in Supple-
mentary Tables 2 and 3.
miR-28-5p, but Not miR-28-3p, Significantly
Suppresses Proliferation and Induces Apoptosis
and G1 Arrest in CRC Cells
To elucidate the roles of miR-28-5p and miR-28-3p
in CRC tumorigenesis, HCT116 and RKO CRC cell lines
(endogenous miR-28 expression levels of colon cell lines
are shown in Supplementary Figure 4) were transfected
Figure 2. Biological effects of
miR-28-5p in proliferation, apo-
ptosis, and cell cycle in vitro. (A, B)
epresentative experiment of the
roliferation effect of miR-28-5p
nd miR-28-3p in HCT116 and
KO colon cell lines. Cell numbers
ere counted every 24 hours for 4
ays post-transfection with SCR,
iR-28-5p, or miR-28-3p. miR-
8-5p, but not miR-28-3p, inhib-
ted growth in both HCT116 and
KO cell lines. Values represent
he mean of 3 replicates  stan-
ard deviation (***P  .005, Stu-
ent t test). Two independent ex-
eriments were performed. (C)
mmunoblotting with anti-PARP1
8 hours after transfection of
CT116 and RKO cell lines with
CR, miR-28-5p, or miR-28-3p.
raphic represents the ratio be-
ween cleavage and total PARP1
orm. miR-28-5p, but not miR-28-
p, increased PARP1 cleavage
orm. (D) Fluorescent-activated
ell sorting analysis 48 hours
ost-transfection with SCR, miR-
8-5p, or miR-28-3p. Represen-
ative experiment was performed
n duplicate; mean standard de-
iation (*P  .05, Student t test).
wo independent experiments
ere performed.with SCR, pre-miR-28-5p, or pre-miR-28-3p. Expressionof miRNAs was confirmed by quantitative real-time PCR
(Supplementary Figure 5). In both cell lines, we found
that cells overexpressing miR-28-5p grew significantly less
(P  .005) than did cells transfected with control or
iR-28-3p (Figure 2A and B). This result was also con-
rmed in the HCT116 and RKO cell lines using the
-(4,5-dmethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
ide assay (Supplementary Figure 6A and B). In contrast,
n both cell lines overexpressing miR-28-3p, there were no
tatistically significant differences at any time (HCT116,
 .25; RKO, P  .81) compared with cells transfected
with control (Figure 2A and B). Therefore, the in vitro
results suggest that miR-28-5p, but not miR-28-3p, has a
biological effect on proliferation.
We then explored the possibility that the effect ofmiR-28-5p on proliferation could be due to an increase in
w
c
d
R
t
w
r
r
w
i
I
t
m
a
t
p
p
c
c
R
2
m
m
f
g
H
(
v
i
.
4
t
.
b
i
g
i
2
w
n
s
a
c
p
s
a
T
C
t
m
B
A
SIC
A
N
D
TR
A
N
SLA
TIO
N
A
L
A
T
890 ALMEIDA ET AL GASTROENTEROLOGY Vol. 142, No. 4apoptosis or to defects in the cell cycle. To test whether
miR-28-5p had an effect on apoptosis, we measured poly-
(adenosine diphosphate-ribose) polymerase 1 (PARP1)
protein, which is specifically cleaved by caspases and pro-
motes apoptosis. PARP1 cleavage forms are one of the
most reliable apoptotic markers.13,14 Cells transfected
ith pre-miR-28-5p expressed 2.2 and 1.8 times more
leaved-PARP1 form (relative to total-PARP1 form) than
id cells transfected with control in the HCT116 and
KO cell lines, respectively (Figure 2C). In agreement with
he results of the proliferation assays, cells transfected
ith miR-28-3p presented a PARP1 cleaved to total form
atio similar to the control (Figure 2C). In addition, our
esults were confirmed by caspases 3/7, 8, and 9 activities,
hich were all higher in miR-28-5p–transfected cells than
n the SCR-transfected cells (Supplementary Figure 6C).
n order to analyze possible differences in the cell cycle,
he HCT116 cell line was transfected with either SCR,
iR-28-5p, or miR-28-3p and analyzed by fluorescent-
ctivated cell sorting. Compared with the control, cells
ransfected with miR-28-5p had a significantly higher
ercentage of cells in G1 phase and a significantly lower
ercentage of cells in S phase, suggesting that miR-28-5p
auses G1 arrest (P  .05) (Figure 2D). Despite being
oncomitantly transcribed and being part of the same
NA stem-loop hairpin, these data suggest that miR-
8-5p has a tumor-suppressive role in CRC and that
iR-28-3p does not have the same biologic role.
miR-28 Disrupts Tumor Growth In Vivo
Because our in vitro studies indicated that miR-
28-5p acts as a tumor suppressor in CRC, we analyzed the
overall effect of miR-28 in vivo. For that purpose, we
generated stable clones overexpressing miR-28, and ex-
pression of miR-28-5p and miR-28-3p was verified by
quantitative real-time PCR (Supplementary Figure 7).
HCT116 colon cancer cells stably transfected with
pBABE-empty or pBABE-miR-28 were subcutaneously in-
jected into the left and right flanks of each mouse, respec-
tively (n  9). Both cell lines were injected into the same
ice to decrease inter-mouse variability. Tumors derived
rom the HCT116 stably expressing pBABE-miR-28 cells
rew much slower than did tumors derived from the
CT116 stably expressing pBABE-empty cells (Figure 3A).
Accordingly, final tumor volume in pBABE-miR-28 tu-
mors was significantly reduced (P  .01) compared with
pBABE-empty tumors (Figure 3B and C). miR-28 expres-
sion levels were confirmed in these tumors. In pBABE-
miR-28 tumors, miR-28-5p and miR-28-3p were increased
(P  .01) when compared with pBABE-empty tumors
Figure 3D). In conclusion, this xenograft experiment re-
ealed that expression of miR-28 disrupts tumor growth
n vivo.
Opposite Effects of miR-28-5p and miR-28-3p
in Cell Migration and Invasion
To better understand the biological importance ofmiR-28-5p and miR-28-3p in CRC, we explored whether gthese miRNAs could be involved in colon cancer metas-
tasis. To evaluate the migratory capacity of HCT116 cells
expressing either miRNA, we used Transwell cell migra-
tion assays. Overexpression of miR-28-5p led to a signif-
icant reduction in cell migration (P  .01), whereas over-
expression of miR-28-3p led to a significant increase (P 
05) in cell migration compared with the control (Figure
). The same result was obtained when using SW480
ransfected cells (miR-28-5p, P  0.05; miR-28-3p; P 
01) (Supplementary Figure 8). To determine whether
oth miR-28-5p and miR-28-3p also played a role in
nvasion, we used Transwell chambers coated with Matri-
el. HCT116 cells expressing miR-28-5p had a reduction
n invasiveness (P  .05), whereas cells expressing miR-
8-3p had an increase in invasiveness (P  .01) compared
ith the control (Figure 4). Although no statistically sig-
ificant differences were obtained for SW480 cell line, the
ame trend was observed—miR-28-5p overexpressing cells
re less invasive and miR-28-3p are more invasive than
ontrol (miR-28-5p, P  .25; miR-28-3p, P  .12) (Sup-
lementary Figure 8). The effect of miR-28-3p, which
howed a growth rate similar to the control, on migration
nd invasion appears to be independent of cell growth.
herefore, although both miRNAs are down-regulated in
RC, they play different roles in the migration phenotype.
miR-28 Increases Metastasis In Vivo
As miR-28-5p and miR-28-3p exert opposite effects
on migration and invasion in vitro but are transcribed
concomitantly in cells, we investigated the effect of global
miR-28 expression on metastasis in vivo. For this purpose,
we intravenously injected mice with pBABE-empty or
pBABE-miR-28 cells. After 35 days, the mice were sacri-
ficed. At necropsy, tumors were found in the liver, kidney,
lung, and spinal cord. We found an increased number of
mice with metastases in all tumor sites in the pBABE-
miR-28 group compared with the pBABE-empty group
(Figure 5A). In particular, metastases in the liver and lung
were found at a statistically significant higher frequency
in the pBABE-miR-28 group than were in the pBABE-
empty group (P  .05). Examples of tumor metastases
from the 3 most frequent locations—liver, kidney, and
lung—are presented with H&E staining and anti–green
fluorescent protein labeling (Figure 5B). In addition, the
number of tumors in liver and kidney was higher in the
pBABE-miR-28 group than in pBABE-empty (Figure 5C).
In particular, in the pBABE-miR-28 group, 6 mice pre-
sented liver tumors with a mean of 1.5  0.8 tumors per
mice, and in the pBABE-empty group, there was only 1
mouse that developed only 1 liver tumor. Regarding the
kidney, in the pBABE-miR-28 group, 10 mice presented
kidney tumors, with a mean of 14.6  4.2 tumors per
mice (considering both kidneys), and in the pBABE-empty
group, 6 mice developed kidney tumors, with an average
of 6  4.2 tumors per mouse (P  .005). An example of
he tumors can be visualized in Figure 5D. Although
iR-28-5p and miR-28-3p had contrasting effects on mi-
ration and invasion in vitro, and although in vivo sub-
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April 2012 ROLE OF miR-28-5p AND miR-28-3p IN COLON CANCER 891cutaneous tumorigenesis appeared to correlate with the
growth-inhibiting effects of miR-28-5p, the overall in vivo
results of the metastasis experiments resembled the effects
caused by miR-28-3p, indicating that this miRNA may
have a predominant effect on metastasis.
miR-28-5p and miR-28-3p Targets
To identify miR-28-5p and miR-28-3p targets that
could be involved in the biological effects caused by these
miRNAs, we first used an in silico approach. By selecting
the targets predicted to be regulated by miR-28-5p or
miR-28-3p in PITA, TargetScan, and miRanda programs
simultaneously, we found 5784 mRNAs. Of these mRNAs,
2629 were predicted to be a target of miR-28-5p but not
Figure 3. miR-28 decreases tu-
mor volume in mice xenografts.
(A, B) HCT116-pBABE-empty
(control) and HCT116-pBABE-
miR-28 (stably expressing miR-
28) were subcutaneously injected
in the left and right flanks of 9
mice, and tumor volume was
measured during the (A) course of
he experiment and (B) at the end
f the experiment (21 days post
noculation). Tumor volumes in the
CT116-pBABE-miR-28 group
ere lower than those in the
CT116-pBABE-empty group
**P  .01, Student t test). (C)
hotographs show tumors ex-
ised from 5 mice in each group.
D) Quantitative real-time PCR
nalysis shows miR-28-5p and
iR-28-3p expression in the tu-
ors extracted from the mice
mean  standard deviation)
**P .01, Student t test).miR-28-3p; 1305 were predicted to be a target of miR-28-3p but not miR-28-5p; and 925 were predicted to be
targets of both miRNAs. To narrow the list of potential
targets, we focused on those that have been described as
up-regulated in colon cancer (given that miR-28 is down-
regulated) and have been reported to be involved in the
biological functions investigated here. Therefore, we
searched for miR-28-5p targets involved in proliferation
and miR-28-3p targets involved in metastasis, and we
considered targets that were predicted by at least 2 pro-
grams. In this way, we identified CCND1, HOXB3, and
NM23-H1.
We first used immunoblotting to detect changes at the
protein level for several predicted targets of interest in
cells transfected with SCR, miR-28-5p, or miR-28-3p. We
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892 ALMEIDA ET AL GASTROENTEROLOGY Vol. 142, No. 4found a 51% reduction in the level of cyclin D1 (encoded
by the CCND1 gene) in cells in which miR-28-5p was
restored. On the contrary, no differences in cyclin D1
levels were detected in miR-28-3p–expressing cells com-
pared with SCR-transfected cells (Figure 6A). We also
found that HOXB3 was a target of miR-28-5p because this
miRNA reduced HoxB3 protein expression by 35% (Figure
6B). Regarding miR-28-3p, we found that the protein
Nm23-H1 was down-regulated by 52% in cells expressing
Figure 4. Effect of mir-28-5p and miR-28-3p on migration and invasion
in vitro. Absorbance was measured for cells on the bottom of noncoated
and Matrigel-coated Transwell chambers at 24 hours (for migration) and
48 hours (for invasion) after HCT116 cells expressing miR-28-5p or
miR-28-3p were plated. Results are shown relative to SCR. A represen-
tative experiment is shown. Mean of triplicates  standard deviation is
shown (*P  .05; **P  .01, Student t test). Microscopy images (50)
how the migratory and invasive cells on Transwell assays.miR-28-3p (Figure 6C).To determine whether the effect on these targets was
caused by direct binding of the miRNAs or by an indirect
effect, we cloned the predicted mRNA binding sites (Fig-
ure 6D and E; Supplementary Figure 9) downstream of
the modified coding region of firefly luciferase in pGL3
reporter vector. We found that miR-28-5p significantly
reduced luciferase activity in the HOXB3 reporter con-
struct by 38% (P  .01) (Figure 6D). Also, miR-28-3p
reduced luciferase activity in the NM23-H1 reporter con-
struct by 34% (P  .01) (Figure 6E), and no significant
differences were found when cells were cotransfected with
miR-28-5p and the NM23-H1 construct (Supplementary
Figure 10). To confirm this specific interaction, we mu-
tated the miRNA-binding sites, and the luciferase activity
for the PGL3-HOXB3 and PGL3-NM23-H1 constructs was
restored to the same levels as the control. Regarding
CCND1, although we found a significant decrease in lu-
ciferase activity in miR-28-5p–transfected cells, the bind-
ing site mutation did not fully restore the luciferase ac-
tivity to the control level (Supplementary Figure 9). In
summary, we found that miR-28-5p targeted cyclin D1
and HoxB3 and that miR-28-3p targeted Nm23-H1; this
could explain, at least in part, the biological effects ob-
served.
Discussion
In the present study, we analyzed 2 independent sets
of human CRC samples, for a total of 108 (47 paired with
normal tissue), and found significant down-regulation of
both mature miR-28 forms. Our study is the first to show
down-regulation of miR-28 in cancer. In the literature, only
1 study extensively analyzed miR-28 function in cancer,
namely in myeloproliferative neoplasms. Girardot et al iden-
tified miR-28 overexpression in platelets of BCR-ABL–nega-
tive myeloproliferative neoplasm patients and found my-
eloproliferative leukemia virus oncogene to be the main
target, which is important for megakaryocyte differentia-
tion.15 In normal colon tissue, in situ hybridization shows
that miR-28-5p and miR-28-3p are predominantly expressed
in epithelial cells (Supplementary Figure 11). In addition, a
couple of profiling studies showed miR-28 up-regulation in
renal cell carcinoma16 and during glioma progression.17 It is
ell established that miRNAs can function as either tumor
uppressors or oncogenes, depending on the tumor tissue
nd the cell type.5 Therefore, when studying miRNAs, it is
essential to take into consideration the cellular context.5,18
One of the best examples is miR-125a/b, which has been
shown to be down-regulated in glioblastoma, breast, pros-
tate, ovarian, and nonsmall cell lung cancer, but up-regu-
lated in myelodysplastic syndrome and acute myeloid leuke-
mia patients with t(2;11)(p21;q23) and in urothelial
carcinoma.18,19 Noteworthy, miRNA variation levels between
normal tissue and tumors of 50% are reported frequently,
and the Volinia et al study, which represents the largest
miRNA profiling study reported so far, shows as highly
significant consistent variations of 20%.20
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April 2012 ROLE OF miR-28-5p AND miR-28-3p IN COLON CANCER 893As down-regulation of miR-28-5p and miR-28-3p had
never been described before, we analyzed their roles in
CRC in detail. This study provides evidence that strand-
specific 5p and 3p miRNAs have distinct functions (Fig-
ure 6F). Concordantly with the role of a tumor-suppressor
gene, miR-28-5p suppressed cell proliferation, causing ap-
optosis and G1 arrest in the cell cycle; however, miR-28-3p
had no effect on proliferation in vitro. Therefore, the
overall effect in vivo was, as expected, a significant de-
crease in tumor volume. In contrast, miR-28-5p and miR-
28-3p caused opposite effects in migration and invasion
in vitro. The miR-28–injected mice developed more me-
tastases than did the control mice, which is in agreement
with the in vitro effect observed for miR-28-3poverex-
pressing cells. To our knowledge, only 2 studies have
addressed the distinct roles of 5p and 3p strands, but
none of them have investigated the in vivo effect or the
Figure 5. miR-28 increases me-
tastasis in vivo. (A, B) HCT116-
pBABE-empty (control) and
HCT116-pBABE-miR-28 (stably
expressing miR-28) were injected
in the vein tail of mice. (A) Thirty-
ve days postinjection metasta-
es were detected in the liver, kid-
ey, lung, and spinal cord. The
ercentage of mice with metasta-
es in these organs was consis-
ently higher in miR-28–express-
ng tumors than in the control. (B)
icroscopy images (100)
how H&E (HE) and antigreen
uorescent protein (GFP) immu-
ohistochemical staining for
iver, kidney, and lung metastatic
umors. (C) Number of tumors
bserved within the liver and kid-
eys. ***P  .005. (D) Photo-
raphs of HCT116-pBABE-
mpty (left panel) and HCT116-
BABE-miR-28 (right panel)
ice show the sites with metas-
asis (white arrows) found in
30% of each group of mice.distinct targeting mechanisms in detail. These studiesshowed the different effects of miR-125a-3p and miR-
125a-5p in lung cancer cells19 and miR-34c-3p and miR-
34c-5p in the cervical tumor cell line SiHa.21
Recently, Yang et al identified the erythroid 2–related factor
2 as a target of miR-28 in breast cancer.22 To understand the
nderlying mechanisms of miR-28, we searched for miRNA
argets (Figure 6F). Cyclin D1, encoded by the CCND1 gene,
s a well-known oncogene that is overexpressed in several
ypes of tumors, including CRC.23 This protein is a key
layer in cell-cycle regulation, in particular in the G1S
hase transition,24,25 and its inhibition reduces growth and
tumorigenicity in human colon cancer cells.26 We found that
miR-28-5p, but not miR-28-3p, targets cyclin D1. This is in
agreement with the biological functions of miR-28-5p, as
only miR-28-5p and not miR-28-3p caused G1 arrest. Al-
though cyclin D1 protein levels were decreased in miR-28-
5ptransfected cells, it remains to be determined whether
this is a consequence of a direct miR::mRNA interaction or
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894 ALMEIDA ET AL GASTROENTEROLOGY Vol. 142, No. 4an indirect effect through miR-28-5p targeting of other
mRNAs in pathways where cyclin D1 is involved. The
miR-28-5p::CCND1 binding site predicted in silico showed a
slight luciferase reduction that was not abrogated by the
binding site mutation, showing that at least in this site there
is no direct interaction. However, and although not pre-
dicted by our program’s analysis, we do not exclude the
possibility that other miR-28-5p::CCND1 binding sites might
exist. In addition, we also found HOXB3 to be a target of
miR-28-5p. HOXB3 has been described as being significantly
overexpressed in colon cancer.27 Although the role ofHOXB3
in colon cancer has not been explored, Palakurthy et al
described a mechanism by which HOXB3 exerts it oncogenic
role, showing that it is essential for epigenetic silencing of
the tumor-suppressor RASSF1A,28 the promoter of which is shypermethylated in colon tumors.29 These authors also dem-
nstrate in a lung cancer cell line that HOXB3 increases
umor growth both in vitro and in vivo.29 In addition,
HOXB3 has been demonstrated to regulate cellular prolifer-
ation of hematopoietic stem cells30 and of Rat-1 cell line.31
The interaction between miR-28-5p and HOXB3 occurs
through a direct binding as demonstrated by the luciferase
assay results. Our data demonstrate that, in vivo, miR-28
promotes metastasis and that, in vitro, miR-28-3p induces
migration and invasion. As miR-28 was reduced in the tu-
mors, we looked for an antimetastatic mRNA as a target,
which would suppress metastasis without affecting tumor
growth.32 Interestingly, we found that miR-28-3p has the
apacity of regulatingNM23-H1, the first metastasis-suppres-
Figure 6. miR-28-5p targets cy-
clin D1 and HoxB3, and miR-
28-3p targets Nm23-H1. Western
blot analysis shows (A) cyclin D1,
(B) HoxB3, and (C) Nm23-H1 ex-
pression in scrambled, miR-28-
5p, and miR-28-3p transfected
HCT116 cells. Expression levels
were normalized for vinculin or
glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) protein
levels and were compared with
the SCR transfection (1). (D, E)
The predicted miRNA::mRNA in-
teraction sites are shown in the
top panels. The bottom panels
show luciferase activity for the
predicted interaction sites (D)
PGL3-HOXB3-WT constructs
cotransfected with SCR (n 1) or
miR-28-5p and (E) PGL3-NM23-
H1-WT construct cotransfected
with SCR (n  1) or miR-28-3p.
The same experiment was also
performed using constructs with a
mutated interaction site—PGL3-
HOXB3-Mut and PGL3-NM23-
H1-Mut. Values represent the
mean  standard deviation of 2
independent experiments per-
formed in 4 replicates (**P  .01,
Student t test). (F) The proposed
mechanism for miR-28-5p and
-3p function in CRC is shown.or gene identified.33–35 Remarkably, it has been previously
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April 2012 ROLE OF miR-28-5p AND miR-28-3p IN COLON CANCER 895reported that this gene is overexpressed in colon carcinoma
cells, especially in the early stages, and that it limits the
invasive potential of human cancer cells without having an
effect on proliferation.36 In addition, NM23-H1 inhibits liver
metastases of colon.37
In the future, prospective studies should be performed
to address clinical correlations and systematic experi-
ments should be conducted to identify all potential tar-
gets that can explain the distinct biological effects.
In conclusion, this is the first study to report down-
regulation of miR-28 in human tumorigenesis. In CRC,
miR-28 suppresses proliferation but activates metastasis;
this is a consequence of the distinct roles of the miR-28
hairpin RNA products, miR-28-5p and miR-28-3p. Such
information has direct consequences for the design of
miRNA gene therapy trials. The manipulation of the ex-
pression of specific miRNAs by using the precursor mol-
ecules can produce additional clinical effects due to the
transcription of 5p and 3p genes with distinct biological
effects.
Supplementary Material
Note: To access the supplementary material ac-
companying this article, visit the online version of Gastro-
enterology at www.gastrojournal.org, and at doi:10.1053/
j.gastro.2011.12.047.
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Microsatellite Analysis
Microsatellite analysis was performed on DNA
extracted from frozen tissue samples by a standard phe-
nol-chloroform procedure. MSI was evaluated with a flu-
orescence-based PCR method using the 5 markers of the
Bethesda panel (ie, D5S346, D17S250, D2S123, BAT25,
and BAT26) plus BAT40. Analysis of PCR products was
done with an automated DNA sequencer. Tumors were
classified as MSS, MSI-L, and MSI-H according to the
guidelines of the International Workshop of Bethesda.1
RNA and Protein Extraction
RNA was isolated using Trizol reagent (Invitro-
gen), according to manufacturer’s instructions. RNA
quantity and purity was assessed with NanoDrop ND-
1000 (Thermo Fisher Scientific, Wilmington, DE). RNA
integrity was analyzed by gel electrophoresis. RNA sam-
ples were denaturated at 70°C for 5 minutes, immedi-
ately placed on ice, and loaded on an agarose gel stained
with ethidium bromide. Intensity of the 18S and 28S
bands was examined.
Total protein extracts were prepared in ice-cold lysis
buffer (0.5% Nonidet P-40, 250 mM sodium chloride, 50
mM HEPES, 5 mM EDTA, and 0.5 mM ethylene glycol-
bis(-aminoethyl ether)-N,N,N=,N=-tetraacetic acid) con-
taining phosphatase inhibitor cocktail 2 (Sigma-Aldrich,
St Louis, MO), protease inhibitor (Clontech, Mountain
View, CA), and dithiothreitol (Invitrogen).
Reverse Transcription Quantitative Real-
Time PCR
miRNA expression was evaluated using TaqMan
miRNA assays (Applied Biosystems). Briefly, complemen-
tary DNA was synthesized using RNA as a template, gene-
specific stem-loop Reverse Transcription primer, and the
TaqMan microRNA reverse-transcription kit (Applied Bio-
systems). Quantitative real-time PCR was carried out in a
CFX384 real-time system (Bio-Rad, Hercules, CA) using
complementary DNA, TaqMan probe, and TaqMan univer-
sal PCRmaster mix (Applied Biosystems). Experiments were
performed in duplicate and normalized to small nuclear
RNA U6, which was used as an internal control. Relative
expression levels were calculated using the comparative cy-
cle threshold method. Stability of the reference gene be-
tween samples was analyzed. PCR efficiency was determined
using the formula: Efficiency  101/slope1.
Cell Culture, STR DNA Fingerprinting, and
miRNA Mimics Transfection
Human CRC HCT116, RKO, and SW480 cell lines
(purchased from American Type Culture Collection, Ma-
nassas, VA) were grown as suggested by the supplier. Cells
were cultured at 37°C in 5% CO2.All cell lines used in this study were validated by STR
DNA fingerprinting using the AmpFSTR Identifiler kit,
according to manufacturer instructions (Applied Biosys-
tems). The STR profiles were compared with known ATCC
fingerprints (ATCC.org), to the Cell Line Integrated Molec-
ular Authentication database version 0.1.200808 (http://
bioinformatics.istge.it/clima/),2 and to the MD Anderson
fingerprint database. STR profiles of HCT116, RKO, and
SW480 cell lines matched known DNA fingerprints and
were unique.
Pre-miRNA miRNA precursor molecules for hsa-miR-
28-5p and hsa-miR-28-3p and pre-miR miRNA precursor
SCR #2 were purchased from Ambion (Austin, TX).
Transfections were performed using 50 nM miRNA spe-
cific-strand precursor molecules or control and Lipo-
fectamine 2000 reagent (Invitrogen), according to man-
ufacturer’s instructions. RNA and proteins were collected
at 48 hours after transfection. miRNA transfection effi-
ciencies were evaluated by reverse transcription quantita-
tive real-time PCR.
3-(4,5-Dmethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) Assay
We seeded 5  103 HCT116 cells transfected with
ither SCR or miR-28-5p in a 96-well plate in 8 replicates
or each condition. At each time point (0, 24, 48, 72, and
6 hours post transfection), the colorimetric reagent was
dded to the cells. After 2-hour incubation at 37°C,
imethylsulfoxide was added. Proliferation was assessed
y measuring absorbance at 580 nm using the Spectra-
ax Plus384 microplate reader (Molecular Devices,
Sunnyvale, CA). Experiment was performed 2 times in-
dependently.
Apoptosis Quantification
Protein levels of the apoptotic molecular marker
PARP1, full-length, and cleavage PARP1 forms were as-
sessed by Western blot analysis using PARP antibody
(9542) from Cell Signaling Technology (Danvers, MA) in
the HCT116 and RKO cell lines transfected with SCR,
miR-28-5p, or miR-28-3p. Relative intensity of bands
observed by Western blotting was obtained using ImageJ
software (http://imagej.nih.gov/ij/). In addition, caspase
3/7, 8, and 9 activity was measured.
Caspase 3/7, 8, and 9 Activity
Caspase activity was measured using Caspase-Glo
3/7 Assay Systems, Caspase-Glo 8 Assay Systems, and
Caspase-Glo 9 Assay Systems (Promega Corporation, Mad-
ison, WI) in HCT116 cells transfected with SCR, miR-28-5p,
or miR-28-3p. The assay was performed 48 hours post
transfection according to manufacturer’s instructions, and
luminescence was measured in a POLARstar OPTIMA mi-
croplate reader (BMG Labtech, Ortenberg, Germany).
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For fluorescent-activated cell sorting analysis,
6  105 HCT116 cells transfected with either SCR,
iR-28-5p, or miR-28-3p were plated onto 6-well
lates. After 48 hours, cells were collected and fixed
ith 70% ice-cold ethanol. Cells were stained with a
olution containing 0.05 mg/mL propidium iodide
Sigma-Aldrich) and 0.1 mg/mL RNase A (Roche, In-
ianapolis, IN) in phosphate-buffered saline. Cell-cycle
nalysis was performed in a FACSCalibur flow cytom-
ter (Becton Dickinson, San Jose, CA). Results were
nalyzed using ModFit LT software.
In Vitro Cell Migration and Invasion Assays
After 24- or 48-hour incubation (for migration
and invasion assay, respectively) at 37°C with 5% CO2,
cells were fixed with paraformaldehyde (USB Corpora-
tion, Cleveland, OH). Cells on the upper surface of the
chamber (nonmigratory cells) were removed using cotton
swabs, and cells on the bottom surface (migratory cells)
were stained with crystal violet in 20% methanol for 20
minutes. Finally, 30% acetic acid was added to dissolve
the crystal violet and absorbance was measured in a
SpectraMax Plus384 spectrophotometer (Molecular De-
vices) at 590 nm.
Establishment of miR-28-Expressing Cell Line:
Cell Transduction With Retroviral Vector
A PCR fragment of 483 nt that included the
human miR-28 precursor and flanking sequences was
amplified using primers with BamHI and EcoRI endo-
nucleases restriction sites (Supplementary Table 4).
pBABE-puro retroviral plasmid and miR-28-containing
fragment were digested with BamHI and EcoRI en-
zymes and ligated using T4 DNA ligase (New England
Biolabs, Ipswich, MA). Constructs were checked by
direct sequencing. The retroviral plasmid pBABE-
miR-28 was transiently transfected together with
pVSV-G vector into GP2-293 cells using Lipofectamine
2000 reagent (Invitrogen). The retroviral plasmid
pBABE-empty was used as a control. Cells were fed
with fresh medium the day after transfection. Viral
supernatant was collected 3 days after transfection,
filtered through 0.45-m pore, and supplemented with
Sequa-brene (Sigma-Aldrich). HCT116 cells, which are
known to have metastatic potential,3 were infected and
elected using puromycin. Successful establishment of
CT116-pBABE-miR-28 cell line was verified by re-
erse transcription quantitative real-time PCR.
Cell Transduction With Lentiviral Vector
As pBABE-puro does not contain green fluores-
cent protein marker, and to facilitate the detection of the
human colon cancer cells in the in vivo studies, HCT116-
pBABE-empty and HCT116-pBABE-miR-28 cells were
transduced in parallel with empty pRRL-CMV-PGK-GFP- pWPRE (Tween) lentiviral vector. Briefly, pTween vector
was cotransfected with the packaging vector pCM-
VDR8.74 and the envelope vector pMD.G into 293FT
cells using Lipofectamine 2000 reagent. Forty-eight
hours after transfection, supernatant containing the vi-
rus was collected, filtered through 0.45-m pore, and
upplemented with Sequa-brene. HCT116-pBABE-empty
nd HCT116-pBABE-miR-28 were incubated with the
iral soup for 45 minutes and centrifuged at 32°C at
800 rpm, plus another 1 hour and 15 minutes in the
ncubator at 37°C. Infection efficiency was evaluated by
ow cytometry by detecting the percentage of green flu-
rescent protein–positive cells (85%).
miRNA Target Prediction
We performed in silico analysis to determine miR-
28-5p- and miR-28-3p-predicted targets using an in-house
Perl script that scans the databases for the algorithms PITA
(http://genie.weizmann.ac.il/pubs/mir07), TargetScan (http://
www.targetscan.org), miRanda (http://www.microrna.org),
and RNA22 (http://cbcsrv.watson.ibm.com/) for target
identification. miR-28 sequence annotation was obtained
from the miRBase database (http://www.mirbase.org/)
(Supplementary Table 4).
Western Blot Analysis for miRNA Targets
Proteins were collected 48 hours after cells were
transfected with SCR, miR-28-5p, or miR-28-3p. Brad-
ford assay was used to measure protein concentration.
Proteins were separated by polyacrylamide gel (Bio-Rad)
electrophoresis and were transferred to 0.2-m nitrocel-
lulose membranes (Bio-Rad). The following antibodies
were used: anti–cyclin D1 (sc-20044), anti-HoxB3 (sc-
28606), and anti-Nm23-H1 (sc-343) all from Santa Cruz
Biotechnology (Santa Cruz, CA). Proteins were detected by
chemiluminescence. Antiglyceraldehyde-3-phosphate de-
hydrogenase from Cell Signaling Technology or anti-vincu-
lin (sc-5573) from Santa Cruz Biotechnology were used as
normalizers.
Luciferase Reporter Assays
Fragments of about 200 nt that contained the
miR-28-5p and miR-28-3p putative binding sites were
amplified by PCR using primers containing the XbaI
restriction enzyme site (Supplementary Table 4). PCR
products were purified, digested, and directly cloned into
the Xbal site of the pGL3 control vector (Promega Cor-
poration, Madison, WI) located downstream of the firefly
luciferase reporter gene. The QuikChange II XL site-
directed mutagenesis kit (Agilent Technologies, Santa
Clara, CA) was used to generate mutations in the
miRNA-binding site (Supplementary Table 4).
HCT116 cells were seeded (1  105 cells/well) in 24-
well plates. After 24 hours, cells were cotransfected with
50 nM SCR, miR-28-5p, or miR-28-3p and 0.4 g pGL3-
utative binding site plasmids or pGL3-mutated putative
April 2012 ROLE OF miR-28-5p AND miR-28-3p IN COLON CANCER 896.e3binding site plasmids, together with Renilla luciferase
construct, which was used as a normalization reference.
Transfections were performed in OPTI-MEM I (Invitro-
gen) using Lipofectamine 2000 reagent. Cells were lysed
48 hours after transfection, and luciferase activity was
measured using a dual-luciferase reporter assay system
(Promega Corporation) in the veritas microplate lumi-
nometer (Turner Biosystems, Sunnyvale, CA). Two inde-
pendent experiments were performed with 4 replicates
each. Normalized relative luciferase activity was calcu-
lated by the formula: [firefly luciferase]/[Renilla lu-
ciferase] activity. All constructs were confirmed by direct
sequencing using an ABI 3730xl DNA analyzer sequencer
(Applied Biosystems).Supplementary References
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Institute Workshop on Microsatellite Instability for Cancer Detec-
tion and Familial Predisposition: development of international cri-
teria for the determination of microsatellite instability in colorectal
cancer. Cancer Res 1998;58:5248–5257.
2. Romano P, Manniello A, Aresu O, et al. Cell line data base:
structure and recent improvements towards molecular authen-
tication of human cell lines. Nucleic Acids Res 2009;37:D925–
D932.
3. Rajput A, Dominguez San Martin I, Rose R, et al. Characterization
of HCT116 human colon cancer cells in an orthotopic model.
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d e PCR. Equation and P values were determined using R software.
896.e4 ALMEIDA ET AL GASTROENTEROLOGY Vol. 142, No. 4Supplementary Figure 1. Calibration curve determination of Taqman
ilutions of complementary DNA were amplified by quantitative real-timassays for miR-28-5p, miR-28-3p, and small nuclear RNA U6. Serial 10-foldSupplementary Figure 2. Evaluation of the reference gene small
nuclear RNA U6 (snRNA U6) variations between samples from normal
colon and tumor tissue. There are no differences in small nuclear RNA
U6 expression between the 2 groups (P  .41, Mann–Whitney–Wilc-
oxon test).
AApril 2012 ROLE OF miR-28-5p AND miR-28-3p IN COLON CANCER 896.e5Supplementary Figure 3. Twenty-four normal specimens from the first set of patients were paired with colon cancer tissues from the same patient.
ll values of miRNA expression levels were normalized by small nuclear RNA U6. Significant differences were ***P  .005 using paired t test.Supplementary Figure 4. Endogenous levels of miR-28-5p and miR-28-3p in 10 colon cancer cell lines. Small nuclear RNA U6 was used as a
normalizer.
896.e6 ALMEIDA ET AL GASTROENTEROLOGY Vol. 142, No. 4Supplementary Figure 5. miR-28-5p and miR-28-3p levels were
measured by quantitative real-time PCR after transient transfection of
HCT116 cells with miR-28-5p and miR-28-3p precursors. Values were
normalized to small nuclear RNA U6 and are representative of 2 inde-
pendent experiments. Values shown are relative to negative control.
iments. Values shown are relative to the control pBABE-empty (n  1).Supplementary Figure 6. 3-(4,5-dmethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide proliferation assay in (A) HCT116 and (B) RKO cell lines.
miR-28-5p, but not miR-28-3p, inhibited cell growth compared with SCR. Values represent the mean  standard deviation of 8 replicates. (C)
Caspase activity was measured in the HCT116 cell line 48 hours after transfSupplementary Figure 7. miR-28-5p and miR-28-3p levels were
measured by quantitative real-time PCR after generating the stable
clone pBabe-miR-28 in the HCT116 cell line. Values were normalized to
small nuclear RNA U6 and are representative of 2 independent exper-ection with SCR (n  1), miR-28-5p, or miR-28-3p.
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binding site was mutated. NS, not statistically significant (Student t test).
April 2012 ROLE OF miR-28-5p AND miR-28-3p IN COLON CANCER 896.e7Supplementary Figure 8. Effect of mir-28-5p and miR-28-3p in mi-
ration and invasion in vitro in SW480 cell line. Absorbance was mea-
ured for cells on the bottom of noncoated and Matrigel-coated Trans-
ell chambers at 24 hours (for migration) and 48 hours (for invasion)
fter SW480 cells expressing miR-28-5p or miR-28-3p were plated.
esults are shown relative to SCR. A representative experiment is
hown. Mean of triplicates  standard deviation is shown (*P  .05;
*P  .01, Student t test).Supplementary Figure 9. Luciferase activity of HCT116 cells
otransfected with SCR (n  1) or miR-28-5p and PGL3-CCND1-WT.
Experiment was also performed with a construct in which the binding
site was mutated (***P  .005, Student t test).Supplementary Figure 10. Luciferase activity of HCT116 cells
cotransfected with SCR (n  1) or miR-28-5p and PGL3-NM23-H1-
WT. Experiment was also performed with a construct in which the
896.e8 ALMEIDA ET AL GASTROENTEROLOGY Vol. 142, No. 4Supplementary Figure 11. In situ hybridization analysis for miR-28-5p and miR-28-3p in normal colon tissue. Frozen tissue sections were
digested with proteinase K and loaded onto Ventan Discovery Ultra. The tissue slides were incubated with double-DIG labeled miRCURY LNA
Detection probe, and the digoxigenin was detected with a polyclonal anti-DIG antibody and UltraMap Blue anti-Ms Detection Kit. H&E staining was
performed. Microscopy images were obtained with a magnification of 100Supplementary Table 1. Efficiency of Taqman Assay for
miR-28-5p (Assay Number
000411), miR-28-3p (Assay
Number 002446), and snRNA U6
(Assay Number 001973) Using the
Ct Slope Method
Taqman assay R2 Slope Efficiencya
miR-28-5p 0.9979 3.5601 0.91
miR-28-3p 0.9997 3.2352 1.04
snRNA U6 0.9956 3.2498 1.03
aPCR efficiency was determined using the formula: Efficiency 
101/slope 1..
Supplementary Table 2. miRNA-28-5p and miR-25-3p
Expression (Using Ct Method) in
Normal Colon and Colorectal
Cancer Samples for 2 Independent
Sets
Mean SEM
miR-28-5p
First set of samples
Normal 0.058 0.003
Tumor 0.044 0.003
MSS 0.043 0.004
MSI 0.046 0.004
Second set of samples
Normal 0.238 0.025
Tumor 0.151 0.019
miR-28-3p
First set of samples
Normal 0.029 0.001
Tumor 0.022 0.002
MSS 0.022 0.002
MSI 0.022 0.002
Second set of samples
Normal 0.319 0.028
Tumor 0.161 0.017
NOTE. Values were normalized to small nuclear RNA U6.
SEM, standard error of mean.
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April 2012 ROLE OF miR-28-5p AND miR-28-3p IN COLON CANCER 896.e9Supplementary Table 3. miR-28-5p Expression in Colorectal Cancer Compared With Normal Colon in 2 Independent Sets of
Samplesa
Gene Type
Reaction
efficiency Samples Expression Standard error 95% CI P value Result
iR-28-5p Target 0.9094 First set (paired) 0.620 0.3890.971 0.2582.380 .000 Down
Second set
(paired)
0.641 0.3201.254 0.1732.544 .003 Down
First set (all) 0.711 0.4411.209 0.2112.282 .001 Down
8 Reference 1.0309 1
OTE. Small nuclear RNA U6 was used as a reference gene.
I, confidence interval.aUsing Pfaffl Method, REST 2009 Software (Qiagen, V2.0.13).Supplementary Table 4. Sequences of Mature Human miR-28-5p and miR-28-3p According to miRBase, Primers Used to
Amplify miR-28, and Primers Used to Generate PGL3 Constructs for Luciferase Assays and to
Generate Deletions in the miRNA-Binding Site
Sequences
ature miRNA
hsa-miR-28-5p AAGGAGCUCACAGUCUAUUGAG
hsa-miR-28-3p CACUAGAUUGUGAGCUCCUGGA
rimers
mir-28-Fw-BamHI CGGATCCAGGCCCTTCAAGGACTTTCT
miR-28-Rv-EcoRI CGAATTCACAGAGCTCCTGCTGTGTCA
Primer for PGL3 construct
CCND1_XbaI_Fw CGTCTAGAGTCCCACTCCTACGATACGC
CCND1_XbaI_Rv CGTCTAGACTTGCCTCAAAGTCCTGCTT
HOXB3_XbaI_Fw CGTCTAGAAAGGACATTGTGTTTCCTGTCA
HOXB3_XbaI_Rv CGTCTAGACAAAGAAAGTTCCAAGAGGGAAT
NM23_XbaI_Fw CGTCTAGAGCAGACCACATTGCTTTTCA
NM23_XbaI_Rv CGTCTAGAAACCAACTCAATGAATCCTATGC
Primers for mutagenesis
CCND1_Mutagenesis_Fw GGTTCAACCCACAGCTACTTGCATATTCTAAAACCATTCCAT
CCND1_Mutagenesis_Rv ATGGAATGGTTTTAGAATATGCAAGTAGCTGTGGGTTGAACC
HOXB3_Mutagenesis_Fw GTTCTAAAAGGCATGAACTCATCGTCACTGTATAGTCCTG
HOXB3_Mutagenesis_Rv CAGGACTATACAGTGACGATGAGTTCATGCCTTTTAGAAC
NM23_Mutagenesis_Fw AGAGGACCAGGCTGTAGGATATTTACAGGAACTTCATC
NM23_Mutagenesis_Rv GATGAAGTTCCTGTAAATATCCTACAGCCTGGTCCTCTNOTE. Restriction sites for endonucleases are underlined.
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3. General Discussion 
 
Due to the role of miRNAs in controlling expression of protein-coding mRNAs or 
non-protein-coding transcripts, any deregulation in miRNA levels affects a high number 
of targets, which might lead to consequences in an extensive number of cellular 
functions. Herein, I highlight the relevance of miRNAs in colorectal cancer 
pathogenesis. In addition, I discuss how the innovative data concerning the differential 
role of the strand-specific mature miRNAs originated from the same pre-miRNA 
(specifically, the pre-miR-28 that originates miR-28-5p and miR-28-3p) holds a 
tremendous impact on miRNA-based therapy design. 
 
     3.1 The Broad Relevance of Deregulated microRNAs in Colorectal Cancer 
In 2004, Lui and Calin et al. were the first to describe a microarray-based 
genome-wide miRNA profiling [1, 2]. The study analyzed RNA from 20 normal human 
tissues (colorectal tissue was not included) and revealed tissue-specific miRNA 
expression signatures [1, 2]. In 2005, Lu et al. performed the first bead-based genome-
wide miRNA profiling in a large panel of samples that included varied human tissues 
(including colorectal) [2, 3]. When analyzing the miRNA expression profiles, the 
authors were able to classify human tumors based on the developmental lineage and 
the differentiation state [2, 3]. This study also concluded that there was a general 
miRNA downregulation in tumors versus normal tissues [3]. Few months later, Volinia 
et al. performed a large-scale miRNA profiling analysis using samples from 6 different 
tumor types and established tumor-specific signatures, which further proved the 
involvement of miRNAs in cancer pathogenesis. However, the authors did not found 
the general miRNA downregulation described in Lu et al. study [4]. With the miRNA 
field getting more attention from the researchers, genome-wide miRNA profiles 
became common. Commercial miRNA arrays were generalized and nowadays include a 
larger number of miRNAs. Regarding colorectal cancer, miRNA wide-range profiling 
analysis are not only used to distinguish miRNA levels between normal and tumor 
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tissue but also to obtain profiles that are able to distinguish tumors according to the 
clinico-pathologic or  molecular features [5]. Importantly, different tumor types have 
different miRNA signatures. 
Some protein coding genes are known to display antagonistic functions in 
oncogenesis depending on the cellular context. This is the case of Maf b-Zip 
transcription factors [6], p21Cip1/Waf1 [7] and WT1 [8], among others. The same dual 
role can occur for miRNAs. Therefore, depending on the tissue and cellular type, a 
miRNA can function as an oncogene or as a tumor suppressor. Depending on the 
tumor type, miRNA targets might be different, which can partially explain this duality. 
Our work was the first to show that miR-28 (-5p and -3p) expression was 
downregulated in colorectal cancer compared with normal colon tissue. Our 
conclusion is supported by the results obtained in two independent sets of samples. 
Moreover, a recent profiling study in colorectal cancer using miRNA microarray data 
further strengthened our results by showing miR-28 (-5p and -3p) downregulation in 
colorectal cancer [9]. Before our study, the analysis of miR-28 expression had only 
been described for other tumor or cell types and found miR-28 to be upregulated in 
tumors compared with normal tissues/cells [10-12]. Additionally, these reports did not 
differentiate between the two miR-28 mature forms. In the literature, other miRNAs 
are described to have a dual oncogenic/tumor suppressor function, depending on the 
tissue or cellular type: the same miRNA can be upregulated in some tumor types but 
downregulated in others. This is the case of miR-15a/miR-16-1 cluster that is 
downregulated in CLL, diffuse large B-cell lymphoma, multiple myeloma, pituitary 
adenoma, prostate and pancreatic cancer while upregulated in nasopharyngeal 
carcinoma [13]. miR-15a/miR-16-1 cluster has distinct targets in the different tumor 
types [13] and it is particularly well know that this cluster is involved in apoptosis in 
leukemia by directly targeting the anti-apoptotic Bcl-2 mRNA (miR-15a/miR-16-1 
cluster as a tumor suppressor) [14]; whereas upregulated miR-15a/miR-16-1 cluster in 
nasopharyngeal carcinoma has the tumor suppressor BRCA1 as a target (miR-15a/miR-
16-1 cluster as an “oncomiR”). In the same line of evidence, miR-17-92 cluster is 
frequently overexpressed in lung, colon, small-cell lung cancer, lymphoma, multiple 
myeloma and medulloblastoma [13, 14], while LOH in miR-17-92 locus is present in 
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patients with melanoma, ovarian and breast cancer [13]. The same dualism occurs in 
different tumor types regarding two miRNA families: let-7 and miR-29 family [13]. Also, 
miR-125a/b is downregulated in glioblastoma, breast, prostate and ovarian cancer 
while upregulated in myelodysplastic syndrome, in acute myeloid leukemia with 
t(2;11)(p21;q23) and in urothelial carcinoma [13]. In conclusion, based on the 
literature it is not uncommon to identify miRNAs´ dual role as tumor suppressor or as 
oncogene, according to the cellular context. Consequently, the targets and functions 
that miRNAs play in cancer are always dependent on the tumor type we are analyzing. 
In our work, described in Chapter 2, we found that miR-28-overexpressing 
colorectal cancer cells decreased tumor growth in mice xenografts. Other miRNAs that 
suppress/decrease colorectal tumorigenicity in in vivo models include, miR-148b [16], 
let-7a [17], let-7c [18], miR-143 [19, 20], miR-145 [20], miR-26b [21], miR-133b [22], 
miR-491 [23], while miR-211 [24] and miR-95 [25] potentiates tumor growth in vivo. 
Presently, the in vivo effects that miR-28 causes in other tumor types are not yet 
described in the literature. The tumor suppressor behavior we found for miR-28 can be 
partially explained by the miR-28-5p effects on decreasing cell proliferation, induction 
of apoptosis and G1-arrest when colorectal cancer cells are transfected with miR-28-
5p. Furthermore, we found Cyclin D1 as a miR-28-5p target in HCT116 colorectal 
cancer cell line. The protein encoded by CCND1 (Cyclin D1) forms a complex with and 
functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell 
cycle G1/S transition. The study described in Chapter 2 was the first to report an 
inverse relation between miR-28-5p expression levels and Cyclin D1 protein levels in 
cancer cells. Regarding colorectal cancer solely, an analysis of the present literature 
can provide us a larger spectrum on how miRNAs regulate G1 cell cycle transition in 
colorectal cancer.  Nie et al. found Cyclin D1 was a target of miR-365, which is a miRNA 
downregulated in colorectal cancer that is able to inhibit cell cycle progression upon 
restoration of it expression [26]. miR-145 directly regulates CDK6, a major Cyclin D1-
dependent kinase [20]. Additionally, this miRNA controls the expression of other G1 
cell-cycle regulators as CCND2 and E2F3 [20]. Faltejskova  et al. found that 
overexpression of miR-378, miR-422a and miR-375 inhibited G1/S transition but no 
targets were described [27]. Another study showed that miR-342 overexpression led to 
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G(0)/G(1) cell cycle arrest and that it was  associated with reduced levels of Cyclin E 
and CDK2 protein in colorectal cancer cells. On the other hand, after miR-342 
transfection, Cyclin D1 and CDK6 protein expression levels remained unchanged [28]. 
Ectopic expression of miR-185 induces G1-arrest by directly interfering with RhoA and 
Cdc42 levels. Both RhoA and CDC42 proteins are well known cell cycle regulators that 
can control Cyclin D1, among other proteins [29]. Additionally, CDC42 has also been 
described as regulated by miR-137 [30] and by miR-21 in colorectal cancer cells [31]. 
Several studies associate miRNAs in colorectal cancer to cell cycle regulation: Luo et al. 
[32] reported that inhibition of miR-17 induced G0/G1 arrest and targets RND3; Wang 
et al. [33] proved that let-7a enhanced expression reduced G0/G1 arrest and that it 
targets NIRF; and Baraniski et al. [34] showed that miR-30a-5p causes G-1 arrest by 
targeting DTL. However, any of these studies reported direct targets of the cyclin-
dependent kinase (CDK)-cyclin complexes [32, 33, 34]. 
Additionally, we found that HOXB3 was other target of miR-28-5p. Homeobox 
genes of the Hox family were originally discovered in controlling body structure and 
development of Drosophila melanogaster [35]. Hox genes are located contiguously in 
clusters and encode transcription factors [35]. In humans, 39 Hox genes were 
identified [35]. Hox genes are not only expressed during embryogenesis, but also 
throughout postnatal life and aberrant Hox gene expression is found in cancer [35, 36]. 
It is well know that Hox genes can be regulated by epigenetic mechanisms as well as by 
miRNAs [35]. miR-10a targets HOXA3, HOXD10 [37] and HOXA1, according to luciferase 
experimental results [38]. miR-196 represses HOXB8 through mRNA cleavage [39]. 
Both miRNAs, miR-10a and miR-196b, are located within the Hox gene clusters locus 
[35]. Hox gene activity is tissue specific [35]. In colorectal cancer, HoxB3 is upregulated 
in left-sided large intestine carcinomas compared to normal tissue [40]. The function of 
HoxB3 in colorectal cancer was not described so far. However, taking into account the 
role of Hox genes in other tumor types, we can speculate it might play a role in 
proliferation and apoptosis [35].  For example, Morgan et al. designed a novel cell-
permeable peptide, named HXR9, to interfere with the capacity of Hox to bind to PBX 
co-factor, and demonstrated that HXR9 caused apoptosis in melanoma cells in vitro 
and tumor growth retardation in a mouse melanoma cell line in vivo [41]. Later, 
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Plowright et al. used the same peptide to study the role of Hox in NSCLC where several 
Hox genes were upregulated compared with normal adjacent tissue, including HoxB3, 
and proved that blocking Hox activity triggers apoptosis in NSCLC cells in vitro and 
blocks tumor growth of a NSCLC cell line in vivo [42].  The same result was obtained in 
an ovarian cell line [43]. Furthermore, Costa et al. showed that HOXA9 (one of the 
genes of Hox family) was activated in glioblastoma versus normal brain tissue and that 
it increases cell proliferation and inhibits apoptosis [44]. Together, studies support a 
role of Hox genes in regulating apoptosis and inducing proliferation.  
In the study described in Chapter 2, we also found miR-28 as being a metastasis 
promoter in colorectal cancer cells in vivo. Several miRNAs have been directly 
implicated in the metastatic process of colorectal cancer, being pro-metastatic or anti-
metastatic [45]. EMT is a signature of the metastatic process [46]. From all miRNAs 
involved in EMT, miR-200 family is probably the most recognized as a master regulator 
of epithelial phenotype [47]. Members of miR-200 family target ZEB1 and ZEB2/SIP1 
transcription factors, which in turn strongly repress E-cadherin transcription. E-
cadherin loss is a characteristic of EMT [46, 48]. Inhibition of the miR-200 family 
members was sufficient to upregulate ZEB1 and/or ZEB2, to reduce E-cadherin and to 
induce EMT in cancer cell lines [46, 48, 49] while upregulation of those miRNAs 
triggered the reverse process [46, 48, 49].  Remarkably, several members of miRNA-
200 family were downregulated in cells that had undergone EMT in response to TGF-β 
[47]. Notably, in a feedback loop mechanism, ZEB1 repressed two of the miR-200 
members, namely miR-200c and miR-141 [49, 50]. Interestingly, in colorectal 
carcinomas, ZEB1 is aberrantly up-regulated in dedifferentiated tumor cells at the 
invasive front, which associates with loss of the basement membrane [51]. In addition, 
SIX1 - a protein that induces EMT in colorectal cancer cells - is able to inhibit the 
transcriptional activity of the miR-200 family in a colorectal cell line [52]. Also, in the 
colorectal cancer cell lines SW480 and SW620, it was proved the inhibition of ZEB1 by 
miR-200c [53]. Although several of these studies were performed in colorectal cancer 
cell lines, literature reports comparing miR-200c levels between normal and colorectal 
cancer specimens showed an upregulation of miR-200c in the colorectal tissue [54], 
which is contradictory with the potential anti-metastatic role. However, miR-200 levels 
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should be determined analyzing only in the dedifferentiated tumor cells at the invasive 
front of the tumor. 
The process that initiates with the EMT results in enhanced cell migration and 
invasion [55]. The migratory and invasive phenotype is a feature that characterizes 
metastasis and this topic has been explored by researchers. miR-141 is considered an 
anti-metastatic gene in colorectal cancer cells in vitro because it inhibits migration and 
invasion [56]. Also, miR-345 is considered an anti-metastatic gene. miR-345 promoter 
methylation led to it downregulation in colorectal cancer and low miR-345 expression 
levels are associated with lymph node metastasis. When miRNA levels were restored, 
cell invasiveness through membrane of transwell chamber significantly decreased [57]. 
Likewise, miR-137 [58] and let-7c [59] blocked invasion of the colorectal cancer cells. 
Wang et al. reported miR-31 suppression decreases migration but increases invasion in 
a colon cell line; therefore, the effect of miR-31 in metastasis remains inconclusive 
[60]. 
When exploring the functional role of miRNAs in the metastatic process, 
literature studies that used both in vitro and in vivo approaches are much less common 
than studies that used only in vitro methodologies, probably to the higher cost of the 
in vivo models. Although the mice model does not reproduce exactly the human 
biology, it can provide us further information on the miRNAs biological effects. In fact, 
the combination of in vitro and in vivo methods is, in our opinion, a good strategy in 
order to answer to the biologic questions that are proposed in this thesis. Regarding 
the study of miRNA role in metastasis of colorectal cancer cells, only Schimanski et al. 
[61], Wang et al. [62] and Lui et al. [63] gave a step forward by using mice models 
besides the in vitro approaches. Schimanski et al. demonstrated that miR-196a 
expression increased migration and invasion in colon cancer cells and it increased lung 
metastasis in mice xenografts. By doing so, the authors performed the first functional 
study on colorectal metastasis in vivo.  Importantly, miR-196a did not have an impact 
neither in proliferation nor in apoptosis, reinforcing miR-196a as an pro-metastatic 
gene [61]. Also Wang et al. showed that lung metastasis incidence in nude mice was 
lower in a colon cell line stably expressing miR-342 vector than in mice injected with 
the empty control vector [62]. Lui et al. demonstrated that a colorectal cell line 
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overexpressing miR-499-5p promoted lung and liver metastasis, probably thought the 
targeting of FOXO4 and PDCD4 [63]. Several in vitro studies have also demonstrated 
the implication of miRNAs in colorectal cancer migration/invasion as it is the case of 
Cottonham et al. study that demonstrated miR-21 and miR-31 involvement in cell 
motility and invasion by direct suppressing TIAM1 in colon carcinoma cells [64]. Finally, 
several other miRNAs such as miR-185 and miR-133b have also been proposed as 
implicated in the metastatic process [65] but were not functionally validated yet.  
The role of the miRNAs on EMT, migration, invasion and metastatic tumor 
formation is only possible due to the miRNA function of targeting mRNAs, which are 
directly or indirectly linked with the molecular pathways that regulate metastatic 
process.  In the work described in this thesis, we found NM23-H1 to be targeted by 
miR-28-3p. The anti-metastatic properties of NM23 are described since 1988 and it is 
considered the first metastatic suppressor gene to be described in the literature [66]. 
Until present, our study is the first describing NM23 regulation by miRNAs.  
 
3.2 Therapeutic Implications of microRNAs: Relevance of microRNA Strand-Specific   
Mechanisms  
miRNAs are deregulated in human cancers and are crucial regulators of cancer 
development and progression, which turns miRNAs into attractive therapeutic targets 
[67, 68]. Due to the fact that a single miRNA might target several mRNAs, we would be 
able to regulate the expression of several genes in core signaling pathways involved in 
cancer by interfering with the expression of a single miRNA [67, 68], and this is  
particularly attractive in the field of oncology [69]. For example, miR-21 targets 
multiple important components of the p53, TGF-β, and mitochondrial apoptosis 
tumor-suppressive pathways [69, 70] and therefore constitutes an important 
therapeutic target. However, the fact that a miRNA can have multiple targets can also 
constitute a disadvantage due to the potential side-effects. Thus, any potential miRNA 
target needs not only to be predicted by computer algorithms but also to be 
experimentally validated [67]. Off-target effects and lack of efficient delivery systems 
are some of the challenges facing RNA-based therapies [67, 68]. It is necessary to 
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overcome these issues so that small RNAs turn from the successful research tools, for 
gene functional studies that we currently use, into clinical therapeutic tools [67]. 
Strategies to regulate both oncogenic and tumor suppressor miRNAs are being 
developed.  
As progress has been made toward the design and delivery of short interfering 
and short hairpin RNAs for therapeutic gene silencing, downregulation of a single 
oncogenic miRNA became an attractive strategy. For this propose, methodologies to 
inhibit miRNA function are being developed and these include the use of anti-miRNA 
oligonucleotides (AMOs)/antagomiRs  (such as 2-O-methyl AMOs, 2-O-methoxyethyl 
AMOs, LNAs and other modified oligonucleotides), miRNA sponges, and miRNA 
masking [67, 71] (Figure 7). Anti-miRNA oligonucleotides are synthetic antisense 
nucleotides complementary to miRNAs that bind to it and inhibit the interaction 
between miRNA and their mRNA targets [72]. Lanford et al. used LNAs complementary 
to miR-122 to treat chimpanzees infected with chronic hepatitis C virus infection [73]. 
This treatment is now is phase II clinical trials [74]. miRNA sponges [72] are artificial 
competitive inhibitors that function in a similar way as the natural decoy ceRNAs. 
These are vectors encoding transcripts containing multiple, tandem binding sites to a 
miRNA of interest, expressed under strong promoters. miRNA sponges will compete 
with the miRNA target and derepress the miRNA-mRNA binding, by sequestering the 
miRNAs. Remarkably, a single sponge can be used to block multiple miRNAs, those 
who will bind to the seed region encoded by the sponge [72, 75, 76]. A dynamic 
technology developed in Drosophila based on miRNA sponges, named miR-SP, allows 
in vivo miRNA silencing, with precise in vivo spatial resolution [72, 77]. Finally, the 
miRNA masking approach is based in single-stranded 2'-O-methyl-modified 
oligonucleotide (or other chemically modified oligonucleotide) fully complementary to 
the miRNA binding site. miRNA mask does not bind directly to the miRNA but instead 
binds to the mRNA target of a specific miRNA blocking the access of the miRNA to its´ 
target.  This method is gene-specific and miRNA-specific [72, 78]. Choi et al. tested this 
approach in vivo in zebra fish [72, 78].  
Although studies on oncogenic miRNAs are extremely important and despite 
the contribution of oncogenic miRNAs to tumorigenesis (that is undisputable), some 
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studies showed that there is a general repression of mature miRNAs in human cancers 
[3, 13]. The global miRNA loss enhances tumorigenesis, as demonstrated by Kumar et 
al. in a study where cancer cells expressing shRNAs targeting three different 
components of the miRNA processing machinery were used to induce a decrease in 
miRNA maturation [80]. Also, Dicer knockout enhanced tumor development in mice 
[80]. Therefore, therapies that are able to contradict miRNA downregulation and to 
restore miRNA levels are most needed [81]. miRNA levels can be restored  (“miRNA 
replacement therapy”) using two approaches: 1) direct delivery of miRNA 
oligonucleotide mimics - synthetic RNA duplexes consisting of a guide strand that is 
identical to the mature miRNA sequence and a passenger strand partially or fully 
complementary to the guide strand, which are generally chemically modified to reduce 
oligonucleotide degradation and enhance it stability, permeability and activity; 2) 
introduction of the miRNA gene via an expression vector (e.g., plasmid, virus) [67, 69] 
(Figure 7). Small molecules that can reverse the epigenetic changes caused on miRNAs 
can also be used [69]. The research study described in this thesis embraces this issue 
and provides insight for the design of strategies to restore tumor suppressor miRNA 
levels. Henry et al. study compared miRNA mimics oligonucleotides and expression 
vectors for miRNA mimics [69]. The authors concluded that miRNA mimics 
oligonucleotide are commonly used for in vitro transfections because of the simplicity 
of the transfection (using lipid-based reagents or electroporation) [70]. Currently, 
miRNA oligonucleotide mimics are also becoming more widely used in vivo. However, 
the cost to synthetize and purify these oligonucleotides is high, and their expression 
after transfection is not long lasting, which constitutes the main disadvantage [69].  On 
the other hand, when miRNAs are delivered into the cells through a vector and miRNAs 
are introduced into the nucleus, the miRNA expression after transfection lasts much 
longer than when using miRNA oligonucleotide mimics [69]. The authors also state 
that, when using this strategy, the likelihood of off-targets effect is reduced because 
the miRNA is processed normally through the cell machinery and the -5p and -3p 
strands are completely natural to the cell [69]. The novelty of the work described in 
this thesis complements exactly this issue. If the miRNA introduced into the cell is 
processed by the cell machinery and originates only one single mature RNA, or two 
mature RNAs (-5p and -3p strands) with cooperative functions (e.g., both strands 
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decrease proliferation) the use of vector delivery strategy is advantageous. But if the 
miRNA introduced into the cell originates two mature RNAs (-5p and -3p strands) with 
distinct functions, this will create undesired side effects. Our work elucidates that miR-
28 delivery decreases tumor growth but has the undesired effect of increasing 
metastasis, and that this is probably caused by the distinct -5p and -3p effects on 
colorectal cells. 
 
Figure 7. Schematic representation of strategies to either decrease or increase miRNA 
levels. (LNA: locked nucleic acid - adapted from http://www.exiqon.com/lna-
technology) 
 
Numerous studies used the above described strategies for in vivo miRNA 
delivery into cancer cells. Regarding miRNA oligonucleotide mimics in vivo delivery and 
focusing on colorectal cancer in particular, Kitade et al. tested the capacity of miR-143, 
which is downregulated in colorectal cancer compared with normal tissue, as a 
therapeutic target [82]. The authors chemically modified miR-143 oligonucleotide 
mimics by introducing an aromatic benzene-pyridine compound to the 3′-overhang 
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region of the RNA-strand, which consequently improved its nuclease resistance 
compared with the commercially available miR-143 [82]. Then, the authors tested it 
clinical application and found xenografted tumors of colorectal cancer were decreased 
after weekly intravenous injections (5 weeks treatment) compared with the control 
animals [82]. Although this is a single example on the use of miRNA mimics 
oligonucleotide in colorectal cancer in vivo, numerous studies have been published in 
other tumor types, suggesting the importance for cancer treatment [69]. Regarding 
miRNA vector in vivo delivery, no studies on colorectal cancer were reported so far, 
but only in other tumor types [69]. The first study demonstrating that therapeutic 
delivery of a tumor suppressor miRNA through a vector could be effective in vivo was 
described in 2009 [71]. Kota et al. used a mouse model of hepatocarcinoma, in which 
MYC expression was induced by tetracycline, to demonstrate that therapeutic delivery 
of miR-26a through an adeno-associated virus vector suppresses tumorigenesis. 
Importantly, the adeno-associated virus system used was effective and no measurable 
liver toxicity was found after systemic administration [71, 83]. In lung cancer, Trang et 
al. provided proof-of-concept for let-7 replacement therapy [84]. The authors analyzed 
the impact of intranasal administration of a lentiviral vector expressing the tumor 
suppressor let-7a and, in established KRAS dependent mice lung tumors, observed 
tumor remission in the lentivirus-treated group of mice compared with the baseline 
and lentivirus-control groups [84]. Another example of the modulation of miRNA 
activity as a therapeutic strategy in vivo is Wang et al. study [85]. The authors 
constructed an adenovirus expressing miR-101 that was intratumoraly injected  into a 
gastric xenograft tumor model [85]. The tumors in the mice group treated with miR-
101-adenovirus were significantly smaller than tumors treated with the control-
adenovirus, and any mice showed notable toxic effect [85].  In summary, miRNA 
replacement therapy holds potential as a promising approach in cancer treatment. 
 
3.3 Concluding remarks 
Each of the miRNAs deregulated in cancer holds great potential to act as a therapeutic 
target. This is the case of miR-28 that we found deregulated in colorectal tumors. miR-
28 connects with the widespread network of miRNAs that works together to influence 
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tumors´ proliferation, apoptosis, cell cycle, or metastasis, by targeting mRNAs 
implicated in several pathways. Therefore, modulation of miRNA levels constitutes a 
powerful tool to control cellular gene expression and cellular biology.  Although much 
still needs to be done to translate miRNA-based therapies into the clinical practice, 
several therapeutic strategies are being developed. For cases in which stem-loop 
miRNAs encode two mature miRNAs, as it is the case of pre-miR-28, studies analyzing 
the function of -5p and -3p strands need to be perform. This, together with the 
analysis of the overall consequences of the pre-miRNA, is crucial for the design of 
miRNA-based therapies, due to the possibility of undesirable side-effects. 
Taken together, the study presented here encloses the following major 
conclusions: 
• miR-28 is downregulated in human colorectal cancer compared with normal 
colorectal tissue. 
• miR-28-5p decreases proliferation, increases apoptosis, causes G1-arrest, and 
decreases migration and invasion in colorectal cancer cells.  
• miR-28-3p has no effect on proliferation but increases migration and invasion 
in colorectal cancer cells. 
• Overall, pre-miR-28 decreases tumor growth but increases metastasis in vivo. 
• We experimentally proved that miR-28-5p represses Cyclin D1 and HOXB3 
expression, while miR-28-3p targets NM23-H1 in colorectal cancer cells. 
Computational algorithm predictions indicate that hundreds of mRNAs can be 
regulated exclusively by miR-28-5p, exclusively by miR-28-3p or by both. 
• Hairpin loop pre-miR-28 encodes miR-28-5p and miR-28-3p mature miRNAs, 
which have distinct functions. All other pre-miRNAs in which both -5p and -3p 
strands are active should be functionally analysed due to possible inconvenient 
effects. The possible dual role of -5p and -3p strands has direct implications on 
the design of miRNA-based therapeutic approaches.  
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MicroRNAs (miRNAs) are small noncod-
ing RNAs of approximately 22 nucleotides 
in length that regulate gene expression 
post-transcriptionally. These small RNAs 
are fundamental regulators of several cel-
lular processes, such as differentiation, 
development, apoptosis, proliferation, cell 
cycle regulation and metabolism, through 
the binding to 3' untranslated regions, 
coding sequence or 5' untranslated regions 
of target messenger RNAs (mRNAs), pre-
venting their translation or causing their 
degradation.1 A modest change in only 
one miRNA will affect multiple mRNA 
targets; consequently, the deregulation 
of miRNAs has important consequences 
to the cellular homeostatic stability, and 
aberrant miRNAs expression patterns have 
been described in several types of cancer.2 
Recently, miRNAs have been implicated 
in the metastatic process of several tumors 
such as human breast and colorectal 
cancers3 and, as reported this issue of 
Cancer Biology & Therapy by Guo et al. 
in neuroblastoma.4 These are extracranial 
solid tumors, arising from neural crest 
cells, that are most common in infants 
and children; metastasis, the main cause 
of death, is present at the time of diag-
nosis in approximately 60% of patients.5 
Metastatic disease may cause bone pain, 
bone marrow suppression and weight 
loss, but some patients do not present 
symptoms.6 Therefore, the study by Guo 
et al. is important for the identifica-
tion of specific miRNAs responsible for 
metastasis not only to better understand 
the molecular behavior of theses tumors 
but also to identify markers of early 
diagnosis/prognosis, and in the future, 
possible new therapeutic targets.
Using a heterotopic transplant mouse 
model of neuroblastoma and a microRNA 
microarray analysis approach, Guo et 
al. identified 54 miRNAs differentially 
expressed between primary and metastatic 
neuroblastoma tumors.4 Three of the 
top ten downregulated miRNAs in this 
study, namely miR-7, miR-338-3p and 
the let-7 family, have an anti-metastatic 
role in other tumors types.7 Specifically, in 
breast cancer, Reddy et al. described that 
endogenous miR-7 expression is positively 
regulated by the homeodomain transcrip-
tion factor HoxD10, a gene that has been 
linked with the invasive and metastatic 
potential in human breast cancer cells. 
In this breast cancer cell line, the authors 
showed that miR-7 introduction suppresses 
motility, invasiveness, anchorage inde-
pendence and tumorigenesis.8 Regarding 
miR-338-3p, it has been suggested that 
this microRNA contributes to the forma-
tion of basolateral polarity in epithelial 
cells, which can be important for metas-
tasis prevention.9 Concerning the let-7 
family, several studies demonstrate that it 
can inhibit tumorigenesis and metastasis 
as it targets important oncogenes such as 
RAS, MYC and HMGA2. Interestingly, 
MYC and let-7 are involved in a feed-
back loop since MYC can be a target of 
let-7 and at the same time can control its 
expression. In breast tumor cells, Dangi-
Garimella et al. demonstrate that RKIP 
represses metastasis, in part, through a 
signalling cascade that involves the inhibi-
tion of MAPK, MYC and LIN28, leading 
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the neuroblastoma cell surface activate 
a CASP8-dependent checkpoint and 
block cell invasion into an inappropriate 
microenvironment.11 This mechanism 
is inactive in the absence of CASP8.11,12 
Interestingly, integrins are also predicted 
to be a target of miR-29a/b, which is over-
expressed in metastatic versus primary 
neuroblastoma.4 In addition to CASP8 
deletion and methylation,12 it is tempt-
ing to speculate that another mechanism 
by which CASP8 is downregulated in 
metastatic neuroblastoma is through 
miR-29a/b overexpression. However, it 
is imperative to validate this hypothesis 
through functional studies.
It will be important in future studies 
to functionally validate the interference 
between the other miRNAs that were dif-
ferently expressed (primary versus meta-
static NB) in the Guo et al. study and 
the predicted targets. In humans, neuro-
blastoma can metastasize to bone, bone 
marrow, lung, liver and/or non-contigous 
lymph nodes.13 It will be also interesting to 
analyse differences at the microRNA level 
between the different metastatic sites.
In conclusion, the identification of dif-
ferentially expressed microRNA in the 
metastasis of neuroblastoma is an impor-
tant step towards the understanding of the 
metastatic process in this disease.
to the induction of let-7 and the conse-
quent downregulation of its targets.10
In the present reported study, Guo et 
al. also identified several miRNAs whose 
association with metastases was not pre-
viously described. In futures studies, it 
will be important to further analyse those 
miRNAs with the purpose of understand-
ing their functional role in metastisa-
tion. In addition to the identification of 
miRNAs involved in the neuroblastoma 
metastatic process, and using computer-
aided algorithms, Guo et al. suggest 
potential mRNA targets that can be regu-
lated by those miRNAs. Interestingly, 
some of those targets have been described 
as deregulated in neuroblastoma.4 For 
example, according to Guo et al. miR-29-
a/b is overexpressed in metastatic neuro-
blastoma and one of the predicted targets 
of this microRNA is CASP8. The absence 
of this apoptosis-mediated protein has 
been implicated in neuroblastoma metas-
tasis in vivo. In chick embryos, Stupack et 
al. detected lung and bone marrow neu-
roblastoma metastases mostly in embryos 
bearing tumors deficient in CASP8 when 
compared to CAPS8-positive tumors. 
Furthermore, reconstitution of CASP8 
expression significantly suppressed 
metastasis.11 The authors propose that 
unligated or antagonised integrins on 
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Figure 1 Two small non-coding RNAs (miR-9 and miR-10b) and the complex 
regulatory network of cancer metastasis (data from ref [2, 5, 6]).
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Metastasis accounts for more than 
90% of cancer patients’ mortality. The 
metastatic process involves multiple 
steps [1]. Initially, cancer cells from the 
primary tumor invade adjacent stroma. 
To acquire this capacity, cells undergo a 
process called epithelial-mesenchymal 
transition (EMT), in which cells in re-
sponse to signals from the surrounding 
stroma, undergo a switch between cell 
phenotypes and acquire mesenchymal 
properties and show reduced intercel-
lular adhesion, allowing cells to be-
come motile. Then cells enter systemic 
circulation, either through the blood or 
lymph, and finally extravasate into the 
parenchyma of distant tissues, where 
they form micrometastasis and prolifer-
ate to form secondary tumors [2].
MicroRNAs (miRNAs) are a class of 
non-coding RNAs with approximately 
22 nt length that regulate gene expres-
sion post-transcriptionally by binding 
to 3′ untranslated region (UTR), coding 
sequence or 5′ UTR of target messenger 
RNAs (mRNAs), leading to inhibition 
of translation or mRNA degradation 
[3]. Tumors present aberrant expression 
of miRNAs patterns. miRNAs have 
been described as regulators of several 
biological processes such as apoptosis, 
proliferation, differentiation, and more 
recently, metastasis [4]. miRNAs can 
function either as suppressors or pro-
moters of metastasis according to their 
mRNA targets [1, 2]. Elucidation of the 
role of miRNAs in metastasis can lead 
to a better understanding of this process 
and consequently lead to new treatments 
for patients with late-stage tumors.
In 2007, Ma and coworkers from 
Weinberg’s group reported the first 
study about the role of miRNAs in tumor 
metastasis [5]. The authors identified 
three miRNAs, namely miR-155, miR-9 
and miR-10b, as being upregulated in 
breast cancer cell lines and showed that 
miRNA-10b, by targeting HOXD10a, 
induce the pro-metastatic gene RHOC 
and consequently contribute to me-
tastasis [5]. In a recent publication in 
Nat Cell Biol [6], Ma and colleagues 
elegantly show the involvement of 
miR-9 in the metastasis-regulating sig-
naling network (Figure 1). A common 
approach to identify miRNA targets is 
the use of computational algorithms 
whereby the authors identify and further 
confirm by luciferase assay and western 
blot that the cell-cell adhesion receptor 
E-cadherin (encoded by CDH1) is a di-
rect target of miR-9. This miRNA binds 
to CDH1 3′UTR region as a decrease in 
luciferase activity was detected in cells 
co-transfected with miR-9 and CDH1 
3′UTR reporter gene. To further confirm 
this result, the authors show that co-
transfection of miR-9 and CDH1 3′UTR 
reporter gene containing a mutation in 
the seed-target region do not cause a 
decrease in luciferase activity [6].
This finding is important because, 
as it has long been recognized, loss of 
E-cadherin expression is one of the hall-
marks of EMT process [7]. E-cadherin is 
a transmembrane protein whose primary 
function is to mediate cell adhesion. 
The cytoplasmic tail of E-cadherin as-
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sociates with several proteins including 
β-catenin. Besides its involvement in 
cell adhesion, β-catenin is an essential 
effector of the Wnt signaling pathway 
which is frequently upregulated in tu-
mors [8]. Specifically, β-catenin forms 
a transcription factor complex with 
TCF to regulate gene expression. When 
β-catenin escapes degradation, it accu-
mulates in the cytosol and can enter the 
nucleus where it will act as a transcrip-
tional co-regulator [7, 8]. miR-9 upregu-
lation in breast cancer cells suppresses 
E-cadherin that consequently loses its 
capacity to sequester β-catenin and 
potentiates the Wnt signaling. In fact, 
the authors show that miR-9 expression 
increases β-catenin activity in cell lines 
with a basal E-cadherin expression. In 
vivo, miR-9 overexpressing tumor xe-
nografts develop more micrometastasis 
than tumor xenografts without miR-9 
overexpression. In addition, in vivo, 
inhibition of miR-9 can decrease metas-
tasis formation [6]. Silencing of miR-9 
and modulating E-cadherin expression 
may represent a new therapeutic ap-
proach in advanced breast cancers to 
prevent metastasis formation.
Study by Ma et al. is exciting because 
the authors demonstrate the contribu-
tion of miR-9 not only for EMT but 
also for induction of angiogenesis that 
is essential for metastasis to develop. 
VEGFA is a key pro-angiogenic protein 
and a target of β-catenin [9]. Ma et al. 
show that miR-9 overexpression up-
regulates VEGFA and that it correlates 
with E-cadherin expression. In vivo, the 
same result is obtained: VEGFA plasma 
levels in miR-9-overexpressing tumor 
xenografts are higher than in controls 
indicating the role of miR-9 in tumor 
angiogenesis. However, by itself E-
cadherin and β-catenin do not induce 
VEGFA upregulation [6]. Therefore, 
other miR-9 targets have to be consid-
ered. In future studies it will be interest-
ing to answer the question what other 
proteins/pathways may mediate VEGFA 
upregulation via miR-9 overexpression. 
Finally, Ma et al. explore upstream 
pathway of miR-9 expression regula-
tion and find out its activation by MYC/
MYCN. The authors correlate miR-9 
upregulation with MYC amplification 
in neuroblastomas tumor samples and 
also with metastatic breast tumors [6]. 
However, the number of breast cancer 
samples used in the study is reduced and 
so it remains to be determined if miR-9 
can be used as a prognostic marker since 
large breast cancer association studies 
are needed for this. In conclusion, this 
study convincingly identifies a new 
player in both EMT and angiogenic 
processes – miR-9, and opens intriguing 
new avenues of diagnostic and therapy: 
Do miR-9 levels in tumors and/or 
plasma of breast cancer patients predict 
metastasis? Should anti-miR-9 (and 
anti-miR-10b) be used for metastases 
prophylaxis in cancer patients?
Currently the role of miRNAs as one 
of key regulators of the metastatic pro-
cess is starting to be clarified. Similar 
to miRNAs, other non-coding RNAs 
(ncRNAs) were shown to be deregu-
lated in tumors [10]. In the future, it 
will be interesting to address the role of 
other ncRNAs in the complex molecular 
puzzle of metastasis.
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Identifying breast cancer risk in BRCA1-
negative (and BRCA2-negative) families 
is an important medical issue. BRCA1 is a 
tumor suppressor gene that is important in 
the regulation of several cellular functions, 
such as DNA damage, the cell cycle, recruit-
ment of chromatin-modifying proteins and 
ubiquitin ligase activity.1 BRCA1 mutations 
are well-known risk factors for developing 
breast cancer. These mutations may cause 
wild-type BRCA1 loss of function or create 
gain-of-function BRCA1-mutated proteins.1 
Although some researchers have focused their 
attention on understanding how BRCA1 muta-
tions affect cellular physiology and therefore 
affect cancer risk,1 others have focused on 
finding new genetic markers in the BRCA1 
gene that can help predict breast cancer risk. 
However, less than 5% of all persons suscep-
tible to breast cancer can be determined by 
analyzing BRCA1 mutation status;2,3 thus, new 
markers in the BRCA1 gene must be identified. 
New players in the predisposition mechanism 
are microRNAs (miRNAs) (Fig. 1, see opposite 
page). This class of small, noncoding RNAs is 
approximately 22 nucleotides in length and 
can regulate gene expression post-transcrip-
tionally by binding the 3’ untranslated region 
(UTR), the coding sequence or 5’UTR of target 
messenger RNAs (mRNAs), which can lead to 
inhibition of translation or mRNA degradation. 
It is already known that genetic variations in 
miRNAs or miRNA target sites can interfere 
with the miRNA-mRNA interaction, which then 
can affect expression levels of several proteins 
involved in cancer genesis and development, 
such as oncogenes and tumor suppressor 
genes (for a review see ref. 4).
Recently in Cell Cycle, Pelletier et al.3 
described rare BRCA1 halotypes in the 3’UTR 
associated with breast cancer risk. The authors 
sequenced the BRCA1 3´UTR of breast cancer 
patients and found three previously reported 
and one novel single-nucleotide polymor-
phism (SNP). Using an outstanding normal 
population repository of 2250 individuals 
from 46 different geographic populations, the 
authors determined the variants’ frequencies. 
Pelletier et al. analyzed 8 SNPs and identified 
five haplotypes, three of which were located 
on the 3’UTR of BRCA1, that were present in 
the breast cancer population but rarely found 
in the control population. The frequency of 
these haplotypes also differed according to 
ethnicity and tumor subtype. Interestingly, 
these rare haplotypes were not associated 
with the most common BRCA1mutations and 
therefore might be independent markers of 
breast cancer risk. Given their potential as bio-
markers, further study of the SNPs identified 
by Pelletier et al. is needed, particularly with 
respect to any disruptions in the interaction 
between miRNAs and mRNA that these varia-
tions might create. 
Another example of a BRCA1 SNP show-
ing an association with breast cancer risk was 
reported by Nicoloso et al.5 Those authors 
reported that the BRCA1 SNP rs799917 is asso-
ciated with susceptibility to breast tumor and 
that this risk is particularly increased for spo-
radic breast cancer. The authors showed that 
miR-638 interacts more strongly with allele [C] 
of SNP rs79991 than with the [T] allele. This 
difference in interaction was also confirmed at 
the protein level.5 
In addition, miRNA-mRNA interactions 
dependent on SNPs have also been described 
in other tumor types. For instance, the labo-
ratories of Slack and Weidhaas were the first 
to describe a SNP associated with non–small 
cell lung cancer risk in the KRAS 3’UTR that 
interferes with let-7 binding. The variant allele 
alters let-7-mediated regulation of KRAS, 
increasing its expression.6
These results demonstrate the importance 
of SNPs in conveying susceptibility to different 
kinds of cancer. The study by Pelletier et al.3 
is particularly vital because it describes new 
genetic markers in BRCA1 3’UTR noncoding 
regions that can improve our determination of 
breast cancer susceptibility. Inclusion of these 
SNPs in BRCA1 haplotypes that are associated 
with breast cancer risk may guide future stud-
ies of functional miRNA interactions and their 
cellular consequences. This has the potential 
to greatly increase our ability to diagnose 
BRCA1-negative breast cancer at an earlier 
stage.
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Abstract. IQGAP1 knockout mice develop gastric cancer, but 
the IQGAP1 protein is associated with some advanced-stage 
human cancers. IQGAP1 expression is regulated by a microRNA, 
miR-124, through a binding site at the 3'-untranslated region, 
where a single nucleotide polymorphism (SNP) exists in the 
core binding region. We asked whether IQGAP1 expression 
is associated with breast cancer development and whether 
genetic variants at the miR-124 binding site are important. We 
genotyped the IQGAP1 SNP rs1042538 A/T in 1,541 breast 
cancer cases and 1,598 controls and analyzed the frequency 
of the variant and interactions with major risk factors in these 
populations. We also measured the expression of IQGAP1 at 
both mRNA and protein levels in different IQGAP1 genotypes. 
The IQGAP1 TT genotype, compared with the AA genotype, 
was associated with a significantly lower risk of developing 
breast cancer [P=0.049, odds ratio (OR), 0.78; 95% confidence 
interval (CI), 0.61-0.99]. In case-only analyses, the TT, compared 
with the AA, genotype was associated with progesterone 
receptor-positive subjects (OR, 1.35; 95% CI, 1.00-1.83). The 
expression levels of IQGAP1 protein were significantly higher 
in the TT genotype compated to the AA genotype. The 
presence of SNPs at the miR-124 binding site may be a marker 
for predicting breast cancer risk and prognosis. 
Introduction
During embryonic development and throughout adult life in 
humans, gene expression is tightly regulated by a complex 
biological network in a tissue-specific manner and in close 
interaction with the environment to ensure accurate spatial 
and temporal differentiation of multiple organs with distinct 
functions. Significant deviation in the key regulators of this 
network via mutations often results in pathogenesis, including 
cancer. Subtle differences in the key regulatory genes via 
single nucleotide polymorphisms (SNPs) can result either in 
non-pathologic differences, such as hair color, or in increased 
propensity for a diseased state, such as cancer. Revealing the 
roles of these SNPs is a major area of research in the realm of 
molecular epidemiology in the era of postgenomic medicine (1).
In recent years, studies have revealed the importance of a 
class of small non-coding RNAs, microRNAs (miRNAs), that 
are critically involved in regulating gene expression (2). miRNAs 
directly regulate about 30% of the genes in the human genome 
via degradation or translational inhibition of their target 
messenger RNAs (mRNAs) and are thus important regulators 
of cellular processes such as differentiation, proliferation, 
mobility, and apoptosis (3,4). The first miRNA-target mRNA 
pair to be verified in vivo was let-7 miRNA and its target, 
lin-41; and the natural interaction between this miRNA and 
its target is one of the best understood (5). miRNAs suppress 
gene expression mainly by binding to the complementary 
sequences in the 3 untranslated regions (UTRs) of mRNA of 
their target genes (6), although some miRNAs have been shown 
to act as an enhancer element to increase gene expression (7). 
It is generally believed that nucleotides 2-8 from the 5' end of 
miRNA, called the ‘seed region’, are the most critical for 
miRNA binding (8). Perfect Watson-Crick complementarity 
is observed in these 7 consecutive base pairs in most cases. 
Therefore, a single nucleotide change in this region may cause 
sufficient disruption in binding to deregulate the target genes (9). 
If the target gene is an oncogene, a tumor suppressor gene, or 
other regulatory genes that are critical for homeostasis, the 
single nucleotide change in the miRNA binding site may alter 
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the expression of these genes and shift the normal cellular 
program to a cancer-prone state, thus increasing cancer risk 
and/or conferring a specific cancer phenotype (10,11).
Breast cancer is the most common cancer among women in 
developed countries, and an alarming increase in incidence 
has been seen in developing countries (12). Germline mutations 
in BRCA1 and BRCA2 genes account for only 5% of all 
breast cancer cases in the general population (13,14). Other 
low-penetrance genetic variants, especially in as-yet unknown 
combinations, are expected to explain most breast cancer 
incidence (15). Investigators, including those in our group, 
have hypothesized that the 3' UTRs of miRNA target genes 
may harbor such important variants (10,16). Saunders et al 
(17) conducted a bioinformatic survey of the human genome 
for SNPs in putative miRNA target sites and found an appreciable 
level of variations within predicted as well as experimentally 
verified miRNA targets. One of the SNPs highlighted in the 
study of Saunders et al was SNP rs1042538 in the IQGAP1 
gene (encoding IQ motif-containing GTPase-activating protein 1), 
and this SNP has been experimentally verified to disrupt a 
miRNA target site sequence for miRNA-124 (miR-124) (18). 
The scaffold protein IQGAP1 integrates signaling pathways 
and participates in diverse cellular activities that are important 
for both normal development and diseased states (19-24). 
IQGAP1 has attracted attention from cancer and developmental 
biologists because IQGAP1 expression appears to play an 
opposite role in normal development and in cancer progression. 
Studies with human tumor tissues have suggested that IQGAP1 
is an oncogene, which is overexpressed in a number of human 
solid neoplasms, including cancers of the colon, ovaries, 
stomach, and breast as well as glioblastoma (25-29). Functional 
studies have established the fact that IQGAP1 interacts with 
and regulates the actin-Cdc42/Rac1-mitogen-activated protein 
kinase pathway, thus contributing to its role in cell migration 
and invasion (19). Furthermore, another report suggested that 
IQGAP1 is involved in the expansion of cancer stem cells in 
glioblastoma and that together with IGFBP2 was associated 
with shorter survival in glioblastoma patients (27). Similarly, 
IQGAP1 was shown to be a marker of poor prognosis in ovarian 
cancer (26). In gastric cancer, it was shown that IQGAP1 was 
up-regulated by gene amplification (30).
However, the putative oncogenic properties of IQGAP1 
have been contradicted by the finding that the deletion of 
IQGAP1 in mice resulted in hyperplasia in gastric epithelial 
cells (31), suggesting that the IQGAP1 gene plays an important 
role in normal development and actually has an antiproliferative 
function in normal epithelial cells. In other words, the IQGAP1 
gene may have a tumor suppression function in normal cells but 
may turn into an oncogene in tumor cells through an unknown 
mechanism. These conflicting properties of IQGAP1 suggest 
that IQGAP1 function may be dependent on developmental 
stage and cell type. However, determining the exact role and 
regulation of IQGAP1 in normal and cancer development will 
require more extensive studies, including population-based 
and functional studies.
A large number of SNPs have been found within the 
sequence of the IQGAP1 gene, but SNP rs1042538 is 
recognized as the only one targeted by a miRNA with a 
high frequency of variation in Chinese population. This SNP 
(A/T variant) is one of the seven consecutive nucleotides 
corresponding to the seed region of miR-124 (Fig. 1). The A 
allele, together with the other six, form a perfect pairing with the 
seed, which is responsible for the down-regulation of IQGAP1 
by miR-124 (17). Therefore, we conducted a case-control 
study to investigate whether this SNP at the miRNA-binding 
site on the IQGAP1 gene plays a role in breast cancer development 
and prognosis in a Chinese population.  
Patients and methods
Patients and controls. Study patients were recruited from the 
Breast Cancer Research Center in Tianjin medical University 
Cancer Hospital, and clinical information was acquired from the 
Tianjin Cancer Registry upon the approval of the Institutional 
Review Board (32). This study included 1,541 patients with 
newly diagnosed and histologically confirmed breast cancer, 
who were consecutively recruited between January 1, 2007 and 
February 28, 2008. The response rate of the eligible patients 
we recruited was ~95%. 
We also recruited 1,598 cancer-free women (controls) during 
this study period who were genetically unrelated to one another 
and living in the nearby community. The response rate of the 
eligible controls who were approached for recruitment was 
~90%. The controls were frequency-matched to the cases by 
age (±5 years).
After the study participants signed an informed consent 
form, they were interviewed for demographic data and infor-
mation about major risk factors, including family history. For 
the cases, we also collected information about tumor features 
and disease severity, including morphologic characteristics, 
mean age at diagnosis, infiltrating/invasive ductal carcinoma 
(IDC) status, tumor size, presence of lymph node and/or organ 
metastasis, clinical stage, and estrogen receptor (ER) and 
progesterone receptor (PR) status. Each eligible subject donated 
20 ml of blood, which was collected into heparinized tubes 
and used for biomarker assays, including DNA extraction and 
genotyping.
Genotyping. From each blood sample, a leukocyte cell pellet, 
obtained from the buffy coat by centrifugation of 1 ml of 
whole blood, was used for DNA extraction. Genomic DNA was 
isolated with the Qiagen DNA Blood mini Kit (Qiagen Inc., 
Valencia, CA) according to the manufacturer's instructions. 
For genotyping the rs1042538 A/T SNP, both the amplifying 
primers and the Taqman mGB probes were designed for the 
Taqman SNP Genotyping assays (Applied Biosystems, Foster 
City, CA). more than 10% of the samples were randomly 
selected for repeated assays, and the results were 100% 
concordant.
Quantitative measurement of IQGAP1 mRNA and protein 
expression. Total RNA was isolated from 37 frozen breast 
cancer tissues from patients with known genotypes of IQGAP1 
(AA or TT), as determined from their blood samples. The 
extraction and purification of total RNA were performed with 
TRIzol reagent (Invitrogen) according to the manufacturer's 
instructions. RNA quality and concentration were determined 
with the Agilent 2100 Bioanalyzer (Agilent Technologies). 
Real-time quantitative polymerase chain reaction (PCR) was 
performed in a 96-well reaction plate (microAmp® Optical 
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96-Well Reaction Plate, Applied Biosystems) on an ABI PRISm® 
7500 Sequence Detector System (Applied Biosystems), according 
to the manufacturer's instructions.
RT-PCR for IQGAP1 expression was done using power 
SYBR Green one-step RT-PCR master mix reagent kit (P/N 
4391178). All primers were synthesized by Sangon Corp. 
(Shanghai, China). In order to normalize the differences in the 
amount of total RNA used in each reaction, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) RNA was measured as 
endogenous control. Each sample was analyzed in duplicate 
and the coefficient of variation of all reactions was <5%. The 
relative expression level of IQGAP1 to GADPH was described 
using the equation: expression = 2-ΔCt. Western blotting was 
done to evaluate the effect of miR-124 on the expression of 
IQGAP1 in cell lines, mm231 and LN299, using actin as a 
control. IQGAP1 protein expression was measured through 
Western blotting using actin as a loading control in 48 breast 
cancer tissues with IQGAP1 AA or TT genotype.
Statistical analyses. We used the χ2 test to compare differences 
in frequency distributions of demographic variables, risk 
factors, and alleles of the IQGAP1 polymorphism between 
the cases and controls. We also tested the Hardy-Weinberg 
equilibrium of genotype distributions in the controls. In 
addition, we used unconditional univariate and multivariate 
logistic regression analyses to examine the association between 
the SNP and breast cancer risk by estimating odds ratios 
(ORs) and 95% confidence intervals (CIs) with and without 
adjustment for age and other risk factors. Finally, we stratified 
the genotype data according to age, family history, and clinical 
variables (including morphologic characteristics, tumor size, 
presence of lymph node and/or organ metastases, tumor stage, 
and ER and PR status) of breast cancer patients by using the 
χ2 test and logistic regression. The expression levels of IQGAP1 
between AA and TT genotypes were compared with use of 
the rank-sum test. All statistical analyses were two-sided and 
performed with use of SAS software (version 9.0; SAS Institute, 
Cary, NC), and a P=0.05 was considered statistically significant. 
Results
Case-control analysis of the IQGAP1 SNP. This case-control 
study included 1,541 breast cancer cases and 1,598 controls, 
and the distributions of known risk factors between cases and 
controls are shown in Table I. Age was adequately matched 
between cases and controls (P=0.242).
Genomic DNA for IQGAP1 SNP genotyping was isolated 
from the peripheral blood of all participants with use of the 
Taqman assay. The distribution of the IQGAP1 genotypes 
(rs1042538) is shown in Table II. The SNP was in Hardy-
Weinberg equilibrium in controls (P=0.469). The AA genotype 
was found in 33.42% of cases and 32.17% of controls, whereas 
the TT genotype was found in 17.26% of cases and 19.52% of 
controls. The TT genotype, compared with the AA genotype, 
was associated with a significantly lower risk of developing 
breast cancer (P=0.049, OR, 0.78; 95% CI, 0.61-0.99). In other 
words, women with the AA genotype were more likely than 
those with the TT genotype to develop breast cancer. 
We also separated the cases into those with IDC (about 2/3 
of all cases) and others (mainly including adenocarcinoma, 
carcinoma simplex, mucinous carcinoma, medullary carcinoma, 
lobular carcinoma). The two groups of cases were used in 
case-control analyses, and results revealed that in non-IDC 
cases only, those with the TT genotype had a significantly 
lower risk of developing cancer (OR=0.69; 95% CI, 0.50-0.94) 
than did those with the AA genotype (Table II). Thus, it 
appears that the effect of the IQGAP1 SNP is less apparent in 
more aggressive and invasive stages of breast cancer, when 
many genetic and epigenetic factors become involved.
Case-only analysis of IQGAP1 genotypes. The patient data 
we collected included information on mean age at diagnosis, 
Figure 1. The base-pairing of the miR-124 seed region and the 3'-UTR of the IQGAP1 gene, including the rs1042538 polymorphism. SNP rs1042538 has an 
A/T variation, which is one of the seven consecutive nucleotides corresponding to the seed region of miR-124. The A allele, together with the other six, forms 
a perfect pairing with the seed, which is responsible for the down-regulation of IQGAP1 by miR-124; the T allele forms a non-perfect pairing with the seed 
and may escape the regulation of miR-124. 
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IDC status, tumor size, presence of lymph node and/or organ 
metastasis, clinical stage, and ER/PR status. Our analysis did 
not reveal association between any genotypes and mean age at 
diagnosis (P=0.387), IDC status (IDC vs. non-IDC, P=0.194), 
tumor size (P=0.821), lymph node metastases (P=0.652), 
clinical stage (P=0.773), or ER status (P=0.386) (Table IV). 
Our analysis revealed significant association between genotypes 
and PR status of cases. Specifically, cases with the TT genotype 
were more likely to be PR-positive than were those with the AA 
genotype (OR, 1.35; 95% CI, 1.00-1.83) (Table III). Furthermore, 
in ER-negative cases, the IQGAP1 genotype was significantly 
associated with PR status. Cases with AT or TT genotypes, 
compared with the AA genotype, were more likely to be 
PR-positive (P=0.022) (OR for AT genotype, 1.50; 95% CI, 
1.01-2.23; OR for TT genotype, 1.91; 95% CI, 1.18-3.09) 
(Table IV).
Analysis of IQGAP1 expression. Our hypothesis was that 
IQGAP1 TT genotype, evading the regulation of miR-124, 
would have a higher level of IQGAP1 expression. We thus 
measured IQGAP1 expression at mRNA and protein levels 
using breast cancer tissue. IQGAP1 mRNA was higher in AA 
genotype than in TT genotype (0.040 vs. 0.025), the difference 
between the AA genotype and the TT genotype was not 
significant (rank-sum test, P=0.109) (Fig. 2A). The relative 
IQGAP1 protein levels were higher in TT genotype than in 
Table I. Frequency distributions of selected variables in breast cancer cases and cancer-free controls in Chinese women.
 No. (%) of subjects
 ----------------------------------------------------------------------------------
Variables Cases (n=1,541) Controls (n=1,598) OR (95% CI)  P-valuea
Age (years)
 ≤50   739 (47.96)   733 (45.87)  0.242
 >50   802 (52.04)   865 (54.13)
Frequency of pregnancy
 ≤2   710 (46.07)   728 (45.56) 1.00 0.771
 >2   831 (53.93)   870 (54.44) 0.94 (0.80-1.11)
Duration of breastfeeding (months)
 ≤12   733 (47.57)   604 (37.80) 1.00 <0.001
 >12   808 (52.43)   994 (62.20) 0.66 (0.56-0.77)
menopausec
 No   731 (47.65)   706 (44.54) 1.00 0.081
 Yes   803 (52.35)   879 (55.46) 0.81 (0.64-1.03)
Oral contraceptionc
 Never 1,197 (81.87) 1,321 (84.46) 1.00 0.057
 Ever   265 (18.13)   243 (15.54) 1.14 (0.93-1.41)
Smoking statusc
 Never 1,309 (87.85) 1,478 (93.25) 1.00 <0.001
 Ever   181 (12.15)   107    (6.75) 2.23 (1.70-2.93)
Benign breast diseasec
 Never 1,129 (73.79) 1,465 (92.78) 1.00 <0.001
 Ever   401 (26.21)   114    (7.22) 4.41 (3.49-5.58)
Family history of cancerb,c
 No 1,061 (68.90) 1,409 (88.45) 1.00 <0.001
 Yes   479 (31.10)    184 (11.55) 3.24 (2.65-3.95)
CI, confidence interval; OR, odds ratio. aTwo-sided χ2 test. bFirst- and second-degree relatives. cDue to missing values, the number of cases and 
controls are less than 1,541 and 1,598, respectively.
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AA genotype (125.46 vs. 51.35), the difference between the 
TT genotype and the AA genotype was statistically significant 
(rank sum test, P=0.039) (Fig. 2B).
Discussion
We began this case-control study to find an answer to the 
question of whether the SNP at the miR-124 binding site on 
the 3'-UTR of the cytoskeleton-organizing gene IQGAP1 
had any effect on breast cancer risk. We did not have an a 
prior prediction because the published results on the function 
of IQGAP1 appeared to be contradictory. On the one hand, 
removal of the IQGAP1 gene predisposed mice to the 
development of gastric cancer. On the other hand, IQGAP1 
expression was elevated in many cancers and in some tumors 
correlated with poor prognosis. Our case-control study showed 
that the AA genotype of the miR-124 binding site SNP on 
IQGAP1, which renders its down-regulation by miR-124, was 
associated with increased risk of breast cancer. Although this 
does not prove that IQGAP1 plays a role in tumor suppression, 
the result is consistent with the knockout mouse studies that 
suggest that IQGAP1 is a negative regulator for cancer 
development. We also examined IQGAP1 expression in breast 
cancer tissues and their adjacent pathologically normal tissues 
and found that indeed, IQGAP1 was up-regulated in breast 
cancer tissue, similar to findings in other previously reported 
studies (33). moreover, IQGAP1 knockdown experiments 
showed that reduction of IQGAP1 resulted in increased cell 
growth in non-cancer breast epithelial cells but resulted in 
decreased cell growth in breast cancer cells, supporting that 
IQGAP1 plays an opposite role in normal development and 
cancer. Or in other words, IQGAP1 may indeed act as a tumor 
suppressor in breast cancer initiation but act as an oncogene 
after cancer has developed. Therefore, our findings may help 
explain the apparently contradictory results regarding IQGAP1 
in the same human populations, at least partially removing the 
argument that IQGAP1 may work differently in humans and 
mice.
The A allele, which binds perfectly with miR-124 and leads 
to the down-regulation of IQGAP1 expression, is associated 
with increased risk of breast cancer. This finding suggests 
that IQGAP1, and by extension cytoskeleton organization, is 
critical for normal breast cell development. A lack of IQGAP1 
and disrupted cytoskeleton organization contributed to breast 
cancer development or hyperplasia in gastric epithelial cells in 
the mouse studies (31), although it is not known whether there 
were any abnormalities in breast epithelial cells in the IQGAP1 
gene knockout mice or whether the A allele of our studied 
SNP had any effect on gastric cancer development. Nevertheless, 
because cytoskeleton structure is critical for maintaining highly 
organized and polarized epithelia cell sheets, the requirement 
for sufficient IQGAP1 expression is quite logical. Further 
case-control studies are clearly warranted in other types of 
cancer.
Our population-based case-control study suggests that the 
T allele of the miR-124 binding site SNP on the IQGAP1 gene 
is a ‘good’ variant that has a breast cancer protection function. 
Of interest, the T allele was found in frequencies of 40, 10, and 
10%, respectively, for the Hapmap panels of Asian, European, 
and African women. It is well established that breast cancer 
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incidence is much lower among Asian women than among 
women of European or African descent. Such differences have 
often been attributed to different lifestyles in the absence of 
known genetic factors. However, if the T allele is indeed 
protective, this allele and other similar alleles may, at least in 
part, constitute the genetic basis for the varying incidence in 
breast cancer among Asian, European, and African women. 
Future population-based studies in European and African 
women cohorts will be needed to test this hypothesis.
In our study, we also evaluated the potential association of 
this SNP with breast cancer prognosis. This was because 
IQGAP1 has been shown to be overly expressed in cancer, and 
expression levels have been associated with poor prognosis in 
several other cancer types, including glioblastoma (34). This 
association is not surprising because enhanced cell migration, 
invasion, and metastasis of cancer cells require heightened 
cytoskeleton reorganizing activities. However, we were 
initially surprised with our analysis results that showed a lack 
of correlation of this SNP with major clinical parameters such 
as metastasis and tumor invasiveness in our breast cancer 
cases. We did observe some association with PR status, but 
the significance of this association is currently unclear. A few 
Table III. Association of the IQGAP1 polymorphism with clinical characteristics of breast cancer cases.
 IQGAP1 rs1042538 (A/T) genotype frequency
 ---------------------------------------------------------------------------------------------------------------
Variables No. of AA AT TT P-valuea
   patients (n=515) (n=760) (n=266) 
Age at diagnosis (years) 1,540b 51.61±10.50 52.13±11.11 51.14±10.18 0.387
morphology 1,541  
 IDC  345 (66.99) 525 (69.08) 195 (73.31) 0.194
 Others  170 (33.01) 235 (30.92) 71 (26.69) 
 OR (95% CI)  1.00 0.91 (0.72-1.15) 0.74 (0.53-1.03) 
Tumor size 1,395b  
 ≤2 cm  171 (36.93) 242 (35.12) 87 (35.80) 0.821
 >2 cm  292 (63.07) 447 (64.88) 156 (64.20) 
 OR (95% CI)  1.00 1.08 (0.85-1.38) 1.05 (0.76-1.45) 
Lymph node metastases 1,534b  
 No  309 (60.47) 473 (62.48) 159 (59.77) 0.652
 Yes  202 (39.53) 284 (37.52) 107 (40.23) 
 OR (95% CI)  1.00 0.92 (0.73-1.16) 1.03 (0.76-1.39) 
Clinical stage 1,394b
 0+I  122 (26.41) 193 (27.97) 63 (26.03) 0.773
 Ⅱ+Ⅲ+Ⅳ  340 (73.59) 497 (72.03) 179 (73.97) 
 OR (95% CI)  1.00 0.92 (0.71-1.21) 1.02 (0.72-1.45) 
ER 1,515b
 -  224 (44.09) 314 (42.32) 125 (47.17) 0.386
 +  284 (55.91) 428 (57.68) 140 (52.83) 
 OR (95% CI)  1.00 1.08 (0.86-1.35) 0.88 (0.66-1.19) 
PR 1,515b    
 -  241 (47.44) 314 (42.32) 106 (40.00) 0.085
 +  267 (52.56) 428 (57.68) 159 (60.00) 
 OR (95% CI)  1.00 1.23 (0.98-1.54) 1.35 (1.00-1.83)c 
CI, confidence interval; ER, estrogen receptor; IDC, infiltrating ductal carcinoma; OR, odds ratio; PR, progesterone receptor. aTwo-sided χ2 test 
for difference in frequency distribution of variables between IQGAP1 genotypes. bDue to missing values, n is <1,541. cStatistically 
significant.
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Table IV. Association of the IQGAP1 polymorphism with clinical characteristics of breast cancer in estrogen receptor-negative 
cases.
 IQGAP1 rs1042538 (A/T) genotype frequency
 ---------------------------------------------------------------------------------------------------------------
Variables No. of AA AT TT P-valuea
   patients (n=224) (n=314) (n=125) 
Tumor size 603b    
 ≤2 cm  64 (32.00)   97 (33.68) 36 (31.30) 0.873
 >2 cm  136 (68.00) 191 (66.32) 79 (68.70) 
 OR (95% CI)  1.00 0.93 (0.63-1.36) 1.03 (0.63-1.69) 
Lymph node metastases 663    
 No  129 (57.59) 199 (63.38) 78 (62.40) 0.381
 Yes  95 (42.41) 115 (36.62) 47 (37.60) 
 OR (95% CI)  1.00 0.79 (0.55-1.11) 0.82 (0.52-1.28)  
Clinical stage 603b    
 0+I  41 (20.60) 74 (25.61) 27 (23.48) 0.441
 Ⅱ+Ⅲ+Ⅳ  158 (79.40) 215 (74.39) 88 (76.52) 
 OR (95% CI)  1.00 0.75 (0.49-1.16) 0.85 (0.48-1.47) 
morphology 663    
 IDC  158 (70.54) 223 (71.02) 93 (74.40) 0.721
 Others  66 (29.46) 91 (28.98) 32 (25.60) 
 OR (95% CI)  1.00 0.98 (0.67-1.42) 0.82 (0.50-1.35) 
PR 662b    
 -  173 (74.76) 217 (70.21) 80 (63.30) 0.022
 +  51 (25.24) 96 (29.79) 45 (36.70) 
 OR (95% CI)  1.00 1.50 (1.01-2.23)c 1.91 (1.18, 3.09)c 
CI, confidence interval; IDC, infiltrating ductal carcinoma; OR, odds ratio; PR, progesterone receptor. aTwo-sided χ2 test for difference in 
frequency distribution of variables between IQGAP1 genotypes. bDue to missing values, n is <663, the total number of patients with AA, AT, 
or TT genotypes. cStatistically significant.
Figure 2. IQGAP1 expression in tumor tissue with IQGAP1 AA or TT genotypes. (A) Comparison of IQGAP1 expression at mRNA level between IQGAP1 
genotypes (AA and TT) in breast cancer tissue. The difference of IQGAP1 mRNA between the TT genotype and the AA genotype was not significant 
(rank-sum test, P=0.109). (B) Comparison of IQGAP1 expression at protein level between IQGAP1 genotypes (AA and TT) in breast cancer tissue. IQGAP1 
protein was higher in TT genotype than in AA genotype, the difference between the TT genotype and the AA genotype was statistically significant (rank-sum 
test, P=0.039). 
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other studies have also shown an association between genetic 
variations and PR status. In a case-control study with more 
than 9,000 subjects, Pooley et al (35) found that a coding 
SNP (rs3218536) in one of the DNA double-strand break 
repair genes, XRCC2, was strongly associated with risk of 
developing PR-positive breast cancer. In another study, 
Synowiec et al (36) reported an association between the 
RAD51-135G/C polymorphism and PR expression (OR=6.33; 
95% CI=1.15-35.01).
Our results suggest a number of possibilities. First, IQGAP1 
expression in breast cancer may not be strongly regulated by 
miR-124, and thus the SNP site for miR-124 binding may be 
irrelevant. Although we do not have direct evidence to support 
this possibility, one study found that miR-124 promoter is 
methylated in acute lymphoblastic leukemia (ALL) and that 
the expression of miR-124 in ALL is very low (37). Our 
analysis of miR-124 expression supported this observation 
that miR-124 is decreased in cancer tissue compared with 
adjacent normal tissue. A second scenario is that IQGAP1 
expression levels may be less important to breast cancer 
because other genes in the same pathway are more activated. 
If this is true, then the expression of IQGAP1 should not be 
correlated with prognosis of breast cancer. We tested this 
hypothesis by examining the gene expression profile data in 
the public domain and showed that indeed, IQGAP1 expression 
levels in two breast cancer datasets did not correlate with 
grade or metastasis. We also showed that IQGAP1 expression 
did not correlate with grade in gastric cancer. In contrast, 
IQGAP1 expression levels were associated with grade and 
poor survival in gliomas, consistent with the literature.
In this study, we could not evaluate the association between 
IQGAP1 SNP genotypes and breast cancer survival, mainly 
because the breast cancer cases recruited for our study were 
relatively recent, which meant that there was not enough 
follow-up time for analysis of survival or distant metastasis. 
However, in the van't Veer et al (38) study, clinical follow-up 
of 78 breast cancer patients for more than 5 years after 
lumpectomy showed that IQGAP1 expression levels were not 
correlated with distance metastasis. Therefore, the role of 
IQGAP1 in cancer prognosis is apparently dependent on cancer 
type.
In conclusion, we have conducted the first epidemiologic 
study of the association between the IQGAP1 SNP within the 
miR124 binding site and breast cancer risk. Our study showed 
that the regulation of IQGAP1 could be complex and that the 
role of IQGAP1 in cancer cannot be generalized. However, 
the role of this SNP in cancer risk may be broader because of 
the different frequency distributions of demographic variables, 
risk factors, and alleles of the IQGAP1 polymorphism between 
Chinese women and women of other ethnic groups. Because 
of its potential significance, this study should be replicated with 
populations of various ethnic backgrounds. Once validated, 
this SNP may be important for genetic testing and screening 
of individuals at high risk of breast cancer. 
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ancer
. Introduction
MicroRNAs (miRNAs) are small non-coding RNAs (ncRNAs),
pproximately 20 nucleotides (nt) in length, that regulate gene
xpression posttranscriptionally by binding to 3′untranslated
egions (UTR), coding sequences or 5′UTR of target messenger RNAs
mRNAs), and leading to inhibition of translation or mRNA degra-
ation [1–3]. It is estimated that miRNAs regulate approximately
0% of the human protein-coding genome [1].  miRNAs control the
xpression of genes involved in several biologic processes, includ-
ng apoptosis, proliferation, differentiation, and metastasis [1–3].
Two decades ago, both the existence and the importance of
iRNAs were completely unknown. Until then, the scientiﬁc com-
unity focused on genes that codify for protein. The classical
ogma that DNA is transcribed into RNA, which then is translated
nto protein, pushed aside the study of all the non-protein-coding
equences. Only in 1993 did the importance of miRNAs begin to be
evealed [4,5]. This review will highlight the pioneer studies that
ave contributed to the brief history of miRNAs (Fig. 1).
. Discovery of the ﬁrst miRNA: lin-4
Lin-4 was the ﬁrst miRNA to be discovered, in 1993, by the
oint efforts of Ambros’s and Ruvkun’s laboratories [3,4]. In the
ematode Caenorhabditis elegans,  heterochronic genes control the
emporal development pattern of all larval stages. One of these
enes is lin-4, discovered by the isolation of a null mutation that
∗ Corresponding author. Tel.: +1 713 792 5461; fax: +1 713 745 4528.
E-mail addresses: gcalin@mdanderson.org, inesalme@gmail.com (G.A. Calin).
027-5107/$ – see front matter ©  2011 Elsevier B.V. All rights reserved.
oi:10.1016/j.mrfmmm.2011.03.009causes a failure in temporal development [6,7]. Animals with lin-
4 loss-of-function mutations are missing some adult structures,
are incapable of laying eggs, and reiterate early development pro-
grams at inappropriate late larval stages. Lin-4 activity is required
for the transition from the L1 to L2 stage of larval development
[7,8]. In 1987, Ferguson et al., at Horvitz’s laboratory, found that
a suppressor mutation in the gene lin-14 was  able to revert the
null-lin-4 mutation phenotype [9].  In fact, null mutations in lin-14
gene caused an exactly opposite phenotype of the null-lin-4 muta-
tions [8,9]. This interesting opposite phenotype between defects in
lin-4 and lin-14 genes indicated that lin-4 could negatively regu-
late lin-14 [8]. In 1989, Ambros worked with Ruvkun, at Horvitz’s
laboratory, to clone the lin-14 gene [8,10].  At this time, the two col-
leagues followed two  independent research careers, with Ambros
focusing on the lin-4 gene and Ruvkun on the lin-14 gene.
Ambros, together with Lee and Feinbaum, found that a 700-bp
fragment could contain lin-4 gene but could not ﬁnd the conven-
tional start and stop codons. Even so, they introduced mutations
in the putative open reading frame but lin-4 function remained
unchanged. Therefore, Ambros concluded that lin-4 did not encode
a protein [4,8]. In addition, they found two  very small lin-4 tran-
scripts of only 61 nt and 22 nt in length [4].  On the other hand,
Ruvkun and his colleagues Wightman and Ha found that lin-14 was
downregulated at a posttranscriptional level and that the lin-14
3′UTR region was  sufﬁcient for the temporal regulation [5].  The two
groups shared their unpublished data, and in June 1992 Ambros and
Ruvnkun independently came to the same conclusion: lin-4 tran-
scripts were complementary to a repeated sequence in the 3′UTR
of the lin-14 gene [4,5,8].  In December 1993, Ambros and Ruvkun
independently reported in the same issue of Cell that the small and
non-protein-coding transcript lin-4 regulates lin-14 through its 3′
2 M.I. Almeida et al. / Mutation Research 717 (2011) 1– 8
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TR region [4,5,8].  A new unexpected cellular regulatory mecha-
ism involving a non-protein-coding transcript had been found!
. Discovery of a second microRNA: Let-7
Likewise lin-4, let-7 is a heterochronic gene of C. elegans and
as the second miRNA to be discovered, in 2000, seven years after
he ﬁnding of the ﬁrst miRNA. Reinhart et al. at Ruvkun’s labora-
ory reported that let-7 was a 21-nt RNA controlling the L4-to-adult
ransition of larval development [11]. Loss of let-7 activity causes
eappearance of larval cell fates during the adult stage of develop-
ent, while increased let-7 activity causes precocious expression
f adult fates [11]. Remarkably, the authors found that the retarded
et-7 phenotype could partially suppress lin-41 (a let-7 target) loss-
f-function mutations [11]. In fact, let-7 is complementary to two
losely spaced sites in lin-41 3′UTR. Deletion of the lin-41 3′UTR
egion and let-7 mutations abolish lin-41 downregulation, showing
hat both partners are necessary for this mechanism [11–13].
Let-7 controls late temporal transitions during development
cross animal phylogeny. Unlike lin-4, the let-7 sequence is con-
erved across species from ﬂies to humans [14], a fact that had a
ajor effect on the study of miRNAs in other organisms [15,16]. let-
 RNA was detected in vertebrate, ascidian, hemichordate, mollusk,
nnelid, and arthropod but not in RNAs from plant and unicellular
rganisms [14,16]. In humans, it was detected at different expres-
ion levels in the majority of the tissues, including brain, heart,icroRNA; UTR: untranslated regions; CDS: coding sequences; LNA: locked nucleic
kidney, liver, lung, trachea, colon, small intestine, spleen, stomach,
and thymus [14]. The let-7 miRNA family refers to miRNAs that
share complete sequence identity with let-7 at the 5′ ends, termed
seed regions, and therefore can regulate the same targets [15]. The
let-7 family within humans comprises 12 miRNAs. Some members
of the let-7 family identiﬁed and functionally analyzed in C. ele-
gans include miR-48, miR-84, and miR-241 [17–19]. These miRNAs
act redundantly to control the L2-to-L3 transition, by repressing
hbl-1 [19]. Functional cooperation among miRNA family members
continues to be studied [20].
The discovery that let-7 is conserved across species triggered
a revolution in the research of a new class of small ncRNAs,
called miRNAs. Currently, thousands of miRNAs have been iden-
tiﬁed in humans and other species, and miRNA online sequences
repositories, such as the miRbase database, are available [21–23].
Furthermore, current tools and software developed for miRNA
target prediction facilitate studies of miRNAs functional network
[24,25].
4. miRNA biogenesis pathway and miRNAs functionmiRNAs are encoded in the genome as long primary tran-
scripts (named pri-miRNAs) that contain a cap structure at the 5′
end and are poly-adenylated at the 3′ end. Pri-miRNAs are pro-
cessed by the cellular RNaseII enconucleaseIII Drosha, together
with DGCR8/Pasha proteins, into a structure of 60–110 nt, called
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recursor-miRNA (pre-miRNA), which is then exported from the
ucleus to the cytoplasm by an Exportin-5-dependent mecha-
ism. In the cytoplasm, the pre-miRNA is cleft by the RNaseIII
nzyme Dicer-1, together with TRBP/PACT proteins, producing a
hort imperfect double-stranded miRNA duplex. This duplex is then
nwound by an helicase into a mature miRNA, approximately 20 nt
n length, which is then incorporated into a multicomponent com-
lex constituted by Argonaute family protein members known as
ISC [26].
In a historical perspective, the knowledge acquired from RNAi
as determinant for understanding miRNAs processment and
ctivity. In 2000, Zamore et al. studied the RNAi process and found
hat double-stranded RNA fragments of 21–23 nt were targeting
he mRNA cleavage [27]. The functional unit of RNAi was there-
ore the same size as miRNAs. In 2001, two reports were crucial for
lucidation of the miRNA biogenesis mechanism, as both reports
uggested an involvement of RNAi pathway components in miRNAs
aturation [28,29].  Grishok and colleagues showed that a homo-
ogue of Drosophila Dicer (dcr-1) and two homologues of rde-1
alg-1 and alg-2) were essential for lin-4 and let-7 activity. Inac-
ivation of these genes caused phenotypes similar to lin-4 and let-7
utations [28]. Simultaneously, Hutvágner et al. found that let-7
re-miRNA is cleaved by Dicer. In fact, when cells were transfected
ith siRNA duplex corresponding to human Dicer enzyme, pre-let-
 accumulated in the cells [29]. Taken together, these two  studies
orroborated the intersection between RNAi and miRNA pathway
nd opened the door for understanding the formation of mature
iRNAs.
In the miRNA biogenesis pathway, Drosha and Dicer are spa-
ially separated, being localized in the nucleus and the cytoplasm,
espectively. In 2004, Lund et al. reported that Exportin-5 was
he key player mediating the efﬁcient nuclear export of the short
iRNA precursors [30]. However, some miRNAs such as miR-29b
re predominantly located in the nucleus [31]. In 2007, Hwang et
l. found that some miRNAs contain additional sequence elements
hat control their subcellular localization. In fact, miR-29b pos-
esses a hexanucleotide terminal motif that directs its import into
he nucleus. These authors showed that, despite the small size of
iRNAs, they can contain additional cis-acting regulatory motifs
hat might inﬂuence their posttranscriptional behavior, and they
oncluded that miRNAs with common 5′ ends, predicted to regulate
he same targets, might have distinct functions [31].
miRNAs’ main function is to inhibit protein synthesis of
rotein-coding genes, either by inhibition of translation or mRNA
egradation. However, the relative contribution of each mecha-
ism to repression was unknown until recently. In an elegant study,
uo et al. used ribosome proﬁling to measure the overall effects
n protein production and simultaneously measured effects on
RNA levels. They concluded that inhibition of translation (no
hanges in mRNA levels of miRNA targets) had a modest inﬂuence
n repressing protein levels, whereas mRNA destabilization was
he predominant miRNAs mechanism of action to decrease their
argets levels [32].
In addition to mRNAs repression, miRNAs have been also
eported to activate translation of targeted mRNAs [33,34].  Vasude-
an et al. were the ﬁrst to clearly demonstrate that, in some
nstances, miRNAs can work as translational activators. TNF
U-rich elements recruited miR-369-3 to mediate translation
pregulation, exclusively under serum starvation conditions. In
ddition, upon cell cycle arrest, let-7 and the synthetic miRNA-
xcr4 induced translation, whereas they repressed translation in
roliferating cells. Therefore, miRNAs can switch between transla-
ion repression and activation in coordination with the cell cycle
34]. In 2008, Place et al. provided new evidence that miRNAs can
nduce gene expression and were the ﬁrst to show that miRNAs
an target gene promoters. These authors showed that miR-373esearch 717 (2011) 1– 8 3
targets the promoter of E-cadherin and CSDC2 and induced their
expression [35].
For a long time, studies on miRNA-target interaction were con-
ﬁned to 3′UTR of mRNAs, probably because the ﬁrst studies on miR-
NAs focused on this region. In 2007, Lytle et al. were the ﬁrst to sug-
gest that miRNAs could associate to any position of target mRNAs
and demonstrated that mRNA targets were efﬁciently repressed
by miRNA-binding sites in 5′UTR [36]. In 2008, Tay et al. reported
that binding sites in coding sequences are abundant and exper-
imentally showed that mouse Nanog,  Oct4, and Sox2 genes have
miRNA-binding sites in their coding sequences. MiRNAs targeting
these genes modulate embryonic stem cell differentiation [37].
In 2010, Eiring et al. reported a remarkable ﬁnding for our under-
standing of how miRNAs function. These authors found that, in
addition to miRNAs gene silencing activity through base pairing
with mRNA targets, miRNAs also have decoy activity that inter-
feres with the function of regulatory proteins [38]. In particular,
miR-328 binds to hnRNP E2 independently of the miRNA’s seed
region and prevents its interaction with CEBPA mRNA [38]. In con-
clusion, these authors introduced the new concept that miRNAs can
work as molecular decoys for RNA-binding proteins [38].
5. MicroRNAs in disease: an historical perspective
5.1. MicroRNAs in cancer
The ﬁrst report suggesting a role of miRNAs in cancer was pub-
lished in 2002 [38]. MiR-15 and miR-16 were found to be located at
chromosome 13q14, a region frequently deleted in chronic lympho-
cytic leukemia (CLL). Calin et al. discovered that both genes were
deleted or downregulated in greater than 60% of B-cell human CLL,
indicating that these genes behave as tumor suppressors in CLL [39].
Consequently, the same group found that a signiﬁcant percentage
of miRNAs is located at fragile sites and in regions altered in can-
cers, including regions of ampliﬁcation or loss of heterozygosity or
breakpoints, suggesting that miRNAs as a new class of genes had a
relevant role in human cancer pathogenesis [40].
Oligonucleotide miRNA microarrays and, more recently, deep
sequencing (next generation sequencing) have permitted the anal-
ysis of the entire known miRNAome. In addition, other methods
such as bead-ﬂow cytometry, quantitative real-time polymerase
chain reaction, and high-throughput array-based Klenow enzyme
assay have been used to assess miRNA expression in tumors
and other diseases. To date, altered miRNA expression had been
reported in almost all types of cancer [41].
In 2005, the ﬁrst reports addressing the biological function of
miRNAs in cancer were published. MicroRNAs can act as onco-
genes (oncomirs) or tumor suppressors and are involved in a variety
of pathways deregulated in cancer [42]. In March 2005, Johnson
et al. reported the ﬁrst miR-target interaction with relevance to
cancer. The authors demonstrated that in C. elegans let-7 targets
let-60, encoding the C. elegans ortholog of human oncogene RAS.
In addition, they showed that human RAS expression is regulated
by let-7 in cell culture. Accordingly, let-7 expression is decreased
in lung cancer compared with normal tissue, and it correlates
with the increased RAS protein levels detected in lung tumor sam-
ples [43]. Cimmino et al. reported that miR-15 and miR-16, the
ﬁrst two miRNAs associated with cancer, play a role in apoptosis
regulation by targeting the anti-apoptotic BCL2 mRNA [44]. Also
in 2005, He et al. studied for the ﬁrst time the contribution of
miRNAs to tumor development in vivo. By overexpressing the miR-
17-22 cluster, which is upregulated in human lymphoma, they were
able to accelerate lymphomagenesis in a mouse B-cell lymphoma
model carrying c-myc oncogene [45]. Furthermore, O’Donnell et al.
reported for the ﬁrst time that a transcription factor, speciﬁcally
MYC, modulated the expression of the same cluster of miRNAs
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nd consequently the E2F1 expression [46]. From 2005 until the
resent, hundreds of scientiﬁc communications have reported on
he role of miRNAs in tumors, as well as the regulation of miR-
As by other transcription factors such as TP53 (for a detailed
eview see [47]). In 2010, Medina et al. reported results in mice that
onditionally overexpressed miR-21 (without other predisposing
enetic backgrounds), clearly demonstrating that overexpression
f a single miRNA, speciﬁcally miR-21, was sufﬁcient to cause tumor
evelopment. In addition, these authors proved that tumor volume
nd survival were dependent on miR-21 overexpression and that
he tumors regressed when miR-21 was inactivated, proving for the
rst time an oncogenic miRNA addiction for tumor cells [48].
MicroRNAs deregulation can be caused by several mechanisms
ncluding deletion, ampliﬁcation, mutation, or dysregulation of
ranscription factors that target speciﬁc miRNAs. In addition, miR-
As can be controlled by epigenetic mechanisms. In 2006, Saito
t al. were the ﬁrst to demonstrate that miRNAs expression could be
ontrolled by the two major epigenetic mechanisms: DNA methy-
ation and histone modiﬁcations [49,50].  When Saito et al. simulta-
eously treated a human bladder carcinoma cell line with 5-aza-2-
eoxycytidine (a DNA methylation inhibitor) and 4-phenylbutyric
cid (a histone deacetylase inhibitor), 17 of 313 human miRNAs
ere found to be upregulated. In particular, miR-127 was upregu-
ated after treatment with these drugs and expression of one of its
argets, BCL6, was suppressed [49]. Accordingly, miR-127 expres-
ion was downregulated in primary human bladder and prostate
umors compared with normal tissue [49]. Therefore, these authors
oncluded that in cancer tissue miR-127 is subject to epigenetic
ilencing [49]. This ﬁnding opened the ﬁeld of epigenetics to
iRNAs regulation [50]. Interestingly, a bidirectional connection
etween epigenetics and miRNAs has been established. On the one
and, epigenetic mechanisms control miRNAs; on the other hand,
iRNAs can target essential epigenetic key players. One of the
rst reports suggesting methylation could be controlled by miR-
As was published in 2004; Bao et al. suggested that miR-165/166
re important for methylation of PHB gene in Arabidopsis [50,51].
In cancer patients, metastasis is the principal cause of death. The
etastatic process involves multiple steps: cell motility, invasion
f adjacent stroma, intravasation, systemic dissemination (though
ither the blood or lymph), extravasation into the parenchyma of
istant tissues, and ﬁnally proliferation at a new site, giving rise
o secondary tumor. In this process, miRNAs have a dual role as
hey can promote or inhibit metastasis [52]. The ﬁrst ﬁnding about
iRNAs functioning as metastasis activators was reported by Ma
t al. [53]. MiR-10b positively regulates cell migration and invasion
n vitro and is capable of initiating tumor invasion and metas-
asis in vivo. MiR-10b acts by directly targeting HOXD10, which
s a transcriptional repressor of RHOC, a key player in metasta-
is. Concordantly, miR-10b expression is elevated in about 50% of
etastatic breast tumors compared with metastasis-free tumors
r normal breast tissues [53]. Along the same line, Huang et al.
ound that human miR-373 and miR-520c stimulated cancer cell
igration and invasion in vitro and in vivo [54].
In contrast, miRNAs can prevent tumor metastasis. Tavazoie
t al. published the initial study of miRNAs as metastasis sup-
ressors [55]. In breast cancer, patients with low expression levels
f miR-335, miR-126, and miR-206 had a shorter median time to
etastatic relapse. Restoration of their expression in breast cancer
ell lines decreased the number of metastases in inoculated mice.
hese miRNAs have distinct mechanisms for metastasis suppres-
ion: restoration of miR-126 expression signiﬁcantly suppressed
verall tumor growth, whereas restoration of miR-335 or miR-206
evels altered cell morphology, possibly causing a decrease in cell
otility [55].
It was therefore not surprising that Lujambio et al. reported
n 2008 that DNA methylation-associated silencing of tumor-esearch 717 (2011) 1– 8
suppressor miRNAs contributed to the development of human
cancer metastasis and that the reintroduction of miR-148a and
miR-34b/c in cancer cells with epigenetic inactivation inhibited
their motility, reduced tumor growth, and inhibited metastasis for-
mation in xenograft models, with an associated downregulation of
the miRNA oncogenic target genes, such as C-MYC, E2F3, CDK6, and
TGIF2 [56].
5.2. MicroRNAs in cardiovascular diseases
In 2005, Zhao et al. reported that miR-1-1 and miR-1-2 were
speciﬁcally expressed in cardiac and skeletal muscle precursor cells
and that miR-1 regulates ventricular cardiomyocytes. MiR-1 over-
expression speciﬁcally in the developing heart of a mouse model
led to a decreased pool of proliferating ventricular cardiomyocytes
[57]. In the same year, Kwon et al. found that miR-1 in Drosophila
modulates cardiogenesis [58]. Subsequently, Chen et al. in 2006
reported that miRNA-1 promotes myogenesis, whereas miR-133,
clustered together with miR-1 on mouse chromosome 2, stimu-
lates myoblast proliferation [59]. These three reports were the ﬁrst
to suggest a possible involvement of miRNAs in cardiac-related
human diseases. van Rooij et al. published the ﬁrst report associat-
ing miRNAs with heart failure and cardiac hypertrophy [60], which
occurs in response to stress and injury and is characterized by an
increase in cardiomyocyte size with no change in myocyte number
[61]. By miRNA microarray analysis, more than 12 miRNAs were
identiﬁed as deregulated during cardiac hypertrophy and heart
failure [60]. Interestingly, overexpression of miR-195 led to heart
failure in a mouse model and to hypertrophic growth of cultured rat
cardiomyocytes [60,61]. Several subsequent studies demonstrated
miRNA aberrant patterns in cardiac hypertrophy and analyzed their
roles [61], including that of miR-21, which is also one of the most
deregulated miRNAs in cancer [62,63], suggesting common miRNA
pathways involved in both abnormal states.
5.3. MicroRNAs in autoimmune diseases
Psoriasis is the most prevalent chronic inﬂammatory skin
disease in adults and the ﬁrst inﬂammatory disease in which
miRNAs were implicated [64]. In 2007, Sonkoly et al. found that
miR-203, which is expressed in keratinocytes, is upregulated in
psoriasis-affected skin compared with healthy human skin or
another chronic inﬂammatory skin disease. Interestingly, miR-203
targets SOCS-3 [64]. It had previously been found that SOCS-3
suppression leads to sustained activation of STAT3 in response
to IL-6 and that constitutive activation of STAT3 in keratinocytes
leads to the spontaneous development of psoriasis in mice [64–66].
MiR-146 is the other miRNA that Sonkoly et al. found associated
with psoriasis. It was  found upregulated in psoriasis patients and
is absent from keratinocytes and dermal ﬁbroblasts but expressed
by immune cells [64]. The upregulation of a miRNA associated with
inﬂammation is not surprising because results from several studies
support a role of a deregulated immune system in psoriasis [67].
MiR-146 targets IRAK1 and TRAF6, both regulators of the TNF-
signaling pathway [68]. Treatments using anti-TNF agents such as
inﬂiximab, etanercept, and adalimumab are effective for psoriasis
[69,70]. Therefore, future studies should address treatments with
miR-203 and miR-146 antagomirs for psoriasis patients to improve
their quality of life [64].
Rheumatoid arthritis (RA) is a systemic autoimmune disorder
characterized by chronic inﬂammation of synovial tissue [71]. In
2008, three studies reported the ﬁrst association studies between
RA and miRNAs. Stanczyk et al. found increased expression of miR-
155 and miR-146 in RA synovial ﬁbroblasts and RA synovial tissue
[72]; one month later, Nakasa et al. conﬁrmed the expression of
miRNA-146 in RA synovial tissue and further described its induc-
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ion by stimulation with TNF and IL-1 [73]. In the same year, Pauley
t al. reported increased expression of miR-146 in RA peripheral
lood mononuclear cells, similar to the results found in synovial
issue/ﬁbroblasts [74]. Taken together, these results suggest that
iR-146 can be used as a biomarker for RA. In addition, several
ther miRNAs have been implicated in RA, such as miR-155, miR-
32, miR16 [75], miR-346 [76], and miR-223 [77].
For lupus erythematosus (SLE), an autoimmune disorder char-
cterized by excessive production of a variety of auto-antibodies
gainst several self-antigens [78], few studies have been published
bout the differently expressed miRNAs. Nonetheless, miRNAs
ight be implicated in the etiology of this disease, and evidence
uggests that miRNAs are potential diagnostic markers in SLE
79–82]. Dai et al. described for the ﬁrst time 16 miRNAs dif-
erently expressed in SLE [79]. These authors were also the ﬁrst
o describe 66 miRNAs differently expressed in patients with
upus nephritis [83]. Several studies in 2010 conﬁrmed the link
etween miRNAs and SLE/lupus nephritis. Two miRNAs (miR-21
nd miR-148a) are overexpressed in CD4+ T cells from patients
ith lupus. MiR-148a directly downregulates DNMT1 expression
nd miR-21 indirectly downregulates DNMT1 expression by target-
ng RASGRP1, an important autoimmune gene. By causing DNMT1
ownregulation, both miRNAs contribute to DNA hypomethyla-
ion in lupus CD4+ T cells [80]. Te et al. analyzed miRNAs in lupus
ephritis patients from two racial groups (African American and
uropean American) and concluded that ﬁve miRNAs (miR-371-5P,
iR-423-5P, miR-638, miR-1224-3P, and miR-663) were differen-
ially expressed across different racial groups [81]. Recently, Zhao
t al. showed that miR-125 expression was reduced, and accord-
ngly expression of its predicted target KLF13 was  increased, in SLE
atients [82].
Although further studies with larger numbers of samples are
ecessary, these studies implicate miRNAs in immune disease
athogenesis and suggest that they can be used as potential diag-
ostic markers.
.4. MicroRNAs in neurodegenerative diseases
A signiﬁcant number of miRNAs is speciﬁcally expressed in the
entral nervous system and plays a role in neuronal development
84]. Consequently, it seems natural that miRNAs have been linked
o neurodegenerative diseases such as Alzheimer’s, Parkinson’s,
nd Huntington’s disease, which are caused by excessive neuronal
eath in the diseased brain [85]. In 2007, there were reported
he ﬁrst studies associating miRNAs with neurodegenerative dis-
ases. Using Purkinje cells, Schaefer et al. suggested an involvement
f miRNAs in neurodegenerative disorders by showing progres-
ive neurodegeneration (cerebellar degeneration and development
f ataxia) in the absence of the miRNA biogenesis key compo-
ent DICER, which consequently causes progressive loss of miRNAs
86,87]. Lukiw et al. found that miR-9, miR-25b, and miR-128 were
pregulated, and that miR-124a was downregulated, in Alzheimer’s
isease brain (hippocampal region) samples when compared with
ged-match controls [88,89]. In the same year (2007), an miRNA
mportant for maturation and function of dopaminergic neurons,
iR-133b, was one of the ﬁrst miRNAs reported to be lost in mid-
rain tissue in Parkinson’s disease [90].
MiRNA expression proﬁles for neurodegenerative diseases are
hallenging for two main reasons: (1) some miRNAs are expressed
peciﬁcally by only some brain regions or brain cell types; and
2) unlike cancer, it is much more challenging to obtain disease-
ffected and healthy tissue from the same patient, which in turn
akes it more difﬁcult to control these types of studies [91]. Since
007, several studies have linked miRNA modiﬁcations to regu-
ation of proteins involved in these diseases [92]. Although studies
eem to indicate that miRNAs can participate in neurodegenerativeesearch 717 (2011) 1– 8 5
disease initiation or progression, more work is necessary to clarify
whether changes in miRNA expression directly contribute to the
pathogenesis of neurodegenerative diseases or whether they are
secondary events caused by deregulated pathways in these diseases
[89]. It is predicted that in the next few years, increased research
on miRNAs will lead to novel insight in this ﬁeld [91].
6. MicroRNAs as molecular biomarkers
In a clinical context, miRNAs can be extremely useful in disease
diagnosis and prognosis and in prediction of therapeutic response.
In 2004, Takamizawa and coworkers were the ﬁrst to pinpoint the
prognostic value of miRNAs by showing that let-7 expression was
reduced in lung cancers and that lung cancer patients with low
let-7 expression levels have a signiﬁcantly shorter survival after
potentially curative resection [93]. In 2005, Calin et al. reported
the ﬁrst study showing the diagnostic/prognostic importance of
miRNAs at the genome-wide level [94]. These authors found that
miRNA expression proﬁles could be used to distinguish normal B
cells from malignant B cells in patients with CLL. In fact, a unique
miRNA expression signature is associated with prognostic factors
such as ZAP-70 expression (predictor of early disease progression)
and mutational status of IgVh. In addition, these authors found
nine miRNAs that were differently expressed between patients
with a short interval from diagnosis to initial therapy and patients
with a signiﬁcantly longer interval. Furthermore, this study also
highlighted the fact that one mechanism of miRNA deregulation
is mutation: a germline mutation in the precursor of miR-16-1-
miR15a caused low levels of miRNA expression both in vitro and
in vivo [94].
Currently, the clinical utility of miRNAs as diagnostic/prognostic
biomarkers has been demonstrated in several types of cancer by
numerous studies using tumor samples removed during surgery
or biopsies [42]. For non-malignant diseases, however, larger and
more studies should be conducted.
7. MicroRNAs as biomarkers in plasma or serum
Current techniques for cancer diagnosis commonly involve a
biopsy of the cancer tissue. Because this technique is invasive and
unpleasant for patients, some studies have been focused on the
search for biomarkers in human ﬂuids such as plasma/serum, urine,
or saliva. Blood samples from patients are usually readily avail-
able and many biological molecules, as circulating nucleic acids,
can be found in blood serum/plasma, including miRNAs [95,96].
These small non-coding RNAs in the blood are incorporated into
microparticles and exosomes (50- to 90-nm membrane vesicles)
that prevent their degradation, conferring an advantage to the
use of miRNAs as markers in serum [95]. In addition, detection of
miRNAs in serum is easy owing to highly sensitive PCR detection
methods, the lack of post-processing modiﬁcations of miRNAs, and
simple methods of miRNAs extraction from serum [95]. The ﬁrst
report addressing the utility of miRNAs as diagnostic tools in bio-
logical ﬂuids was  published in 2008 by Chim et al. in a study that
detected placental miRNAs in the maternal plasma [97]. In the same
year, Lawrie et al. [98], by comparing serum from patients with
diffuse large B-cell lymphoma and healthy controls, found that miR-
155, miR-210, and miR-21 levels were signiﬁcantly upregulated in
patients. Interestingly, these miRNAs have been shown to be dereg-
ulated in tumors. Moreover, high expression of miR-21 in patients
serum was correlated with improved relapse-free survival times
[98]. To date, miRNAs deregulation in serum of cancer patients have
been described for several cancers, including leukemia, lymphoma,
and gastric, colorectal, lung, oral and squamous cell, breast, ovarian,
prostate, pancreatic, and hepatocellular cancers [96].
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Furthermore, a recent report analyzed miRNAs plasma levels
n patients with RA or osteoarthritis. Remarkably, plasma miR-
32 was signiﬁcantly higher in healthy controls than in RA or
steoarthritis patients and therefore it can be a potential diagnostic
arker. In addition, plasma miRNA levels correlated with disease
ctivity in RA. However, miRNAs included in this study failed to
ifferentiate between RA and osteoarthritis. Thus, other miRNAs
peciﬁc to each disease should be studied. Interestingly, this study
lso analyzed miRNAs present in synovial ﬂuid and demonstrated
hat miRNAs from plasma and from synovial ﬂuid have different
rigins [99,100].
To translate the evaluation of miRNAs expression in serum
nto a clinical routine for diagnosis and prognosis, it is still nec-
ssary to standardize the methodologies used for these studies,
.e., serum/plasma extraction procedures and storage conditions,
ousekeeping miRNAs for normalization in serum samples, or the
se of the same statistical methods for data analysis [95]. In addi-
ion, large studies reporting miRNA levels in plasma and serum with
etailed clinical data information, together with normal controls
rom both sexes and different ages, are still needed [96].
. Therapeutic implications
MiRNAs are aberrantly expressed in several diseases; therefore,
t is not surprising that these small ncRNAs represent potential
herapeutic targets for the diseases they are functionally asso-
iated with. MiRNAs that are upregulated in diseases should be
argeted using anti-miRNAs, which are antisense oligonucleotides
ith speciﬁc modiﬁcations [101]. For instance, antagomirs, a class
f anti-miRNAs that is cholesterol-conjugated to facilitate cellular
ntake and serum protein binding, could be used to block oncomirs
n cancer [101,102].  In 2004, Hutvágner et al. successfully copied
he phenotype of let-7 loss-of-function mutation by injecting a
′-O-methyl oligonucleotide complementary to let-7 miRNA into
. elegans larvae [103]. In 2005, Krützfeldt et al. reported for the
rst time the use of antagomirs in vivo in mammals [104]. Using
 mouse model, Krützfeldt and colleagues systemically delivered
ia intravenous injection antagomirs against miR-16, miR-122,
iR-192, and miR-194 that speciﬁcally downregulated the cor-
esponding miRNAs. Silencing of miRNAs using antagomirs was
ong lasting, and miR-16-antagomir effects were detected in mul-
iple tissues, except in the brain, possibly due to the blood-brain
arrier [101,102,104,105].  Other approaches to efﬁciently inhibit-
ng miRNAs in vivo include the use of locked nucleic acid (LNA)
ligos or 2′-O-methoxyethyl phosphorothioate (MOE) modiﬁca-
ion [102]. Elmén et al. evaluated for the ﬁrst time the effect
f an LNA-anti-miRNA in non-human primates, with surprising
esults. These authors intravenously injected an LNA-anti-miRNA-
22 into African green moneys and were able to efﬁciently silence
he mature miR-122. The effect was long-lasting and safe, as nei-
her toxicity associated with LNA nor histopathological changes
ere detected [106]. Two years later, Lanford et al. described the
tility of anti-microRNAs for the clinical practice. MiR-122 is a liver-
xpressed miRNA essential for hepatitis C virus (HCV) replication.
sing an LNA-anti-miR-122, the authors were able to suppress HCV
iremia in chronically HCV-infected chimpanzees. Moreover, this
herapy generated a high barrier to resistance, and no side effects
ere detected [107].
In addition to these direct-inhibitory methodologies, an indi-
ect technology can be used through downregulation of miRNA
iogenesis pathway components. Tetracycline-inducible shRNAs
ould be used to downregulate Dicer or Drosha, key components of
he miRNA-biogenesis pathway; however, this mechanism should
e tightly controlled, as downregulation of this pathway will have
n effect on all miRNAs [101,102].esearch 717 (2011) 1– 8
On  the other hand, when miRNAs downregulation promotes dis-
ease, as it is the case of some miRNAs downregulated in tumors and
that function as tumor suppressors, a therapeutic approach would
be to restore the mature miRNA levels in the proper tissue/cells. In
this situation, it should be used synthetic RNA duplexes, resembling
siRNA molecules, that will mimics miRNAs duplex and will be rec-
ognized by RISC complex [102]. This complex will process it as the
endogenous miRNA, by loading the stand with the sequence identi-
cal to the mature miRNA. This approach still needs to be evaluated in
vivo because some challenges, such as stability and delivery strate-
gies, need to be improved [101,102,108].  The use of short-hairpins
driven by Pol III promoters could be a strategy for re-expression
of miRNAs in the cells [108], although the dosage used in this
mechanism has to be narrowly controlled, since sustained shRNA
high-level expression in livers of adult mice has been shown to be
fatal [109]. In 2009, Kota et al. demonstrated how useful systemic
administration of miRNAs can be for anti-cancer therapy. MiR-26a
is expressed at low levels in hepatocellular carcinoma but normally
expressed in other tissues. These authors used an adeno-associated
virus to mediate miR-26a delivery in a mouse model of liver cancer
and were able to reduce cancer cell proliferation and induce tumor
cell apoptosis, which consequently caused tumor regression. Since
only cancer cells present miR-26a downregulation, the delivery was
highly speciﬁc and did not affect normal tissue, which was tolerant
to miR-26a restoration [110].
9. Concluding remarks
MiRNAs were discovered in 1993 and rapidly became an excit-
ing topic of research during the last decade, with the number of
published studies growing exponentially. Like miRNAs, other ncR-
NAs have recently been linked to diseases [111,112].  Therefore, we
may  predict that our understanding of how other classes of ncR-
NAs mediate disease regulation will advance rapidly. Also, we fully
acknowledge that before the “miRNA revolution” started, the lit-
erature was recording few pioneering studies on the roles of long
RNAs that do not codify for proteins (for review see Mattick [113]).
It is expected that in future years the acquired biological knowl-
edge concerning miRNAs can be widely translated into the clinic.
Despite major challenges that still need to be overcome (such as
tissue-speciﬁc delivery), miRNAs hold great potential as therapeu-
tic targets.
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MicroRNA Down-Regulated in Human
Cholangiocarcinoma Control Cell Cycle Through
Multiple Targets Involved in the G1/S Checkpoint
Alexandru V. Olaru,1* Gabriel Ghiaur,2* Sumitaka Yamanaka,1 Delgermaa Luvsanjav,1 Fangmei An,1
Irinel Popescu,3 Sorin Alexandrescu,3 Sarah Allen,4 Timothy M. Pawlik,5 Michael Torbenson,6
Christos Georgiades,7 Lewis R. Roberts,8 Gregory J. Gores,8 Anne Ferguson-Smith,4 Maria I. Almeida,9
George A. Calin,9 Esteban Mezey,1 and Florin M. Selaru1
MicroRNAs (miRs) recently emerged as prominent regulators of cancer processes. In the cur-
rent study we aimed at elucidating regulatory pathways and mechanisms through which miR-
494, one of the miR species found to be down-regulated in cholangiocarcinoma (CCA), partic-
ipates in cancer homeostasis. miR-494 was identiﬁed as down-regulated in CCA based on miR
arrays. Its expression was veriﬁed with quantitative real-time reverse-transcription polymerase
chain reaction (qRT-PCR). To enforce miR expression, we employed both transfection meth-
ods, as well as a retroviral construct to stably overexpress miR-494. Up-regulation of miR-494
in cancer cells decreased growth, consistent with a functional role. mRNA arrays of cells
treated with miR-494, followed by pathway analysis, suggested that miR-494 impacts cell cycle
regulation. Cell cycle analyses demonstrated that miR-494 induces a signiﬁcant G1/S check-
point reinforcement. Further analyses demonstrated that miR-494 down-regulates multiple
molecules involved in this transition checkpoint. Luciferase reporter assays demonstrated a
direct interaction between miR-494 and the 30-untranslated region of cyclin-dependent kinase
6 (CDK6). Last, xenograft experiments demonstrated that miR-494 induces a signiﬁcant can-
cer growth retardation in vivo. Conclusion: Our ﬁndings demonstrate that miR-494 is down-
regulated in CCA and that its up-regulation induces cancer cell growth retardation through
multiple targets involved in the G1-S transition. These ﬁndings support the paradigm that
miRs are salient cellular signaling pathway modulators, and thus represent attractive therapeu-
tic targets. miR-494 emerges as an important regulator of CCA growth and its further study
may lead to the development of novel therapeutics. (HEPATOLOGY 2011;54:2089-2098)
C
holangiocarcinomas (CCAs) are epithelial can-
cers of the biliary tree.1 CCAs are usually
diagnosed late in their progression and patient
survival is usually measured in months.2 Primary scle-
rosing cholangitis (PSC) is a major CCA risk factor in
the U.S., whereas infection with Opistorchis viverrini
and Chlonorchis sinensis represents a major CCA risk
factor in Southeast Asia.3,4 These observations lead to
the hypothesis that inﬂammation in the biliary tree is
a major predisposing factor to cancer formation.
Abbreviations: APC, allophycocianin; BrdU, bromodeoxyuridine; CCA, cholangiocarcinoma; CCND1, cyclin D1; CCNE2, cyclin E2; CDK4, cyclin-dependent
kinase 4; CDK6, cyclin-dependent kinase 6; DMEM, Dulbecco’s Modiﬁed Eagle’s Medium; eGFP, enhanced green ﬂuorescence protein; FCS, fetal calf serum;
HDAC1, histone deacetylase 1; HuCCT1-EV, HuCCT1-MIEG3-empty control; HuCCT1-494V, HuCCT1-MIEG3-miR494; IPA, ingenuity pathway analysis;
IRES2, internal ribosome entry site 2; MIEG3, MSCV-IRES-enhanced-GFP-3; miR, microRNA; NBD, normal biliary duct epithelia; NSM, nonspeciﬁc mimic;
P/S, penicillin/streptomycin; PSC, primary sclerosing cholangitis; qRT-PCR, quantitative real time RT-PCR; UTR, untranslated region.
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Molecular characterization of CCAs5 further suggested
that inﬂammation and cholestasis, through modulation
of genes involved in DNA damage repair, promote
cancer development.
MicroRNAs (miRs) are short, single-stranded
sequences of RNA that were recently demonstrated to
play a major role in the regulation of virtually all cel-
lular processes.6,7 In addition, microRNAs were also
implicated in all solid cancers evaluated to date.6,8,9
miRNAs act mainly by decreasing protein expression
at a posttranscriptional level, largely through nucleo-
tide complementarity to the 30 untranslated region
(UTR) of corresponding species of messenger RNA
(mRNA).10
The involvement of miRs in the genesis or homeo-
stasis of CCA was reported in several studies. Altera-
tions of miR expression was ﬁrst reported in CCA cell
lines,11 then in human tissues.12 Subsequent studies
demonstrated that the expression of miRs-7a, -29, and
-370 is linked to cholangiocarcinogenesis, either
through an interleukin (IL)-6-dependent pathway, or
by interacting with Mcl-1.13-16 Further work linked
miRs to cholangiocyte immune responses to infection,
suggesting miR implication in inﬂammation-derived
carcinogenesis.17-20
One major hurdle in identifying miR roles and
mechanisms in cancer results from the high number of
predicted targets for any single miR species.21 None-
theless, experimental validation conﬁrms only a small
fraction of these targets.21 To complicate matters, con-
served miR binding sites are as widespread in the open
reading frame as they are in the 30UTR, and are also
common in the 50UTR regions.22 Therefore, employ-
ing in silico search engines as a sole modality to iden-
tify biologically relevant targets appears to have rela-
tively low accuracy. Fortunately, recent work
demonstrated that decreasing amount of the target
mRNA species account for 84% of the miR effects
on protein expression.23 Therefore, it appears that
screening for alterations in mRNA levels in response
to miR manipulation through either mRNA arrays or
sequencing offers a valuable complement to search
strategies employing in silico engines.
In the current study we found that miR-494 is
down-regulated in human CCAs. To obtain a compre-
hensive and unbiased view regarding the effects of
miR-494 in cancer cells, we performed mRNA arrays
on cells overexpressing miR-494 and on negative con-
trol. By employing pathway analysis and then conﬁrm-
ing the results with western blotting we found that
miR-494 exerts moderate effects on multiple molecules
along the canonical G1-S transition pathway. These
actions appear to converge to restore the G1-S check-
point, which explains, at least in part, the delayed
growth of cells expressing miR-494.
Materials and Methods
Human Tissues. The human specimens were
obtained at surgery performed at the Johns Hopkins
Hospital, the Mayo Clinic, and Fundeni Clinical Insti-
tute. The normal bile duct (NBD) specimens were
obtained from surgical resections performed for other
cancers. Informed consent was obtained from all
patients.
Cell Lines. HuCCT1 and TFK1 cells were main-
tained in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) supplemented with 10% fetal calf serum
(FCS), 1000 U/mL penicillin/streptomycin (P/S), as
described.24 H69 cells, a gift from Dr. D. Jefferson
(Tufts University, Boston, MA), are normal human in-
trahepatic cholangiocytes transformed with SV-40.
They were derived from a normal liver prior to liver
transplantation.25
RNA Extraction. Total RNA extraction was per-
formed by lysing cells in TRIzol reagent (Invitrogen,
Carlsbad, CA).
Quantitative Real-Time Reverse-Transcription Po-
lymerase Chain Reaction (qRT-PCR) for miR
Expression. We performed miR qRT-PCR to evaluate
the expression of candidate miRs. TaqMan miR Assays
(Applied Biosystems, Foster City, CA) were used.
Cycle passing threshold (Ct) was recorded and normal-
ized to RNU6B expression. Relative expression was
calculated as 2Ct_miR-Ct_RNU6B. PCR reactions were
carried out in duplicate.
Transfection of miR Mimic. The synthesized miR-
494 mimic was purchased from Dharmacon (Lafayette,
CO). Approximately 30%-50% conﬂuent cells were
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transfected with 60 nM of miR-494 mimic or mimic-
negative control using Lipofectamine RNAi MAX
(Invitrogen). RNA and proteins were harvested 72
hours after transfection.
Western Blotting. Western blotting was performed
per standard protocols. Antibodies to Phospho-Rb,
CDK4, CCND1, and CCNE2 were purchased from
Cell Signaling, and CDK6 was purchased from Santa
Cruz Biotechnology.
Cell Counting. Ten thousand cells were plated in
24-well plates (day 0), transfected 24 hours later (day
1), and counted daily for a total of 5 days (days 2-6)
using a hemocytometer and an inverted-light
microscope.
Complementary DNA (cDNA) Picroarrays and
Filtering Genes. The Illumina cDNA microarray plat-
form in the Johns Hopkins genomics facility was used
for cDNA microarrays. Cells were treated with miR-
494 or NSM and 72 hours later the RNA was
extracted. Candidate genes were ﬁltered as follows:
genes with expression in either HuCCT1 or TFK1
cells under 3,000 units were eliminated from analysis
due to low expression. Genes that demonstrated less
than a 20% decrease in both HuCCT1 and TFK1
cells upon stimulation with miR-494 were eliminated.
From 24,527 tags, the list of genes was reduced to
137. These genes were input into ingenuity pathway
analysis (IPA) to identify the pathways in which they
are involved.
Proliferation Assay with Bromodeoxyuridine
(BrdU) Incorporation. At 72 hours posttransfection,
cells were cultured for 10 minutes with 10 lM BrdU
in DMEM. Subsequently, the cells were ﬁxed and per-
meabilized, then treated with 100 lL PBS, 300 lg/mL
DNase I (BD PharMingen) for 1 hour at 37C in the
dark. After washing, the cells were stained with allo-
phycocianin (APC)-labeled anti-BrdU antibody for 20
minutes at room temperature in the dark and analyzed
by FACSCalibur.
Cell Cycle Analysis by Flow Cytometry. Cells were
incubated with propidium iodide (PI) staining buffer
(phosphate-buffered saline [PBS] 0.1 mg/mL PI, 0.6%
NP40, 2 mg/mL RNase A for 30 minutes on ice
[Roche Diagnostics]). The DNA content was analyzed
using FACSCalibur (BD Biosciences, San Jose, CA)
and Cell Quest software (BD Biosciences). Nocodazole
treatment, where applicable, was performed 24 hours
prior to harvesting cells at a ﬁnal concentration of 100
ng/mL.
Retroviral Vectors, Viral Supernatant Production,
and Viral Transduction. MSCV-based bicistronic ret-
roviral vector, MIEG326 was used to express miR-494.
The genomic DNA sequence from 80 to þ80 of
miR-494 was ampliﬁed using PCR primers ﬂanked by
EcoRI (50) and XhoI (30) and cloned into the multiple
cloning site of MIEG3. The expression of miR-494
was linked with expression of enhanced green ﬂuores-
cence protein (eGFP) by way of internal ribosome
entry site 2 (IRES2).
The plasmid DNA was used to generate viral super-
natant from Phoenix-gp cells as described.27 To stably
express miR-494, 1  105 HuCCT cells were incu-
bated with 3 mL of viral supernatant containing 8
mg/mL of hexadimethrine bromide (Polybrene, Sigma-
Aldrich, Milwaukee, WI). After 6-8 hours, the viral su-
pernatant was discarded and fresh DMEM was added.
Two days after transduction, cells were harvested and
sorted for eGFP expression.
Luciferase Reporter Assay. A portion of the CDK6
30UTR, containing miR-494 predicted binding site,
was ampliﬁed using linker primers containing XbaI
restriction sites. Next we employed the Gene Tailor
Site-Directed Mutagenesis System (Invitrogen) to
introduce mutations in the miR-494 binding site. The
sequences of primers is provided in the Supporting
Materials. After sequence veriﬁcation, 6,000 cells per
well were seeded onto 96-well plates on the day prior
to transfection. Cells were transfected with miR-494
mimic (Dharmacon) or the control, then with the
pGL3 vector and an internal control pRL-CMV
(Renilla luciferase). Forty-eight hours later the lucifer-
ase reporter assay was performed using a Dual-Glo Lu-
ciferase Assay System (Promega). The luminescence in-
tensity of ﬁreﬂy luciferase was normalized to that of
Renilla luciferase. The effect of miR-494 on the wild-
type or mutant CDK6 30UTR was calculated as a frac-
tion of the effect exerted by the negative control
(NSM). The raw data allowing direct comparison of
wildtype and mutant CDK6 30UTR luciferase activ-
ities are available in Supporting Materials.
Subcutaneous Tumor Formation. HuCCT1-
MIEG3-E and HuCCT1-MIEG3-miR494 were grown
in T175 plastic ﬂasks. Then 3.25 million cells were
resuspended in 350 lL of PBS and 200 lL of Matri-
gel. The cells were injected subcutaneously into 6-
week-old NOD/SCID mice (strain 394) purchased
from Charles River Laboratories. Tumors were meas-
ured with a caliper. The reason we chose the NOD/
SCID mouse model instead of the SCID mouse was
based on the following rationale: Severe combined
immune-deﬁcient (SCID) mice have T and B cell deﬁ-
ciencies28; however, they retain residual immunity
from natural killer (NK) cells and complement. The
nonobese diabetic (NOD)/SCID mice represent a
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theoretical advantage for tumor xenotransplantation
compared to the SCID mice because they have less re-
sidual immunity resulting from defects in complement
pathway and macrophage function.29 In addition,
NOD/SCID mice housed in clean conditions may
have fewer NK cells.29 Due to these considerations, we
thought that choosing NOD/SCID mice for our xeno-
transplantation experiments might offer higher tumor
engraftment.
Results
We previously identiﬁed miR species dysregulated in
CCA.28 For the purpose of this study we concentrated
on miRs that were down-regulated in CCA versus nor-
mal biliary duct epithelia (NBD). The arrays were per-
formed on ﬁve NBDs and ﬁve CCAs. Data were ﬁl-
tered as described.30 In brief, raw expression data less
than ﬁve were considered to be at background levels.
We then performed 75th percentile normalization.
miR species demonstrating a statistically signiﬁcant dif-
ference (unpaired Student’s t test) between the CCA
and NBD group were retained for further analyses.
The candidate miRs were then ordered by the mean
expression in NBDs, because a higher expression in
normal tissue is suggestive of a putative role, which
might be lost in cancer. The top ﬁve miRs are dis-
played in Table 1. We selected miR-494 for all subse-
quent studies. To conﬁrm these initial miR array data,
real-time qRT-PCR analysis was performed using 12
human CCA as well as ﬁve normal cholangiocyte
specimens. As shown in Fig. 1A, miR-494 is uniformly
and signiﬁcantly down-regulated in human CCA speci-
mens versus normal specimens. In addition, the level
of miR-494 in a transformed normal cholangiocyte
cell line, H69, was similar to the level found in
NBDs. Correspondingly, the level of miR-494 in a
cholangiocarcinoma cell line, HuCCT1, was similar to
the level found in human primary CCA specimens
(Fig. 1A, last lane). Because H69 and HuCCT1 cell
lines closely mimic the levels of miR-494 in normal
and malignant cholangiocytes, respectively, they were
used as an in vitro model to further characterize the
function of miR-494 in CCA.
To verify our ﬁndings we measured the levels of
miR-494 in a larger cohort of CCA specimens that
was obtained after the screening experiments. As Fig.
1B demonstrates, miR-494 was found to be statisti-
cally signiﬁcantly down-regulated in a group of 43
CCA versus 30 normal tissues.
To characterize the function of miR-494 in cancer,
miR-494-mimic or nonspeciﬁc mimic (NSM) were
transfected into HuCCT1 cells. Cells transfected with
miR-494 showed a signiﬁcant decrease in growth as
early as day 2 and this difference became more obvious
at later timepoints (Fig. 2A). Once we established that
miR-494 promotes decreased cancer cell growth, we
Table 1. miR-494 Is Overexpressed in Human CCA Versus
Normal Biliary Epithelium
Mean NBD Mean CCA NBD/CCA t-test
hsa-miR-494 300.37 32.25 9.314657911 0.01
hsa-miR-370 137.87 13.82 9.973922306 0.00
hsa-miR-513 46.04 3.70 12.45113096 0.00
hsa-miR-188 31.37 2.05 15.28287383 0.00
hsa-miR-560 8.53 1.17 7.298486017 0.02
Microarray data is presented. The top ﬁve downregulated miRs in CCA are
displayed. The miRs are ordered based on the expression of miR-494 in normal
biliary epithelium. NBD, normal biliary duct epithelium; CCA, cholangiocarci-
noma; NBD/CCA, average expression in NBD divided by average expression in
CCA; t-test, unpaired Student’s t-test.
Fig. 1. (A) miR-494 is down-regulated in CCA versus normal biliary epithelium. Crosses, normal cholangiocytes; Circles, malignant cholangio-
cytes; X-axis, specimens; lane 1, H69 normal cholangiocytes; lanes 2-6, primary human normal biliary epithelium; lanes 7-13, primary human
CCA; lane 14, HuCCT1 malignant cholangiocytes. Y-axis, qRT-PCR expression of miR-494 versus RNU6B. (B) qRT-PCR expression of miR-494 is
decreased in a large cohort of CCA versus normal. X-axis, normal and CCA specimens, respectively, are shown. Y-axis, expression of miR-494
versus RNU6B.
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sought to further delineate the speciﬁc mechanisms
underlying its function. First, we conﬁrmed the effects
of miR-494 on cancer cell proliferation. Malignant
HuCCT1 cells were transfected with miR-494 or
NSM and analyzed for BrdU incorporation. As shown
in Fig. 2B, HuCCT1 cells transfected with miR-494
have signiﬁcantly decreased BrdU uptake when com-
pared to cells transfected with NSM, which explains,
at least in part, the difference in their growth.
To obtain a mechanistic view into the effects of
miR-494 in cancer cells, and because miR-induced
destabilization of mRNA is the main reason for
decreased protein levels,23 we stimulated two different
CCA cell lines, HuCCT1 and TFK1 cells, with a
miR-494 mimic and performed cDNA microarray
analysis to quantify changes in mRNA levels. We
added the second CCA cell line to circumvent any
potential cell line-speciﬁc biases. The list of genes
identiﬁed to be down-regulated upon miR-494 stimu-
lation in both cell lines was then ﬁltered and input
into IPA (Ingenuity Systems, Redwood City, CA),
with the purpose of identifying general mechanisms of
miR function. Of note, this analysis was performed on
mRNA species that are reported to be down-regulated
by miR-494 on the cDNA arrays, irrespective of pres-
ence of binding site in the 30UTR or in silico search
engine prediction. IPA reported that the top two net-
works associated with the list of genes regulated by
miR-494 were ‘‘Cell Cycle, Antigen Presentation, Cel-
lular Function,’’ and ‘‘Cell Cycle, Cancer, Genetic Dis-
order,’’ respectively (Supporting Table 1). Furthermore,
the top-ranked molecular and cellular function of the
genes regulated by miR-494 was reported to be ‘‘Cell
Cycle’’ (Supporting Table 1).
Data obtained from (1) cell growth and prolifera-
tion and (2) cDNA arrays coupled with IPA analysis
suggested that miR-494 exerts its function mainly
through regulation of cell cycle. To identify the precise
effects of miR-494 on cell cycle, we performed cell-
cycle analysis by PI staining. These experiments
Fig. 2. (A) HuCCT1 malignant cholangiocytes display decreased growth upon miR-494 reinforced expression. X-axis, HuCCT1 cells counted at
days 1, 2, 3, and 4 after transfection of miR-494. Y-axis, counts 103 of HuCCT1 cells transfected with miR-494 (green line) or the control
NSM (red line). Average of ﬁve experiments, n ¼ 5. (B) HuCCT1 malignant cholangiocytes display decreased proliferation upon miR-494 rein-
forced expression. Flow cytometric analysis of BrdU incorporation of HuCCT1 cells transfected with miR-494 (right panel) or NSM (left panel).
Percentage displayed represent percentage BrdU-positive cells of total cells. X-axis, forward scatter (FSC); Y axis, BrdU incorporation, representa-
tive of three experiments with three replicates per experiment. (C) HuCCT1 display G1 arrest upon reinforced miR-494 expression. Flow cytometric
analysis of cell cycle by way of PI staining of HuCCT1 cells transfected with miR-494 (right panel) or NSM (left panel). X-axis, DNA content as
measured by PI incorporation. Y-axis, cell counts for each phase of the cell cycle. This experiment was performed without nocodazole. The ﬁgure
is representative of three experiments with three replicates per experiment. (D) HuCCT1 cells treated with nocodazole display a more pronounced
G1 arrest upon reinforced miR-494 expression. Flow cytometric analysis of cell cycle upon nocodazole treatment of HuCCT1 cells transfected
with miR-494 (right panel) or NSM (left panel). X-axis, DNA content as measured by PI incorporation. Y-axis, cell counts for each phase of the
cell cycle. This experiment was performed with nocodazole. The ﬁgure is representative of three experiments with three replicates per experiment.
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demonstrate an increased in G0/G1 fraction in miR-
494 transfected cells (Fig. 2C), consistent with data
obtained from BrdU incorporation experiments. This
difference becomes more robust upon treatment with
Nocodazole, a microtubule-destabilizing agent (Fig.
2D). Interestingly, the down-regulation of miR-494 in
HuCCT1 cells has no impact on cell cycle distribu-
tion, presumably because of low baseline levels of
miR-494 in these cells (Supporting Fig. 1). Of note,
the transfection of H69 normal cholangiocytes with
miR-494 had no effect on cell cycle progression de-
spite up-regulation of miR-494 by 18-fold (Supporting
Fig. 2).
To study the molecular mechanisms responsible for
the miR-494-induced G1/S arrest, we queried IPA
with regard to genes impacted by miR-494 that are
also involved in the G1/S checkpoint. As Fig. 3 shows,
based on cDNA microarray data, miR-494 appears to
regulate several molecules involved in the G1/S check-
point. The mRNA levels of cyclin-dependent kinase 4
(CDK4), cyclin-dependent kinase 6 (CDK6), cyclin-
D1 (CCND1), cyclin-E2 (CCNE2), and histone-
deacetylase-1 (HDAC1) decreased following miR-494
stimulation. We then veriﬁed if miR-494 impacts the
protein levels of these targets by treating HuCCT1
cells with miR-494 mimic and performing western
blotting for these putative targets. As seen in Fig. 4A,
expression of miR-494 results in decreased protein lev-
els of CDK6, CDK4, CCND1, CCNE2, and
HDAC1. If the effects of miR-494 on these proteins
are signiﬁcant, then, we hypothesized, the ﬁnal step in
the G1 to S transition checkpoint should be affected.
We therefore determined whether cells treated with
miR-494 showed decreased phosphorylation of Rb. In
accord with our hypothesis, we found a decreasing
level of phospho-Rb in cells treated with miR-494
(Fig. 4A). We therefore concluded that treatment of
cancer cells with miR-494 reinstates the G1/S check-
point through the coordinated down-regulation of
CDK6, CDK4, CCND1, CCNE2, and HDAC1,
resulting in decreased phosphorylation of Rb and,
ﬁnally, delayed cell cycle progression.
The therapeutic up-regulation of miR-494 speciﬁ-
cally in cancer cells, without affecting normal sur-
rounding cells, may prove difﬁcult from a practical
perspective, in particular if high levels of miR-494
Fig. 3. Genes with altered expression upon
miR-494 stimulation are involved in the G1/S
checkpoint. CCND1, CCNE2, CDK4, and
HDAC1 were identiﬁed to be regulated by
miR-494. They are involved in the ﬁnal steps
of G1/S checkpoint regulation. The decreas-
ing levels of these molecules results in
decreased phosphorylated Rb, with the end
result of reinforcement of G1/S checkpoint.
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need to be delivered. To accomplish a lower, more
physiologic level of miR-494 up-regulation than in
transfection experiments, we inserted the genomic
locus of miR-494 in a retrovirus, MSCV-IRES-
Enhanced-GFP-3 (MIEG3). We then infected
HuCCT1 cells with MIEG3-miR-494 and determined
the level of miR-494 up-regulation. Compared to cells
infected with MIEG3 alone, cells infected with
MIEG3-miR-494 displayed a 2.5-fold up-regulation of
miR-494 (Supporting Fig. 3A). Of note, this level of
miR-494 is higher than in CCA, and close to the level
of miR-494 in normal cholangiocytes. In spite of this
modest up-regulation of miR-494, cells infected with
MIEG3-miR494 behaved similarly to cells transfected
with miR-494, displaying restoration of the G1-S
checkpoint (Supporting Fig. 3B).
To study the mechanism of miR-494-directed down-
regulation of CDK6, CDK4, CCND1, CCNE2, and
HDAC1, we searched for conserved binding sites in the
30UTR of these genes by employing TargetScan
(www.targetscan.org). We found that CDK6 is the only
gene that has a conserved binding site in its 30UTR. The
binding site is located at position 228-234 in the
30UTR. A fragment of CDK6 30UTR, containing the
putative miR-494 binding site was cloned into a lucifer-
ase vector. We chose to clone a fragment of CDK6
30UTR because the whole length of the 30UTR is
10,208 nucleotides. Although cloning the whole 30UTR
would have been ideal, previous experience shows that
cloning of large fragments is difﬁcult to achieve due to
the adverse effect of size of insert on ligation and trans-
formation efﬁciencies.31 In addition, the standard in the
ﬁeld is to clone a fragment of the 30UTR containing the
putative miR binding side into the reporter vector.32
Cells transfected with the CDK6 30UTR fragment
showed on average a 30% reduction in luciferase activity
upon treatment with miR-494 compared to a nonspe-
ciﬁc miRNA mimic (NSM). This decrease was statisti-
cally signiﬁcant, with a P-value of less than 0.001 (Stu-
dent’s unpaired t test). Upon miR-494 binding site
mutation, the effect of miR-494 on CDK6 was lost, as
evinced by similar luciferase activity between miR-494
and NSM-treated cells (P ¼ 0.15, Student’s unpaired t
test, Fig. 4B, Supporting Fig. 4).
To study the effects of miR-494 up-regulation in
vivo, we injected HuCCT1-MIEG3-empty (control,
HuCCT1-EV) and HuCCT1-MIEG3-miR494
(HuCCT1-494V) cells subcutaneously in NOD/SCID
mice. Each mouse was injected with 3.25 million
HuCCT1-EV cells in the right ﬂank and with 3.25
million HuCCT1-494V in the left ﬂank. Mice formed
large tumors in the right ﬂank (HuCCT1-EV),
whereas they had very small nodules in the left ﬂank
(HuCCT1-494V, Fig. 5A,B). The mice were sacriﬁced
and the tumors removed and analyzed histologically.
All three HuCCT1-EV tumors were large and formed
almost exclusively of cancer cells. One HuCCT1-494V
mass was completely devoid of cancer cells, one
HuCCT1-cells was composed mainly of inﬂammatory
cells with no clear evidence of cancer, whereas the
third HuCCT1-494V mass had inﬂammatory cells and
very few cancer cells (Fig. 5C; the left panel shows the
histology for HuCCT1-EV and the right panel shows
the histology for HuCCT1-494V).
Fig. 4. (A) Protein expression of miR-494 target genes decrease upon miR-494 stimulation. Representative western blots for CCND1, CCNE2,
CDK4, HDAC1, and phospho-Rb are shown. Equal protein loading was performed, as shown by b-actin. (B) miR-494 directly interacts with bind-
ing site in the 30UTR of CDK6. Y-axis, relative luminescence normalized to the luminescence level in NSM treatment. X-axis, treatment conditions.
NSM, non-speciﬁc mimic; 494M, miR-494 mimic; CDK6, correct orientation fragment of CDK6 30UTR containing miR-494 binding site; CDK6
Mut, fragment of CDK6 30UTR containing a mutated miR-494 binding site. Shown is the standard error of the mean. miR-494 induces a statisti-
cally signiﬁcant decrease in luminescence (P < 0.001, Student’s t test) of the forward CDK6 30UTR fragment versus NSM.
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Discussion
MicroRNAs recently emerged as salient regulators of
cancer homeostasis.33 In addition, there is evidence
that miRs may be valuable as in vivo therapeutics.34,35
In the current study, we report that: (1) miR-494 is
down-regulated in cancer; (2) miR-494 modulates
multiple key players along the canonical G1 to S pro-
gression; (3) miR-494 induces a robust G1 arrest con-
tributing, at least in part, to decreased cancer cell
growth; and (4) miR-494 induces decreased tumor
growth in vivo.
Many miR-based studies published to date focused
on identifying pairs of interacting miR-mRNA.
Although this approach brings invaluable information,
it is of somewhat limited value in characterizing the
global network regulatory effects of miRs. Further-
more, the effects of an miR species on the protein
level of a target mRNA is usually modest, arguing that
the interaction between one miR and one target is
probably not sufﬁcient to account for the effects of
miRs on cell phenotype.36 Therefore, miRs do not
appear to function as on-off switches for any given tar-
get, but rather to function as rheostats to make ﬁne-
scale adjustments on multiple targets with a signiﬁcant
change in cell phenotype.36
The current data suggest that the manipulation of a
sole miR species results in a signiﬁcant phenotypic
effect, such as decreased cancer cell growth. Except for
CDK6, miR-494 exerted less than a 50% decrease in
the level of the proteins tested (CDK4, CCND1,
CCNE2, HDAC1, and phospho-RB). We believe that
the effects of miR-494 are likely the end result of si-
multaneous action on multiple proteins along the
same canonical pathway. Our ﬁndings further solidify
the theory that miRs act as signaling pathway modula-
tors, where relatively modest input may result in large
responses.37 Signaling pathways, which are highly
dynamic, nonstoichiometric systems, with nonlinear
dose-dependent responses, thus appear to be the ideal
theater for miR function.37
The unbiased identiﬁcation of regulatory molecules
downstream of miR-494 by employing cDNA arrays,
followed by western blot veriﬁcation, unraveled a sur-
prising coordination in the actions of miR-494. Our
data suggest that miR-494 is a signiﬁcant modulator
of the G1-S transition canonical pathway by control-
ling expression of proteins involved at multiple steps.
Previous data showed that exposure of murine bron-
chial cells to benzo(a)pyrene (a known carcinogen) up-
regulates several miR species, including miR-494, and
increases the percent of cells in the G1 phase of cell
cycle.38 In the current study we demonstrate that miR-
494 up-regulation in human cancer cells has a direct
effect on cell cycle regulation. We further demonstrate
that miR-494 directly interacts with the 30UTR of
CDK6 and results in a decrease of CDK6 at the pro-
tein level.
In the current article we report that miR-494 acts
on multiple targets involved in the regulation of the
Fig. 5. (A) miR-494 induces can-
cer growth retardation in vivo.
HuCCT1-EV and HuCCT-494V were
injected in mice. The upper panel
shows the tumors formed from
HuCCT1-EV cells, which were signiﬁ-
cantly larger than the tumors formed
from HuCCT1-494V cells (lower
panel). (B) HuCCT1-494V tumors
were signiﬁcantly smaller than
HuCCT1-EV tumors. The mean per-
cent tumor versus mouse body
weight are displayed in the ﬁgure.
(C) HuCCT1-494V masses had no to
very few cancer cells, whereas the
HuCCT1-EV masses were composed
almost exclusively of cancer cells.
The HuCCT1-EV tumors were large
and composed almost entirely of
viable cancer cells. Of the HuCCT1-
494V masses, one had no cancer
cells, the second showed no clear
evidence of cancer cells, and the
third (shown in the ﬁgure) demon-
strates very rare cancer cells amid
inﬂammatory cells and ﬁbrosis.
2096 OLARU ET AL. HEPATOLOGY, December 2011
G1-S transition checkpoint. CDK6 appears to be a
direct target, whereas the rest of the targets appear to
be indirect. We believe that uncovering the rheostat
qualities of miR-494 onto the G1/S transition check-
point and understanding its downstream effectors
sheds new light onto miR-dependent cell growth regu-
lation. Understanding of the global phenotypic effects
of, as well as pathway modulation induced by, miR-
494 is therefore crucial.
We found that, whereas the up-regulation of miR-
494 in cancer cells induced G1 arrest, in normal cells
it did not. Our ﬁndings advocate for a nonlinear rela-
tionship between the level of miR-494 and its effects,
consistent with its involvement in cell signaling path-
ways. Also importantly, the lack of a cell-cycle impact
of miR-494 in normal cells is reassuring from the per-
spective of developing miR-494-based therapeutics for
in vivo delivery.
A previously published article reported that miR-494
is up-regulated in human retinoblastoma compared to
normal retina.39 We report a down-regulation of miR-
494 in human cholangiocarcinoma as well as functional
implications. The fact that miR-494 appears to be up-
regulated in retinoblastoma and down-regulated in chol-
angiocarcinoma is not singular in the microRNA litera-
ture. Previously published studies reported contradictory
expression levels, and sometimes roles, for several miRs
in cancers arising in different organs. We suspect, as
others, that the role of miRs is tissue and/or organ and/
or context speciﬁc. Such examples include miR-31,40,41
miR-126,42,43 and others.
The data presented here suggest that miR-494 may
represent a valuable therapeutic strategy for CCA treat-
ment. In contrast to the more widely studied small
interfering RNA (siRNA) species, miRs may offer the
added beneﬁt of being intrinsic molecular species. We
speculate that because miRs are naturally occurring
species, identifying miRs with impact on cellular func-
tions may be extremely useful for utilizing their built-
in, multi-pathway effects. Although their pervasive
effects on multiple mRNA species may be construed as
detrimental in terms of potential off-target effects, we
hypothesize that it is precisely this quality that makes
miRs potent agents. In addition, we theorize that a
fully developed miR-based anticancer therapeutic agent
will be difﬁcult to evade by cancer cells, speciﬁcally
because of the wide impact of miRs on multiple mole-
cules within the same pathway.
Acknowledgment: We thank Dr. Stephen J. Meltzer
for mentorship and support, Drs. Joshua Mendell, Chi
V. Dang, Victor Velculescu, and James Potter for
invaluable advice and guidance throughout this pro-
ject. We thank Dr. Ralph Hruban and Anirban Maitra
for providing CCA and normal specimens, cell lines,
as well as advice. H69 cells were a gift of Dr. D. Jef-
ferson, Tufts University.
References
1. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis,
diagnosis, and treatment. Hepatology 2008;48:308-321.
2. Farley DR, Weaver AL, Nagorney DM. ‘‘Natural history’’ of unresected
cholangiocarcinoma: patient outcome after noncurative intervention.
Mayo Clin Proc 1995;70:425-429.
3. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence
and risk factors for cholangiocarcinoma in primary sclerosing cholangi-
tis. Am J Gastroenterol 2004;99:523-526.
4. Watanapa P, Watanapa WB. Liver ﬂuke-associated cholangiocarcinoma.
Br J Surg 2002;89:962-970.
5. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epi-
thelial cell carcinogenesis: linking inﬂammation to oncogenesis. Am J
Physiol Gastrointest Liver Physiol 2001;281:G626-634.
6. Mendell JT. MicroRNAs: critical regulators of development, cellular
physiology and malignancy. Cell Cycle 2005;4:1179-1184.
7. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell
2005;122:6-7.
8. Negrini M, Nicoloso MS, Calin GA. MicroRNAs and cancer—new
paradigms in molecular oncology. Curr Opin Cell Biol 2009;21:
470-479.
9. Croce CM. Causes and consequences of microRNA dysregulation in
cancer. Nat Rev Genet 2009;10:704-714.
10. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of
a new tale. Cancer Res 2006;66:7390-7394.
11. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT,
et al. Involvement of human micro-RNA in growth and response to
chemotherapy in human cholangiocarcinoma cell lines. Gastroenterol-
ogy 2010;130:2113-2129.
12. Chen L, Yan HX, Yang W, Hu L, Yu LX, Liu Q, et al. The role of
microRNA expression pattern in human intrahepatic cholangiocarci-
noma. J Hepatol 2010;50:358-369.
13. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The
MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival
signaling in malignant human cholangiocytes. J Biol Chem 2010;282:
8256-8264.
14. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1
protein expression and apoptosis. Oncogene 2007;26:6133-6140.
15. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T. Epigenetic reg-
ulation of microRNA-370 by interleukin-6 in malignant human chol-
angiocytes. Oncogene 2008;27:378-386.
16. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of
DNA methyltransferase-1 and tumor suppressor gene expression by
interleukin-6 in human malignant cholangiocytes. Hepatology 2010;51:
881-890.
17. Chen XM, Splinter PL, O’Hara SP, LaRusso NF. A cellular micro-
RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to
cholangiocyte immune responses against Cryptosporidium parvum
infection. J Biol Chem 2007;282:28929-28938.
18. Gong AY, Zhou R, Hu G, Li X, Splinter PL, O’Hara SP, et al. Micro-
RNA-513 regulates B7-H1 translation and is involved in IFN-gamma-
induced B7-H1 expression in cholangiocytes. J Immunol 2009;182:
1325-1333.
19. O’Hara SP, Splinter PL, Gajdos GB, Trussoni CE, Fernandez-Zapico
ME, Chen XM, et al. NFkappaB p50-CCAAT/enhancer-binding pro-
tein beta (C/EBPbeta)-mediated transcriptional repression of micro-
RNA let-7i following microbial infection. J Biol Chem 2010;285:
216-225.
HEPATOLOGY, Vol. 54, No. 6, 2011 OLARU ET AL. 2097
20. Hu G, Zhou R, Liu J, Gong AY, Eischeid AN, Dittman JW, et al.
MicroRNA-98 and let-7 confer cholangiocyte expression of cytokine-in-
ducible Src homology 2-containing protein in response to microbial
challenge. J Immunol 2010;183:1617-1624.
21. Gunaratne PH, Creighton CJ, Watson M, Tennakoon JB. Large-scale
integration of MicroRNA and gene expression data for identiﬁcation of
enriched microRNA-mRNA associations in biological systems. Methods
Mol Biol 2010;667:297-315.
22. Schnall-Levin M, Zhao Y, Perrimon N, Berger B. Conserved micro-
RNA targeting in Drosophila is as widespread in coding regions as in
30UTRs. Proc Natl Acad Sci U S A 2010;107:15751-15756.
23. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs pre-
dominantly act to decrease target mRNA levels. Nature 2010;466:835-840.
24. Hansel DE, Rahman A, Hidalgo M, Thuluvath PJ, Lillemoe KD, Shulick
R, et al. Identiﬁcation of novel cellular targets in biliary tract cancers using
global gene expression technology. Am J Pathol 2003;163:217-229.
25. Grubman SA, Perrone RD, Lee DW, Murray SL, Rogers LC, Wolkoff LI,
et al. Regulation of intracellular pH by immortalized human intrahepatic
biliary epithelial cell lines. Am J Physiol 1994;266:G1060-1070.
26. Ghiaur G, Lee A, Bailey J, Cancelas JA, Zheng Y, Williams DA. Inhi-
bition of RhoA GTPase activity enhances hematopoietic stem and pro-
genitor cell proliferation and engraftment. Blood 2010;108:2087-2094.
27. Wahlers A, Schwieger M, Li Z, Meier-Tackmann D, Lindemann C,
Eckert HG, et al. Inﬂuence of multiplicity of infection and protein sta-
bility on retroviral vector-mediated gene expression in hematopoietic
cells. Gene Ther 2010;8:477-486.
28. Bosma MJ, Carroll AM. The SCID mouse mutant: deﬁnition, charac-
terization, and potential uses. Annu Rev Immunol 2010;9:323-350.
29. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB,
Tennent B, et al. Multiple defects in innate and adaptive immunologic
function in NOD/LtSz-scid mice. J Immunol 2010;154:180-191.
30. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, et al. Micro-
RNA-21 is overexpressed in human cholangiocarcinoma and regulates
programmed cell death 4 and tissue inhibitor of metalloproteinase 3.
Hepatology 2009;49:1595-1601.
31. Yoshida N, Sato M. Plasmid uptake by bacteria: a comparison of meth-
ods and efﬁciencies. Appl Microbiol Biotechnol 2010;83:791-798.
32. Wu J, Qian J, Li C, Kwok L, Cheng F, Liu P, et al. miR-129 regulates
cell proliferation by downregulating Cdk6 expression. Cell Cycle 2010;
9:1809-1818.
33. Sotiropoulou G, Pampalakis G, Lianidou E, Mourelatos Z. Emerging
roles of microRNAs as molecular switches in the integrated circuit of
the cancer cell. RNA 2009;15:1443-1461.
34. Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL,
Hwang HW, et al. Therapeutic microRNA delivery suppresses tumori-
genesis in a murine liver cancer model. Cell 2009;137:1005-1017.
35. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M,
Munk ME, et al. Therapeutic silencing of microRNA-122 in primates
with chronic hepatitis C virus infection. Science 2010;327:198-201.
36. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The
impact of microRNAs on protein output. Nature 2010;455:64-71.
37. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduc-
tion. Nat Rev Mol Cell Biol 2010;11:252-263.
38. Duan H, Jiang Y, Zhang H, Wu Y. MiR-320 and miR-494 affect cell
cycles of primary murine bronchial epithelial cells exposed to benzo[a]-
pyrene. Toxicol In Vitro 2010;24:928-935.
39. Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, Zheng J, et al. Identiﬁcation of
miRNAs associated with tumorigenesis of retinoblastoma by miRNA
microarray analysis. Childs Nerv Syst 2009;25:13-20.
40. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, et al.
MicroRNA-31 functions as an oncogenic microRNA in mouse and
human lung cancer cells by repressing speciﬁc tumor suppressors. J
Clin Invest 2010;120:1298-1309.
41. Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M,
et al. Molecular proﬁling uncovers a p53-associated role for micro-
RNA-31 in inhibiting the proliferation of serous ovarian carcinomas
and other cancers. Cancer Res 2010;70:1906-1915.
42. Donnem T, Lonvik K, Eklo K, Berg T, Sorbye SW, Al-Shibli K, et al.
Independent and tissue-speciﬁc prognostic impact of miR-126 in non-
small cell lung cancer: coexpression with vascular endothelial growth
factor-A predicts poor survival. Cancer 2010;117:3193-3200.
43. Li XM, Wang AM, Zhang J, Yi H. Down-regulation of miR-126
expression in colorectal cancer and its clinical signiﬁcance. Med Oncol
2010 [Epub ahead of print].
2098 OLARU ET AL. HEPATOLOGY, December 2011
REVIEW
Long non-coding RNAs and cancer: a new frontier
of translational research?
R Spizzo1, MI Almeida2,3, A Colombatti1 and GA Calin2
Tiling array and novel sequencing technologies have made available the transcription proﬁle of the entire human genome.
However, the extent of transcription and the function of genetic elements that occur outside of protein-coding genes,
particularly those involved in disease, are still a matter of debate. In this review, we focus on long non-coding RNAs (lncRNAs)
that are involved in cancer. We deﬁne lncRNAs and present a cancer-oriented list of lncRNAs, list some tools (for example,
public databases) that classify lncRNAs or that scan genome spans of interest to ﬁnd whether known lncRNAs reside there, and
describe some of the functions of lncRNAs and the possible genetic mechanisms that underlie lncRNA expression changes in
cancer, as well as current and potential future applications of lncRNA research in the treatment of cancer.
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INTRODUCTION
Non-protein-coding RNAs (ncRNAs) are gaining the attention of
researchers in many ﬁelds, and the number of published articles is
exponentially growing.1 MicroRNAs (miRNAs) belong to a small
ncRNA group and are the most studied among ncRNAs; however,
many more types of ncRNAs exist. In fact, tiling array and novel
sequencing technologies have made available the transcription
proﬁle of the entire human genome, which showed a widespread
transcription activity.2 However, the extent of transcription (that is,
whether ncRNAs are mainly localized in close proximity to protein-
coding genes (PCGs) or widespread throughout the genome) and
the function of genetic elements that occur outside of PCGs are
still a matter of debate.3 - 5 Moreover, by more traditional means,
several researchers have cloned RNA transcripts whose nature is
probably not to code proteins and that have a longer sequence
than miRNAs do. These can be grouped under the classiﬁcation of
long ncRNAs (lncRNAs).
The human genome census reveals a striking predominance
of non-coding regions (http://www.ncrna.org/statgenome/index.
html?view¼ class&gid¼ hg18). In fact, PCG exons represent about
1.6% of the 3 109 base pairs of the human genome. Moreover,
the number of PCGs is quite steady during evolution in metazoa
(G value paradox), whereas the size of genomes tends to
increase.6 Conservation among genomes also occurs within
intergenic regions, suggesting that these regions are important
in the fundamental processes involved in life. Finally, the largest
part of the human genome, about 46%, is made up of repetitive
elements (such as transposons) that probably have been one of
the driving forces of evolution.7 It is worth mentioning that in
most cases transposons do not code for proteins, and recently
they have been found to be related to cancer processes.8,9
In this review, we focus our attention on lncRNAs that are
involved in cancer. First, we will deﬁne lncRNA and present a
cancer-oriented list of lncRNAs. Second, we will list some tools (for
example, public databases) that classify lncRNAs or that scan
genome spans of interest to ﬁnd whether known lncRNAs reside
there. Some of the databases can also be used to search for
lncRNAs that are involved in a process or disease of interest (for
example, cancer). Finally, we will describe some of the functions of
lncRNAs, possible genetic mechanisms that underlie lncRNA
expression changes in cancer, and current and potential future
applications of lncRNA research in the treatment of cancer.
DEFINITION OF lncRNA
The most commonly used deﬁnition of lncRNA is an RNA molecule
that is longer than 200 nucleotides and that is not translated into a
protein. However, this deﬁnition may be too simple and does not
take into account certain issues. First, the cutoff of 200 nucleotides
was arbitrarily chosen and it was set more on the basis of RNA
binding to silica columns during RNA puriﬁcation rather than for
its functional meaning.2 Second, a PCG is usually deﬁned as a
transcript that contains an open reading frame (ORF) longer than
100 amino acids.10 However, lncRNAs can contain ORFs longer
than 100 amino acids and not necessarily synthesize polypeptides;
plus, polypeptides shorter than 100 amino acids can be functional
in organisms and are not by-products of canonical proteins.11
Finally, and even more confounding, the same RNA can contain
both PCGs and non-coding functions.12 - 14 These issues demon-
strate how little we currently know about ncRNAs (particularly
lncRNAs) and how difﬁcult it is to form a deﬁnition.
One updated deﬁnition that we agree with takes into account
some of the aforementioned issues15 and deﬁnes lncRNAs as RNA
molecules that may function as either primary or spliced
transcripts and do not ﬁt into known classes of small RNAs, such
as miRNAs, piwi-interacting RNAs and small nucleolar RNAs, or
into classes of structural RNAs (for example, transfer RNAs, small
nuclear RNAs and spliceosomal RNAs). The strengths of this
deﬁnition are the absence of ORF restriction, given the fact that a
RNA molecule can possess both coding and non-coding activities,
and the absence of length restriction that was arbitrarily set. Other
investigators have proposed bioinformatic tools to clarify or adjust
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the 100-amino acid ORF length cutoff to determine whether an
RNA molecule codes for a protein (reviewed in Dinger et al.).10 The
strengths of Mercer’s deﬁnition are the absence of ORF restriction,
as a matter of fact a RNA molecule can possess both coding and
non-coding activities, and the absence of length restriction that
was arbitrarily set.
Additionally, we must point out that in this review we use the
abbreviation lncRNA, which should not be confused with long
intergenic ncRNAs (lincRNAs)16,17, which are a subtype of lncRNAs.
CLASSIFICATION OF LNCRNAS AND PUBLIC DATABASES
Generating comprehensive classiﬁcations of lncRNAs is not an
easy task. In fact, many lncRNA classiﬁcations are annotations from
larger databases or projects (for example, GeneBank, Fantom3),
and information about the real nature (protein-coding, non-
protein-coding or mixed) and function of lncRNAs cannot be
gleaned from these sources. Similarly, some lncRNAs have been
described in only one published study and no further reports
exist.18,19 Some lncRNAs have been grouped on the basis of their
position relative to host PCG (for example, overlapping RNA, cis-
antisense RNA, antisense RNA, bidirectional RNA, intronic RNA,
promoter- or enhancer-correlated RNA).15 As it usually happens for
all classiﬁcations, the same lncRNA may be listed under different
groups. For example, lncRNAs predicted by computational models
(for example, RNAz or Evofold) are often listed under different
names in databases obtained from sequencing projects.
To facilitate the difﬁcult task of organizing lncRNAs, we have
listed the current online databases that include ncRNAs (Table 1).
These databases collect lncRNAs originated from GenBank
annotations or from published articles. Some of these databases
list both ncRNAs that have been experimentally proven and those
that are purely computational predictions (based on RNA Z or
Evofold) or have been annotated as ncRNAs on the basis of the
predicted size of their ORFs.
We found the functional RNA project database (fRNA) worth
visiting. It uses a University of California Santa Cruz genome
browser interface that contains many ncRNA tracks that have
already been set up in a Genome Browser graphic interface, which
allows the user to search for speciﬁc ncRNAs along with other
features in the genomic context of interest. Although both fRNA
and the Noncode project allow the user to search for functional
classes or processes (for example, ﬁnd all known ncRNAs that are
involved in the cell cycle or in DNA replication or transcription),
fRNA allows the user to search by disease (for example, cancer) as
well. The ncRNA expression database, on the other hand, contains
a large data set of ncRNA expression proﬁles that were obtained
from three different experiment sets: Allen Brain Atlas (mouse),
GNF Atlas (mouse and human) and V1.0 Compugen array (mouse).
Although these expression data sets are not cancer-oriented, we
foresee that eventually the ncRNA expression database, as well as
others that are listed in Table 1, will be matched with other data
sets that are more cancer-oriented (for example, Oncomine;
https://www.oncomine.org). For now, the genomic positions of
several lncRNAs can be matched to databases that collect lists of
single-nucleotide polymorphisms (SNPs) associated with cancer
(http://cistrome.dfci.harvard.edu/CaSNP/; Hindorff et al.)172 or cancer-
associated genetic regions (for example, http://cancergenome.
nih.gov, http://decipher.sanger.ac.uk, the Cancer Workbench at
https://cgwb.nci.nih.gov/cgi-bin/heatmap and National Center for
Biotechnology Information Gene Expression Omnibus at http://
www.ncbi.nlm.nih.gov/geo/).14,27
CANCER-RELATED LNCRNAS
In this review, we focused our efforts on developing a list of
lncRNAs that have been linked to cancer by various means. We
mainly used three of the online databases to retrieve lncRNAs
(that is, the LncRNA database, Noncode and the RNA Database),
and we searched Pubmed for articles linking these lncRNAs to
cancer. In Table 2, we report our ﬁndings.
In some cases the link between the lncRNA and cancer was
obvious, and cancer was actually the model where these lncRNAs
were ﬁrst described for the ﬁrst time (for example, MALAT-1,
Table 1. Public ncRNA databases
Website (reference) Name Species MicroRNA Small
nucleolar
RNA
Infrastructural RNA
(ribosomal RNA, transfer
RNA, small nuclear RNA)
Notes
http://biobases.ibch.poznan.pl/ncRNA/ Multiple
kingdoms
Excluded Excluded Excluded
http://www.noncode.org/ 20 Noncode Multiple
kingdoms
Included Included Small nuclear RNA
excluded
Experiment-based, ncRNAs
divided on the basis of
function (pf classes) and
disease association
http://research.imb.uq.edu.au/rnadb/ 21 Rnadb Multiple
kingdoms
Included Included Excluded
http://www.ncrna.org/ 22 fRNA Multiple
kingdoms
Included Functional ncRNA catalog,
microarray info about ncRNA,
dedicated UCSC page
http://escience.invitrogen.com/ncRNA/ Human,
mouse
Excluded Excluded Excluded
http://rnaqueen.sysu.edu.cn/
ncRNAimprint/ 23
ncRNA
imprint
Mammals Included Included Excluded Focused only on imprinting
ncRNAs
http://jsm-research.imb.uq.edu.au/
nred/cgi-bin/ncrnadb.pl 24
NRED Human,
mouse
Excluded Excluded Expression data
http://www.lncrnadb.org/ 25 lncRNAdb Multiple
kingdoms
Excluded Excluded Excluded
http://rfam.sanger.ac.uk/ 26 Rfam Multiple
kingdoms
Included Included
Abbreviations: fRNA, functional RNA; lncRNA, long non-coding RNA; ncRNA, non-protein-coding RNA; UCSC, University of California Santa Cruz. The website,
reference and content are listed for each database, along with the most interesting feature of each website.
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Table 2. lncRNAs that have been or might be (*) linked to cancer
lncRNA Molecular mechanism Tumor Reference Genome position Website
aHIF Messenger RNA decay Multiple cancers 28 - 30 hg19 chr14:61,283,843 -
61,285,036
Noncode
Air Epigenetic regulation * 31 NA lncRNAdb
ak023948 Unknown Papillary thyroid
carcinoma
32 hg18 chr8:134136386-
134139194
lncRNAdb
alpha 250/ alpha 280 Antisense, transcription
regulation
* 33,34 hg19 chr5:149,828,969-
149,829,248
lncRNAdb
anril Antisense, transcription
regulation
Prostate cancer 35,36 hg18 chr9:21,984,790-
22,111,091
lncRNAdb
anti-NOS2A NA Central nervous
system tumors
37 hg18 chr17:57,692,139-
57,696,081
lncRNAdb
antisense tgf beta 3 NA * 38,39 NA lncRNAdb
BA318C17.1 NA Colon cancer 40 hg19 chr20:14,864,899-
14,910,132
Rnadb
bc200 Protein binding Multiple cancers 41,42 hg19 chr2:47,562,454-
47,562,653
lncRNAdb
car intergenic 10 Regulation of gene expression * 43 hg18 chr10:127,690,946-
127,693,326
lncRNAdb
ccnd1-associated ncrnas Regulation of gene expression * 44,45 hg19 chr11:69,453,875-
69,455,874
lncRNAdb
dhfr upstream transcripts Regulation of gene expression * 46 hg18 chr5:79,985,935-
79,986,521
lncRNAdb
e2f4 antisense NA * 47 NA lncRNAdb
emx2os Antisense-sense pairing Dicer1 * 48 - 50 hg18 chr10:119,233,794-
119,294,569
lncRNAdb
gas5 Decoy of glucorticoid receptor Breast cancer 51 hg18 chr1:172,099,662-
172,103,748
lncRNAdb
GNAS1-as RNA NA * 52 - 56 hg19 chr20:57,393,804-
57,425,958
Noncode
h19 Transcription regulation
(contains miR-675)
Multiple cancers 57 - 59 hg18 chr11:1,972,982-
1,975,641
lncRNAdb
h19 antisense Regulation of gene expression * 60 NA lncRNAdb
h19 upstream conserved 1
and 2
NA * 61 NA lncRNAdb
His-1 RNA NA * 62,63 hg19 chr2:145,456,944-
145,465,439
Noncode
HOTAIR Epigenetic regulation Multiple cancers 64 - 66 hg18 chr12:52,642,363-
52,648,782
lncRNAdb
hotairm1 NA * 67 - 69 hg18 chr7:27,102,268-
27,106,109
lncRNAdb
Hoxa11 antisense NA * 70 - 73 hg19 chr7:27,225,048-
27,228,956
Noncode
hoxd3as NA * 74,75 NA lncRNAdb
HULC Micro RNA decoy Multiple cancers 76 - 78 hg18 chr6:8,597,441-8,599,080 lncRNAdb
krasp1 Micro RNA decoy Prostate cancer 14 hg18 chr6:54,743,128-
54,743,996
lncRNAdb
KvlQT1-AS (Kcnq1ot1) DNMT1 interaction and
transcription
gene silencing
Colon cancer 79 hg19 chr11:2,465,330-
2,870,445
Noncode
LEU2 Pri-micro RNA, other Chronic lymphocytic
leukemia
80 hg19 chr13:50,556,688-
50,699,677
lncRNAdb
LOC285194 NA Osteosarcoma 81 hg18 chr3:117,911,325-
117,918,575
lncRNAdb
LUST RNA--RNA interaction, RNA
splicing
* 19 hg18 chr3:50,112,040-
50,113,425
lncRNAdb
MALAT-1 (NEAT2) RNA splicing, small RNA
production,
protein interaction
Multiple cancers 82 - 84 hg18 chr11:65,021,809-
65,030,513
lncRNAdb
MEG3 NA Multiple cancers 85,86 hg18 chr14:100,362,198-
100,397,121
lncRNAdb
MER11C RNA--protein interaction,
regulation
of gene expression
Cell lines 83 hg18 chr11:50,410,308-
50,411,367
lncRNAdb
Msx1 antisense NA * 87 - 90 NA Noncode
ncR-uPAR RNA--protein interaction * 18 hg18 chr5:76,043,519-
76,044,442
lncRNAdb
NCRMS NA * 91 hg19 chr12:97,886,239-
97,954,478
Noncode
NDM29 NA Neuroblastoma 92 hg18 chr11:8,917,158-
8,917,288
lncRNAdb
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PCA3/DDR3 and HOTAIR). However, we also found some lncRNAs
for which a link to cancer has not yet been fully elucidated, but
preliminary ﬁndings indicate that it could be worthwhile to
investigate the possible connection (these lncRNAs are marked
with an asterisk in Table 2). For example, the lncRNA Air (antisense
to Igf2r RNA) is involved in the imprinting of the Igfr2 locus.31
Despite the association of Igfr2 with cancer138 and the association
of Air with Igfr2,139 we did not ﬁnd any articles that directly
examine the relationship between Air and cancer in humans.
Moreover, although alpha 250/alpha 280 lncRNA regulates RPS14
transcription, which has been shown in short hairpin RNA screens
to be a causal factor in 5q- syndrome,33 no studies have yet
examined the direct involvement of alpha 250/alpha 280 lncRNA
in 5q-syndrome.140
Some lncRNAs that we included contain small ncRNA (for
example, miRNA and small nucleolar RNA). Although these
lncRNAs host small RNAs, this may not be their exclusive
function. For example, the knockout model of LEU2, which
includes miR-15/16 as well, showed a more aggressive phenotype
than did the miR-15/16 knockout model, which may indicate
Table 2. (Continued )
lncRNA Molecular mechanism Tumor Reference Genome position Website
NEAT1/TncRNA RNA nuclear export,
paraspeckle
organization
* 93 - 96 hg18 chr11:64,946,845-
64,950,577
lncRNAdb
Nkx2.2AS NA * 97,98 NA lncRNAdb
NRON NFAT nuclear trafficking,
RNA-protein binding
* 99,100 NA lncRNAdb
NSCLC B2 NA * 101,102 hg19 chr6:11,192,694-
11,205,944
Rnadb
NTT sense/antisense NA * 103,104 hg19 chr6:136,265,389-
136,282,959
Noncode
p53 mRNA RNA protein binding Multiple cancers 12 hg19 chr17:7571720-7590863 lncRNAdb
p53int1 NA * 105 hg19 chr17:7,588,578-
7,589,689
Rnadb
PCA3/DD3 NA Prostate cancer 106 hg18 chr9:78,569,172-
78,592,305
Noncode
PCGEM1 NA Prostate cancer 107 hg18 chr2:193,322,816-
193,349,870
Noncode
PCNA-AS NA * 108 hg19 chr20:5,100,232-
5,100,615
Rnadb
PINC NA * 109 NA lncRNAdb
PR Antisense Regulation of gene expression * 110 hg18 chr11:100,505,018-
100,574,851
lncRNAdb
PRINS NA * 111,112 hg18 chr10:24,576,060-
24,584,981
lncRNAdb
PTENP1 Micro RNA decoy Prostate cancer 14 hg18 chr9:33,663,502-
33,667,418
lncRNAdb
RMRP Mitochondrial RNA processing
endoribonuclease, hTERT-
dependent
small interfering RNA pathway
Leukemia and
lymphoma
113,114 hg19 chr9:35,657,750-
35,658,014
Rnadb
RPS6KA2 antisense
transcript
NA Cell lines 115 NA lncRNAdb
saf NA Cell lines 116 hg19 chr10:90,751,179-
90,752,732
Rnadb
SRA RNA RNA-protein binding,
transcription
factor co-activator
Breast cancer 117,118 hg19 chr5:139,930,090-
139,937,036
Noncode
TERC Telomere template Multiple cancers 119 hg19 chr3:169,481,881-
169,483,646
Noncode
terra Telomerase regulation Multiple cancers 120,121 NA lncRNAdb
tie-1AS RNA--RNA interaction * 122 - 124 NA lncRNAdb
Tsix Antisense of Xist * 125,126 hg18 chrX:72,928,765-
72,965,791
lncRNAdb
UBE3A antisense NA * 127,128 hg19 chr15:25,264,182-
25,299,063
Noncode
uca1 NA Bladder cancer 129,130 hg19 chr19:15,939,757-
15,946,226
Rnadb
WT1-AS NA * 131 hg18 chr11:32,413,861-
32,418,212
lncRNAdb
xist X inactivation Multiple cancers 125,132 -
134
hg19 chrX:73,043,280-
73,072,588
Noncode
Zeb2NAT NA * 135,136 hg18 chr2:144,992,452-
144,995,153
lncRNAdb
Zfas1 NA Breast cancer 137 hg19 chr20:47,894,715-
47,905,797
lncRNAdb
Abbreviations: lncRNA, long non-protein coding RNA; NA, not available. For each lncRNA, the name, function, tumor model in which it has been evaluated,
and genomic position are listed, along with the public website where each lncRNA can be found.
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that LEU2 can participate in chronic lymphocytic leukemia
development.80
Some lncRNAs have been associated with cancer but are not
listed in the public data sets that we used to prepare Table 2. For
example, regions that are extremely conserved among human,
mouse and rat genomes141 are expressed in cancer tissue
differently than in normal tissues and are regulated by methyla-
tion as well.142 - 146 The extremely high level of conservation
among these lncRNAs, which are referred to as ultraconserved
genes or transcribed UCRs, is their most peculiar feature.
LNCRNA FUNCTION
The function of ncRNAs is the most difﬁcult and least understood
aspect of ncRNA research. Better understanding ncRNA function
will help clarify the real impact of genomic pervasive transcription
on cell biology and evolution.147 As we gathered information
about the lncRNAs involved in cancer, we also collected examples
of lncRNA function (Figure 1).
The ﬁrst example that we describe is for lincRNAs. LincRNAs
were ﬁrst described using histone mark signatures, speciﬁcally
trimethylation in lysine 4 and lysine 36 of histone 3 (H3K4m3,
H3K36m3 or simply K4K36). The K4K36 mark detects active trans-
cription units of both PCGs and ncRNAs. After excluding known
genes (PCGs and ncRNAs), researchers have been able to retrieve
novel transcriptional units. The ﬁrst reports analyzed mouse and
human cell lines, uncovering about 3000 lincRNAs.16,148 However,
many more lincRNAs may remain to be discovered in other
settings.149 Certain, lincRNAs were discovered before the use of
the K4K36 signature such as MALAT-182 and HOTAIR, which was
the ﬁrst lncRNA ever described to interact with polycomb proteins
and suppress gene transcription.64 Moreover, other histone
signatures might reveal new lncRNAs.150
About 20% of lincRNAs bind to polycomb repressive complex 2,
indicating that lincRNAs might regulate gene expression by
directing the polycomb protein group to target DNA regions,
inducing changes in histone marks and chromatin structure and
ultimately suppressing transcription activity.148,151 The current
model proposes that lincRNAs directly bind to the polycomb
proteins and direct them to speciﬁc DNA segments in the human
genome. However, how the lincRNA-polycomb complex recog-
nizes the target DNA is not currently known.152 We do not
currently know whether transcription factors bind lincRNAs as
well, and whether RNA-binding proteins regulate lincRNAs as they
do with miRNAs.153
Another class of lncRNAs that seems to regulate
gene expression by changes in chromatin status includes
antisense transcripts (reviewed in Morris and Vogt).154 Antisense
ncRNA transcripts overlap PCG but are transcribed in the
opposite direction. Although one would expect small interfering
RNA (siRNA) machinery to degrade messenger RNA after the
sense--antisense pairing, the mechanism in act instead
seems to be the modiﬁcations of histone marks at the promoter
region of the sense transcript (that is, PCGs). Apparently,
antisense lncRNAs drive (cytosine-5)-methyltransferase 3A
(DNMT3A) to the DNA of the host PCG to methylate histones
at lysine 9 and 27 or CpG islands and ultimately silence
transcription.
Several oncogenes or tumor-suppressor genes exhibit antisense
transcription and consequent transcription gene silencing
(for example, p21, c-Myc, p15, p53, TIE1 and PU.1).35 Interestingly,
Figure 1. LncRNA categories and functions. Several classes and functions of lncRNAs are depicted. The main function of lncRNA seems so far
to regulate PCG transcription; indeed, lncRNA can either enhance or repress PCG transcription by changes in the chromatin state of the PCGs
(for example, by histone methylating or acetylating). Enhancer RNAs derive from transcription of enhancer elements that can be located
several kilobases upstream of target genes. Enhancer DNA can both regulate gene expression by DNA looping and direct DNA--DNA
interaction with the target promoter, and they also transcribe non-polyA RNAs (that is, eRNA). The function and the role of eRNAs is at this
moment unknown. Overall, both long ncRNAs (lincRNA, a-ncRNAs and AS-ncRNAs) and small ncRNAs (for example, siRNA and miRNA)
regulate transcription and post transcription steps of protein synthesis, respectively. At the bottom of coding and non-coding transcription
units that are shown in picture, the reader can find the peak diagram for CHIP-seq experiments concerning histone modifications: H3K4Me1,
mono methylation at lysine 4 of histone 3 (often found near regulatory elements); H3K4Me3, tri methylation at lysine 4 of histone 3 (often
found near promoters); H3K36Me3, tri methylation at lysine 36 of histone 3 (often found near active transcripts).
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exogenous siRNAs that are in antisense orientation compared with
PCG promoters are also effective at silencing transcription.155
However, how the antisense lncRNAs are regulated has not yet
been explored.
LincRNAs, antisense lncRNAs, and other lncRNAs44,156 can be
classiﬁed among the chromatin-associated RNAs (CARs) because
their function apparently relies on the ability of the RNA to
somehow bind to genomic DNA and consequently regulate
chromatin states (euchromatin versus heterochromatin).44,156
Mondal et al.43 performed a thorough investigation of CARs
throughout the genome of a human skin ﬁbroblast cell line by
deep sequencing of DNA-associated RNA after micrococcal
nuclease treatment. They identiﬁed several CARs and reported
that one CAR can activate transcription of neighboring genes.
Another class of lncRNAs that seems to regulate the transcrip-
tion activity of host PCGs comprises the promoter upstream
transcripts (PROMPTs). PROMPTs are localized upstream of
promoters of some PCGs and they can be transcribed in both
the sense and antisense orientations. PROMPTs seem to be a
byproduct of RNA pol II activity; however, preliminary ﬁndings
suggest that PROMPTs control promoter methylation.45 When
Preker et al. ﬁrst described PROMPT existence, they used a peculiar
approach: they inhibited exosome key proteins by using siRNA to
prolong the half-life of short-lived RNA transcripts. In this way, they
were able to identify a plethora of PROMPTs. However, the function
and impact of PROMPTs in cell biology have not yet been explored.
It is possible that lincRNAs, PROMPTs, and antisense RNAs, or
CARs in general, have interdependent functions. For example,
antigene RNAs are synthetic RNA molecules that when designed
to be complementary to PCG promoters can either repress or
activate gene expression. Antigene RNAs rely on RNA--RNA
interaction with antisense transcripts that are generated nearby
targeted promoters and on Ago proteins binding.157 It is possible
that PROMPTs, lincRNAs and antisense lncRNAs interact and
recapitulate antigene RNA mechanism; it is known that PROMPTs
and antisense lncRNAs can interact with each other to trigger the
antigene RNA pathway.158 In another example of lncRNA
interdependent function, lincRNAs can interact with PROMPTs or
antisense lncRNAs to ultimately direct polycomb protein
complexes to targeted promoters of PCGs.36 Further examples
of lncRNA function are discussed in other reviews.159,160
LNCRNA NETWORKS
Another interesting lncRNA function is target decoy or mimicry:
lncRNAs can deceive another RNA or protein away from its natural
target. For example, Poliseno et al.14 described pseudogenes as
decoys for miRNAs. They reported that the PTEN gene and the
PTEN pseudogenes (PTENP1) share a high degree of sequence
homology and are targeted by the same miRNAs (that is, miR-17,
-21, -214, -9 and -26 families). Thus, changes in PTENP1 expression
levels indirectly affect PTEN expression levels by sequestering
PTEN-targeting miRNAs. For instance, if PTENP1 expression levels
decrease, miRNAs will be able to target PTEN and ultimately
downregulate PTEN expression levels. Poliseno et al.14 also noted
a similar mechanism for RAS pseudogenes. Another example of a
lncRNA that acts as a miRNA decoy is the highly upregulated liver
cancer transcript (HULC), which binds to and inhibits miR-372.76
Target decoys occur not only in cancer but also in infectious
diseases: two studies reported that virus-encoded transcripts can
act as miRNA decoys; in this case the net effect was to sequester
and downregulate the miRNAs of the host organism.161,162
A similar example exists in plants for endogenous pseudogene
transcripts that share a high degree of sequence homology with
PCG transcripts, although in this case the pseudogenes contain
point mutations within the miRNA-binding sites. Apparently, these
pseudogenes not only sequester miRNAs from their PCG target,
but also reduce miRNA expression levels.163
One particular type of lncRNA decoy involves proteins.
PROMPTs, such as GAS5, can bind to transcription-factor proteins
that would otherwise bind to the DNA promoters; thus, the RNA
transcript decoy sequesters the transcription factor, which is no
longer able to affect downstream target genes.164 GAS5 accom-
plishes this with a stem-loop structure in its sequence resembling
the glucocorticoid receptor DNA-binding element. GAS5 seems to
regulate other receptors (that is, androgen, mineralcorticoid and
progesterone) by the same means. Interestingly, the interaction
between GAS5 and the glucocorticoid receptor is modulated by
dexamethasone, a glucocorticoid receptor agonist.164 At the same
time, GAS5 has been shown to be regulated by mammalian target
of rapamycin pathway and to mediate rapamycin effect on cell
cycle in T cells (reviewed in Williams et al.).165
NcRNA decoys can target not only ncRNA--mRNA or DNA--
protein interactions, but also interactions between ncRNAs. For
example, miRNAs can target other ncRNAs as they do with
messenger RNA; Calin et al.144 showed that miR-155 targets
transcribed UCRs in both in vitro models and chronic lymphocytic
leukemia patients. These ﬁndings support the existence of
networks among ncRNAs and between ncRNAs and PCGs that
are involved in cancer.
LNCRNA EXPRESSION IN CANCER
In cancer biology, one of the ﬁrst evidences that researchers seek
is gene expression differences between tumor and normal
samples. The breadth of knowledge concerning lncRNA expres-
sion proﬁles in tumor and normal samples is quite modest at this
time. It is likely that commercial gene expression arrays that have
been used for PCGs contain probes that hybridize to lncRNAs, and
it may be possible to retrieve cancer-related lncRNA expression
proﬁles from public, tumor-speciﬁc gene-expression data sets (for
example, Oncomine, Gene Expression Omnibus). However, to our
knowledge this has not yet been done.
To identify novel transcripts, some investigators have used the
Affymetrix tiling array, which can test for lncRNA gene expres-
sion.166,167 Others have performed custom array proﬁling on large
sample sets of a few lncRNAs.144,168 Most articles concerning
lncRNA expression in cancer have shown a selected number of
lncRNAs probed in tumor samples (Table 2 lists tumor types that
have been tested for lncRNA expression). We also found a few
articles (not included in Table 2) reporting the existence of
transcriptionally active regions that are located outside known
PCGs and are differentially expressed between normal and tumor
tissues or are expressed under stress conditions.166,167 Gibb et al.
used SAGE library generation to compare lncRNA expression in
normal and dysplastic oral mucosa.169
Cancer biologists also seek to uncover genetic mutations (for
example, ampliﬁcations, deletions and sequence mutations) in
the lncRNA sequence. For example, sequence mutations in
RNA component of mitochondrial RNA processing endoribonu-
clease (RMRP) lncRNA are responsible for cartilage-hair
hypoplasia syndrome, which is also known to increase the risk
of developing several types of tumors.170,171 Some investigators
have already sequenced select classes of lncRNAs to ﬁnd
mutations.166,172
In recent years, using SNP arrays to study very large populations
(in the thousands), researchers have discovered several SNPs that
are associated with certain traits or diseases, such as cancer
(http://www.genome.gov/gwastudies contains a list of SNPs
associated with several diseases).173 In some cases, disease-
associated SNPs are in genomic spans outside of PCG tran-
scripts;174,175 these genomic spans would be good candidates
regions to search for novel transcripts. Some researchers have
already found SNPs that are located within lncRNA transcripts and
are associated with cancer. For example, Yang et al. showed that
among six SNPs that are located within the boundaries of UCRs,
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two of them (that is, rs2056116 and rs9572903) were signiﬁcantly
associated with familial breast cancer.176 Cabili et al.,27 while
reporting on a census of 8195 lincRNAs in 24 different
human tissues, noted that the genomic positions of 414 lncRNAs
were related to SNPs that have been associated with several
diseases.173
DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF LNCRNAS
The relatively new ﬁeld of lncRNA research is expanding quickly,
but many gaps still need to be ﬁlled. Only recently has the number
of lncRNAs in the human genome become clear.27 Moreover,
researchers have not extensively investigated lncRNA expression
in large and clinically controlled tumor data sets, nor is lncRNA
function well understood.149 Few examples of transgenic models
of lncRNA have been published to date.80,177
We foresee potential uses of lncRNAs in the clinical setting for
oncology or for other ﬁelds. LncRNAs may be useful as novel
biomarkers for diagnosis, prognosis and prediction of response to
therapy. The lncRNA PCA3/DD3, for example, has already been
assayed in controlled clinical settings. PCA3/DD3 was originally
discovered in a differential display analysis comparing normal and
tumor prostate samples.178 The features that make PCA3/DD3 a
promising biomarker are its unique expression proﬁle in prostate
tumors compared with normal prostate and other tissues, its
highly increased expression levels (that is, about 60 times) in
prostate tumors compared with normal tissues, its expression in
early-stage tumors and detectability in urine. PCA3/DD3 has been
tested as a biomarker in clinical trials and compared with standard
prostate markers (that is, prostate-speciﬁc antigen). However, the
effectiveness of PC3/DD3 as a biomarker was about the same as
that of prostate-speciﬁc antigen.106,179
The marked increase or decrease in lncRNA expression levels in
tumors compared with normal tissues seems to be a feature
shared among lncRNAs. Indeed, HOTAIR was found to be
upregulated by hundreds or thousands of times in metastatic
breast cancer tissue compared with normal breast tissue.64 Such a
large difference in lncRNA expression levels in tumors compared
with normal tissues is a topic for future clinical research, although
lncRNAs must be assayed in larger clinical data sets. Other
lncRNAs might be promising biomarkers as well.106,179
Another potential avenue of lncRNA research relates to the
discovery of circulating miRNAs in serum, plasma and other body
ﬂuids, demonstrating that miRNAs may act not only within cells,
but also at other sites within the body.180 It is highly probable that
other types of ncRNAs, including lncRNAs, can be present in body
ﬂuids, as suggested by, for example, their presence in the secreted
exosomes. LncRNAs found in numerous quantities in body ﬂuids
could be detected using simple quantitative reverse transcriptase
polymerase chain reaction. This could represent an unexpected
and yet unexplored gold mine of potential biomarkers predictive
of survival or response to therapy.
LncRNAs might also be useful as therapeutic agents. The small
size of miRNAs offers an intrinsic advantage in their use as
therapeutic bullets by in vivo administration.181 However, because
lincRNAs are much longer than miRNAs, they could not be used
directly as therapeutic bullets but would require gene therapy
delivery systems (for example, viruses), which would carry
potential risks. On the other hand, lncRNAs could be targeted
with synthetic siRNAs or miRNAs. Another way to target lncRNAs
would be with drugs designed speciﬁcally to interact with
lncRNAs, as vault RNAs naturally do. Vault RNAs belong to the
largest ribonucleoprotein complex in eukaryotic cells (that is,
vault), and they are involved in multidrug resistance.182 Gopinath
et al. showed that vault RNAs directly bind to chemotherapeutic
agents, indicating that it would also be possible to design small
molecules that interact with lncRNAs. Of course, vault RNAs are
technically short RNAs, ranging from 80 to 90 nucleotides;
however, examples of longer RNAs involved with drug interaction
exist, such as aptamers.183 - 186
Targeting transcripts the size of lncRNAs may seem like a
daunting task, but there is a precedent for fragmenting large
ribonucleoprotein complexes into more manageable sizes. This
strategy has been applied in the design of ligands that can bind to
expanded rCUG and rCAG repeat RNAs that are expressed in
myotonic dystrophy type 1 and interact with the Muscleblind-like
1 protein.187 Moreover, systematic evolution of ligands by
exponential enrichment (SELEX) approach can be used to identify
chemicals that interact with lncRNAs.160
As well as being potential markers or therapeutic targets,
lncRNAs could be used as models to develop novel strategies to
target tumor cells. For example, synthetic RNA molecules that
form hairpin structures simulating DNA transcription factor-
binding elements can be generated to target and regulate
transcription factor activity as GAS5 does.164 Synthetic lncRNAs
that contain mutant miRNA-binding sites can sequester and
reduce expression levels of miRNAs, as it happens in plants.163
Finally, small molecule compounds could be used to target
lncRNAs. Indeed, small molecule compounds have already been
tested for other uses in clinical trials to determine toxicity, body
distribution and pharmacokinetics, and in some cases, their use in
humans is already approved by the US Food and Drug
Administration. Their use with lncRNAs requires only identifying,
either by in silico predictions or by large library screens, the small
molecules that target lncRNA or ribonucleoprotein complexes.
If such compounds exist, the transition time from lab to clinic
would be very short, which would be good news not only for
scientists, but especially for patients with cancers and other
diseases.
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Introduction: microRNAs (miRNAs), small noncoding RNAs, are deregulated in
several diseases including cancer. miRNAs regulate gene expression at a post-
transcriptional level by binding to 5¢UTR, coding regions or 3¢UTR of messenger
RNAs (mRNA), inhibiting mRNA translation or causing mRNA degradation. The
same miRNA can have multiple mRNA targets, and the same mRNA can be
regulated by various miRNAs.
Areas covered: Recently, seminal contributions by several groups have impli-
cated miRNAs as components of an RNA--RNA language that involves cross-
talk between competing endogenous RNAs through a decoy mechanism.
We review the studies that described miRNAs as players in a biological decoy
activity. miRNAs can either be trapped by competing endogenous RNAs or
interact with proteins that have binding sites for mRNAs.
Expert opinion: The miRNA decoy functions have implications for the
design of therapeutic approaches in human diseases, including specific ways
to overcome resistance to drug therapy and future miRNA-based clinical
trials design.
Keywords: mimic, regulation, sponge, therapeutic potential
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1. Introduction
Contrary to the case with protein-coding genes, there is a proportional increase between
the number of noncoding transcripts (ncRNA, RNAs that do not codify for proteins
but influence by variousmechanisms their expression and function) and the complexity
among the species [1,2], with the ratio of noncoding to coding sequences being about
47:1 in humans [3]. The use of massively parallel sequencing platforms of “next-
generation sequencing,” with use of the RNA sequencing (RNA-seq) application,
revealed thousands of transcripts and opened the door to a comprehensive study of
the nonprotein-coding transcriptome [4,5]. Up to 97% of the human genome consists
of nonprotein-coding DNA [6], and noncoding transcripts comprise a heterogeneous
group that includes, among other, microRNAs (miRNAs), small nucleolar RNAs
(snoRNAs), infrastructural RNAs (ribosomal RNA [rRNA], transfer RNAs [tRNAs],
and small nuclear RNAs [snRNAs]), long intergenic noncoding RNAs (lincRNAs),
antisense transcripts, noncoding transcribed ultraconserved regions, and promoter
upstream transcripts (PROMPTs) [7]. The ncRNAs can be intergenic or can overlap
with the coding regions loci, being antisense or intronic [2]. The paradigm of RNA as
a mere intermediary between DNA and protein became obsolete when it became
evident that the previously called “junk” DNA [8] could be of major importance for
biologic diversity [5] and may have key biological functions [9]. Although much
still needs to be studied about the function of ncRNAs, the top of the iceberg is
being revealed as we increase our understanding of the importance of ncRNAs in the
regulation of gene expression.
10.1517/14712598.2012.693470 © 2012 Informa UK, Ltd. ISSN 1471-2598 1
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In this review, we intend to focus on the studies that identi-
fied the miRNA decoy activity, and we propose to emphasize
the potential significance of these studies for therapy.
2. Current evidence
miRNAs are small ncRNAs, approximately 20 nucleotides
long, that control gene expression at a posttranscriptional level
by mRNA degradation or translation inhibition, through the
binding to 5´UTR, coding sequences, or 3´UTR of target
mRNAs [10]. miRNAs can regulate multiple target genes, and
simultaneously, target genes can be regulated by multiple miR-
NAs. Victor Ambros’ and Gary Ruvkun´s groups first discov-
ered miRNAs in 1993 as a new mechanism of gene regulation
inCaenorhabditis elegans [11,12]. In 2000, Pasquinelli et al. proved
that let-7 was conserved among species, opening the door for the
study of miRNAs in humans [13]. Later, in 2002, it was reported
thatmiRNAswere deregulated in cancer [14]. To date, thousands
of studies have analyzed the expression of miRNAs and
its role in cancer and in cardiovascular, autoimmune, and
neurodegenerative diseases [10].
Recently, another function for miRNAs was found: the
decoy activity. In early 2010, Perrotti´s group reported the par-
adigm shift in miRNA function [15]. hnRNP E2 is a member of
the family of RNA-binding proteins whose members are
involved in mRNA processing, nucleocytoplasmic export, and
translation of mRNAs [16]. In cells in which the BCR/ABL
oncogene is expressed, causing an arrest of differentiation in
myeloid blast crisis chronic myelogenous leukemia, there is an
increase of hnRNP E2 protein [17]. hnRNP E2 interacts with
the transcription factor CEBPA, inhibiting the translation of
mRNA. Using RNA electrophoretic mobility shift assays, UV
crosslinking, and RNA immunoprecipitation assays, the
authors found that miR-328 (that is downregulated in a
BCR/ABL-dependent manner) competes with CEBPA mRNA
for the hnRNP E2 binding site [15]. They also proved that
restoration of miR-328 expression interferes with hnRNP
E2 function of translation inhibition by preventing CEBPA::
hnRNPE2 binding and consequently restores, in vivo and
in vitro, CEBPA mRNA translation [15] (Figure 1A). Besides
the decoy activity, miR-328 also functions in the canonical
way by suppressing translation of mRNA encoding the
PIM1 protein kinase through base pairing interaction [15].
Later the same year, Poliseno et al. reported in Nature the
intriguing discovery that pseudogenes could function as a decoy
for miRNAs’ effects on corresponding protein-coding genes [9].
The authors used as a model the well-known tumor suppressor
PTEN and its pseudogene PTENP1, which has a high sequence
homology with part of the PTEN 3´UTR [9]. The authors proved
that PTENP1 is targeted by some of the miRNAs that target
also PTEN, including miR-19b and miR-20a. Through a
miRNA-dependent mechanism, overexpression of PTENP1
3´UTR resulted in the derepression of PTEN (and consequently
proved that PTENP1 has a role as a tumor suppressor), and
expression of PTEN 3´UTR resulted in the derepression of
PTENP1 [9]. In addition, the authors showed that the same decoy
mechanism is present when analyzing other genes and their
related pseudogenes, such as the KRAS gene and its pseudogene
KRAS1P [9]. This new concept was further developed 1 year later,
when the same group showed that not only noncoding genes can
compete for miRNAs binding sites, but also protein-coding
transcripts can compete with one another [18]. Transcripts that
have the same miRNA binding sites (or miRNA response ele-
ments [MREs]) are called “competing endogenous RNAs” (ceR-
NAs) [19] and may act as natural miRNA sponges. The authors
used bioinformatics (MRE enrichment----MuTaME----analysis)
and biological approaches to validate ceRNA for PTEN [18].
Some of these mRNAs are SERINC1, VAPA, and CNOT6L,
whose expression in human prostate cancer and glioblastoma
samples was significantly different between PTEN-high and
PTEN-low groups [18]. In addition, silencing of these ceRNAs
resulted in a decrease in luciferase activity when cells were
co-transfected with a luciferase vector containing the PTEN 3´
UTR.The authors further proved that this correlationwas depen-
dent on the miRNAs, since regulation of PTEN expression by
SERINC1, VAPA, and CNOT6L ceRNAs vanished in the cells
with a defect in themiRNAprocessingmachinery [18] (Figure 1B).
In the same issue of Cell, three articles reported “out-of-the-
box” discoveries about coding transcripts and competing
endogenous RNAs. Sumazin et al. used a multivariate analysis
method, named Hermes, to combine gene expression data
with miRNA profiles in glioblastoma and found 7,000 genes
whose transcripts were involved in sponge regulatory interac-
tions (modulator and sponges share miRNAs binding sites)
and 148 genes that were involved in nonsponge regulatory
interactions (modulator and sponges that do not necessarily
share miRNA binding sites) [20]. Moreover, the authors
focused on the PTEN transcript to perform validation
Article highlights.
. RNA transcripts that have the same specific miRNA
binding sites can compete for miRNAs binding.
. miRNAs can be trapped by ceRNAs that function as
natural miRNA sponges.
. miRNAs function as RNA decoys upon interaction with
heterogeneous ribonucleoproteins, as hnRNP (that have
binding sites for mRNAs).
. Decoy mechanisms involving miRNAs and the balance
between levels of specific ceRNAs should be considered
when designing new therapeutic approaches aiming to
correct gene expression.
. The hypothesis that miRNA-based decoy mechanisms
play a role in the resistance to therapy is worthy of
being explored.
. For therapeutic approaches using precursor microRNAs,
when two mature forms are processed, their expression,
function and mRNA targets should be considered, as
some of these could be ceRNAs for both 3p and 5p of
that specific miRNA.
This box summarizes key points contained in the article.
M. I. Almeida et al.
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studies for PTEN miRNA-mediated decoy in glioblastoma
cell lines [20].
In another study, Karreth et al. identified PTEN ceRNAs in
a mouse model of melanoma with use of the sleeping beauty
transposon system [21]. The authors further validated ZEB2 as
a ceRNA decoy for PTEN by demonstrating that ZEB2
depletion downregulates PTEN and that this reduction was
dependent on the 3´UTR (ZEB depletion suppressed luci-
ferase activity of PTEN 3´UTR reporter) and on miRNAs
(ZEB2 depletion does not reduce PTEN expression in cells
with a defect in the miRNA processing machinery) [21]. Finally,
Cesana et al. reported that a long noncoding RNA, linc-MD1,
acts as a ceRNA for MAML1 and MEF2C mRNAs, two tran-
scription factors that regulate muscle-specific genes, by interact-
ing with miR-133 and miR-135, thereby regulating muscle
differentiation [22].
All of the above-mentioned studies were crucial to a new
understanding of the importance of miRNAs in mediating
mRNA decoys, and their significance has been highlighted
in several articles. For example, McCarthy [23] stated that a
subtle reduction in few mRNA could cause widespread
effects. Rigoutsos and Furnari [24] indicated that the relative
amount of mRNAs and corresponding ceRNAs should be
considered and they introduced the intriguing hypothesis
that the decoy mechanism may also occur in cases in which
PTEN levels are reduced without mutation, such as in Cow-
den disease and Bannayan-Zonana syndrome. In addition,
Swami [25] questioned how this decoy applied in noncancer-
related genes. In the “Expert Opinion” section, we give our
opinion from a therapeutic point of view.
3. Expert opinion: potential therapeutic
consequences
The capacity of multiple mRNAs to compete for available
miRNAs introduces a new challenge for miRNA-based
‘Double decoy’
hypothesisIn CML-BC
miR-328
CEBPA translation 
suppression
Differentiation 
arrest
miR-328 and CEBPA compete 
for hnRNPE2 binding
Decoy activity
miR-328
hnRNP E2
CEBPA mRNA
hnRNP E2
::
CEBPA mRNA
CEBPA translation
Differentiation
miR-328 decoy
hnRNP E2
::
miR-328
ceRNAs – PTEN gene and 
PTENP1 pseudogene
RNA transcript A
Responsive element Y
RNA transcript B
Responsive element Y
microRNA Y
PTENP1
PTEN::miRNA
PTEN
Increased 
proliferation
PTENP1 3′UTR
PTEN::miRNA 
derepression
PTEN
Decreased 
proliferation
A. B. C. 
Competitive endogenous RNAs
(RNA transcripts with responsive
element Y)  
RNA-binding proteins
microRNA Y
interacts with
miRNA-associated decoy
mechanisms 
Figure 1. The decoy by microRNAs. A. miR-328 decoy. In blast crisis chronic myelogenous leukemia (CML-BC), miR-328 is
downregulated. The RNA binding protein hnRNP E2 interacts with CEBPA mRNA, suppressing it translation and causing a
differentiation arrest. When miR-328 restoration is induced, miR-328 interacts with hnRNP E2, releasing CEBPA from the translation
inhibitory effects of hnRNAPE2 and leading toCEBPAmRNA translation. B. Complementary endogenous RNAs (ceRNAs) -- PTENgene
andpseudogene.Thebasicprincipleof ceRNAis thatdifferentRNAs (e.g.,RNAtranscriptAandRNAtranscriptB) that contain thesame
microRNA binding sites (e.g., responsive element Y) can compete with each other for those microRNAs (e.g., microRNA Y). The first
example of ceRNAs was the PTEN gene and it pseudogene PTENP1, that share samemicroRNA responsive elements. When PTENP1 is
silenced, the tumor suppressor PTEN is decreased leading to an increase in cell proliferation. Accordingly, when PTENP1 3C¸UTR is
overexpressed, PTEN levels increaseddue toadecoy for themicroRNAs, causingadecrease in cell proliferation.C. Thehypothesis states
that the same miRNA can be trapped between binding to proteins and to ceRNAs. This represents a combination of the two
experimentally identified instances presented in (A) and (B). WhenmiRNA Y interacts with an RNA binding protein, the effect of this
interaction on the competingmRNA species could be variable. In the case ofmiR-328 and hnRNP E2, the interaction ofmiRNAYwith
the protein induces mRNA translation. However, one could hypothesize that interaction of miRNA Y with a protein that stabilizes
mRNAs and induces translation (e.g. hnRNPA1) could result in reducedexpressionofmRNAcontaining the samemiRNAbinding sites.
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cancer therapies because the expression levels of the several
transcripts regulated by the miRNAs need to be specifically
taken into account. miRNAs have been suggested not only
as therapeutic targets in several diseases but also as therapeutic
tools because miRNAs can regulate the protein expression of
major genes involved in disease and therefore influence
patient outcome. There are two major strategies to modulate
miRNA expression and consequently influence gene expres-
sion: miRNA antagonists (e.g., to knock down miRNA onco-
genic activity) and miRNA mimics (e.g., to restore miRNA
tumor suppressor activity). The decrease in miRNA levels
may be achieved by using chemically modified antisense
oligonucleotides such as 2´-O-methyl, 2´-O-methoxyethyl,
morpholino oligomers and locked nucleic acid (LNA) [26].
All of these molecules function as miRNA sponges, since
they are designed to be complementary to miRNAs and to
sequester miRNAs and derepress the mRNA targets. Studies
have indicated that research using LNAs (first described in
the late 1990s) is quickly progressing. miR-122 reduction
using LNA (complementary with miR-122 sequence) was
tested in primates [27]. Lanford et al. successfully suppressed
chronic hepatitis C virus infection in chimpanzees by using
LNA against miR-122 and obtained long-lasting but no
secondary effects [27]. In contrast to the chemically engineered
antagomirs, ceRNAs function as natural biological sponges.
In the case of PTEN and its pseudogene PTENP1, if we
could therapeutically overexpress the pseudogene, PTEN
would be automatically derepressed since miRNAs would
bind mainly to the pseudogene. If we could modulate the
levels of ceRNAs, we could restore the expression of a full
network of mRNA through miRNAs interaction. It is
therefore crucial, when deciding on a therapeutic approach
involving miRNAs, to consider not only the miRNA levels
in that specific cancer, but also the expression balance between
the levels of the ceRNAs. In addition, not only the amount of
transcripts but also the stability of the miRNA::mRNA bind-
ing should be analyzed. Furthermore, in light of the Perrotti
group’s publication, the same miRNA could bind both ceR-
NAs and also proteins with binding sites for specific mRNAs
(maybe themselves ceRNAs). This introduces another level of
complexity since, for example, hnRNPs are members of a
large family of proteins that are usually highly overexpressed
in human cancers [15] and therefore could easily trap the
interactor miRNAs (Figure 1C).
It is well known that miRNAs are involved in drug resis-
tance [28]. An unexpected consequence of the ceRNA concept
is the fact that resistance to therapy can be caused by an abnor-
mal balance between the ceRNA network components. For
example, the cancer-specific overexpression of pseudogene(s)
of a gene involved in blocking the activity of a drug can “trap”
miRNA molecules that otherwise in normal cells would bind to
and downregulate the specific drug-resistance gene. In this case,
the gene involved in blocking the activity of a drug would be
translated causing drug resistance. Indeed, if a miRNA that
targets genes inducing drug resistance is trapped by ceRNAs,
it is expected that the mRNAs involved in drug resistance are
derepressed, which would contribute to increased resistance
to specific drugs. Also, the opposite mechanism can be
postulated -- the release of miRNAs that target genes involved
in the induction of cell death by the drug, due to downregula-
tion of ceRNAs. This will lower the malignant cell sensitivity to
drug with consequent increased cell survival and resistance to
particular chemotherapeutic regimens. Therefore, in cancer
cells, the interactor miRNAs are “used” by the interaction
with the multiple ceRNA messengers instead of directly
targeting and consequently downregulating the coding genes
(Figure 2). The mechanisms of ceRNA expression variation
are the well-known ones for any coding or noncoding gene:
genomic deletions or amplifications, chromosome transloca-
tions, loss-of-function or gain-of-function mutations or pro-
moter methylation. Of course, in the absence of experimental
proof on the therapeutic consequences of ceRNAs, this is a
hypothesis, but one well worth exploring!
Finally, another intriguing possibility is the fact that the
two distinct miRNAs generated from the same hairpin pre-
cursor can function as a decoy if they share also common tar-
gets. This could profoundly influence the design of clinical
studies involving miRNA-based therapy. Although studies
involving miRNA inhibitors are already being developed in
primates, efforts to apply miRNA mimics to therapy are pro-
gressing more slowly. One important aspect to consider when
designing therapeutic approaches for miRNA mimics is the
fact that precursor miRNAs can generate two different mature
miRNAs, -5p and -3p, depending on the hairpin stem-
loop strand of the precursor miRNA, which may have cooper-
ative or different functions. This is the case of miR-28, which
we recently reported to be downregulated in colon cancer [29].
We reported that miR-28-5p, but not miR-28-3p, affects
colon cancer cell proliferation by increasing apoptosis and
causing G1 arrest. On the other hand, miR-28-5p decreases
while miR-28-3p increases colon cancer cells migration and
invasion. These differential effects are partially explained
by the different mRNA targets. In vivo, we observed that
miR-28 expression disrupts tumor growth but increases
metastasis [29]. Furthermore, we identified several common
mRNA targets that are predicted to interact in independent
sites for 5p and 3p miR-28, sometimes separated only
by few nucleotides. Similarly, Jiang et al. reported that
miR-125a-5p and miR-125a-3p, which are downregulated
in non-small cell lung cancer, have opposite effects in vitro
on invasion and migration in cells of this tumor type [30].
Consequently, when designing vectors using precursor
miRNA, it is essential to consider the function of both -5p
and -3p mature forms because one of the strands may cause
adverse effects. Furthermore, the main challenge for miRNA
mimics will be the in vivo delivery strategies. Since the ceRNA
mechanism suggests the existence of multiple miRNAs that
target simultaneously the same spectrum of coding genes
and pseudogenes/other ncRNAs, the 5p/3p pairs of miRNAs
could represent examples of such decoy miRNAs.
M. I. Almeida et al.
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4. Conclusion
One of the main challenges for application of miRNA-
based therapies is the in vivo delivery method. In most cases,
the delivery should be tissue-specific (and in some cases,
even cell type-specific); in addition, the secondary undesirable
effects should be controlled and the effect produced should be
stable and long-lasting. Furthermore, the ceRNAs network
and the expression levels of ceRNAs should be considered
when designing the therapeutic approach for a particular
miRNA-target gene.
In conclusion, it seems to be a question of time until miRNA-
based therapies can be used to treat cancer as well as cardiovascu-
lar, inflammatory, and neurodegenerative diseases. Until then,
efforts should be made to solve all of the above-mentioned issues.
It is expected that in the next few years, similar to what happened
in themiRNAs field, a second boon in the long noncodingRNAs
field will emerge and additional functions for these genes will be
revealed. This is the case, for example, of regions in the genome
that have a high level of homology and conservation between
species and whose ultraconserved transcripts have been shown
to be deregulated in cancer [31] but whose function has not yet
been described. Certainly, the efficiency of ceRNA effects
in vivo and the simplicity of this powerful concept remind us
that the ncRNA El Dorado is a land where both scientists and
clinicians should step without dogmas set in stone, but instead
should be ready to accommodate new ideas that could benefit
the people who need them at most ----the patients!
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Modulation of MicroRNA-194 and Cell Migration by
HER2-Targeting Trastuzumab in Breast Cancer
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Abstract
Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of the HER2 oncoprotein, can
effectively target HER2-positive breast cancer through several mechanisms. Although the effects of trastuzumab on cancer
cell proliferation, angiogenesis and apoptosis have been investigated in depth, the effect of trastuzumab on microRNA
(miRNA) has not been extensively studied. We have performed miRNA microarray profiling before and after trastuzumab
treatment in SKBr3 and BT474 human breast cancer cells that overexpress HER2. We found that trastuzumab treatment of
SKBr3 cells significantly decreased five miRNAs and increased three others, whereas treatment of BT474 cells significantly
decreased two miRNAs and increased nine. The only change in miRNA expression observed in both cell lines following
trastuzumab treatment was upregulation of miRNA-194 (miR-194) that was further validated in vitro and in vivo. Forced
expression of miR-194 in breast cancer cells that overexpress HER2 produced no effect on apoptosis, modest inhibition of
proliferation, significant inhibition of cell migration/invasion in vitro and significant inhibition of xenograft growth in vivo.
Conversely, knockdown of miR-194 promoted cell migration. Increased miR-194 expression markedly reduced levels of the
cytoskeletal protein talin2 and specifically inhibited luciferase reporter activity of a talin2 wild-type 39-untranslated region,
but not that of a mutant reporter, indicating that talin2 is a direct downstream target of miR-194. Trastuzumab treatment
inhibited breast cancer cell migration and reduced talin2 expression in vitro and in vivo. Knockdown of talin2 inhibited cell
migration/invasion. Knockdown of trastuzumab-induced miR-194 expression with a miR-194 inhibitor compromised
trastuzumab-inhibited cell migration in HER2-overexpressing breast cancer cells. Consequently, trastuzumab treatment
upregulates miR-194 expression and may exert its cell migration-inhibitory effect through miR-194-mediated
downregulation of cytoskeleton protein talin2 in HER2-overexpressing human breast cancer cells.
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Introduction
HER2 is amplified and overexpressed in 25–30% of human
breast cancers. Treatment with trastuzumab (HerceptinH), a
humanized murine anti-HER2 monoclonal antibody [1], pro-
duced an objective response rate of 15% in extensively pretreated
patients [2] and in 26% of previously untreated women with
HER2-overexpressing metastatic breast cancer [3]. Trastuzumab
in combination with chemotherapy was significantly more effective
than chemotherapy alone in prolonging the time to disease
progression, duration of response and overall survival [4,5,6,7],
resulting in its approval by the FDA in 1998. Trastuzumab
provided one of the first deliberately targeted therapies for a
human cancer and has now become the first-line treatment of
choice for patients with primary or recurrent HER2-overexpress-
ing breast cancer [8].
Trastuzumab-based combination treatment with chemotherapy
are, however, effective in 60–70% of the HER2-overexpressing
breast cancers [7,9] and trastuzumab resistance often develops
during the course of treatment [9,10]. Improving response to
trastuzumab and reducing trastuzumab resistance is a critical and
urgent priority for improving the clinical management of a
substantial subset of patients with breast cancer. While significant
progress has been achieved, molecular mechanisms underlying the
action of trastuzumab are still not fully elucidated. Treatment with
trastuzumab inhibits proliferation of breast cancer cells by
blocking the phosphatidylinositol-3-kinase (PI3K) signaling path-
way, upregulating the cyclin dependent kinase inhibitor p27Kip1
and inducing G1 arrest of the cell cycle
[11,12,13,14,15,16,17,18,19,20]. We and others have also illus-
trated the ability of trastuzumab to interfere with DNA repair
[14,21] and tumor angiogenesis [22,23,24,25,26,27]. Others have
provided evidence that trastuzumab can cleave the extracellular
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e41170
domains of HER2 receptors [28,29], mediate antibody-dependent
cellular cytotoxicity [30,31,32], and can induce apoptosis
[33,34,35].
Despite these many observations, the effects of trastuzumab on
regulation of cellular processes by microRNA (miRNA) are still
not investigated in depth. miRNAs are small non-coding RNAs of
19–25 nucleotides that can negatively regulate gene expression at
post-transcriptional and transcriptional levels [36,37]. The binding
of miRNAs to complementary sites in the 39- untranslated regions
(UTRs) and other regions of protein-coding mRNA sequences
cause either degradation of the mRNA or inhibition of translation
[36,37]. miRNAs have been demonstrated to regulate many
normal physiological processes [36,37], to participate in malignant
transformation at many sites including breast cancer [38,39,40],
and to mediate sensitivity to chemotherapy and radiotherapy
[41,42,43]. In this report, we have measured the effect of
trastuzumab on miRNAs and the role of miRNAs in trastuzu-
mab-mediated regulation of human breast cancer cells that
overexpress HER2. We have found that treatment with trastuzu-
mab affected expression of several miRNAs. miR-194 was
upregulated and downregulated talin2, inhibited cell migration
and invasion, which may contribute to the anti-tumor activity of
trastuzumab on HER2-overexpressing breast cancer cells.
Materials and Methods
Cell lines and cell culture
Human breast cancer cell lines BT474, SKBr3, MDA-MB-361
and MDA-MB-231 were originally purchased from the American
Type Culture Collection (Manassas, VA) and stored, recovered
and used at early passage from cryopreservation in liquid nitrogen.
SKBr3, MDA-MB-361 and MDA-MB-231 cells were maintained
in RPMI 1640 medium containing 10% fetal bovine serum (FBS),
2 mM L-glutamine, penicillin (100 units/mL), and streptomycin
(100 mg/mL). BT474 cells were grown in complete medium
containing DMEM supplemented with 10% FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate (Sigma, St. Louis, MO), 100
units/ml of penicillin, and 100 mg/ml streptomycin. All cell culture
media were obtained from the Media Preparation Core Facility at
the University of Texas MD Anderson Cancer Center. All cell
lines were cultured in a humidified air supplemented with
5% CO2 at 37uC and tested monthly for mycoplasma with a
MycoSensor PCR Assay Kit from Stratagene (Cat# 302109,
La Jolla, CA). All cell lines were authenticated by the Cell Line
Core Facility at the University of Texas MD Anderson Cancer
Center with short tandem repeat DNA fingerprinting in April,
2011.
Reagents
Trastuzumab (HerceptinH) manufactured by Genentech Inc
(South San Francisco, CA) was purchased from Division of
Pharmacy at the University of Texas MD Anderson Cancer
Center. Human immunoglobin G (hIgG) served as control for
trastuzumab and was purchased from Calbiochem (La Jolla, CA).
Antibodies reactive with vinculin and total Rb were purchased
from Cell Signaling Technology, Inc. (Beverly, MA). Antibody
against talin2 was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). miR-194 precursor and its miRNA negative
controls, miR-194 inhibitor and its negative inhibitor, and
TaqMan assay for miR-194 were purchased from Applied
Biosystems Incorporated (ABI, Foster City, CA). Small interfering
RNAs (siRNAs) targeted to talin2 and talin1 were from
Dharmacon (Lafayette, CO) or Ambion (Austin, TX). Epidermal
growth factor (EGF) used in cell culture was ordered from Sigma
(St. Louis, MO). Transfection reagents used were Lipofectamine
2000 from Invitrogen (Grand Island, NY) and DharmaFECT #4
from Dharmacon.
Preparation of Total RNA
Total RNA was extracted with the TRIzol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions. RNA
purity was assessed by measuring absorption at 260 nm (A260)
and at 280 nm (A280) (samples that had A260/A280 ratio of 1.9–
2.1 were considered acceptable) and by ethidium bromide staining
of 18S and 28S RNA on gels after electrophoresis. RNA
concentrations were determined from the A260. Before perform-
ing the microRNA assay, each RNA sample was treated by DNase
with a Turbo DNase kit (Ambion, Austin, TX).
miRNA Microarray Profiling
miRNA profiling was performed in the non-coding RNA core
facility at M.D, Anderson Cancer Center. Briefly, 5 mg of RNA
from each tissue sample was labeled with biotin by reverse
transcription using random octomers in duplicate. Hybridization
was carried out on the second version of a miRNA-chip A-MEXP-
1246 version (http://www.ebi.ac.uk/arrayexpress/arrays/A-
MEXP-1246), which contained 559 human and 393 mouse
miRNA probes, 962 human ultraconserved sequences in quadru-
plicate. Each oligo was printed in duplicate in two different slide
locations. Hybridization signals were detected by biotin binding of
a Streptavidin-Alexa647 conjugate (one-color signal) using a
GenePix 4000B scanner (Axon Instruments). We quantified
images using the GenePix Pro 6.0 (Axon Instruments). Raw data
were analyzed in BRB-ArrayTools developed by R. Simon and
A.P. Lam (version: 4.2.1, National Cancer Institute). Expression
data were normalized by quantiles method of the Bioconductor
package. Statistical comparisons were done using BRB class
comparison t-test. A total of 16 samples from BT474 cells (8 from
wild-type or trastuzumab-sensitive cells and another 8 from
trastuzumab-resistant cells) and 8 samples from SKBr3 cells (4
from wild-type or trastuzumab-sensitive cells and another 4 from
trastuzumab-resistant cells) were analyzed. Samples were discard-
ed if more than 87.5% and 75% for BT474 and SKBr3 cell line,
respectively, of missed values occurred (the miRNAs are retained
when present in at least the smallest group in the dataset), missed
values were replaced with 4.500001 (basic expression value, log2)
after normalization. miRNAs significant at 0.05 level of the
univariate test were reported. This microRNA microarray data
regarding breast cancer cell lines treated with or without
trastuzumab have been deposited into the ArrayExpress (http://
www.ebi.ac.uk/miamexpress/).
Quantitative Reverse Transcription–Polymerase Chain
Reaction (QRT-PCR) Analysis
QRT-PCR was performed to assess mir-194 levels with the use
of a Prism 7900HT Sequence Detection System (ABI, Foster City,
CA) and TaqMan Real-Time PCR Assay (ABI). Total RNA was
reversely transcribed into complementary DNA (cDNA) with
specific stem-loop RT primer and a cDNA kit from ABI. Hsa-
miR-194 was purchased from ABI (Assay ID 000493). Amplifi-
cations were carried out in triplicate on MicroAmp optical 96-well
microliter plates (ABI). Thermal cycling conditions were as follows:
95uC for 5 minutes, followed by 40 cycles of 95uC for 10 seconds
and 59uC for 40 seconds. U6 RNA was used as an internal control
in all QRT-PCR assays for miRNA. The DDCT method was used
to compare the relative expression levels between treatments. The
Trastuzumab and miR-194-Talin2-Migration Pathway
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final PCR results were expressed as the relative expression
compared to individual control sample in each assay.
RNA Blotting
miR-194 Northern blotting was performed as described
previously [44]. Briefly, total RNA isolation was performed using
the Tri-Reagent (Invitrogen). RNA samples of 25 mg each were
run on 15% acrylamide denaturing (urea) criterion precast gels
(Bio-Rad), and then transferred onto Hybond-N_membrane
(Amersham Pharmacia Biotech). The hybridization with a DNA
oligonucleotide probe complementary to the mature miR-194
sequence end-labeled with [c-32P] ATP was performed at 42uC in
7% SDS/0.2 M Na2PO4 (pH 7.0) overnight. The membrane was
washed twice at 42uC with 26 standard saline phosphate EDTA
(SSPE, 0.18 M NaCl/10 mM phosphate, pH 7.4/1 mM EDTA)/
0.1% SD S and twice with 0.56 SSPE/0.1% SDS. The blot was
stripped by boiling in 0.1% SDS/0.16 SSC for 10 min and was
reprobed U6 snRNA as a loading control.
miRNA Transfection
BT474 or SKBr3 cells were seeded on 6-well culture plates and
transfected with a negative control sequence or miR-194 using the
DF4 reagent (Dharmacon). The mixture of miRNA (15 nM final
concentration) and DF4 reagent (12.5 nM final concentration)
were incubated for 20 min before being added to cells. Transfec-
tion was carried out for 72 hrs and cells were harvested for
extraction of RNA or protein.
Cell Proliferation Assays
A crystal violet cell proliferation assay was used to assess
anchorage-dependent cell proliferation as described previously
[15]. Briefly, BT474 stable cells that either express empty vector or
miR-194 were seeded and cultured in triplicate in 96-well cell
culture plates for different intervals. The cells were washed with
phosphate-buffered saline, fixed in 1% glutaraldehyde, and stained
with 0.5% crystal violet (Sigma Chemical Co.) dissolved in
methanol. The dye that stained the cells on the plates was then
eluted with Sorenson’s buffer (0.9% sodium citrate, 0.02 N HCl,
and 45% ethanol), and directly measured with the use of a Vmax
microplater reader (Molecular Devices, Sunnyvale, CA) at a
wavelength of 560 nm. Cell number was expressed as the optical
density (OD) at 560 nm.
BT474 Human Breast Cancer Xenografts in Nude Mice
The BT474 xenograft model was established in female nu/nu
Balb/c mice as described previously [22] . Briefly, BT474 wild-
type cells or stable transfectants expressing miR-194 were injected
subcutaneously into two mammary fat pads of 4-week-old BALB/
c athymic Nu/Nu mice (obtained from the in-house animal facility
at the Department of Experimental Radiation Oncology, the
University of Texas MD Anderson Cancer Center). Experiments
with nu/nu mice were reviewed and approved by the Institutional
Animal Care and Use Committee at the University of Texas MD
Anderson Cancer Center. All mice were maintained under specific
pathogen-free conditions and given sterile food and water. Once
the tumors became palpable (at day 14 after injection), the mice
were randomly divided into two treatment groups (6 mice per
group): 1) intraperitoneal injection with control hIgG (1 mg/kg)
twice a week for 3 weeks.; or 2) intraperitoneal injection with
trastuzumab (1 mg/kg) twice a week for 3 weeks. At the end of
treatment, all tumors were collected and weighed. A portion of the
xenografts was used for RNA and protein isolation; another
portion was fixed in formalin and embedded in paraffin; and third
portion was frozen in liquid nitrogen. Experiments with nude mice
were repeated twice with similar results.
miR-194 Expression Construct
A miR-194 core fragment was amplified from BT474 genomic
DNA by using the following primer set: CTAAGCTTAGTGGG-
CATGGGACACTCT (miR-194-2F) & CTGAATT-
CACCTGCCTCTCCTTCTTCGT (miR-194-2R) and sub-
cloned into pEGPF-C1 vector digested with HindIII and EcoRI.
The sequence of this miR-194 construct was verified by direct
sequencing and QRT-PCR after transient expression.
Generation of Trastuzumab-resistant Cells and Stable
Clones that Express miR-194 in BT474 and SKBr3 cells
Trastuzumab-resistant SKBr3 and BT474 cells were generated
as reported previously [45]. Two stable clones that express miR-
194 and two control clones that express the backbone vector
(pEGPF-C1) were established in BT474 cells using previously
reported methods [46] .
Generation of 39 UTR reporter constructs of talin2
Prediction of miR-194 binding sites was performed using
TargetScan software (http://www.targetscan.org/). A fragment of
39-9UTR region of the talin2 contains the predicted binding site
for miR-194 and was amplified by PCR using the primers:
TCTAGAGGCTGCATGATCGTGATGT (forward) and
TCTAGATCATAAAGAGGTCCAGGAGCA (reverse), which
contained Xba I restriction sites (underlined nucleotides). The
PCR product was purified, digested and cloned into pGL3 vector
(Promega, Madison, WI) via the Xba I site, which is located
downstream of the firefly luciferase reporter gene. QuikChangeH
II XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa
Clara, CA) was used to generate a deletion mutation in the miR-
194 seed region according to the manufacturer’s instructions.
Following mutagenic primers: 59-GGGTGCACGTTTCATG-
GACAACAAAGAAAAGTCAGT-39 (deletion sense) and 59-
ACTGACTTTTCTTTGTTGTCCATGAAACGTGCACCC-
39 (deletion antisense) were utilized. Generated constructs were
confirmed by direct sequencing using an ABI 3730xl DNA
sequencer at the DNA Analysis Core Facility at the University of
Texas MD Anderson Cancer Center.
Dual Luciferase Reporter Assay
Luciferase activity assays were performed as previously reported
[46] . Briefly, cells were seeded in 6-well plates, cotransfected with
miR-194 precursor or its negative control and a wild-type or
mutated talin2 39-UTR reporter construct as described above. A
Renilla luciferase vector (pRL-TK) served as an internal control
and was included in all samples. After transfection for 16 hrs, cells
were split into 12-well plates, harvested after 24 hrs and Firefly
and Renilla luciferase activities were measured sequentially using
the dual luciferase assay kit (Promega) and a luminometer. Results
were expressed as relative luciferase activity after normalization
with Renilla luciferase activity. Results represent three independent
experiments and each performed in triplicate.
Immunoblot Analysis
Total cell lysates were prepared and Western blotting was
performed as described previously [15]. Briefly, cells were
transfected with miR-194 precursors for 3 days, and then
harvested for total lysate preparation. Total lysates were separated
on 6% SDS-polyacrylamide gel and blotted onto nitrocellulose
membrane. The membrane was incubated with horseradish
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peroxidase–conjugated secondary antibody (1:2000; GE health-
care) and bound antibody was visualized with the use of a
SuperSignal West Dura chemiluminescent kit (Thermo Fisher,
Rockford, IL).
Flow Cytometry
The percentage of the sub-G1 cell population (apoptotic cells)
and the cell cycle distribution were determined based on relative
DNA content with the use of flow cytometry as described
previously [15].
Cell Migration Assay
26105 of BT474 cells or 56104 SKBr3 cells in 0.5 ml of serum-
free medium were introduced into the upper compartment of the
BD BioCoat control inserts (Cat. # 354578, BD Discovery
Labware, Bedford, MA) fitted with membranes of 8 micron
porosity separating the upper and lower compartments. The lower
compartment was filled with normal culture medium, medium
supplemented with 10% FBS. After 16 hrs of incubation, cells
were wiped off from the upper surface of each insert. The cells on
the lower surface, which represented the cells that migrated
through control insert membrance, were fixed and stained with
Diff-Quick (Siemens, Deerfield, IL) and counted by microscopic
examination in 10 representative fields. Cell migration was
expressed as relative migration relative to the migration of each
control group. Cell migration at each control group was arbitrarily
set as 1. Each condition was assayed in triplicate and each
experiment was repeated at least three times.
Cell Invasion Assay
Invasion assays were performed using BD Biocoat Matrigel
Invasion Chambers (Cat. # 354480, BD Discovery Labware,
Bedford, MA) that contain an 8 micron pore size PET membrane
with a thin layer of MATRIGEL Basement Membrane Matrix by
following the manufacturer instructions. Briefly, control-treated or
miR-194 (or trastuzumab)-treated BT474 or SKBr3 cells were
introduced into the upper compartment, incubated for 24 hrs,
fixed and stained after removing non-invading cells as described
above for the Cell Migration Assay. Cell invasion is then
calculated as the percent invasion through the matrigel matrix
and membrane relative the migration through the control
membrane. Cell invasion at each control group was arbitrarily
set as 1. Cell invasion data was expressed as relative invasion
relative to the invasion of control group.
In Vitro Scratch Assay
BT474 (56106 cells/well) or SKBr3 (26106 cells/well) cells
were seeded to 90% confluence in a 6-well plate for overnight
culture. The following day a scratch was made through the center
of each well using a 200-mL pipette tip, creating an open ‘‘scratch’’
or ‘‘wound’’ that was clear of cells. The dislodged cells were
removed by three washes with complete culture media, and cells
were incubated under standard conditions. Migration into the
open area was documented at 72 hrs post-scratching.
Vinculin Immunofluorescence (IF) Staining
SKBr3 cells were seeded at 1.56105 cells onto collagen (10 mg/
ml) and poly-L-lysine (1 mg/ml) coated glass coverslips in 6-well
dishes. Cells were grown for 16 hrs and then either cultured
untreated or treated with control hIgG (10 mg/ml) or trastuzumab
(10 mg/ml) for 16 hrs. Cells were fixed in ice-cold MeOH at
220uC for 5 min. Fixed cells were permeabilized and immuno-
stained with rabbit anti-vinculin and followed by incubation with
secondary antibody secondary antibody conjugated with Alexa
Fluor 594 (Invitrogen). Coverslips were mounted on glass slides
and examined using an Olympus FluoView FV1000 confocal
microscope (Center Valley, PA).
Ethics Statement
All animal experiments with nu/nu mice were reviewed and
approved by the Institutional Animal Care and Use Committee at
the University of Texas MD Anderson Cancer Center. Animals
were euthanized when the mice became morbid or the tumor size
is 1.5 cm in the largest diameter.
Statistical Analysis
All experiments were repeated at least three times on different
occasions. The results are presented as the mean 6 SD for all
values. A paired Student’s t test was used to evaluate statistically
significant differences in miR-194 levels between the treatment
groups and the vehicle control group. P,0.05 was considered
statistically significant. All statistical tests and corresponding P
values were two-sided.
Results
Trastuzumab treatment upreguates miR-194 in HER2
overexpressing breast cancer cells
To determine the effects of trastuzumab treatment on miRNAs
in HER2-overexpressing breast cancer cells, SKBr3 and BT474
cells were treated with trastuzumab or control hIgG. RNA was
extracted and profiled on a miRNA chip (ArrayExpress) that
contained 559 human miRNA probes and 962 human ultra-
conserved sequences. Raw data were analyzed using a GeneSpring
GX 7.3. The filter on fold change was set at 1.2 since this
threshold had been demonstrated to reflect a significant biological
difference [47]. As shown in Table 1, trastuzumab treatment in
SKBr3 cells increased 23 human miRNAs including miR-194 and
miR-629, but decreased 33 human miRNAs in SKBr3 cells. In
BT474 cells, trastuzumab treatment upregulated more miRNAs
than it downregulated. As shown in Table 2, trastuzumab
increased 40 human miRNAs including miR-194, decreased 18
human miRNAs in BT474 cells. To visualize the clusters of the
differentially expressed miRNAs in response to trastuzumab
treatment in the two cell lines, hierarchical clustering was
performed using one minus correlation as a distance measure
and average linkage method for defining the distance between the
clusters (Fig. S1). When miRNA changes were compared in
SKBr3 and BT474 breast cancer cells, miR-194 upregulation was
the only change shared by both cell lines. Consequently, miR-194
was selected for further study.
Trastuzumab upreguates miR-194 in cell culture and in
xenografts
To confirm that miR-194 was upregulated by trastuzumab
(Tables 1 & 2), total RNA was extracted from trastuzumab-treated
SKBr3 and BT474 cells in culture and subjected to quantitative
reverse-transcription PCR (QRT-PCR) and Northern blot anal-
yses. QRT-PCR analysis confirmed that trastuzumab treatment
increased miR-194 by 1.64 fold in SKBr3 cells (Fig. 1A) and by
1.95 fold in BT474 cells (Fig. 1A). Northern blotting further
confirmed that trastuzumab treatment increased miR-194 level by
2.1 fold in BT474 cells (Fig. 1C). An assay with a miR-194-specific
sensor reporter also indicated that trastuzumab increased miR-194
expression (data not shown). Consistent with above results in cell
culture, QRT-PCR analysis of BT474 xenograft tumor samples
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Table 1. miRNAs affected by trastuzumab in SKBr3 cells.
Unique ID
Mean ratio of
trastuzumab vs
control hlgG
p-value
(t-test)
Geom mean of intensities in
SKBr3 cells treated with
control hIgG for 20 hrs
(BRC20)
Geom mean of intensities
in SKBr3 cells treated with
trastuzumab for 20 hrs
(BRHCT20)
hsa-mir-548b-A 0.065146674 0.0002274 347.37 22.63
hsa-mir-551a-P 0.071772555 0.0185408 452.68 32.49
hsa-mir-624-A 0.072392834 0.0169737 312.6 22.63
hsa-mir-648-A 0.075340413 0.0148338 300.37 22.63
hsa-mir-544-A 0.076597617 1.10E-05 295.44 22.63
hsa-mir-26a-2-P 0.083364032 0.0067642 271.46 22.63
hsa-mir-508-A 0.086219377 0.0030508 262.47 22.63
hsa-mir-608-P 0.099895462 0.028476 325.24 32.49
hsa-mir-33-A 0.100908274 0.0283768 300.57 30.33
hsa-mir-519a1-5p/526c-A 0.103456158 2.57E-05 218.74 22.63
hsa-mir-433-P 0.103754986 0.0014047 218.11 22.63
hsa-mir-548a3-P 0.110535828 0.033025 204.73 22.63
hsa-mir-516-4-5p-A 0.116595394 0.0157548 194.09 22.63
hsa-mir-520g-P 0.132984662 0.01343 170.17 22.63
hsa-mir-526a-2-P 0.135202744 0.0372519 247.85 33.51
hsa-mir-192-P 0.174889247 0.0003376 397.28 69.48
hsa-mir-519b-3p/526c-A 0.180074799 0.0152054 125.67 22.63
hsa-mir-141-P 0.202469357 0.0036423 111.77 22.63
hsa-mir-153-2-A 0.215605945 0.0208085 104.96 22.63
hsa-mir-381-A 0.240514401 0.0338008 94.09 22.63
hsa-mir-613-P 0.264091493 0.0242617 85.69 22.63
hsa-mir-135b-A 0.277634646 0.0053856 81.51 22.63
hsa-mir-506-P 0.314426262 0.0432334 199.22 62.64
hsa-mir-616-P 0.362195903 0.0017904 62.48 22.63
hsa-mir-651-A 0.381449112 0.0349512 212.82 81.18
hsa-mir-496-P 0.410558781 0.0179086 55.12 22.63
hsa-mir-652-A 0.45070703 0.045327 50.21 22.63
hsa-mir-624-P 0.477062244 0.0097793 139.29 66.45
hsa-mir-200a*-5p-A 0.509914376 0.0301038 44.38 22.63
hsa-mir-135a-1-A 0.558314088 0.0331035 103.92 58.02
hsa-mir-196b-P 0.56347169 0.0475296 2699.55 1521.12
hsa-mir-214-A 0.697566648 0.0485026 1745.74 1217.77
hsa-mir-29a-A 0.713695323 0.0199925 1379.23 984.35
hsa-mir-629-A 1.215502868 0.0165149 1799.28 2187.03
hsa-mir-194-2-A 1.222424312 0.0168992 3056.95 3736.89
hsa-mir-27b-A 1.466522781 0.0174398 838.63 1229.87
hsa-mir-572-P 1.710230649 0.0482883 706.7 1208.62
hsa-mir-518a2-5p/mir527-A 2.068051259 0.0064793 22.63 46.8
hsa-mir-569-P 2.840919134 0.0007198 22.63 64.29
hsa-mir-17-3p-A 2.933274414 0.0304101 22.63 66.38
hsa-mir-431-A 3.683163942 0.0495408 22.63 83.35
hsa-mir-30d-P 3.899322034 0.0487109 29.5 115.03
hsa-mir-96-P 4.094521778 0.022245 44.54 182.37
hsa-mir-557-P 4.207247017 0.0134777 22.63 95.21
hsa-mir-105-2-A 4.314184711 ,1e-07 22.63 97.63
hsa-mir-489-P 4.814453843 0.0087891 54.38 261.81
hsa-mir-505-P 5.205695142 0.0310113 29.85 155.39
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also showed that treatment with trastuzumab induced miR-194
expression by 3.1 fold compared to control hIgG (Fig. 1D).
Collectively, above results confirm that trastuzumab induces miR-
194 in cell culture and in vivo.
Trastuzumab specifically induces miR-194 expression in
trastuzumab-sensitive breast cancer cells
As shown in Figure 1E, miR-194 expression increased only in
trastuzumab-sensitive SKBr3 and BT474 parental cells but not in
trastuzumab-resistant cells. Additionally, miR-194 was not in-
duced by trastuzumab treatment in either the MDA-MB-231
breast cancer cell line that expresses low levels of HER2 and is
insensitive to trastuzumab or the KPL4 breast cancer cell line that
expresses high levels of HER2 and is insensitive to trastuzumab
(Fig. S2). Thus, miR-194 is specifically induced by trastuzumab
treatment and may associate with trastuzumab response.
Increased expression of miR-194 significantly inhibits
migration and invasion of breast cancer cells that
overexpress HER2
We next explored the biological function of miR-194 in breast
cancer. Two approaches were used to study the function of miR-
194 in breast cancer cells: transient and stable expression of miR-
194 in BT474 or SKBr3 breast cancer cells. The effects of
transient and stable expression of miR-194 on cell viability, cell
cycle, apoptosis and cell migration/invasion were evaluated.
Stable expression of miR-194 in subclones of BT474 cells was
confirmed with QRT-PCR and shown in Figure 2A. As shown in
Figure 2B, stable overexpression of miR-194 in two BT474 stable
clones (#22 and #23) produced moderate inhibition of cell
growth as measured with a crystal violet viability assay. No
significant change in cell cycle distribution or apoptosis was
observed in subclones of BT474 with stable overexpression of
miR194 (data not shown). Transient overexpression of miR-194
significantly decreased the ability of SKBr3 cells to migrate
(Fig. 2C). Compared with the negative control miRNA, miR-194
expression reduced SKBr3 cell migration by 56% (Fig. 2D).
Transient overexpression of miR-194 also decreased the ability of
SKBr3 cells to detach from and invade through the matrigel
matrix as illustrated in the cell invasion assay (Fig. 2E). Validation
of miR-194 transient expression was performed with QRT-PCR
and shown in Figure 2F. Additionally, stable overexpression of
miR-194 inhibited the ability of BT474 cells to migrate by 40%
and to invade by 55% (Fig. 2G & 2H). The effect of miR-194 on
HER2-overexpressing breast cancer cells was further evaluated in
a BT474 xenograft model. As shown in Figure 2I, miR-194
expressing BT474 tumors grew significantly less rapidly than did
tumors containing breast cancer cells with an empty vector. Taken
together, these data indicate that miR-194 can significantly inhibit
cell migration/invasion in vitro, and tumor growth in vivo in
breast cancer cells that overexpress HER2.
miR-194 directly targets the talin2 gene and
downregulates talin2 protein
We next asked whether miR-194 targeted the expression of
proteins which regulate migration and invasion of breast cancer
cells (Fig. 2). Based on the UCSC genome database at http://
genome.ucsc.edu/, miR-194-2 maps on human chromosome 11
within an intron of an unknown human gene (AB429224, also
called Homo sapiens cDNA FLJ35483). Using the TargetScan and
miRanda programs, we identified talin2 that encodes a cytoskel-
etal protein as one of many genes targeted by miR-194. The
putative miR-194 target site in the 39-UTR of talin2 gene shows a
close match to nucleotides 2 to 18 of miR-194 (Fig. 3A). The miR-
194 target site is also highly conserved among multiple species
including humans, chimpanzees, mice, rats, rabbits, hedgehogs,
dogs, cats, horses and elephants (Fig. 3A). To determine whether
miR-194 acts directly on talin2 39-UTR, we conducted luciferase
reporter assays, cotransfecting miR-194 and luciferase reporter
constructs containing wild type (underlined letter in Figure 3A) or
mutant (deletion of underlined letter in Figure 3A) talin2 39-UTR.
Luciferase activity was dramatically decreased by approximately
60% in the presence of miR-194 when compared with its negative
miRNA control (Fig. 3B). In contrast, miR-194 did not alter
activity of the mutant talin2 luciferase reporter that contained the
deletion of miR-194 binding site (Fig. 3B), indicating miR-194
specifically act on wild-type talin2 39-UTR. In agreement with the
luciferase reporter results, transient overexpression of miR-194
significantly decreased talin2 protein expression (Fig. 3C). These
data indicate that talin2 is a direct target of miR-194 in breast
cancer cells.
Depletion of talin2 inhibits cell migration and invasion in
breast cancer cells that overexpress HER2
We next asked whether talin2 regulates cell migration and
invasion. Both talin1 and talin2 encode high-molecular-weight
Table 1. Cont.
Unique ID
Mean ratio of
trastuzumab vs
control hlgG
p-value
(t-test)
Geom mean of intensities in
SKBr3 cells treated with
control hIgG for 20 hrs
(BRC20)
Geom mean of intensities
in SKBr3 cells treated with
trastuzumab for 20 hrs
(BRHCT20)
hsa-mir-583-A 5.604502889 0.0038414 50.19 281.29
hsa-mir-640-P 6.07512152 6.07E-05 22.63 137.48
hsa-mir-548d1-A 8.575879397 0.0167225 29.85 255.99
hsa-mir-519a1-3p-A 9.625276182 4.25E-05 22.63 217.82
hsa-mir-605-A 11.04639859 0.0011691 22.63 249.98
hsa-mir-340-P 11.06934673 0.0302754 29.85 330.42
hsa-mir-198-A 11.44410075 0.0041912 22.63 258.98
hsa-mir-19b2-A 12.41228458 0.0020803 22.63 280.89
hsa-mir-518e-3p-A 13.12019443 0.002743 22.63 296.91
doi:10.1371/journal.pone.0041170.t001
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Table 2. miRNAs affected by trastuzumab in BT474 cells.
Unique ID
Mean ratio of
trastuzumab vs
control hlgG
p-value
(t-test)
Geom mean of intensities in
BT474 cells treated with
control hIgG for 48 hrs
(BTC48)
Geom mean of intensities in BT474
cells treated with trastuzumab for
48 hrs (BTHCT48)
hsa-mir-211-P 0.092615377 0.034884 382.01 35.38
hsa-mir-514-2&3-A 0.10147527 0.000624 223.01 22.63
hsa-mir-518e-5p/526c-A 0.116523351 0.019672 194.21 22.63
hsa-mir-452*-3p-A 0.116631449 0.034182 194.03 22.63
hsa-mir-518a2-5p/mir527-A 0.144231995 0.035946 156.9 22.63
hsa-mir-524*-5p-A 0.162257116 0.00944 139.47 22.63
hsa-mir-518b-A 0.173503028 0.012805 130.43 22.63
hsa-mir-105-2-P 0.209385572 0.012188 458.15 95.93
hsa-mir-520h-P 0.227391479 0.002751 99.52 22.63
hsa-mir-519e*-5p-A 0.242584266 0.002037 331.39 80.39
hsa-mir-646-A 0.242915414 0.023069 93.16 22.63
hsa-let-7g-P 0.257715522 5.90E-06 87.81 22.63
hsa-mir-323-A 0.291360886 0.002132 77.67 22.63
hsa-mir-517b-3p-A 0.291698891 0.009441 77.58 22.63
hsa-mir-432-5p-A 0.292150788 0.010767 77.46 22.63
hsa-mir-515-1-5p-A 0.305356902 7.16E-05 74.11 22.63
hsa-mir-548a1-A 0.500150716 0.017816 663.5 331.85
hsa-mir-671-A 0.780467508 0.030883 1862.64 1453.73
hsa-mir-758-P 1.203505577 0.010282 790.74 951.66
hsa-mir-485-3p-A 1.226628339 0.007659 1019.29 1250.29
hsa-mir-102-A 1.238857151 0.007481 1353.11 1676.31
hsa-mir-202-3p-A 1.29220961 0.03779 964.65 1246.53
hsa-mir-629-A 1.363440315 0.017991 2721.96 3711.23
hsa-mir-663-P 1.371448683 0.003362 1647.98 2260.12
hsa-mir-560-P 1.446595051 0.041021 831.29 1202.54
hsa-mir-296-A 1.45630605 0.010238 545.27 794.08
hsa-mir-324-5p-A 1.462267846 0.032113 1455.39 2128.17
hsa-mir-219-1-P 1.517478105 0.000529 17165.19 26047.8
hsa-mir-206-P 1.594267196 0.000415 577.03 919.94
hsa-mir-498-A 1.630858004 0.019047 783.33 1277.5
hsa-mir-19b2-A 1.699504866 0.038757 351.42 597.24
hsa-mir-194-2-A 1.828481053 0.00689 3749.44 6855.78
hsa-mir-219-2-P 1.868439905 0.008312 1298.19 2425.59
hsa-mir-429-P 1.895429772 0.031979 1099.07 2083.21
hsa-mir-564-P 2.086289374 0.018767 875.89 1827.36
hsa-mir-521-2-P 2.461776403 0.010133 22.63 55.71
hsa-mir-126-5p-A 2.653743792 0.002951 1067.1 2831.81
hsa-mir-199a*-3p-A 2.856385329 0.048539 22.63 64.64
hsa-mir-101-1/2-P 3.303137428 0.000142 22.63 74.75
hsa-mir-638-P 3.462660186 0.04302 22.63 78.36
hsa-mir-548a3-P 3.467962881 0.000185 22.63 78.48
hsa-mir-571-A 3.785682722 0.000292 22.63 85.67
hsa-mir-643-P 3.855501547 1.14E-05 22.63 87.25
hsa-mir-662-P 4.589482987 0.009066 22.63 103.86
hsa-mir-559-P 4.655766681 7.55E-05 22.63 105.36
hsa-mir-584-A 5.155103844 0.030886 22.63 116.66
hsa-mir-585-P 6.66195316 0.018554 22.63 150.76
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Table 2. Cont.
Unique ID
Mean ratio of
trastuzumab vs
control hlgG
p-value
(t-test)
Geom mean of intensities in
BT474 cells treated with
control hIgG for 48 hrs
(BTC48)
Geom mean of intensities in BT474
cells treated with trastuzumab for
48 hrs (BTHCT48)
hsa-mir-659-A 6.761655012 0.015715 85.8 580.15
hsa-mir-587-A 7.121078215 0.019825 22.63 161.15
hsa-mir-591-A 8.88054883 0.048778 37.17 330.09
hsa-mir-18b-P 8.956212523 0.023338 71.71 642.25
hsa-mir-152-A 13.43314501 0.036953 37.17 499.31
hsa-mir-642-P 17.71718957 0.006654 22.63 400.94
hsa-mir-21-P 17.86831639 0.004662 22.63 404.36
hsa-mir-567-P 22.46221829 0.007096 22.63 508.32
hsa-mir-337-A 24.40212108 0.008015 22.63 552.22
hsa-mir-652-A 27.14891737 2.90E-05 22.63 614.38
hsa-mir-136-A 32.47459125 0.005502 22.63 734.9
doi:10.1371/journal.pone.0041170.t002
Figure 1. Trastuzumab upregulates miR-194 expression in vitro and in vivo. HER2-overexpressing breast cancer cell lines BT474 (A) and
SKBr3 (B) were treated with trastuzumab (Tras) or control hIgG (10 mg/ml) for 48 hrs. Total RNA was prepared and analyzed by QRT-PCR to measure
miR-194. * p,0.05 compared to hIgG control. (C) Northern blot analysis of miR-194 expression. BT474 cells were treated with Tras or control hIgG
(10 mg/ml) for 48 hrs. Total RNA was prepared and analyzed by Northern blotting to detect miR-194. U6 non-coding small nuclear RNA (snRNA)
served as a loading control. (D) QRT-PCR quantitation of miR-194 expression in vivo. BT474 xenografts in miR-194 levels were measured by QRT-PCR.
* p,0.05 compared to hIgG control. (E) QRT-PCR quantitation of miR-194 expression in trastuzumab sensitive or resistant cell lines. Parental SKBr3
and BT474 (trastuzumab-sensitive), and their derived resistant cells were treated with Tras or control hIgG for 48 hrs. Total RNA was prepared and
analyzed by QRT-PCR to detect miR-194. * p,0.05 compared to hIgG control.
doi:10.1371/journal.pone.0041170.g001
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cytoskeletal proteins that concentrate in focal adhesions and link
integrins to vinculin and actin [48,49]. To study the role of talin2
in cell migration, SKBr3 cells were transiently transfected with two
siRNAs targeting talin2 or a negative control siRNA, and cell
migration and invasion were assayed as described in Material and
Methods. As shown in Figure 3D, knockdown of talin2 signifi-
cantly inhibited migration of SKBr3 cells compared to the control
siRNA. Talin2 silencing decreased cell invasion capacity as well
(Fig. 3E). Two siRNAs used to downregulate talin2 was confirmed
with Western blotting and shown in Figure 3F. Above data
indicate that talin2 silencing decreases cell migration and invasion
of SKBr3 cells.
Trastuzumab treatment inhibits cell migration and
disrupts the normal vinculin staining pattern in breast
cancer cells that overexpress HER2
While the effects of trastuzumab on cancer cell proliferation,
angiogenesis, and apoptosis have been investigated in depth, the
effect of trastuzumab on cell migration has received less attention.
Both BT474 and SKBr3 cells respond to trastuzumab treatment,
but are not actively motile. Long intervals are required to measure
cell migration assay or to observe healing of scratches in cancer
cell monolayers. Treatment of BT474 and SKBr3 with trastuzu-
mab for 3 days significantly inhibited the ability of both cell lines to
heal scratch assays (Fig. 4A). To study the effect of trastuzumab on
cell migration over a shorter interval (16 h) and to minimize the
effect of cell proliferation on scratch assays, we have stimulated
SKBr3 cell migration with epidermal growth factor (EGF) and
found that motility of trastuzumab-treated cells was significantly
slower than that of hIgG-treated controls (Fig. 4B). Stimulation of
SKBr3 cells with EGF for 16 hrs had no effect on miR-194
expression (data not shown). Similar results were observed in
transwell cell migration assays (see below).
Treatment with trastuzumab disrupts cytosekeltal
organization
SKBr3 cells were treated with trastuzumab and stained by
immunofluorescence for expression of vinculin, a cytoskeletal
protein associated closely with talin2 and exhibiting a similar
subcellular distribution [49]. In the absence of a specific antibody
for talin2 for immunofluorescence studies, we have used the
Figure 2. Increased miR-194 expression inhibits breast cancer cell migration and invasion. (A) miR-194 expression in the stable clones of
BT474 cells. BT474 cells were stably transfected with an empty pEGFP-C1 vector or pEGFP-miR-194 vector under the selection of G418. Two control
clones #17 and #19 that contain empty vector and two miR-194-expressing clones #22 and #23 were established and subjected for QRT-PCR
analysis. Hsa-miR-194 was purchased from ABI (Assay ID 000493). (B) Cell viability assay of BT474 stable cells that express miR-194 or its control
vector. BT474 cells were stably transfected with empty pEGFP-C1 vector or pEGFP-miR194 construct under the selection of G418. Two control clones
#17 and #19 that contain empty vector and two miR-194-expressing clones #22 and #23 were chosen to measure viability of crystal violet-stained
cells on day 1, day 3 and day 5. (C) Effect of miR-194 precursor on cell migration in SKBr3 cells. SKBr3 cells were transiently transfected with a miR-194
precursor or a control miRNA (miR CTRL) for 48 hrs and motility was measured overnight in a Transwell assay. (D) Quantitation of the SKBr3 cell
migration as shown in (C). * p,0.05 compared to miR control. (E) Effect of miR-194 precursor on cell invasion in SKBr3 cells. SKBr3 cells were
transiently transfected with a miR-194 precursor or a control miRNA (miR CTRL) for 48 hrs and invasion measured overnight. * p,0.05 compared to
miR control. (F) miR-194 expression in transiently transfected SKBr3 cells. SKBr3 cells were transiently transfected with a miR-194 precursor or a
control miRNA (miR CTRL) for 48 hrs. Total RNA was extracted and subjected to QRT-PCR analysis for miR-194 expression. Hsa-miR-194 was purchased
from ABI (Assay ID 000493). (G) Assay of cell migration in BT474 stable cells that express miR-194 or a control vector. The control clone #17 and the
miR-194-expressing clone #22 were chosen to study migration. * p,0.05 compared to #17 control. (H) Cell invasion assay in BT474 stable cells that
express miR-194 or its control vector. The control clone #17 and the miR-194-expressing clone #22 were chosen to study invasion. * p,0.05
compared to#17 control. (I) BT474 xenograft tumor growth in vivo. BT474 xenografts in nude mice were established with the control clone#17 and
the miR-194-expressing clone #22 as described in Methods. Tumors were collected and weighed after 4 weeks. * p,0.05 compared to #17 control.
doi:10.1371/journal.pone.0041170.g002
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behavior of vinculin as a surrogate for talin2. As shown in
Figure 4C, trastuzumab treatment for 16 hrs altered the staining
pattern of vinculin. Instead of well ordered, discrete and focal
staining of vinculin on the cell periphery, trastuzumab treatment
produced disordered and clumpy staining both in the cytoplasm
and at the cell’s periphery. These observations suggest that
trastuzumab can inhibit migration and disrupt the normal
distribution of cytoskeletal proteins in breast cancer cells that
overexpress HER2.
Trastuzumab treatment downregulates talin2 protein
expression in vitro and in vivo in breast cancer cells that
overexpress HER2
From the data presented above, trastuzumab treatment
increases miR-194 (Tables 1 & 2 and Fig. 1) and miR-194
negatively regulates cell migration (Fig. 2) and talin2 expression
(Fig. 3). To determine whether trastuzumab downregulates talin2
expression, BT474, SKBr3 cells and BT474 xenograft tumors
were treated with trastuzumab or control hIgG and total protein
was collected, Western blots prepared and stained with anti-talin2.
As shown in Figure 4D, trastuzumab treatment decreased talin2
protein expression in a dose-dependent manner in BT474 cells.
Quantitation of talin2 protein levels after trastuzumab treatment
in three different experiments confirmed the dose-dependent effect
(Fig. 4E). Trastuzumab treatment also decreased talin2 protein in
SKBr3 cells (Fig. 4F). A similar downregulation of talin2 was
observed in BT474 xenografts growing in nude mice. Trastuzu-
mab inhibited talin2 protein expression (the lower band) in two
different tumors (Fig. 4G). Trastuzumab treatment also produced
a decrease in total Rb protein in BT474 xenografts, consistent with
activity of the antibody in vivo [15].
Knockdown of miR-194 promotes cancer cell migration
and reverses trastuzumab inhibition of cell migration
To determine whether a decrease in miR-194 would increase
motility, SKBr3 cells were transiently transfected with a specific
miR-194 inhibitor or antagomir. As shown in Figure 5A,
transfection of SKBr3 cells with a miR-194 antagomir increased
Figure 3. miR-194 targets the talin2 gene and downregulates talin2 protein levels. (A) Alignment of miR-194 with talin2 (TLN2) 39-UTRs.
Complementary sequences of miR-194 and mammalian talin2 39-UTRs are marked in Bold. The seed sequences of miR-194 are underlined. Has,
human; Ptr, pan troglotydes; Mmu, mus musculus; Rno, rat; Ocu, rabbit; Eeu, hedgehog; Cfa, dog; Fca, cat; Eca, horse; Laf, elephant. The underlined
seed nucleotides were deleted in the talin2 39-UTR mutant reporter construct described in (B). (B) Effect of miR-194 expression on the luciferase
activities of wild-type and mutated talin2 39-UTR reporters. MDA-MB-361 cells were transiently transfected with a miR Control or miR-194 precursor
for 36 hrs. Luciferase activity was determined using a dual luciferase assay. ** p,0.01. (C) Effect of miR-194 expression on talin2 protein levels in
SKBr3 cells. SKBr3 cells were transiently transfected with a miR-194 precursor or a control miRNA (miR CTRL) for 48 hrs. Total protein was prepared
and subjected to Western blotting. (D) Effect of talin2 downregulation on cell migration in SKBr3 cells. SKBr3 cells were transiently transfected with
two siTalin2 (siTLN2 #7 and #8) or its control siRNA (siCTRL) for 48 hrs and then motility was measured overnight in a Transwell assay. * p,0.05
compared to siCTRL. (E) Effect of talin2 downregulation on cell invasion. SKBr3 cells were transiently transfected with two siTalin2 (siTLN2#7 and#8)
or its control siRNA (siCTRL) for 48 hrs and then invasion assay was performed. * p,0.05 compared to siCTRL. (F) Validation of talin2 siRNA efficacy.
SKBr3 cells were transiently transfected with two siTalin2 (siTLN2 #7 and #8) or its control siRNA (siCTRL) or the transfection reagent only (mock) for
48 hrs and total protein was prepared. Western blotting was performed with a talin2 antibody.
doi:10.1371/journal.pone.0041170.g003
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cancer cell migration by more than 55%. The ability of the miR-
194 antagomir to silence miR-194 was confirmed by QRT-PCR
as shown in Figure 5B. Similar results were observed in BT474
cells, where inhibition of miR-194 by a miR-194 antagomir
stimulated BT474 cell migration (Fig. 5C). Consistent with the
results of in vitro scratch assay, trastuzumab treatment decreased
the BT474 cell migration (Fig. 5C). However, trastuzumab
treatment was no longer able to inhibit cell migration in the
presence of miR-194 antagomir or inhibitor (Fig. 5C), indicating
miR-194 induction was required for trastuzumab to slow cell
migration in breast cancer cells.
Figure 4. Trastuzumab treatment downregulates talin2 protein expression and inhibits breast cancer cell migration. (A) Effect of
trastuzumab (Tras) on cell migration in a scratch assay. BT474 and SKBr3 cells were seeded in 6-well plates. After cells had grown to confluence, a
scratch was made in the monolayer. Cells were treated with trastuzumab (Tras) or control hIgG (10 mg/ml) for 72 hrs. Images were recorded at 72 hrs
at 406 enlargement. (B) Effect of trastuzumab on cell migration over a shorter interval (16 h) in a scratch assay. SKBr3 cells were seeded in 6-well
culture plates and cultured overnight to achieve a cell density of full confluence. A scratch was made in the monolayer. Cells were then treated with
trastuzumab (Tras) or control hIgG (10 mg/ml) plus epidermal growth factor (EGF, 20 ng/ml, sigma) for 16 hrs. Images were recorded at the end of
16 hrs of EGF stimulation at 406enlargement. (C) Effect of trastuzumab (Tras) on cytoskeletal vinculin distribution after IF staining. SKBr3 cells were
treated with trastuzumab (Tras) or control hIgG (10 mg/ml) for 48 hrs, and then subjected to IF staining as described in Methods. (D) Effect of
trastuzumab on talin2 protein in BT474 cells. BT474 cells were treated in vitro with different concentrations of trastuzumab for 48 hrs. Total protein
was prepared and subjected to Western blotting. (E) Quantitation of talin2 expression. The talin2 bands on immunoblots from three different
experiments including the one shown in (D) were digitized, normalized to the levels of GAPDH, and expressed as mean levels (error bars correspond
stand deviation). The talin2 expression at trastuzumab 0 concentration was set at 1. (F) Effect of trastuzumab on talin2 protein in SKBr3 cells. SKBr3
cells were treated with trastuzumab (Tras) or control hIgG (10 mg/ml) for 48 hrs. Total protein was prepared and subjected to Western blotting. (G)
Effect of trastuzumab on talin2 protein in BT474 xenografts. BT474 xenografts in nude mice were treated with trastuzumab (Tras) or hIgG 1 mg/kg
intraperitoneally twice a week and for 3 weeks. Total cell lysates were prepared and subjected to Western blotting.
doi:10.1371/journal.pone.0041170.g004
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Discussion
In this study, we have found for the first time that miR-194 is
induced in HER2-overexpressing breast cancer cells by trastuzu-
mab treatment. Forced expression of miR-194 inhibits cell
migration and decreases levels of talin2, a cytoskeletal protein.
Treatment with trastuzumab also inhibits breast cancer cell
migration and decreases talin2 expression. Depletion of miR-194
stimulates breast cancer cell migration and abolishes trastuzumab-
inhibited cell migration.
The regulatory role of miR-194 was first studied in normal and
malignant cells of the gastrointestinal tract. High levels of miR-194
are expressed in the intestines and liver [50,51]. Hepatocyte
nuclear factor (HNF) can induce miR-194 expression during
intestinal epithelial cell differentiation [52,53]. miR-194 suppresses
invasion and migration of liver mesenchymal-like cancer cells [54].
miR-194 expression is elevated in normal colon tissues and low in
colon cancers [55]. Low miR-194 expression has been associated
with large tumor size and advanced stage in gastric cancer [56].
Activation of tumor suppressor p53 can induce miR-194 and its
clustered miR-192 and miR-215 expression [55,57]. miR-192 and
miR-215 can induce p21Cip1 and cell cycle arrest in colon cancer
cells [55]. In endometrial cancer cells, miR-194 has been reported
to inhibit self-renewal factor BMI-1, reduce cell invasion and
inhibit epithelial-mesenchymal transition (EMT) [58]. While
inhibition of cell migration by miR-194 has been demonstrated
in other systems, this is the first report to show that miR-194 can
inhibit breast cancer cell migration (Fig. 2) and that miR-194 and
migration can be regulated by trastuzumab.
Our data suggest that miR-194-induced inhibition of motility is
mediated by downregulation of cytoskeletal proteins. We have
demonstrated for the first time that miR-194 inhibits talin2 protein
expression and binds to the talin2 39-UTR (Fig. 3). In addition to
regulating talin2, we have also observed that miR-194 expression
reduces profilin2, another cytoskeletal protein (data not shown).
However, miR-194 did not bind directly to the profilin2 39-UTR
in a luciferase reporter assay. miR-194 has been shown by others
to target migration-related proteins including N-cadherin, Rac1,
heparin-binding epidermal growth factor–like growth factor, type
1 insulin-like growth factor receptor, protein tyrosine phosphatase-
non receptor type 12, integrin-alpha 9, suppressor of cytokine
signaling 2, and BMI1 polycomb ring finger oncogene [54,56,58].
Inhibition of these other cytoskeletal and migration-related
proteins may contribute to miR-194-induced inhibition of cell
migration/invasion as well.
Talin1 and talin2 are actin-binding cytoskeletal proteins that
play key roles in cell signaling, adhesion, and migration
[48,49,59,60]. Both talin1proteins are closely coupled to vinculin,
another cytoskeletal protein found in focal adhesion complexes
[49]. Both talin1 and talin2 (74% identity) can bind to integrins
and to F actin via FERM (four-point-one, ezrin, radixin, moesin)
domains and are important regulators of integrin activation
[59,60,61,62]. Genetic knockout of talin1 alone does not affect
fibroblast spreading due to the compensatory activity of talin2, but
does impair cytoskeletal organization [63]. Double deletion of
talin1 and talin2 abolishes extracellular matrix–cytoskeletal linkage
through integrins and blocks assembly of focal adhesions [64].
Talin1 knockdown in the absence of talin2 compensation has been
shown to prevent spreading of endothelial cells and block
angiogenesis leading to embryonic death [65]. Forced expression
of talin1 enhances migration and invasion of prostate cancer cells
[66]. Talin1 overexpression is a poor prognostic factor in prostate
[66], liver [67] and oral [68] cancers. The role of talin2 in cancer
cells including in breast cancer has not yet been reported. This
study indicates that suppression of talin2 can inhibit breast cancer
cell migration.
Trastuzumab treatment seems to exert its anti-tumor effect
through multiple mechanisms including inducing miRNAs. After
completing this study, one report has been just published and
shown that trastuzumab treatment can induce miR-26a and miR-
30b, leading to inhibition of cylcin E2 expression and G1 arrest of
the cell cycle [69]. Our study has identified another miRNA (miR-
194) and new target (talin 2, motility) in HER2-overexpressing
breast cancer cells.
In conclusion, our study describes a novel mechanism of
trastuzumab action in breast cancer cells. Treatment with
trastuzumab can activate miR-194 expression, downregulate
Figure 5. miR-194 inhibitor stimulates cell migration and blocks trastuzumab-inhibited cell migration. (A) Effect of miR-194 inhibitor on
cell migration in SKBr3 cells. SKBr3 cells were transiently transfected with a miR-194 inhibitor or its negative control (miR inhibitor CTRL) for 48 hrs
before measurement of migration overnight. * p,0.05 compared to the negative control. (B) Validation of efficacy of miR-194 inhibition. SKBr3 cells
were transiently transfected with a miR-194 inhibitor or its negative control (miR inhibitor CTRL) for 48 hrs. Total RNA was prepared and miR-194
measured by QRT-PCR. * p,0.05 compared to miR inhibitor control. (C) Effect of miR-194 inhibitor on trastuzumab-inhibited cell migration. SKBr3
cells were transiently transfected with a miR-194 inhibitor or its negative control (miR inhibitor CTRL) for 16 hrs, treated with trastuzumab (Tras) or
control hIgG (10 mg/ml) for 36 hrs, and motility was then measured for overnight in Transwell assays. * p,0.05.
doi:10.1371/journal.pone.0041170.g005
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cytoskeletal protein talin2 expression and inhibit cell migration/
invasion in HER2-overexpressing breast cancer cells.
Supporting Information
Figure S1 Heatmap of the differentially expressed
miRNAs in response to trastuzumab treatment in
HER2-overexpressing SKBr3 cells (A) and BT474 cells
(B). To visualize the clusters of expressed miRNAs after
trastuzumab treatment, hierarchical clustering was performed
based on the differentially expressed miRNAs. Names of samples
(top) and miRNAs (side) is shown by using One Minus Correlation
as a distance measure after genes centering and scaling, and
average linkage method for defining the distance between the
clusters. Sample BRC20, SKBr3 cells treated control hIgG for
20 hrs; BRHCT20, SKBr3 cells treated trastuzumab for 20 hrs;
BTC48, BT474 cells treated with control hIgG for 48 hrs;
BTHCT48, BT474 cells treated with trastuzumab for 48 hrs. A
color scale of expression is shown between panel A and B.
(TIF)
Figure S2 Effects of trastuzumab on miR-194 expres-
sion in the MDA-MB-231 cells with low-HER2 level and
the KPL4 cells with high-HER2 level. Two trastuzumab-
insensitive breast cancer cell lines MDA-MB-231 (A) and KPL4
(B) were treated with trastuzumab (Tras) at different concentra-
tions (0, 5, 10 mg/ml) for 48 hrs. Total RNA was prepared and
analyzed by QRT-PCR in triplicate for miR-194 levels.
(TIF)
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